Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30499157,time to maximum plasma concentration,"D3OG was generated rapidly, with a median time to maximum plasma concentration of 2.0 hours (1.0-3.0).",Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499157/),h,2.0,1894,DB00030,Insulin Regular
<,28838325,elimination half-life,"Reveglucosidase alfa plasma concentrations increased linearly with dose, and the elimination half-life was <1.2 h.",A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28838325/),h,1.2,2191,DB00030,Insulin Regular
,28838325,maximum voluntary ventilation,"Subjects receiving 20 mg/kg of reveglucosidase alfa demonstrated increases in predicted maximum inspiratory pressure (13.9%), predicted maximum expiratory pressure (8.0%), forced vital capacity (-0.4%), maximum voluntary ventilation (7.4 L/min), and mean absolute walking distance (22.3 m on the 6-min walk test) at 72 weeks.",A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28838325/),[l] / [min],7.4,2192,DB00030,Insulin Regular
,25092225,fasting C-peptide,"We analyzed data collected in 11 subjects with T2D [6 male, 9 white European and two of Indian ethnicity; age 59.7(12.1) years, BMI 30.1(3.9) kg/m(2), fasting C-peptide 1002.2(365.8) pmol/l, fasting plasma glucose 9.6(2.2) mmol/l, diabetes duration 8.0(6.2) years and HbA1c 8.3(0.8)%; mean(SD)] who underwent a 24-h study investigating closed-loop insulin delivery at the Wellcome Trust Clinical Research Facility, Cambridge, UK.",Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092225/),pm,1002.2,2270,DB00030,Insulin Regular
,25092225,time-to-peak of lispro absorption (t(max)),The time-to-peak of lispro absorption (t(max)) was 109.6 (75.5-120.5) min [median (interquartile range)] and the metabolic clearance rate (MCR(I)) 1.26 (0.87-1.56)×10(-2) l/kg/min.,Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25092225/),min,109.6,2271,DB00030,Insulin Regular
,21910052,area under the concentration-time curve,"The area under the concentration-time curve, the time of maximum concentration, and the maximum concentration were 43.4 ng·h/mL, 0.85 h, and 8.1 ng/mL, respectively, similar to those of FK506.",Effects of water-soluble tacrolimus-PEG conjugate on insulin-dependent diabetes mellitus and systemic lupus erythematosus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21910052/),[h·ng] / [ml],43.4,2393,DB00030,Insulin Regular
,21910052,time of maximum concentration,"The area under the concentration-time curve, the time of maximum concentration, and the maximum concentration were 43.4 ng·h/mL, 0.85 h, and 8.1 ng/mL, respectively, similar to those of FK506.",Effects of water-soluble tacrolimus-PEG conjugate on insulin-dependent diabetes mellitus and systemic lupus erythematosus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21910052/),h,0.85,2394,DB00030,Insulin Regular
,21910052,maximum concentration,"The area under the concentration-time curve, the time of maximum concentration, and the maximum concentration were 43.4 ng·h/mL, 0.85 h, and 8.1 ng/mL, respectively, similar to those of FK506.",Effects of water-soluble tacrolimus-PEG conjugate on insulin-dependent diabetes mellitus and systemic lupus erythematosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21910052/),[ng] / [ml],8.1,2395,DB00030,Insulin Regular
,19014837,T(max),"After administration, LC15-0444 reached T(max) at 0.5 to 5.1 hours, and was eliminated with a t((1/2)) of 16.7 to 21.3 hours.","Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014837/),h,0.5 to 5.1,2419,DB00030,Insulin Regular
,19014837,t((1/2)),"After administration, LC15-0444 reached T(max) at 0.5 to 5.1 hours, and was eliminated with a t((1/2)) of 16.7 to 21.3 hours.","Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014837/),h,16.7 to 21.3,2420,DB00030,Insulin Regular
,19014837,fraction of unchanged drug excreted in urine,The mean fraction of unchanged drug excreted in urine ranged from 0.21 to 0.34 and mean renal clearance was 15.5 to 23.6 L/h.,"Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014837/),,0.21 to 0.34,2421,DB00030,Insulin Regular
,19014837,renal clearance,The mean fraction of unchanged drug excreted in urine ranged from 0.21 to 0.34 and mean renal clearance was 15.5 to 23.6 L/h.,"Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19014837/),[l] / [h],15.5 to 23.6,2422,DB00030,Insulin Regular
,27994752,ED50,"A novel series of substituted 3-(4-aryloxyaryl)propanoic acid derivatives were prepared and evaluated for their activities as GPR40 agonists, leading to the identification of compound 5, which is highly potent in in vitro assays and exhibits robust glucose lowering effects during an oral glucose tolerance test in nSTZ Wistar rat model of diabetes (ED50 = 0.8 mg/kg; ED90 = 3.1 mg/kg) with excellent pharmacokinetic profile, and devoid of cytochromes P450 isoform inhibitory activity.",Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27994752/),[mg] / [kg],0.8,2449,DB00030,Insulin Regular
,27994752,ED90,"A novel series of substituted 3-(4-aryloxyaryl)propanoic acid derivatives were prepared and evaluated for their activities as GPR40 agonists, leading to the identification of compound 5, which is highly potent in in vitro assays and exhibits robust glucose lowering effects during an oral glucose tolerance test in nSTZ Wistar rat model of diabetes (ED50 = 0.8 mg/kg; ED90 = 3.1 mg/kg) with excellent pharmacokinetic profile, and devoid of cytochromes P450 isoform inhibitory activity.",Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27994752/),[mg] / [kg],3.1,2450,DB00030,Insulin Regular
,15823772,baseline-corrected C(max),The mean (SD) baseline-corrected C(max) was significantly higher with oral insulin spray compared with SC insulin (54.0 [20.3] vs 30.8 [6.1] microU/mL; P = 0.028).,Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),[μu] / [ml],54.0,2567,DB00030,Insulin Regular
,15823772,baseline-corrected C(max),The mean (SD) baseline-corrected C(max) was significantly higher with oral insulin spray compared with SC insulin (54.0 [20.3] vs 30.8 [6.1] microU/mL; P = 0.028).,Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),[μu] / [ml],30.8,2568,DB00030,Insulin Regular
,15823772,T(max),Mean (SD) T(max) was significantly shorter with oral insulin spray compared with SC insulin (23.3 [5.2] vs 83.3 [42.2] minutes; P = 0.027).,Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),min,23.3,2569,DB00030,Insulin Regular
,15823772,T(max),Mean (SD) T(max) was significantly shorter with oral insulin spray compared with SC insulin (23.3 [5.2] vs 83.3 [42.2] minutes; P = 0.027).,Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),min,83.3,2570,DB00030,Insulin Regular
,15823772,time to maximal metabolic effect (maximum glucose infusion rate [GIR(max)]),"The mean (SD) time to maximal metabolic effect (maximum glucose infusion rate [GIR(max)]) (44.2 [8.6] vs 100.0 [35.6] minutes) and late time to half-maximal effect (101.0 [41.0] vs 257.2 [27.8] minutes) were shorter with oral insulin spray compared with SC insulin (both, P = 0.028).",Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),min,44.2,2571,DB00030,Insulin Regular
,15823772,time to maximal metabolic effect (maximum glucose infusion rate [GIR(max)]),"The mean (SD) time to maximal metabolic effect (maximum glucose infusion rate [GIR(max)]) (44.2 [8.6] vs 100.0 [35.6] minutes) and late time to half-maximal effect (101.0 [41.0] vs 257.2 [27.8] minutes) were shorter with oral insulin spray compared with SC insulin (both, P = 0.028).",Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),min,100.0,2572,DB00030,Insulin Regular
,15823772,time to half-maximal effect,"The mean (SD) time to maximal metabolic effect (maximum glucose infusion rate [GIR(max)]) (44.2 [8.6] vs 100.0 [35.6] minutes) and late time to half-maximal effect (101.0 [41.0] vs 257.2 [27.8] minutes) were shorter with oral insulin spray compared with SC insulin (both, P = 0.028).",Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),min,101.0,2573,DB00030,Insulin Regular
,15823772,time to half-maximal effect,"The mean (SD) time to maximal metabolic effect (maximum glucose infusion rate [GIR(max)]) (44.2 [8.6] vs 100.0 [35.6] minutes) and late time to half-maximal effect (101.0 [41.0] vs 257.2 [27.8] minutes) were shorter with oral insulin spray compared with SC insulin (both, P = 0.028).",Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),min,257.2,2574,DB00030,Insulin Regular
,15823772,GIR(max),"The baseline-corrected GIR(max) (6.8 [3.3] vs 6.2 [2.3] mg/kg . min) and glucose consumption (396.7 [178.0] vs 432.1 [226.0] mg/kg) during the 120 minutes after study drug administration were comparable between oral and SC insulin, respectively.",Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),[mg] / [kg·min],6.8,2575,DB00030,Insulin Regular
,15823772,GIR(max),"The baseline-corrected GIR(max) (6.8 [3.3] vs 6.2 [2.3] mg/kg . min) and glucose consumption (396.7 [178.0] vs 432.1 [226.0] mg/kg) during the 120 minutes after study drug administration were comparable between oral and SC insulin, respectively.",Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),[mg] / [kg·min],6.2,2576,DB00030,Insulin Regular
,15823772,glucose consumption,"The baseline-corrected GIR(max) (6.8 [3.3] vs 6.2 [2.3] mg/kg . min) and glucose consumption (396.7 [178.0] vs 432.1 [226.0] mg/kg) during the 120 minutes after study drug administration were comparable between oral and SC insulin, respectively.",Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),[mg] / [kg],396.7,2577,DB00030,Insulin Regular
,15823772,glucose consumption,"The baseline-corrected GIR(max) (6.8 [3.3] vs 6.2 [2.3] mg/kg . min) and glucose consumption (396.7 [178.0] vs 432.1 [226.0] mg/kg) during the 120 minutes after study drug administration were comparable between oral and SC insulin, respectively.",Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823772/),[mg] / [kg],432.1,2578,DB00030,Insulin Regular
<,24449674,TSH2/TSH1 ratio,We observed a TSH reduction (TSH2/TSH1 ratio <1) in 36/53 (67.9%) of patients; the median TSH2/TSH1 ratio was 0.71 (IQR 0.37-1.14).,Comparison of TSH Levels with Liquid Formulation Versus Tablet Formulations of Levothyroxine in the Treatment of Adult Hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24449674/),,1,2789,DB00030,Insulin Regular
,24449674,TSH2/TSH1 ratio,We observed a TSH reduction (TSH2/TSH1 ratio <1) in 36/53 (67.9%) of patients; the median TSH2/TSH1 ratio was 0.71 (IQR 0.37-1.14).,Comparison of TSH Levels with Liquid Formulation Versus Tablet Formulations of Levothyroxine in the Treatment of Adult Hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24449674/),,0.71,2790,DB00030,Insulin Regular
,24449674,ratios,"The median TSH2/TSH1 ratios were 0.50 (IQR 0.31-0.72) and 0.85 (IQR 0.65-1.36) for patients with and without interfering factors, respectively.",Comparison of TSH Levels with Liquid Formulation Versus Tablet Formulations of Levothyroxine in the Treatment of Adult Hypothyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24449674/),,0.50,2791,DB00030,Insulin Regular
,19464026,peak plasma concentration (C(max)),"In 9 evaluable subjects, plasma pramlintide concentrations increased dose-proportionately; mean peak plasma concentration (C(max)) (15-microg dose, 93 +/- 9 pg/mL; 30-microg dose, 202 +/- 21 pg/mL) occurred approximately 0.3 h (median time to peak concentration) after administration.","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),[pg] / [ml],93,2983,DB00030,Insulin Regular
,19464026,peak plasma concentration (C(max)),"In 9 evaluable subjects, plasma pramlintide concentrations increased dose-proportionately; mean peak plasma concentration (C(max)) (15-microg dose, 93 +/- 9 pg/mL; 30-microg dose, 202 +/- 21 pg/mL) occurred approximately 0.3 h (median time to peak concentration) after administration.","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),[pg] / [ml],202,2984,DB00030,Insulin Regular
,19464026,time to peak concentration,"In 9 evaluable subjects, plasma pramlintide concentrations increased dose-proportionately; mean peak plasma concentration (C(max)) (15-microg dose, 93 +/- 9 pg/mL; 30-microg dose, 202 +/- 21 pg/mL) occurred approximately 0.3 h (median time to peak concentration) after administration.","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),h,0.3,2985,DB00030,Insulin Regular
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),p,4,2986,DB00030,Insulin Regular
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),p,5,2987,DB00030,Insulin Regular
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),pg,35,2988,DB00030,Insulin Regular
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),mg,129,2989,DB00030,Insulin Regular
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),,132,2990,DB00030,Insulin Regular
,19464026,area under the concentration curve (AUC(0-3h)),"Pramlintide reduced incremental area under the concentration curve (AUC(0-3h)) for glucagon and glucose versus placebo (glucagon: 15-microg dose, 4 +/- 7 pg(*)h/mL; 30-microg dose, 5 +/- 7 pg(*)h/mL; placebo, 35 +/- 9 pg(*)h/mL; glucose: 15-microg dose, 129 +/- 43 mg(*)h/dL; 30-microg dose, 132 +/- 37 mg(*)h/dL; placebo, 217 +/- 56 mg(*)h/dL).","Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19464026/),mg,217,2991,DB00030,Insulin Regular
,16034718,Insulin-AUC (240-480),"Injection of 18 U of RI resulted in significantly higher insulin concentrations in smokers compared to non-smokers, in particular in the later part of the experiment (Insulin-AUC (240-480) 10.5 +/- 2.3 (mean +/- SD) vs. 7.8 +/- 1.6 microU/ml/min, p < 0.05).",Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16034718/),[μu] / [min·ml],10.5,3151,DB00030,Insulin Regular
,16034718,Insulin-AUC (240-480),"Injection of 18 U of RI resulted in significantly higher insulin concentrations in smokers compared to non-smokers, in particular in the later part of the experiment (Insulin-AUC (240-480) 10.5 +/- 2.3 (mean +/- SD) vs. 7.8 +/- 1.6 microU/ml/min, p < 0.05).",Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16034718/),[μu] / [min·ml],7.8,3152,DB00030,Insulin Regular
,16034718,AUC (240-480),"This was also reflected in the PD results with a higher metabolic effect in smokers in the last four hours of the experiment (GIR-AUC (240-480) 0.9 +/- 0.4 vs. 0.6 +/- 0.3 g/kg, p < 0.05).",Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16034718/),[g] / [kg],0.9,3153,DB00030,Insulin Regular
,16034718,AUC (240-480),"This was also reflected in the PD results with a higher metabolic effect in smokers in the last four hours of the experiment (GIR-AUC (240-480) 0.9 +/- 0.4 vs. 0.6 +/- 0.3 g/kg, p < 0.05).",Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16034718/),[g] / [kg],0.6,3154,DB00030,Insulin Regular
,16034718,clearance,"Pharmacokinetic analyses revealed a trend towards a lower insulin clearance in smokers (1.1 +/- 0.2 vs. 1.4 +/- 0.4 l/min, p = 0.08).",Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16034718/),[l] / [min],1.1,3155,DB00030,Insulin Regular
,16034718,clearance,"Pharmacokinetic analyses revealed a trend towards a lower insulin clearance in smokers (1.1 +/- 0.2 vs. 1.4 +/- 0.4 l/min, p = 0.08).",Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16034718/),[l] / [min],1.4,3156,DB00030,Insulin Regular
,32154052,pIC50,"Herein, we present a series of small non-peptide IRAP inhibitors derived from a spiro-oxindole dihydroquinazolinone screening hit (pIC50 5.8).","Synthesis, Evaluation and Proposed Binding Pose of Substituted Spiro-Oxindole Dihydroquinazolinones as IRAP Inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154052/),,5.8,3254,DB00030,Insulin Regular
,32154052,pIC50,A small improvement of potency (pIC50 6.6 for the most potent compound) and an increased solubility could be achieved.,"Synthesis, Evaluation and Proposed Binding Pose of Substituted Spiro-Oxindole Dihydroquinazolinones as IRAP Inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32154052/),,6.6,3255,DB00030,Insulin Regular
,30324757,relative bioavailabilities,"The relative bioavailabilities and pharmacodynamic availabilities were 39.9%, 25.6% for PS-loaded dry powders and 30.1%, 23% for PHT-loaded dry powders, respectively.","Evaluation of inhaled recombinant human insulin dry powders: pharmacokinetics, pharmacodynamics and 14-day inhalation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30324757/),%,39.9,3344,DB00030,Insulin Regular
,30324757,relative bioavailabilities,"The relative bioavailabilities and pharmacodynamic availabilities were 39.9%, 25.6% for PS-loaded dry powders and 30.1%, 23% for PHT-loaded dry powders, respectively.","Evaluation of inhaled recombinant human insulin dry powders: pharmacokinetics, pharmacodynamics and 14-day inhalation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30324757/),%,25.6,3345,DB00030,Insulin Regular
,30324757,relative bioavailabilities,"The relative bioavailabilities and pharmacodynamic availabilities were 39.9%, 25.6% for PS-loaded dry powders and 30.1%, 23% for PHT-loaded dry powders, respectively.","Evaluation of inhaled recombinant human insulin dry powders: pharmacokinetics, pharmacodynamics and 14-day inhalation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30324757/),%,30.1,3346,DB00030,Insulin Regular
,23485230,Maximal Tolerated Dose,The Maximal Tolerated Dose of AVE1642 was 12mg/kg.,"A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23485230/),[mg] / [kg],12,3671,DB00030,Insulin Regular
,18812476,half-life,Albiglutide half-life ranged between 6 and 7 d.,"Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812476/),d,6 and 7,3934,DB00030,Insulin Regular
,16256705,GET,"GET in healthy subjects was 134.7+/-21.6 min, the normal range was calculated from 88.3 to 181.1 min.",Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16256705/),min,134.7,4111,DB00030,Insulin Regular
,16256705,GET,The mean GET in all IDDM patients was significantly prolonged (178.2+/-28.1 min; P<0.001).,Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16256705/),min,178.2,4112,DB00030,Insulin Regular
,16256705,GET,"Mean GET values were 156.9+/-21.5 in group A (P=0.028) and 199.4+/-13.9 min in group B, respectively, suggesting that gastric motility is significantly different from non-diabetic controls even in patients with apparently normal gastric emptying.",Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16256705/),min,156.9,4113,DB00030,Insulin Regular
,16256705,GET,"Mean GET values were 156.9+/-21.5 in group A (P=0.028) and 199.4+/-13.9 min in group B, respectively, suggesting that gastric motility is significantly different from non-diabetic controls even in patients with apparently normal gastric emptying.",Gastric emptying in patients with insulin dependent diabetes mellitus and bioavailability of thioctic acid-enantiomers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16256705/),min,199.4,4114,DB00030,Insulin Regular
,16543910,AUC,"The AUC of glucose in rilmenidine group decreased from 860+/-93 to 737+/-66 mmol/min/l (P<0.05), and in the atenolol group it increased from 937+/-86 to 989+/-88 mmol/min/l (P<0.05).",How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16543910/),[mM] / [l·min],860,4542,DB00030,Insulin Regular
,16543910,AUC,"The AUC of glucose in rilmenidine group decreased from 860+/-93 to 737+/-66 mmol/min/l (P<0.05), and in the atenolol group it increased from 937+/-86 to 989+/-88 mmol/min/l (P<0.05).",How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16543910/),[mM] / [l·min],737,4543,DB00030,Insulin Regular
,16543910,AUC,"The AUC of glucose in rilmenidine group decreased from 860+/-93 to 737+/-66 mmol/min/l (P<0.05), and in the atenolol group it increased from 937+/-86 to 989+/-88 mmol/min/l (P<0.05).",How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16543910/),[mM] / [l·min],937,4544,DB00030,Insulin Regular
,16543910,AUC,"The AUC of glucose in rilmenidine group decreased from 860+/-93 to 737+/-66 mmol/min/l (P<0.05), and in the atenolol group it increased from 937+/-86 to 989+/-88 mmol/min/l (P<0.05).",How can we block sympathetic overactivity? Effects of rilmenidine and atenolol in overweight hypertensive patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16543910/),[mM] / [l·min],989,4545,DB00030,Insulin Regular
,26358287,Duration,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,9.4,4617,DB00030,Insulin Regular
,26358287,Duration,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,15.4,4618,DB00030,Insulin Regular
,26358287,Duration,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,11.8,4619,DB00030,Insulin Regular
,26358287,insulin action,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,9.4,4620,DB00030,Insulin Regular
,26358287,insulin action,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,15.4,4621,DB00030,Insulin Regular
,26358287,insulin action,Duration of NPH insulin action was shorter in R- up (9.4 ± 1.7 h) but longer in R- down (15.4 ± 2.3 h) compared with R+ (11.8 ± 2.6 h) (P < 0.05).,Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26358287/),h,11.8,4622,DB00030,Insulin Regular
,21491144,half-life,Clearance from the lung epithelial lining fluid (ELF) of FDKP and insulin have a half-life of ~1 hour.,Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491144/),h,1,5020,DB00030,Insulin Regular
,21491144,terminal clearance half-life,"The terminal clearance half-life from the lung ELF, estimated from sequential BAL fluid measurements for both components, was ~1 hour.",Insulin lung deposition and clearance following Technosphere® insulin inhalation powder administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21491144/),h,1,5021,DB00030,Insulin Regular
,26111539,maximal,No systemic adverse effects were observed at any dose with maximal CBX129801 plasma concentrations of 735 to 1050 nmol/L during the dosing period (physiological range is 1-3 nmol/L).,A 9-Month Toxicity and Toxicokinetic Assessment of Subcutaneous Pegylated Human C-peptide (CBX129801) in Cynomolgus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111539/),[nM] / [l],735 to 1050,5022,DB00030,Insulin Regular
,26111539,plasma concentrations,No systemic adverse effects were observed at any dose with maximal CBX129801 plasma concentrations of 735 to 1050 nmol/L during the dosing period (physiological range is 1-3 nmol/L).,A 9-Month Toxicity and Toxicokinetic Assessment of Subcutaneous Pegylated Human C-peptide (CBX129801) in Cynomolgus Monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111539/),[nM] / [l],735 to 1050,5023,DB00030,Insulin Regular
,24277680,AUC120 h,"The geometric mean [coefficient of variation (CV) %] AUC120 h values were 89,092 (16), 83,327 (15), 88,944 (23), and 79,846 (19) pmol·h/L for normal hepatic function and mild, moderate, and severe hepatic impairment, respectively.",Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277680/),[h·pM] / [l],"89,092",6409,DB00030,Insulin Regular
,24277680,AUC120 h,"The geometric mean [coefficient of variation (CV) %] AUC120 h values were 89,092 (16), 83,327 (15), 88,944 (23), and 79,846 (19) pmol·h/L for normal hepatic function and mild, moderate, and severe hepatic impairment, respectively.",Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277680/),[h·pM] / [l],"83,327",6410,DB00030,Insulin Regular
,24277680,AUC120 h,"The geometric mean [coefficient of variation (CV) %] AUC120 h values were 89,092 (16), 83,327 (15), 88,944 (23), and 79,846 (19) pmol·h/L for normal hepatic function and mild, moderate, and severe hepatic impairment, respectively.",Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277680/),[h·pM] / [l],"88,944",6411,DB00030,Insulin Regular
,24277680,AUC120 h,"The geometric mean [coefficient of variation (CV) %] AUC120 h values were 89,092 (16), 83,327 (15), 88,944 (23), and 79,846 (19) pmol·h/L for normal hepatic function and mild, moderate, and severe hepatic impairment, respectively.",Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24277680/),[h·pM] / [l],"79,846",6412,DB00030,Insulin Regular
,26770391,recoveries,Mean recoveries of angeloylgomisin H in rat plasma ranged from 86.2% to 92.5%.,Pharmacokinetic and bioavailability study of angeloylgomisin H in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770391/),%,86.2,6907,DB00030,Insulin Regular
,26770391,recoveries,Mean recoveries of angeloylgomisin H in rat plasma ranged from 86.2% to 92.5%.,Pharmacokinetic and bioavailability study of angeloylgomisin H in rat plasma by UPLC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770391/),%,92.5,6908,DB00030,Insulin Regular
,26770391,absolute bioavailability,The absolute bioavailability of angeloylgomisin H was reported as high as 4.9%.,Pharmacokinetic and bioavailability study of angeloylgomisin H in rat plasma by UPLC-MS/MS. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26770391/),%,4.9,6909,DB00030,Insulin Regular
,15696937,bioavailability,"As compared with subcutaneous injection, the relative pharmacological bioavailability was 17.02% calculated by area under the curve of glucose level versus time profile after oral administration of the insulin-liposomes double-coated by CH and CEC to rats.",[Studies on the insulin-liposomes double-coated by chitosan and chitosan-EDTA conjugates]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15696937/),%,17.02,7787,DB00030,Insulin Regular
,15696937,relative bioavailability,"As compared with subcutaneous injection, the relative bioavailability was 8.91% calculated by the area under the curve of serum insulin concentration versus time profile after oral administration of the insulin-liposomes double-coated by CH and CEC to rats.",[Studies on the insulin-liposomes double-coated by chitosan and chitosan-EDTA conjugates]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15696937/),%,8.91,7788,DB00030,Insulin Regular
,16821773,EC(50),"Several compounds, e.g., 6-chloro-3-(1-methyl-1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (1h), were found to be potent openers of Kir6.2/SUR1 K(ATP) channels and were able to suppress glucose-stimulated insulin release from rat islets in vitro (EC(50) = 0.04 +/- 0.01 muM) and in vivo after intravenous or peroral administration to hyperinsulinemic obese Zucker rats (ED(50) = 4.0 mg/kg).","New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821773/),muM,0.04,8133,DB00030,Insulin Regular
,16821773,ED(50),"Several compounds, e.g., 6-chloro-3-(1-methyl-1-phenylethyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (1h), were found to be potent openers of Kir6.2/SUR1 K(ATP) channels and were able to suppress glucose-stimulated insulin release from rat islets in vitro (EC(50) = 0.04 +/- 0.01 muM) and in vivo after intravenous or peroral administration to hyperinsulinemic obese Zucker rats (ED(50) = 4.0 mg/kg).","New 3-alkylamino-4H-thieno-1,2,4-thiadiazine 1,1-dioxide derivatives activate ATP-sensitive potassium channels of pancreatic beta cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16821773/),[mg] / [kg],4.0,8134,DB00030,Insulin Regular
,28185141,Onset of appearance,"Onset of appearance (~3 min), time to 50% of maximum concentration (t Early 50% Cmax; ~20 min) and time to maximum concentration (t max; ~55 min) were all similar between injection regions.",Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185141/),min,3,8291,DB00030,Insulin Regular
,28185141,time to 50% of maximum concentration (t Early 50% Cmax,"Onset of appearance (~3 min), time to 50% of maximum concentration (t Early 50% Cmax; ~20 min) and time to maximum concentration (t max; ~55 min) were all similar between injection regions.",Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185141/),min,20,8292,DB00030,Insulin Regular
,28185141,time to maximum concentration (t max,"Onset of appearance (~3 min), time to 50% of maximum concentration (t Early 50% Cmax; ~20 min) and time to maximum concentration (t max; ~55 min) were all similar between injection regions.",Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185141/),min,55,8293,DB00030,Insulin Regular
,28185141,absolute bioavailability,"Total exposure (AUCIAsp,0-t) was similar for the abdomen, upper arm and thigh, and absolute bioavailability was ~80% after subcutaneous administration of faster aspart in all three injection regions.",Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185141/),%,80,8294,DB00030,Insulin Regular
,30309736,h,The hypoglycemic time after single administration of PE on db/db mice was prolonged from 8.4 h to 54.9 h.,"C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30309736/),,54,8986,DB00030,Insulin Regular
,30309736,half-life,"When the in vivo single- and multiple-dose pharmacokinetics of PE were examined in Sprague-Dawley rats, the half-life was prolonged to 31.7 h, and no accumulation effect was observed.","C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30309736/),h,31.7,8987,DB00030,Insulin Regular
,31250754,encapsulation efficiency (EE),"Additionally, Formulation 3 (F3) has a particle size of 340.40 ± 2.39 nm with narrow uniformity exhibiting encapsulation efficiency (EE) of 72.78 ± 1.25 % produced highest absorption profile of insulin with a bioavailability of 40.23 ±1.29% and reduced blood glucose after its oral administration in rats.",Chitosan-Coated Alginate Nanoparticles Enhanced Absorption Profile of Insulin Via Oral Administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31250754/),%,72.78,9201,DB00030,Insulin Regular
,31250754,bioavailability,"Additionally, Formulation 3 (F3) has a particle size of 340.40 ± 2.39 nm with narrow uniformity exhibiting encapsulation efficiency (EE) of 72.78 ± 1.25 % produced highest absorption profile of insulin with a bioavailability of 40.23 ±1.29% and reduced blood glucose after its oral administration in rats.",Chitosan-Coated Alginate Nanoparticles Enhanced Absorption Profile of Insulin Via Oral Administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31250754/),%,40.23,9202,DB00030,Insulin Regular
,18234062,doubling time,"Three patients with ADPC had a greater than three-fold increase in PSA doubling time while on therapy, one from 11 to 46 months (750 mg), one from 9.5 to 49.5 months (1750 mg), and one from 5.9 to 46.2 months (2500 mg).",A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18234062/),month,11 to 46,9556,DB00030,Insulin Regular
,18234062,doubling time,"Three patients with ADPC had a greater than three-fold increase in PSA doubling time while on therapy, one from 11 to 46 months (750 mg), one from 9.5 to 49.5 months (1750 mg), and one from 5.9 to 46.2 months (2500 mg).",A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18234062/),month,9.5 to 49.5,9557,DB00030,Insulin Regular
,18234062,doubling time,"Three patients with ADPC had a greater than three-fold increase in PSA doubling time while on therapy, one from 11 to 46 months (750 mg), one from 9.5 to 49.5 months (1750 mg), and one from 5.9 to 46.2 months (2500 mg).",A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18234062/),month,5.9 to 46.2,9558,DB00030,Insulin Regular
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,5.7,9742,DB00030,Insulin Regular
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,12.1,9743,DB00030,Insulin Regular
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,19.9,9744,DB00030,Insulin Regular
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,22.7,9745,DB00030,Insulin Regular
,15855574,Duration of action,"Duration of action for insulin detemir was dose dependent and varied from 5.7, to 12.1, to 19.9, to 22.7, to 23.2 h for 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respectively.","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),h,23.2,9746,DB00030,Insulin Regular
,15855574,duration of action,"Interpolation of the dose-response relationships for AUC(GIR) (area under the glucose infusion rate curve) revealed that a detemir dose of 0.29 units/kg would provide the same effect as 0.3 IU/kg NPH but has a longer duration of action (16.9 vs. 12.7 h, respectively).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),,16.9,9747,DB00030,Insulin Regular
,15855574,duration of action,"Interpolation of the dose-response relationships for AUC(GIR) (area under the glucose infusion rate curve) revealed that a detemir dose of 0.29 units/kg would provide the same effect as 0.3 IU/kg NPH but has a longer duration of action (16.9 vs. 12.7 h, respectively).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),,12.7,9748,DB00030,Insulin Regular
,15855574,maximal glucose infusion rate,"Lower between-subject variability was observed for insulin detemir on duration of action (0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, P < 0.05) and GIR(max) (maximal glucose infusion rate) (0.2 and 0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, both P < 0.05).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),[units] / [kg],0.2,9749,DB00030,Insulin Regular
,15855574,maximal glucose infusion rate,"Lower between-subject variability was observed for insulin detemir on duration of action (0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, P < 0.05) and GIR(max) (maximal glucose infusion rate) (0.2 and 0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, both P < 0.05).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),[units] / [kg],0.4,9750,DB00030,Insulin Regular
,15855574,maximal glucose infusion rate,"Lower between-subject variability was observed for insulin detemir on duration of action (0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, P < 0.05) and GIR(max) (maximal glucose infusion rate) (0.2 and 0.4 units/kg insulin detemir vs. 0.3 IU/kg NPH, both P < 0.05).","A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),i,0.3,9751,DB00030,Insulin Regular
,15855574,area over the EGP curve,Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOC(EGP) (area over the EGP curve) of 636 mg/kg (95% CI 279-879) vs. 584 (323-846) and an AUC(PGU) (area under the PGU curve) of 173 (47-316) vs. 328 (39-617) for 0.29 units/kg detemir vs.,"A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),[mg] / [kg],636,9752,DB00030,Insulin Regular
,15855574,area over the EGP curve,Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOC(EGP) (area over the EGP curve) of 636 mg/kg (95% CI 279-879) vs. 584 (323-846) and an AUC(PGU) (area under the PGU curve) of 173 (47-316) vs. 328 (39-617) for 0.29 units/kg detemir vs.,"A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),[mg] / [kg],584,9753,DB00030,Insulin Regular
,15855574,AUC(P,Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOC(EGP) (area over the EGP curve) of 636 mg/kg (95% CI 279-879) vs. 584 (323-846) and an AUC(PGU) (area under the PGU curve) of 173 (47-316) vs. 328 (39-617) for 0.29 units/kg detemir vs.,"A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),,173,9754,DB00030,Insulin Regular
,15855574,AUC(P,Assessment of endogenous glucose production (EGP) and peripheral glucose uptake (PGU) resulted in an AOC(EGP) (area over the EGP curve) of 636 mg/kg (95% CI 279-879) vs. 584 (323-846) and an AUC(PGU) (area under the PGU curve) of 173 (47-316) vs. 328 (39-617) for 0.29 units/kg detemir vs.,"A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15855574/),,328,9755,DB00030,Insulin Regular
,21392075,terminal half-life,Median terminal half-life ranged from 18.5 to 29.6 days.,"Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392075/),d,18.5 to 29.6,10393,DB00030,Insulin Regular
,21392075,clearance (CL),"Population estimates for the clearance (CL), the central volume of distribution (V(1)), the inter-compartmental clearance (Q) and the peripheral volume of distribution (V(2)) were 0.364 l day(-1), 3.28 l, 0.588 l day(-1) and 4.97 l, respectively.","Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392075/),[l] / [day],0.364,10394,DB00030,Insulin Regular
,21392075,central volume of distribution (V(1)),"Population estimates for the clearance (CL), the central volume of distribution (V(1)), the inter-compartmental clearance (Q) and the peripheral volume of distribution (V(2)) were 0.364 l day(-1), 3.28 l, 0.588 l day(-1) and 4.97 l, respectively.","Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392075/),l,3.28,10395,DB00030,Insulin Regular
,21392075,central volume of distribution (V(1)),"Population estimates for the clearance (CL), the central volume of distribution (V(1)), the inter-compartmental clearance (Q) and the peripheral volume of distribution (V(2)) were 0.364 l day(-1), 3.28 l, 0.588 l day(-1) and 4.97 l, respectively.","Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392075/),[l] / [day],0.588,10396,DB00030,Insulin Regular
,21392075,inter-compartmental clearance (Q),"Population estimates for the clearance (CL), the central volume of distribution (V(1)), the inter-compartmental clearance (Q) and the peripheral volume of distribution (V(2)) were 0.364 l day(-1), 3.28 l, 0.588 l day(-1) and 4.97 l, respectively.","Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392075/),l,3.28,10397,DB00030,Insulin Regular
,21392075,inter-compartmental clearance (Q),"Population estimates for the clearance (CL), the central volume of distribution (V(1)), the inter-compartmental clearance (Q) and the peripheral volume of distribution (V(2)) were 0.364 l day(-1), 3.28 l, 0.588 l day(-1) and 4.97 l, respectively.","Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392075/),[l] / [day],0.588,10398,DB00030,Insulin Regular
,21392075,peripheral volume of distribution (V(2)),"Population estimates for the clearance (CL), the central volume of distribution (V(1)), the inter-compartmental clearance (Q) and the peripheral volume of distribution (V(2)) were 0.364 l day(-1), 3.28 l, 0.588 l day(-1) and 4.97 l, respectively.","Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21392075/),l,4.97,10399,DB00030,Insulin Regular
,11009049,time to maximum serum insulin concentration (tmax),"Furthermore, the time to maximum serum insulin concentration (tmax) of BIAsp30 was approximately half the tmax of BHI30 (60 [45-70] versus 110 [90-180] min [median, interquartile range]; P=0.0001) and the maximum insulin concentration (Cmax) was significantly higher for BIAsp30 than for BHI30 (23.4 +/- 5.3 versus 15.5 +/- 3.7 mU x l(-1) [mean +/- SD]; P < 0.0001).",Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009049/),min,60,10995,DB00030,Insulin Regular
,11009049,time to maximum serum insulin concentration (tmax),"Furthermore, the time to maximum serum insulin concentration (tmax) of BIAsp30 was approximately half the tmax of BHI30 (60 [45-70] versus 110 [90-180] min [median, interquartile range]; P=0.0001) and the maximum insulin concentration (Cmax) was significantly higher for BIAsp30 than for BHI30 (23.4 +/- 5.3 versus 15.5 +/- 3.7 mU x l(-1) [mean +/- SD]; P < 0.0001).",Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009049/),min,110,10996,DB00030,Insulin Regular
,11009049,maximum insulin concentration (Cmax),"Furthermore, the time to maximum serum insulin concentration (tmax) of BIAsp30 was approximately half the tmax of BHI30 (60 [45-70] versus 110 [90-180] min [median, interquartile range]; P=0.0001) and the maximum insulin concentration (Cmax) was significantly higher for BIAsp30 than for BHI30 (23.4 +/- 5.3 versus 15.5 +/- 3.7 mU x l(-1) [mean +/- SD]; P < 0.0001).",Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009049/),[mu] / [l],23.4,10997,DB00030,Insulin Regular
,11009049,maximum insulin concentration (Cmax),"Furthermore, the time to maximum serum insulin concentration (tmax) of BIAsp30 was approximately half the tmax of BHI30 (60 [45-70] versus 110 [90-180] min [median, interquartile range]; P=0.0001) and the maximum insulin concentration (Cmax) was significantly higher for BIAsp30 than for BHI30 (23.4 +/- 5.3 versus 15.5 +/- 3.7 mU x l(-1) [mean +/- SD]; P < 0.0001).",Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11009049/),[mu] / [l],15.5,10998,DB00030,Insulin Regular
,14977794,clearance of glucose,"The volume of distribution for the glucose and infused fluid and the plasma insulin levels were similar to the ones recorded in previous volunteer studies, but 50-70% lower values were obtained for the clearance of glucose (mean 0.21 litres min(-1)), endogenous glucose production (1.1 mmol min(-1)) and the elimination rate constant for the infused fluid (median 37 ml min(-1)).",Volume kinetics of glucose 2.5% solution during laparoscopic cholecystectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14977794/),[l] / [min],0.21,11239,DB00030,Insulin Regular
,14977794,elimination rate constant,"The volume of distribution for the glucose and infused fluid and the plasma insulin levels were similar to the ones recorded in previous volunteer studies, but 50-70% lower values were obtained for the clearance of glucose (mean 0.21 litres min(-1)), endogenous glucose production (1.1 mmol min(-1)) and the elimination rate constant for the infused fluid (median 37 ml min(-1)).",Volume kinetics of glucose 2.5% solution during laparoscopic cholecystectomy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14977794/),[ml] / [min],37,11240,DB00030,Insulin Regular
,27604836,thrombin time,"5rolGLP-HV shortened the length of thrombus in thrombosis mice (2.92 ± 0.74 vs. 5.92 ± 1.16 cm, p < 0.01) and extended the thrombin time (15.35 ± 1.22 vs. 8.67 ± 0.89 s, p < 0.01) of normal mice.",Pharmacological Effects and Pharmacokinetic Properties of a Dual-Function Peptide 5rolGLP-HV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27604836/),s,15.35,11904,DB00030,Insulin Regular
,27604836,thrombin time,"5rolGLP-HV shortened the length of thrombus in thrombosis mice (2.92 ± 0.74 vs. 5.92 ± 1.16 cm, p < 0.01) and extended the thrombin time (15.35 ± 1.22 vs. 8.67 ± 0.89 s, p < 0.01) of normal mice.",Pharmacological Effects and Pharmacokinetic Properties of a Dual-Function Peptide 5rolGLP-HV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27604836/),s,8.67,11905,DB00030,Insulin Regular
,17347858,peak responses,"In the patients plasma insulin (baseline, 15.9 +/- 3.9 microIU/ml) and C-peptide (baseline, 2.5 +/- 0.3 ng/ml) showed opposite changes with peak responses at 30 min (insulin, 109.5 +/- 15.6 microIU/ml) or 60 min (C-peptide, 10.3 +/- 1.1 ng/ml).",Plasma ghrelin response to an oral glucose load in growth hormone-deficient adults treated with growth hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17347858/),[μiu] / [ml],109.5,12847,DB00030,Insulin Regular
,17347858,peak responses,"In the patients plasma insulin (baseline, 15.9 +/- 3.9 microIU/ml) and C-peptide (baseline, 2.5 +/- 0.3 ng/ml) showed opposite changes with peak responses at 30 min (insulin, 109.5 +/- 15.6 microIU/ml) or 60 min (C-peptide, 10.3 +/- 1.1 ng/ml).",Plasma ghrelin response to an oral glucose load in growth hormone-deficient adults treated with growth hormone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17347858/),[ng] / [ml],10.3,12848,DB00030,Insulin Regular
,20150302,GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),,7.1,13577,DB00030,Insulin Regular
,20150302,GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),,3.9,13578,DB00030,Insulin Regular
,20150302,time to reach GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),min,116,13579,DB00030,Insulin Regular
,20150302,time to reach GIR(max),"RESULTS Mixing the two insulins shifted the time action curve to the right, with significantly lower glucose infusion rate (GIR) values after the mixed injections between 60 and 190 min and significantly higher values between 270 and 300 min, lowered the GIR(max) (separate 7.1 +/- 1 vs. mix 3.9 +/- 1, P = 0.03), and markedly delayed the time to reach GIR(max) (separate 116 +/- 8 min vs. mix 209 +/- 15 min, P = 0.004).",Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20150302/),min,209,13580,DB00030,Insulin Regular
,21177789,peak plasma concentration,"A clear dose-dependent pharmacodynamic response in circulating IGF-I levels was observed [from a predose mean (SD) IGF-I SD score of -3.2 (1.7) to peak plasma concentration of -0.5 (1.3), 1.6 (1.3), 2.1 (0.5), and 4.4 (0.9) in the four dose groups, respectively].","Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177789/),,-0.5,14044,DB00030,Insulin Regular
,21177789,peak plasma concentration,"A clear dose-dependent pharmacodynamic response in circulating IGF-I levels was observed [from a predose mean (SD) IGF-I SD score of -3.2 (1.7) to peak plasma concentration of -0.5 (1.3), 1.6 (1.3), 2.1 (0.5), and 4.4 (0.9) in the four dose groups, respectively].","Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177789/),,1.6,14045,DB00030,Insulin Regular
,21177789,peak plasma concentration,"A clear dose-dependent pharmacodynamic response in circulating IGF-I levels was observed [from a predose mean (SD) IGF-I SD score of -3.2 (1.7) to peak plasma concentration of -0.5 (1.3), 1.6 (1.3), 2.1 (0.5), and 4.4 (0.9) in the four dose groups, respectively].","Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177789/),,2.1,14046,DB00030,Insulin Regular
,21177789,peak plasma concentration,"A clear dose-dependent pharmacodynamic response in circulating IGF-I levels was observed [from a predose mean (SD) IGF-I SD score of -3.2 (1.7) to peak plasma concentration of -0.5 (1.3), 1.6 (1.3), 2.1 (0.5), and 4.4 (0.9) in the four dose groups, respectively].","Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177789/),,4.4,14047,DB00030,Insulin Regular
,31479925,elimination half-lives,The results show that exenatide and [Gln28]exenatide injected intravenously or subcutaneously at 10 μg/kg have nearly identical pharmacokinetics in the cat-both having elimination half-lives of ∼40 min-but subcutaneously administered [Gln28]exenatide has superior bioavailability-93% for [Gln28]exenatide vs 52% for exenatide.,A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),min,∼40,14392,DB00030,Insulin Regular
,31479925,bioavailability,The results show that exenatide and [Gln28]exenatide injected intravenously or subcutaneously at 10 μg/kg have nearly identical pharmacokinetics in the cat-both having elimination half-lives of ∼40 min-but subcutaneously administered [Gln28]exenatide has superior bioavailability-93% for [Gln28]exenatide vs 52% for exenatide.,A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),%,93,14393,DB00030,Insulin Regular
,31479925,bioavailability,The results show that exenatide and [Gln28]exenatide injected intravenously or subcutaneously at 10 μg/kg have nearly identical pharmacokinetics in the cat-both having elimination half-lives of ∼40 min-but subcutaneously administered [Gln28]exenatide has superior bioavailability-93% for [Gln28]exenatide vs 52% for exenatide.,A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),%,52,14394,DB00030,Insulin Regular
,31479925,half-life,"Finally, subcutaneous injection of a microsphere-[Gln28]exenatide conjugate containing an appropriate self-cleaving linker in the cat provides plasma [Gln28]exenatide with a half-life of about 40 d vs 40 min with the injected free peptide.",A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),d,40,14395,DB00030,Insulin Regular
,31479925,half-life,"Finally, subcutaneous injection of a microsphere-[Gln28]exenatide conjugate containing an appropriate self-cleaving linker in the cat provides plasma [Gln28]exenatide with a half-life of about 40 d vs 40 min with the injected free peptide.",A once-monthly GLP-1 receptor agonist for treatment of diabetic cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31479925/),min,40,14396,DB00030,Insulin Regular
,16472054,relative bioavailability,The relative bioavailability of intranasal insulin compared with subcutaneous insulin was 16.6-19.8% over 2 h and 14.0-19.8% over 5 h.,Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16472054/),%,16.6-19.8,14434,DB00030,Insulin Regular
,16472054,relative bioavailability,The relative bioavailability of intranasal insulin compared with subcutaneous insulin was 16.6-19.8% over 2 h and 14.0-19.8% over 5 h.,Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16472054/),%,14.0-19.8,14435,DB00030,Insulin Regular
,22727067,relative bioavailability,The relative bioavailability of the test formulation was estimated to be 102.1% (13.5%).,"Relative fasting bioavailability of two formulations of nateglinide 60 mg in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22727067/),%,102.1,14459,DB00030,Insulin Regular
,11251329,plasma anti-factor Xa levels,"The plasma anti-factor Xa levels in the 6 healthy volunteers who received a microenema containing 25,000 U of LMWH with 20 mg/ml of Sch were 0.38 U/ml at 15 min and 0.1 U/ml at 240 min.",Intestinal absorption of low molecular weight heparin in animals and human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11251329/),[u] / [ml],0.38,14587,DB00030,Insulin Regular
,11251329,plasma anti-factor Xa levels,"The plasma anti-factor Xa levels in the 6 healthy volunteers who received a microenema containing 25,000 U of LMWH with 20 mg/ml of Sch were 0.38 U/ml at 15 min and 0.1 U/ml at 240 min.",Intestinal absorption of low molecular weight heparin in animals and human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11251329/),[u] / [ml],0.1,14588,DB00030,Insulin Regular
,11136293,first-order elimination (Ke,"A one-compartment linear model was constructed which consisted of two absorption processes, characterized by KIR and KSR, rate constants for immediate-release and sustained-release, respectively, with first-order elimination (Ke; 1.05 h-1).",Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136293/),1/[h],1.05,14673,DB00030,Insulin Regular
,11136293,first-order absorption (KIR,"The surface, unencapsulated drug was immediately absorbed into the central compartment with first-order absorption (KIR; 0.0312 h-1), while the microencapsulated drug was first released in a zero-order fashion into a depot before being absorbed into the central compartment with first-order absorption (KSR; 0.00469 h-1) during a period of tau (1680 h).",Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136293/),1/[h],0.0312,14674,DB00030,Insulin Regular
,11136293,first-order absorption (KSR,"The surface, unencapsulated drug was immediately absorbed into the central compartment with first-order absorption (KIR; 0.0312 h-1), while the microencapsulated drug was first released in a zero-order fashion into a depot before being absorbed into the central compartment with first-order absorption (KSR; 0.00469 h-1) during a period of tau (1680 h).",Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11136293/),1/[h],0.00469,14675,DB00030,Insulin Regular
,15060505,peak difference,"Ephedrine plus caffeine increased systolic blood pressure (peak difference, 11.7 +/- 9.4 mm Hg; compared with placebo, P =.0005) and heart rate (peak difference, 5.9 +/- 8.8 beats/min; compared with placebo, P =.001) and raised fasting glucose, insulin, free fatty acid, and lactate concentrations.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),hg·mm,11.7,14939,DB00030,Insulin Regular
,15060505,peak difference,"Ephedrine plus caffeine increased systolic blood pressure (peak difference, 11.7 +/- 9.4 mm Hg; compared with placebo, P =.0005) and heart rate (peak difference, 5.9 +/- 8.8 beats/min; compared with placebo, P =.001) and raised fasting glucose, insulin, free fatty acid, and lactate concentrations.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),[beats] / [min],5.9,14940,DB00030,Insulin Regular
,15060505,elimination half-life,"Women taking oral contraceptives had prolonged caffeine elimination (mean elimination half-life, 9.7 hours versus 5.0 hours in men; P =.05), but sex differences in pharmacodynamic responses were not seen.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),h,9.7,14941,DB00030,Insulin Regular
,15060505,elimination half-life,"Women taking oral contraceptives had prolonged caffeine elimination (mean elimination half-life, 9.7 hours versus 5.0 hours in men; P =.05), but sex differences in pharmacodynamic responses were not seen.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),h,5.0,14942,DB00030,Insulin Regular
,27169293,half-life (t½,"However, native GLP-1 is not suitable for treatment of diabetes due to its short half-life (t½, 2-5 min).",[Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169293/),min,2-5,15581,DB00030,Insulin Regular
up to,27169293,t½,"Exendin-4 is a polypeptide isolated from lizard saliva, which can bind to GLP-1 receptor, produce physiological effects similar to GLP-1, t½ up to 2.5 h, therefore, we developed a long-lasting GLP-1 receptor agonists and GLP-1-exendin-4 fusion IgG4 Fc [GLP-1-exendin-4/ IgG4(Fc)].",[Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169293/),h,2.5,15582,DB00030,Insulin Regular
,27169293,biological half-life,"Natural biological half-life of exendin-4 was (1.39 ± 0.28) h, GLP-1 in vivo t½ 4 min, indicating that fusion protein has long-lasting effects on the modulation of glucose homeostasis.",[Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169293/),h,1.39,15583,DB00030,Insulin Regular
,27169293,t½,"Natural biological half-life of exendin-4 was (1.39 ± 0.28) h, GLP-1 in vivo t½ 4 min, indicating that fusion protein has long-lasting effects on the modulation of glucose homeostasis.",[Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27169293/),min,4,15584,DB00030,Insulin Regular
,31493626,growth velocity,"At end of study or the 12th month treatment, the means growth velocity was 9.7 cm/year and 9.5 cm/year, for r-hGH Cristalia and Genotropin™, respectively.","Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): A randomized, multicentric, investigator-blind, phase 3 trial. ",Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31493626/),[cm] / [year],9.7,16233,DB00030,Insulin Regular
,31493626,growth velocity,"At end of study or the 12th month treatment, the means growth velocity was 9.7 cm/year and 9.5 cm/year, for r-hGH Cristalia and Genotropin™, respectively.","Efficacy and safety of a biosimilar recombinant human growth hormone (r-hGH Cristalia) compared with reference r-hGH in children with growth hormone deficiency (CERES study): A randomized, multicentric, investigator-blind, phase 3 trial. ",Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31493626/),[cm] / [year],9.5,16234,DB00030,Insulin Regular
,22659626,k(a),"Exenatide exhibited rapid absorption with k(a)=4.45 h(-1), and the two-compartment model well described its pharmacokinetic profile.",Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),1/[h],4.45,16437,DB00030,Insulin Regular
,22659626,S(m1),"For the pharmacodynamic model, exenatide increased insulin release with the estimated S(m1) of 0.822 and SC(50) of 4.02 μg/L.",Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),,0.822,16438,DB00030,Insulin Regular
,22659626,SC(50),"For the pharmacodynamic model, exenatide increased insulin release with the estimated S(m1) of 0.822 and SC(50) of 4.02 μg/L.",Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),[μg] / [l],4.02,16439,DB00030,Insulin Regular
,22659626,S(m2),It was demonstrated that insulin stimulated glucose dissipation (S(m2)=0.0513) and inhibited the production of glucose (I(m)=0.0381).,Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),,0.0513,16440,DB00030,Insulin Regular
,22659626,I(m),It was demonstrated that insulin stimulated glucose dissipation (S(m2)=0.0513) and inhibited the production of glucose (I(m)=0.0381).,Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22659626/),,0.0381,16441,DB00030,Insulin Regular
,27407018,apparent clearance (CL/F),"Mean population apparent clearance (CL/F) was 68.1 L/h, and mean apparent volume of distribution (V/F) was 28.8 L.",Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27407018/),[l] / [h],68.1,16983,DB00030,Insulin Regular
,27407018,apparent volume of distribution (V/F),"Mean population apparent clearance (CL/F) was 68.1 L/h, and mean apparent volume of distribution (V/F) was 28.8 L.",Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27407018/),l,28.8,16984,DB00030,Insulin Regular
,23782587,maximum inhibition,The percentage of DPP-4 inhibition by vildagliptin remained unchanged when vildagliptin was given alone or co-administered with voglibose; maximum inhibition was 98.3 ± 1.4% (mean ± SD) for vildagliptin alone and 97.4 ± 1.1% with co-administration.,Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782587/),%,98.3,17286,DB00030,Insulin Regular
,23782587,maximum inhibition,The percentage of DPP-4 inhibition by vildagliptin remained unchanged when vildagliptin was given alone or co-administered with voglibose; maximum inhibition was 98.3 ± 1.4% (mean ± SD) for vildagliptin alone and 97.4 ± 1.1% with co-administration.,Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782587/),%,97.4,17287,DB00030,Insulin Regular
,11194533,lipemia,"The magnitude of postprandial lipemia (the area bounded by the curve above the fasting concentration) after ingestion of 44 g-DG emulsion was significantly less than that of 44 g-TG emulsion (6.54 +/- 5.12 and 8.45 +/- 7.54 mmol x h/L, mean +/- SD, respectively).",Double-blind controlled study on the effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol responses in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194533/),,6,18217,DB00030,Insulin Regular
,11194533,lipemia,"The magnitude of postprandial lipemia (the area bounded by the curve above the fasting concentration) after ingestion of 44 g-DG emulsion was significantly less than that of 44 g-TG emulsion (6.54 +/- 5.12 and 8.45 +/- 7.54 mmol x h/L, mean +/- SD, respectively).",Double-blind controlled study on the effects of dietary diacylglycerol on postprandial serum and chylomicron triacylglycerol responses in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194533/),,8,18218,DB00030,Insulin Regular
,25963320,half-life,"Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties compared to insulin glargine (IGlar) including a long half-life of ∼25 h and a duration of action >42 h at steady state, providing a flat and stable blood glucose-lowering effect when injected once daily.",Clinical use of insulin degludec. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963320/),h,∼25,18668,DB00030,Insulin Regular
>,25963320,duration of action,"Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties compared to insulin glargine (IGlar) including a long half-life of ∼25 h and a duration of action >42 h at steady state, providing a flat and stable blood glucose-lowering effect when injected once daily.",Clinical use of insulin degludec. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963320/),h,42,18669,DB00030,Insulin Regular
,31093929,half-life,The mean half-life was ~ 55 h independent of the post-dose fasting period.,The Effect of Food Intake on the Pharmacokinetics of Oral Basal Insulin: A Randomised Crossover Trial in Healthy Male Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31093929/),h,55,19164,DB00030,Insulin Regular
,11327477,T1/2glucose,"Reference values for T1/2glucose, Kglucose, and fasting plasma glucose and insulin concentrations during GTT were 45 to 74 minutes, 0.93 to 1.54 %/min, 37 to 104 mg/dl, and 2.8 to 20.6 microU/ml, respectively.","Determination of reference values for glucose tolerance, insulin tolerance, and insulin sensitivity tests in clinically normal cats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327477/),min,45 to 74,19271,DB00030,Insulin Regular
,11327477,Kglucose,"Reference values for T1/2glucose, Kglucose, and fasting plasma glucose and insulin concentrations during GTT were 45 to 74 minutes, 0.93 to 1.54 %/min, 37 to 104 mg/dl, and 2.8 to 20.6 microU/ml, respectively.","Determination of reference values for glucose tolerance, insulin tolerance, and insulin sensitivity tests in clinically normal cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327477/),[%] / [min],0.93 to 1.54,19272,DB00030,Insulin Regular
,11327477,Kglucose,"Reference values for T1/2glucose, Kglucose, and fasting plasma glucose and insulin concentrations during GTT were 45 to 74 minutes, 0.93 to 1.54 %/min, 37 to 104 mg/dl, and 2.8 to 20.6 microU/ml, respectively.","Determination of reference values for glucose tolerance, insulin tolerance, and insulin sensitivity tests in clinically normal cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327477/),[μu] / [ml],2.8 to 20.6,19273,DB00030,Insulin Regular
,11327477,Kitt,"Reference values for Kitt were 1.14 to 7.3%/min, and for SI were 0.57 to 10.99 x 10(4) min/microU/ml.","Determination of reference values for glucose tolerance, insulin tolerance, and insulin sensitivity tests in clinically normal cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327477/),[%] / [min],1.14 to 7.3,19274,DB00030,Insulin Regular
,11327477,SI,"Reference values for Kitt were 1.14 to 7.3%/min, and for SI were 0.57 to 10.99 x 10(4) min/microU/ml.","Determination of reference values for glucose tolerance, insulin tolerance, and insulin sensitivity tests in clinically normal cats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11327477/),[min] / [ml·μu],0.57 to 10.99 x 10(4),19275,DB00030,Insulin Regular
,12561948,half-life,In case of the niosomal form the half-life of insulin was prolonged by 4 -5 hr in contrast to 2 hr for free drug.,Pharmacokinetic study of niosome encapsulated insulin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12561948/),h,4 -5,19365,DB00030,Insulin Regular
,12561948,half-life,In case of the niosomal form the half-life of insulin was prolonged by 4 -5 hr in contrast to 2 hr for free drug.,Pharmacokinetic study of niosome encapsulated insulin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12561948/),h,2,19366,DB00030,Insulin Regular
,12561948,area under the plasma concentration-time curve,"The area under the plasma concentration-time curve for niosomal forms was, 26.07 degrees +/- 0.99 mIU.",Pharmacokinetic study of niosome encapsulated insulin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12561948/),miu,26.07,19367,DB00030,Insulin Regular
,23392128,AUC glucose level,"Compared with a healthy normal control group, GS patients showed a higher AUC glucose level [16.1 (IQR 12.5-25.4 mEq · h/l) vs. 13.0 (IQR 11.9-13.7 mEq · h/l); p < 0.05] and AUC insulin level [81.0 (IQR 58.9-138 µU · h/ml) vs. 46.4 (IQR 35.6-63.3 µU · h/ml); p < 0.01].",Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23392128/),[h·meq] / [l],16.1,19717,DB00030,Insulin Regular
,23392128,AUC glucose level,"Compared with a healthy normal control group, GS patients showed a higher AUC glucose level [16.1 (IQR 12.5-25.4 mEq · h/l) vs. 13.0 (IQR 11.9-13.7 mEq · h/l); p < 0.05] and AUC insulin level [81.0 (IQR 58.9-138 µU · h/ml) vs. 46.4 (IQR 35.6-63.3 µU · h/ml); p < 0.01].",Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23392128/),[h·meq] / [l],13.0,19718,DB00030,Insulin Regular
,23392128,AUC insulin level,"Compared with a healthy normal control group, GS patients showed a higher AUC glucose level [16.1 (IQR 12.5-25.4 mEq · h/l) vs. 13.0 (IQR 11.9-13.7 mEq · h/l); p < 0.05] and AUC insulin level [81.0 (IQR 58.9-138 µU · h/ml) vs. 46.4 (IQR 35.6-63.3 µU · h/ml); p < 0.01].",Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23392128/),[h·µu] / [ml],81.0,19719,DB00030,Insulin Regular
,23392128,AUC insulin level,"Compared with a healthy normal control group, GS patients showed a higher AUC glucose level [16.1 (IQR 12.5-25.4 mEq · h/l) vs. 13.0 (IQR 11.9-13.7 mEq · h/l); p < 0.05] and AUC insulin level [81.0 (IQR 58.9-138 µU · h/ml) vs. 46.4 (IQR 35.6-63.3 µU · h/ml); p < 0.01].",Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23392128/),[h·µu] / [ml],46.4,19720,DB00030,Insulin Regular
,18342586,flow rate,"All analytes including the internal standard (Repaglinide) were chromatographed on reverse phase C(18) column (50 mm x 4.6mm i.d., 5 microm) using acetonitrile: 2mM ammonium acetate buffer, pH 3.4 (90:10, v/v) as mobile phase at a flow rate 0.4 ml/min in an isocratic mode.","Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18342586/),[ml] / [min],0.4,20739,DB00030,Insulin Regular
>,18342586,recoveries,The recoveries from spiked control samples were >79% for all analytes and internal standard.,"Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18342586/),%,79,20740,DB00030,Insulin Regular
,25613938,half-life,"Serum bevacizumab was detected 2 days after the injection, peaked at 14 days, and persisted for up to 60 days with half-life of 21 days.",Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25613938/),d,21,20878,DB00030,Insulin Regular
<,24195794,t(1/2),"Despite the potential therapeutic usage for type 2 diabetes (T2D), GLP-1 has a short half-life in vivo (t(1/2) <2 min).",Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24195794/),min,2,21659,DB00030,Insulin Regular
,21270106,area under the time-concentration curve (AUC) from zero to infinity,"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[h·ng] / [ml],72.4,21994,DB00030,Insulin Regular
,21270106,area under the time-concentration curve (AUC) from zero to infinity,"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[h·ng] / [ml],97.2,21995,DB00030,Insulin Regular
,21270106,area under the time-concentration curve (AUC) from zero to infinity,"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[h·ng] / [ml],105.9,21996,DB00030,Insulin Regular
,21270106,maximal concentration (C(max)),"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[ng] / [ml],38.5,21997,DB00030,Insulin Regular
,21270106,maximal concentration (C(max)),"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[ng] / [ml],50.3,21998,DB00030,Insulin Regular
,21270106,maximal concentration (C(max)),"Considering only the effect of CYP2C8*3, the mean (95% confidence interval) area under the time-concentration curve (AUC) from zero to infinity of repaglinide was 72.4 (6.7-138.0), 97.2 (59.2-135.2), and 105.9 (52.4-159.3) ng · ml(-1) · h and the maximal concentration (C(max)) was 38.5 (3.8-73.2), 50.3 (37.5-63.0), and 60.3 (31.5-89.1) ng · ml(-1), respectively, in carriers of CYP2C8*3/*3, CYP2C8*1/*3, and CYP2C8*1/*1 [p > 0.05, one-way analysis of variance (ANOVA)].",Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21270106/),[ng] / [ml],60.3,21999,DB00030,Insulin Regular
,12174030,half-life,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),h,2.2,22137,DB00030,Insulin Regular
,12174030,clearance,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[ml] / [min],575,22138,DB00030,Insulin Regular
,12174030,volume of distribution,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),l,106,22139,DB00030,Insulin Regular
,12174030,concentration producing the half-maximum effect,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[ng] / [ml],1.5,22140,DB00030,Insulin Regular
,12174030,Hill-coefficient,"There were no significant differences in methylprednisolone half-life (2.2 +/- 0.4 h), clearance (575 +/- 113 mL/min), volume of distribution (106 +/- 22 l), concentration producing the half-maximum effect on CD4+ T-cells (1.5 +/- 0.7 ng/mL), and Hill-coefficient (1.2 +/- 0.1), after single or divided dose.",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),,1.2,22141,DB00030,Insulin Regular
,12174030,total 24 h effect area (AUETC),"However, the total 24 h effect area (AUETC) of lymphocytes, and mainly CD4+ T-cells was significantly more suppressed (P = 0.008) with the divided dosage regimen than after the single dose (8422 +/- 2163 vs. 11,545 +/- 3020 h cells/microL).",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[cells·h] / [μl],8422,22142,DB00030,Insulin Regular
,12174030,total 24 h effect area (AUETC),"However, the total 24 h effect area (AUETC) of lymphocytes, and mainly CD4+ T-cells was significantly more suppressed (P = 0.008) with the divided dosage regimen than after the single dose (8422 +/- 2163 vs. 11,545 +/- 3020 h cells/microL).",Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12174030/),[cells·h] / [μl],"11,545",22143,DB00030,Insulin Regular
,29577579,half-life,The estimated half-life of Fc-apelin-13 in blood was approximately 33 hours.,Hepatic and cardiac beneficial effects of a long-acting Fc-apelin fusion protein in diet-induced obese mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29577579/),h,33,22691,DB00030,Insulin Regular
,22484334,EC (50),"In transient transactivation assay in NIH3T3 cells, NS-1 showed a partial activation against human PPARγ with an EC (50) of 0.91 μM without activating human PPARα and PPARδ.",NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22484334/),μM,0.91,22957,DB00030,Insulin Regular
,22484334,Cmax,"NS-1 showed good in vivo pharmacokinetic profiles in C57BL/6J mice at 30 mg/kg oral dose with Cmax-26 μM, terminal elimination half-life- 2.5h and bioavailability of 85%.",NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22484334/),μM,26,22958,DB00030,Insulin Regular
,22484334,terminal elimination half-life,"NS-1 showed good in vivo pharmacokinetic profiles in C57BL/6J mice at 30 mg/kg oral dose with Cmax-26 μM, terminal elimination half-life- 2.5h and bioavailability of 85%.",NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22484334/),h,2.5,22959,DB00030,Insulin Regular
,22484334,bioavailability,"NS-1 showed good in vivo pharmacokinetic profiles in C57BL/6J mice at 30 mg/kg oral dose with Cmax-26 μM, terminal elimination half-life- 2.5h and bioavailability of 85%.",NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22484334/),%,85,22960,DB00030,Insulin Regular
,25639649,separation time,"The achieved separation time was 125 s when using a capillary with an effective length of 14.7 cm, electric field intensity of 0.96 kV/cm and simultaneous application of a hydrodynamic pressure of 50 mbar.",Rapid determination of branched chain amino acids in human blood plasma by pressure-assisted capillary electrophoresis with contactless conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639649/),s,125,22961,DB00030,Insulin Regular
,25639649,separation efficiency,"The separation efficiency in blood plasma equalled 461 000 theoretical plates/m for valine and isoleucine, and 455 000 theoretical plates/m for leucine; the detection limits are equal to 0.4 μM for all three amino acids.",Rapid determination of branched chain amino acids in human blood plasma by pressure-assisted capillary electrophoresis with contactless conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639649/),[plates·theoretical] / [m],461 000,22962,DB00030,Insulin Regular
,25639649,separation efficiency,"The separation efficiency in blood plasma equalled 461 000 theoretical plates/m for valine and isoleucine, and 455 000 theoretical plates/m for leucine; the detection limits are equal to 0.4 μM for all three amino acids.",Rapid determination of branched chain amino acids in human blood plasma by pressure-assisted capillary electrophoresis with contactless conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639649/),[plates·theoretical] / [m],455 000,22963,DB00030,Insulin Regular
,25639649,detection limits,"The separation efficiency in blood plasma equalled 461 000 theoretical plates/m for valine and isoleucine, and 455 000 theoretical plates/m for leucine; the detection limits are equal to 0.4 μM for all three amino acids.",Rapid determination of branched chain amino acids in human blood plasma by pressure-assisted capillary electrophoresis with contactless conductivity detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25639649/),μM,0.4,22964,DB00030,Insulin Regular
,20147616,terminal half-life,Dose-dependent accumulation of otelixizumab was demonstrated and modeling of the data indicated that the terminal half-life was approximately 1.5 days.,Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of type 1 diabetes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20147616/),d,1.5,23173,DB00030,Insulin Regular
,25358450,Plasma clearance,"Plasma clearance and its interindividual variability [% coefficient of variation (CV)] was estimated to be 1,060 L/h (33.6 %).",Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358450/),[l] / [h],"1,060",23463,DB00030,Insulin Regular
,25358450,Volume of distribution,Volume of distribution was calculated to be 200 L (17.7 %).,Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25358450/),l,200,23464,DB00030,Insulin Regular
,27274195,elimination half-life,Geometric mean elimination half-life ranged from 4.48 to 7.51 hours and apparent clearance ranged from 11.5 to 13.1 L/h across all doses.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27274195/),h,4.48 to 7.51,24058,DB00030,Insulin Regular
,27274195,apparent clearance,Geometric mean elimination half-life ranged from 4.48 to 7.51 hours and apparent clearance ranged from 11.5 to 13.1 L/h across all doses.,"Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27274195/),[l] / [h],11.5 to 13.1,24059,DB00030,Insulin Regular
,15209771,time to maximum glucose infusion rate,"Following inhalation, the time to maximum glucose infusion rate occurred an average of 70 min earlier than with s.c. insulin: 187, 129, 161 and 162 min vs. 227, 241 and 241 min (P < 0.0001).",Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15209771/),min,187,25435,DB00030,Insulin Regular
,15209771,time to maximum glucose infusion rate,"Following inhalation, the time to maximum glucose infusion rate occurred an average of 70 min earlier than with s.c. insulin: 187, 129, 161 and 162 min vs. 227, 241 and 241 min (P < 0.0001).",Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15209771/),min,129,25436,DB00030,Insulin Regular
,15209771,time to maximum glucose infusion rate,"Following inhalation, the time to maximum glucose infusion rate occurred an average of 70 min earlier than with s.c. insulin: 187, 129, 161 and 162 min vs. 227, 241 and 241 min (P < 0.0001).",Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15209771/),min,161,25437,DB00030,Insulin Regular
,15209771,time to maximum glucose infusion rate,"Following inhalation, the time to maximum glucose infusion rate occurred an average of 70 min earlier than with s.c. insulin: 187, 129, 161 and 162 min vs. 227, 241 and 241 min (P < 0.0001).",Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15209771/),min,162,25438,DB00030,Insulin Regular
,15209771,time to maximum glucose infusion rate,"Following inhalation, the time to maximum glucose infusion rate occurred an average of 70 min earlier than with s.c. insulin: 187, 129, 161 and 162 min vs. 227, 241 and 241 min (P < 0.0001).",Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15209771/),min,227,25439,DB00030,Insulin Regular
,15209771,time to maximum glucose infusion rate,"Following inhalation, the time to maximum glucose infusion rate occurred an average of 70 min earlier than with s.c. insulin: 187, 129, 161 and 162 min vs. 227, 241 and 241 min (P < 0.0001).",Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15209771/),min,241,25440,DB00030,Insulin Regular
,15209771,Relative bioavailability,"Relative bioavailability (based on serum insulin levels) ranged from 11.5 to 12.2% for the four doses of inhaled insulin and relative biopotency (based on glucose infusion rates) was 10.0 to 16.5%, respectively.",Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15209771/),%,11.5 to 12.2,25441,DB00030,Insulin Regular
,15209771,relative biopotency,"Relative bioavailability (based on serum insulin levels) ranged from 11.5 to 12.2% for the four doses of inhaled insulin and relative biopotency (based on glucose infusion rates) was 10.0 to 16.5%, respectively.",Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15209771/),%,10.0,25442,DB00030,Insulin Regular
,15209771,relative biopotency,"Relative bioavailability (based on serum insulin levels) ranged from 11.5 to 12.2% for the four doses of inhaled insulin and relative biopotency (based on glucose infusion rates) was 10.0 to 16.5%, respectively.",Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15209771/),%,16.5,25443,DB00030,Insulin Regular
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],87,25579,DB00030,Insulin Regular
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],900,25580,DB00030,Insulin Regular
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],"164,000",25581,DB00030,Insulin Regular
,27185573,area under the curve from zero to infinity [AUC0-∞]),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[h·mg] / [ml],"186,000",25582,DB00030,Insulin Regular
,27185573,maximum serum concentration (Cmax),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],392,25583,DB00030,Insulin Regular
,27185573,maximum serum concentration (Cmax),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],643,25584,DB00030,Insulin Regular
,27185573,maximum serum concentration (Cmax),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],870,25585,DB00030,Insulin Regular
,27185573,serum trough concentration (Ctrough),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],67.1,25586,DB00030,Insulin Regular
,27185573,serum trough concentration (Ctrough),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],71.6,25587,DB00030,Insulin Regular
,27185573,serum trough concentration (Ctrough),"Pharmacokinetic data showed dose-dependent increases in exposure (area under the curve from zero to infinity [AUC0-∞]) (87,900, 164,000, and 186,000 h*mg/ml for the 900, 1200, and 1500 mg/m(2) dose levels, respectively), maximum serum concentration (Cmax) (392, 643, and 870 mg/ml), and serum trough concentration (Ctrough) (67.1, 71.6, and 101 mg/ml).",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),[mg] / [ml],101,25588,DB00030,Insulin Regular
,27185573,half-life,"The mean half-life was 265, 394, and 310 h, respectively.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),h,265,25589,DB00030,Insulin Regular
,27185573,half-life,"The mean half-life was 265, 394, and 310 h, respectively.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),h,394,25590,DB00030,Insulin Regular
,27185573,half-life,"The mean half-life was 265, 394, and 310 h, respectively.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),h,310,25591,DB00030,Insulin Regular
,27185573,Time to response,"Time to response was 41 d, and progression occurred at 126 d.",Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27185573/),d,41,25592,DB00030,Insulin Regular
,30565407,AUCins,"BCLIS also demonstrated significantly higher early exposure (AUCins, 0-60 minutes) and lower late exposure (AUCins,120-600 minutes) than both other insulins.",BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30565407/),min,0-60,25782,DB00030,Insulin Regular
,30565407,AUCins,"BCLIS also demonstrated significantly higher early exposure (AUCins, 0-60 minutes) and lower late exposure (AUCins,120-600 minutes) than both other insulins.",BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30565407/),min,120-600,25783,DB00030,Insulin Regular
,25336915,terminal elimination half-life,"The evogliptin plasma concentration reached its peak within 4-5 hours and decreased relatively slowly, with a terminal elimination half-life of 33-39 hours.","Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25336915/),h,33-39,25940,DB00030,Insulin Regular
,27280398,response rate,The mean estimated response rate were 62.4% (95% Credibility Interval [CrI]: 48.6%-75.3%) in the treatment group and 50.2% (95% CrI: 37.6%-62.8%) in the placebo group.,Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27280398/),%,62.4,26459,DB00030,Insulin Regular
,27280398,response rate,The mean estimated response rate were 62.4% (95% Credibility Interval [CrI]: 48.6%-75.3%) in the treatment group and 50.2% (95% CrI: 37.6%-62.8%) in the placebo group.,Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27280398/),%,50.2,26460,DB00030,Insulin Regular
,16132949,distribution volume,"C-peptide was distributed in two compartments (distribution volume 11.4+/-0.4 ml, 42+/-2% of which was in the accessible compartment).",Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132949/),ml,11.4,26534,DB00030,Insulin Regular
,16132949,Fractional clearance,Fractional clearance of endogenously released insulin after glucose was 0.66+/-0.11 min(-1) and this was reduced to 0.36+/-0.10 min(-1) by GLP-1 (p=0.04).,Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132949/),1/[min],0.66,26535,DB00030,Insulin Regular
,16132949,Fractional clearance,Fractional clearance of endogenously released insulin after glucose was 0.66+/-0.11 min(-1) and this was reduced to 0.36+/-0.10 min(-1) by GLP-1 (p=0.04).,Reduced insulin clearance contributes to the increased insulin levels after administration of glucagon-like peptide 1 in mice. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132949/),1/[min],0.36,26536,DB00030,Insulin Regular
,17706903,Maximum insulin concentration in blood,Maximum insulin concentration in blood was 11.3+/-6.2ng/ml and was reached 6h after administration.,Design and in vivo evaluation of a patch delivery system for insulin based on thiolated polymers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706903/),[ng] / [ml],11.3,27523,DB00030,Insulin Regular
,17706903,relative bioavailability,The relative bioavailability of orally administered patch system versus subcutaneous injection was 2.2%.,Design and in vivo evaluation of a patch delivery system for insulin based on thiolated polymers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17706903/),%,2.2,27524,DB00030,Insulin Regular
,26228184,Cl,"The mean Cl of C-peptide was 0.309 ± 0.329 mL/min/kg, and UER was 0.0329 ± 0.0342 pmol/min/kg.",Effect of gestational age and blood glucose on C-peptide excretion rate and clearance in neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26228184/),[ml] / [kg·min],0.309,28351,DB00030,Insulin Regular
,26228184,UER,"The mean Cl of C-peptide was 0.309 ± 0.329 mL/min/kg, and UER was 0.0329 ± 0.0342 pmol/min/kg.",Effect of gestational age and blood glucose on C-peptide excretion rate and clearance in neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26228184/),[pM] / [kg·min],0.0329,28352,DB00030,Insulin Regular
,25223504,area under the glucose concentration-time curve,"The addition of St John's wort decreased the area under the glucose concentration-time curve [702 (95% confidence interval, 643-761) vs. 629 min*mmol/L (95% confidence interval, 568-690), P = 0.003], and this effect was caused by a statistically significant increase in the acute insulin response.",Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25223504/),[mM·min] / [l],702,31100,DB00030,Insulin Regular
,25223504,area under the glucose concentration-time curve,"The addition of St John's wort decreased the area under the glucose concentration-time curve [702 (95% confidence interval, 643-761) vs. 629 min*mmol/L (95% confidence interval, 568-690), P = 0.003], and this effect was caused by a statistically significant increase in the acute insulin response.",Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25223504/),[mM·min] / [l],629,31101,DB00030,Insulin Regular
,26921845,total s.c,"The final model described rhGH PK as a two compartmental model with parallel linear and non-linear elimination terms, parallel first-order absorption with a total s.c. bioavailability of 87% in rats.",Translational mixed-effects PKPD modelling of recombinant human growth hormone - from hypophysectomized rat to patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26921845/),%,87,31102,DB00030,Insulin Regular
,32787767,Δ1,"Compared to patients with T2DM, serum NOx concentration (Δ1= 16.7 vs. 4.4 μmol/L, P=0.057) of healthy subjects sharply increased within 1 hour after NO3 loading.",Different Pharmacokinetic Responses to an Acute Dose of Inorganic Nitrate in Patients with Type 2 Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787767/),[μM] / [l],16.7,31614,DB00030,Insulin Regular
,32787767,Δ1,"Compared to patients with T2DM, serum NOx concentration (Δ1= 16.7 vs. 4.4 μmol/L, P=0.057) of healthy subjects sharply increased within 1 hour after NO3 loading.",Different Pharmacokinetic Responses to an Acute Dose of Inorganic Nitrate in Patients with Type 2 Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32787767/),[μM] / [l],4.4,31615,DB00030,Insulin Regular
,21303633,maximum concentrations (C(max)),"Single nostril administration revealed enhanced absorption with maximum concentrations (C(max)) of 13, 65, and 96 µU/ml for the 25, 50, and 75 U doses, respectively.","Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21303633/),[µu] / [ml],13,32230,DB00030,Insulin Regular
,21303633,maximum concentrations (C(max)),"Single nostril administration revealed enhanced absorption with maximum concentrations (C(max)) of 13, 65, and 96 µU/ml for the 25, 50, and 75 U doses, respectively.","Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21303633/),[µu] / [ml],65,32231,DB00030,Insulin Regular
,21303633,maximum concentrations (C(max)),"Single nostril administration revealed enhanced absorption with maximum concentrations (C(max)) of 13, 65, and 96 µU/ml for the 25, 50, and 75 U doses, respectively.","Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21303633/),[µu] / [ml],96,32232,DB00030,Insulin Regular
,21303633,C(max),"Dual nostril administration in two cohorts resulted in C(max) of 31/42, 65/52, and 88/79 µU/ml for the 50, 75, and 100 U, respectively.","Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21303633/),[µu] / [ml],31/42,32233,DB00030,Insulin Regular
,21303633,C(max),"Dual nostril administration in two cohorts resulted in C(max) of 31/42, 65/52, and 88/79 µU/ml for the 50, 75, and 100 U, respectively.","Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21303633/),[µu] / [ml],65/52,32234,DB00030,Insulin Regular
,21303633,C(max),"Dual nostril administration in two cohorts resulted in C(max) of 31/42, 65/52, and 88/79 µU/ml for the 50, 75, and 100 U, respectively.","Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21303633/),[µu] / [ml],88/79,32235,DB00030,Insulin Regular
,21303633,C(max),"In the second cohort, C(max) was 23, 19, 56 µU/ml for the 25, P + 25, and 50 U doses, respectively.","Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21303633/),[µu] / [ml],23,32236,DB00030,Insulin Regular
,21303633,C(max),"In the second cohort, C(max) was 23, 19, 56 µU/ml for the 25, P + 25, and 50 U doses, respectively.","Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21303633/),[µu] / [ml],19,32237,DB00030,Insulin Regular
,21303633,C(max),"In the second cohort, C(max) was 23, 19, 56 µU/ml for the 25, P + 25, and 50 U doses, respectively.","Enhanced absorption of Nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21303633/),[µu] / [ml],56,32238,DB00030,Insulin Regular
,30538075,AUC,"Moreover, telmisartan co-administration significantly increased the plasma concentrations of both glucose and insulin at 0.5 h since OGTT (7.64 ± 1.86 mmol/l·min vs 6.77 ± 0.83 mmol/l·min, P = 0.040; 72.91 ± 31.98 μIU/ml·min vs 60.20 ± 24.20 μIU/ml·min, P = 0.037), though the AUC of glucose and insulin after OGTT showed no significant difference.",The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30538075/),mm,6.77,32303,DB00030,Insulin Regular
,30538075,AUC,"Moreover, telmisartan co-administration significantly increased the plasma concentrations of both glucose and insulin at 0.5 h since OGTT (7.64 ± 1.86 mmol/l·min vs 6.77 ± 0.83 mmol/l·min, P = 0.040; 72.91 ± 31.98 μIU/ml·min vs 60.20 ± 24.20 μIU/ml·min, P = 0.037), though the AUC of glucose and insulin after OGTT showed no significant difference.",The influence of telmisartan on metformin pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30538075/),[μiu] / [min·ml],72.91,32304,DB00030,Insulin Regular
,28727908,Tmax,Median MK-8666 Tmax was 2.0-2.5 h and mean apparent terminal half-life was 22-32 h.,Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28727908/),h,2.0-2.5,32582,DB00030,Insulin Regular
,28727908,apparent terminal half-life,Median MK-8666 Tmax was 2.0-2.5 h and mean apparent terminal half-life was 22-32 h.,Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28727908/),h,22-32,32583,DB00030,Insulin Regular
,21147888,insulin sensitivity,"Females showed lower (P < 0.05) fasting EGP [1.4 ± 0.1 mg/(kg · min)] than males [1.7 ± 0.1 mg/(kg · min)] but comparable whole-body insulin sensitivity in clamp tests [females, 8.1 ± 0.4 mg/(kg · min); males, 8.3 ± 0.6 mg/(kg · min)].",Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21147888/),[mg] / [kg·min],8.1,32749,DB00030,Insulin Regular
,21147888,insulin sensitivity,"Females showed lower (P < 0.05) fasting EGP [1.4 ± 0.1 mg/(kg · min)] than males [1.7 ± 0.1 mg/(kg · min)] but comparable whole-body insulin sensitivity in clamp tests [females, 8.1 ± 0.4 mg/(kg · min); males, 8.3 ± 0.6 mg/(kg · min)].",Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21147888/),[mg] / [kg·min],8.3,32750,DB00030,Insulin Regular
,21147888,glucose half-life,"Gut glucose half-life was markedly higher in females (79 ± 2 min) than in males (65 ± 3 min, P < 0.0001) and negatively related to body height (r = -0.481; P < 0.0001).",Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21147888/),min,79,32751,DB00030,Insulin Regular
,21147888,glucose half-life,"Gut glucose half-life was markedly higher in females (79 ± 2 min) than in males (65 ± 3 min, P < 0.0001) and negatively related to body height (r = -0.481; P < 0.0001).",Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21147888/),min,65,32752,DB00030,Insulin Regular
,24798870,tmax,"Absorption of JNJ-41443532 into the systemic circulation occurred at a median tmax of 2 h, and the mean t½ was approximately 8 h for both doses; plasma systemic exposures increased slightly more than dose-proportionally.","CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798870/),h,2,33239,DB00030,Insulin Regular
,24798870,t½,"Absorption of JNJ-41443532 into the systemic circulation occurred at a median tmax of 2 h, and the mean t½ was approximately 8 h for both doses; plasma systemic exposures increased slightly more than dose-proportionally.","CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24798870/),h,8,33240,DB00030,Insulin Regular
,18697865,half-lives,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),min,21,34430,DB00030,Insulin Regular
,18697865,half-lives,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),min,36,34431,DB00030,Insulin Regular
,18697865,MCRs,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[l] / [d·kg],58,34432,DB00030,Insulin Regular
,18697865,MCRs,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[l] / [d·kg],8.1,34433,DB00030,Insulin Regular
,18697865,volumes of distribution,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[l] / [kg],1.0,34434,DB00030,Insulin Regular
,18697865,volumes of distribution,"In pilot iv bolus ghrelin infusions, the median half-lives of acylated and total ghrelin were 21 and 36 min (P<0.01), MCRs 58 and 8.1 liters/kg.d (P<0.01), and volumes of distribution of 1.0 and 0.32 liters/kg (P<0.01), respectively.",Estrogen elevates the peak overnight production rate of acylated ghrelin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[l] / [kg],0.32,34435,DB00030,Insulin Regular
,18697865,peak nighttime acylated ghrelin concentrations,Transdermal E2 supplementation for 3 wk increased peak nighttime acylated ghrelin concentrations from 99+/-12 to 141+/-34 pg/ml (P=0.039).,Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[pg] / [ml],99,34436,DB00030,Insulin Regular
,18697865,peak nighttime acylated ghrelin concentrations,Transdermal E2 supplementation for 3 wk increased peak nighttime acylated ghrelin concentrations from 99+/-12 to 141+/-34 pg/ml (P=0.039).,Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[pg] / [ml],141,34437,DB00030,Insulin Regular
,18697865,peak nighttime production rates,These data predict peak nighttime production rates of acylated ghrelin of 3.8+/-0.9 (E2) and 1.9+/-0.2 (no E2) ng/kg.min (P=0.039).,Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[ng] / [kg·min],3.8,34438,DB00030,Insulin Regular
,18697865,peak nighttime production rates,These data predict peak nighttime production rates of acylated ghrelin of 3.8+/-0.9 (E2) and 1.9+/-0.2 (no E2) ng/kg.min (P=0.039).,Estrogen elevates the peak overnight production rate of acylated ghrelin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18697865/),[ng] / [kg·min],1.9,34439,DB00030,Insulin Regular
,11737733,transport fraction (TF),"The AIB transport fraction (TF), expressed as percentage of injected maternal dose, averaged 29.4 +/- 5.4% and 38.7 +/- 6.2% of the corresponding reference marker value in control and insulin series, respectively.",Effect of insulin on transport kinetics of alpha-aminoisobutyric acid in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737733/),%,29.4,35730,DB00030,Insulin Regular
,11737733,transport fraction (TF),"The AIB transport fraction (TF), expressed as percentage of injected maternal dose, averaged 29.4 +/- 5.4% and 38.7 +/- 6.2% of the corresponding reference marker value in control and insulin series, respectively.",Effect of insulin on transport kinetics of alpha-aminoisobutyric acid in the perfused human placental lobule in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737733/),%,38.7,35731,DB00030,Insulin Regular
,12145241,half-life,"After subcutaneous administration, the half-life of NN2211 was found to be 11-15 h.","Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12145241/),h,11-15,36453,DB00030,Insulin Regular
,19885231,tGIR(max),"Ultra-fast insulin has an earlier onset of action and shorter time to maximal plasma insulin concentration when compared to RHI (tGIR(max) 99 +/- 36 min vs. 154 +/- 74 min, p = 0.002; tC(max) 33 +/- 16 min vs. 97 +/- 39 min, p = 0.00001).",Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19885231/),min,99,37029,DB00030,Insulin Regular
,19885231,tGIR(max),"Ultra-fast insulin has an earlier onset of action and shorter time to maximal plasma insulin concentration when compared to RHI (tGIR(max) 99 +/- 36 min vs. 154 +/- 74 min, p = 0.002; tC(max) 33 +/- 16 min vs. 97 +/- 39 min, p = 0.00001).",Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19885231/),min,154,37030,DB00030,Insulin Regular
,19885231,tC(max),"Ultra-fast insulin has an earlier onset of action and shorter time to maximal plasma insulin concentration when compared to RHI (tGIR(max) 99 +/- 36 min vs. 154 +/- 74 min, p = 0.002; tC(max) 33 +/- 16 min vs. 97 +/- 39 min, p = 0.00001).",Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19885231/),min,33,37031,DB00030,Insulin Regular
,19885231,tC(max),"Ultra-fast insulin has an earlier onset of action and shorter time to maximal plasma insulin concentration when compared to RHI (tGIR(max) 99 +/- 36 min vs. 154 +/- 74 min, p = 0.002; tC(max) 33 +/- 16 min vs. 97 +/- 39 min, p = 0.00001).",Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19885231/),min,97,37032,DB00030,Insulin Regular
,12579845,polydispersity index,"The INS-PLGA-NPs was prepared with poloxamer 188 as a emulsifier, the mean diameter was 149.6 nm and the polydispersity index was decreased to 0.09.",[Study on preparation and oral efficacy of insulin-loaded poly(lactic-co-glycolic acid) nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579845/),,0.09,37170,DB00030,Insulin Regular
,12579845,entrapment efficiency,While the entrapment efficiency was increased to 42.8%.,[Study on preparation and oral efficacy of insulin-loaded poly(lactic-co-glycolic acid) nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579845/),%,42.8,37171,DB00030,Insulin Regular
,11093917,AAUR(net),H produced a 63.7% increase in AAUR(net) (3.29 +/- 0.66 micromol. min(-1).,Effect of hyperinsulinemia on amino acid utilization in the ovine fetus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093917/),[μM] / [min],3.29,37179,DB00030,Insulin Regular
,11093917,uptake rate,"kg(-1) C, P < 0.001), accounting for a 60.1% increase in fetal nitrogen uptake rate (2,064 +/- 108 mg. day(-1).",Effect of hyperinsulinemia on amino acid utilization in the ovine fetus. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093917/),[mg] / [day],"2,064",37180,DB00030,Insulin Regular
,24985105,total bioaccessibility,TNO intestinal model-1 experiments confirmed higher total bioaccessibility of DMC-2 in vitro when delivered in 5011-Nutrasorb (50.2%) or Gelucire-5011 (44.4%) compared with PMI-5011 (27.1%; P = 0.08).,Artemisia dracunculus L. polyphenols complexed to soy protein show enhanced bioavailability and hypoglycemic activity in C57BL/6 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985105/),%,50.2,37313,DB00030,Insulin Regular
,24985105,total bioaccessibility,TNO intestinal model-1 experiments confirmed higher total bioaccessibility of DMC-2 in vitro when delivered in 5011-Nutrasorb (50.2%) or Gelucire-5011 (44.4%) compared with PMI-5011 (27.1%; P = 0.08).,Artemisia dracunculus L. polyphenols complexed to soy protein show enhanced bioavailability and hypoglycemic activity in C57BL/6 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985105/),%,44.4,37314,DB00030,Insulin Regular
,24985105,total bioaccessibility,TNO intestinal model-1 experiments confirmed higher total bioaccessibility of DMC-2 in vitro when delivered in 5011-Nutrasorb (50.2%) or Gelucire-5011 (44.4%) compared with PMI-5011 (27.1%; P = 0.08).,Artemisia dracunculus L. polyphenols complexed to soy protein show enhanced bioavailability and hypoglycemic activity in C57BL/6 mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24985105/),%,27.1,37315,DB00030,Insulin Regular
less,26692235,serum half-life,"Given its short serum half-life of less than 1 h, hypoglycemic effects of repaglinide are expected to cease within a few hours post-ingestion.",Prolonged hypoglycemia after a suicidal ingestion of repaglinide with unexpected slow plasma elimination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26692235/),h,1,37829,DB00030,Insulin Regular
,21923591,elimination half-life,Albumin binding and an elimination half-life of 13 hours combine to allow for once-daily dosing.,Liraglutide: clinical pharmacology and considerations for therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21923591/),h,13,38440,DB00030,Insulin Regular
,21645806,AUC ratio,"Insulin area under the curve (AUC) during ExIGC was significantly higher than insulin AUC during IGC (AUC ratio, 2.0 ± 0.4; P = 0.03).",The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21645806/),,2.0,38491,DB00030,Insulin Regular
,23982218,Peak serum V,"Peak serum V levels were 15.4 ± 6.5, 81.7 ± 40 and 319 ± 268 ng ml(-1) respectively, and mean peak serum V was positively correlated with dose administered (r = 0.992, p = 0.079), although large inter-individual variability was found.",Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982218/),[ng] / [ml],15.4,38887,DB00030,Insulin Regular
,23982218,Peak serum V,"Peak serum V levels were 15.4 ± 6.5, 81.7 ± 40 and 319 ± 268 ng ml(-1) respectively, and mean peak serum V was positively correlated with dose administered (r = 0.992, p = 0.079), although large inter-individual variability was found.",Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982218/),[ng] / [ml],81.7,38888,DB00030,Insulin Regular
,23982218,Peak serum V,"Peak serum V levels were 15.4 ± 6.5, 81.7 ± 40 and 319 ± 268 ng ml(-1) respectively, and mean peak serum V was positively correlated with dose administered (r = 0.992, p = 0.079), although large inter-individual variability was found.",Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982218/),[ng] / [ml],319,38889,DB00030,Insulin Regular
,23982218,half times,Total serum V concentration distribution fit a one compartment open model with a first order rate constant for excretion with mean half times of 4.7 ± 1.6 days and 4.6 ± 2.5 days for the 50 and 100 mg V dose groups respectively.,Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982218/),d,4.7,38890,DB00030,Insulin Regular
,23982218,half times,Total serum V concentration distribution fit a one compartment open model with a first order rate constant for excretion with mean half times of 4.7 ± 1.6 days and 4.6 ± 2.5 days for the 50 and 100 mg V dose groups respectively.,Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982218/),d,4.6,38891,DB00030,Insulin Regular
,23982218,V output,"At steady state, 24 hour urinary V output was 0.18 ± 0.24 and 0.97 ± 0.84 mg in the 50 and 100 mg V groups respectively, consistent with absorption of 1 percent or less of the administered dose.",Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982218/),mg,0.18,38892,DB00030,Insulin Regular
,23982218,V output,"At steady state, 24 hour urinary V output was 0.18 ± 0.24 and 0.97 ± 0.84 mg in the 50 and 100 mg V groups respectively, consistent with absorption of 1 percent or less of the administered dose.",Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982218/),mg,0.97,38893,DB00030,Insulin Regular
,23982218,serum to blood V ratio,The serum to blood V ratio for the patients receiving 100 mg V was 1.7 ± 0.45.,Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982218/),,1.7,38894,DB00030,Insulin Regular
,20139722,EC50,"Akt1 and Akt2 phosphorylation was inhibited in mouse lung with EC50 values of 1.6 and 7 μM, respectively, and with similar potency in other tissues and xenograft tumors.",An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139722/),μM,1.6,39186,DB00030,Insulin Regular
,20139722,EC50,"Akt1 and Akt2 phosphorylation was inhibited in mouse lung with EC50 values of 1.6 and 7 μM, respectively, and with similar potency in other tissues and xenograft tumors.",An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20139722/),μM,7,39187,DB00030,Insulin Regular
,30469166,Recoveries,Recoveries of all four flavonoids ranged from 85.9 to 101.3%.,An accurate and reproducible method for simultaneous determination of four flavonoids in EtOAc extracts from Sophora flavescens Ait. in rat plasma based on UHPLC Q-Exactive Mass spectrometry: Application to a pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30469166/),%,85.9 to 101.3,39518,DB00030,Insulin Regular
,19788433,AUC(0-6 h),The significantly greater systemic insulin concentrations following Actrapid were reflected in the AUC(0-6 h) (910 +/- 270 vs. 472 +/- 245 pmol h/L; 950 +/- 446 vs. 433 +/- 218 pmol h/L; both p < 0.05 for Actrapid vs. 150U Capsulin and 300U Capsulin respectively).,The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788433/),[h·pM] / [l],910,40878,DB00030,Insulin Regular
,19788433,AUC(0-6 h),The significantly greater systemic insulin concentrations following Actrapid were reflected in the AUC(0-6 h) (910 +/- 270 vs. 472 +/- 245 pmol h/L; 950 +/- 446 vs. 433 +/- 218 pmol h/L; both p < 0.05 for Actrapid vs. 150U Capsulin and 300U Capsulin respectively).,The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788433/),[h·pM] / [l],472,40879,DB00030,Insulin Regular
,19788433,AUC(0-6 h),The significantly greater systemic insulin concentrations following Actrapid were reflected in the AUC(0-6 h) (910 +/- 270 vs. 472 +/- 245 pmol h/L; 950 +/- 446 vs. 433 +/- 218 pmol h/L; both p < 0.05 for Actrapid vs. 150U Capsulin and 300U Capsulin respectively).,The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788433/),[h·pM] / [l],950,40880,DB00030,Insulin Regular
,19788433,AUC(0-6 h),The significantly greater systemic insulin concentrations following Actrapid were reflected in the AUC(0-6 h) (910 +/- 270 vs. 472 +/- 245 pmol h/L; 950 +/- 446 vs. 433 +/- 218 pmol h/L; both p < 0.05 for Actrapid vs. 150U Capsulin and 300U Capsulin respectively).,The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19788433/),[h·pM] / [l],433,40881,DB00030,Insulin Regular
,11831892,EC(50),"Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC(50) = 0.36 microM) and PPARgamma (EC(50) = 0.17 microM) activity in vitro.",Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831892/),μM,0.36,41150,DB00030,Insulin Regular
,11831892,EC(50),"Synthesis and structure-activity relationships of tricyclic alpha-ethoxy-phenylpropionic acid derivatives guided by in vitro PPARalpha and PPARgamma transactivation data and computer modeling led to the identification of the novel carbazole analogue, 3q, with dual PPARalpha (EC(50) = 0.36 microM) and PPARgamma (EC(50) = 0.17 microM) activity in vitro.",Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11831892/),μM,0.17,41151,DB00030,Insulin Regular
,22179928,K(D),"Receptor binding of GLP-1 exhibited high capacity and low affinity kinetics for both binding sites (K(D) = 9.94 × 10(3) pM, K(2) = 1.56 × 10(-4) pM(-1)).",Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179928/),pM,9.94 × 10(3),41232,DB00030,Insulin Regular
,22179928,K(2),"Receptor binding of GLP-1 exhibited high capacity and low affinity kinetics for both binding sites (K(D) = 9.94 × 10(3) pM, K(2) = 1.56 × 10(-4) pM(-1)).",Pharmacokinetic/pharmacodynamic modeling of GLP-1 in healthy rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179928/),1/[pM],1.56 × 10(-4),41233,DB00030,Insulin Regular
,28474741,AUC0-2,"The geometric mean AUC0-2 for insulin, glucose and lactate during treatments A and B were 84 h.",Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28474741/),h,84,42723,DB00030,Insulin Regular
,14585085,glucose peak,"After i.v. glucose administration, plasma glucose increased significantly in both groups and the glucose peak was higher in T2DM subjects than in controls (9.67+/-1.25 (s.d.) vs 6.88+/-1.00 mmol/l, P<0.01).","Acute plasma glucose increase, but not early insulin response, regulates plasma ghrelin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14585085/),[mM] / [l],9.67,43993,DB00030,Insulin Regular
,14585085,glucose peak,"After i.v. glucose administration, plasma glucose increased significantly in both groups and the glucose peak was higher in T2DM subjects than in controls (9.67+/-1.25 (s.d.) vs 6.88+/-1.00 mmol/l, P<0.01).","Acute plasma glucose increase, but not early insulin response, regulates plasma ghrelin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14585085/),[mM] / [l],6.88,43994,DB00030,Insulin Regular
,21273395,t(max),"t(max) and t(1/2) were 8 hours (median) and 11.2 to 12.2 hours (geometric mean), respectively.","The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21273395/),h,8,44185,DB00030,Insulin Regular
,21273395,t(1/2),"t(max) and t(1/2) were 8 hours (median) and 11.2 to 12.2 hours (geometric mean), respectively.","The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21273395/),h,11.2 to 12.2,44186,DB00030,Insulin Regular
,18832295,tmax,Vildagliptin was rapidly absorbed (tmax 1.5-2.0 hours) across the dose range of 25 to 200 mg and was quickly eliminated with a terminal elimination half-life (t1/2) of approximately 2 hours.,Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832295/),h,1.5-2.0,44805,DB00030,Insulin Regular
,18832295,terminal elimination half-life (t1/2),Vildagliptin was rapidly absorbed (tmax 1.5-2.0 hours) across the dose range of 25 to 200 mg and was quickly eliminated with a terminal elimination half-life (t1/2) of approximately 2 hours.,Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832295/),h,2,44806,DB00030,Insulin Regular
,18832295,accumulation factors,"Consistent with the short t1/2, no accumulation of vildagliptin was observed following the administration of multiple doses (accumulation factors were 1.00-1.05 across the 25- to 200-mg dose range).",Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832295/),,1.00-1.05,44807,DB00030,Insulin Regular
no less,19203616,extraction recovery,The extraction recovery from plasma was no less than 80%.,High-throughput quantification of a novel thiazolidinedione MCC-555 in rat plasma by ultra-fast liquid chromatography and its application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19203616/),%,80,45087,DB00030,Insulin Regular
,11563410,plasma t 1/2,Nateglinide was rapidly eliminated with plasma t 1/2 = 1.4 hours.,The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563410/),h,1.4,45558,DB00030,Insulin Regular
,11563410,plasma renal clearance,"Its plasma renal clearance, 20.7 ml/min, appears to be due mostly to active tubular secretion.",The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11563410/),[ml] / [min],20.7,45559,DB00030,Insulin Regular
,15920051,time to maximum insulin concentration,"The time to maximum insulin concentration was shorter for oral insulin than for subcutaneous insulin (25.9 +/- 9 vs. 145.7 +/- 49.5 min, P < 0.05).",Dose-response relationship of oral insulin spray in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),min,25.9,45717,DB00030,Insulin Regular
,15920051,time to maximum insulin concentration,"The time to maximum insulin concentration was shorter for oral insulin than for subcutaneous insulin (25.9 +/- 9 vs. 145.7 +/- 49.5 min, P < 0.05).",Dose-response relationship of oral insulin spray in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),min,145.7,45718,DB00030,Insulin Regular
,15920051,Maximum serum insulin levels (C(max)),"Maximum serum insulin levels (C(max)) were comparable between the subcutaneous and 20 puffs of oral insulin (39.1 +/- 19.6 vs. 34.0 +/- 7.4 microU/ml, NS).",Dose-response relationship of oral insulin spray in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],39.1,45719,DB00030,Insulin Regular
,15920051,Maximum serum insulin levels (C(max)),"Maximum serum insulin levels (C(max)) were comparable between the subcutaneous and 20 puffs of oral insulin (39.1 +/- 19.6 vs. 34.0 +/- 7.4 microU/ml, NS).",Dose-response relationship of oral insulin spray in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],34.0,45720,DB00030,Insulin Regular
,15920051,AUC(0-120),"The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively).",Dose-response relationship of oral insulin spray in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],339.8,45721,DB00030,Insulin Regular
,15920051,AUC(0-120),"The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively).",Dose-response relationship of oral insulin spray in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],681.3,45722,DB00030,Insulin Regular
,15920051,AUC(0-120),"The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively).",Dose-response relationship of oral insulin spray in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],"1,586.7",45723,DB00030,Insulin Regular
,15920051,area under the curve from 0 to 120 min,"The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively).",Dose-response relationship of oral insulin spray in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],339.8,45724,DB00030,Insulin Regular
,15920051,area under the curve from 0 to 120 min,"The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively).",Dose-response relationship of oral insulin spray in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],681.3,45725,DB00030,Insulin Regular
,15920051,area under the curve from 0 to 120 min,"The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively).",Dose-response relationship of oral insulin spray in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],"1,586.7",45726,DB00030,Insulin Regular
,15920051,C(max),"The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively).",Dose-response relationship of oral insulin spray in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],7.6,45727,DB00030,Insulin Regular
,15920051,C(max),"The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively).",Dose-response relationship of oral insulin spray in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],16.4,45728,DB00030,Insulin Regular
,15920051,C(max),"The Ins-AUC(0-120) (area under the curve from 0 to 120 min for serum insulin) (339.8 +/- 218, 681.3 +/- 407, and 1,586.7 +/- 8 microU/ml, P < 0.05) and C(max) (7.6 +/- 2.8, 16.4 +/- 9.3, and 39.1 +/- 19.6 microU/ml, P < 0.005) proved a dose-response relationship for the three doses of oral insulin (5, 10, and 20 puffs, respectively).",Dose-response relationship of oral insulin spray in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[μu] / [ml],39.1,45729,DB00030,Insulin Regular
,15920051,onset of action,"Oral insulin had an earlier onset of action (31.7 +/- 12 vs. 77.8 +/- 3 min, P < 0.05), earlier peak (44.2 +/- 10 vs. 159.2 +/- 68 min, P < 0.05), and a shorter duration of action (85.1 +/- 25 vs. 319.2 +/- 45 min, P < 0.05) compared with subcutaneous insulin.",Dose-response relationship of oral insulin spray in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),min,31.7,45730,DB00030,Insulin Regular
,15920051,onset of action,"Oral insulin had an earlier onset of action (31.7 +/- 12 vs. 77.8 +/- 3 min, P < 0.05), earlier peak (44.2 +/- 10 vs. 159.2 +/- 68 min, P < 0.05), and a shorter duration of action (85.1 +/- 25 vs. 319.2 +/- 45 min, P < 0.05) compared with subcutaneous insulin.",Dose-response relationship of oral insulin spray in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),min,77.8,45731,DB00030,Insulin Regular
,15920051,peak,"Oral insulin had an earlier onset of action (31.7 +/- 12 vs. 77.8 +/- 3 min, P < 0.05), earlier peak (44.2 +/- 10 vs. 159.2 +/- 68 min, P < 0.05), and a shorter duration of action (85.1 +/- 25 vs. 319.2 +/- 45 min, P < 0.05) compared with subcutaneous insulin.",Dose-response relationship of oral insulin spray in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),min,44.2,45732,DB00030,Insulin Regular
,15920051,peak,"Oral insulin had an earlier onset of action (31.7 +/- 12 vs. 77.8 +/- 3 min, P < 0.05), earlier peak (44.2 +/- 10 vs. 159.2 +/- 68 min, P < 0.05), and a shorter duration of action (85.1 +/- 25 vs. 319.2 +/- 45 min, P < 0.05) compared with subcutaneous insulin.",Dose-response relationship of oral insulin spray in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),min,159.2,45733,DB00030,Insulin Regular
,15920051,duration of action,"Oral insulin had an earlier onset of action (31.7 +/- 12 vs. 77.8 +/- 3 min, P < 0.05), earlier peak (44.2 +/- 10 vs. 159.2 +/- 68 min, P < 0.05), and a shorter duration of action (85.1 +/- 25 vs. 319.2 +/- 45 min, P < 0.05) compared with subcutaneous insulin.",Dose-response relationship of oral insulin spray in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),min,85.1,45734,DB00030,Insulin Regular
,15920051,duration of action,"Oral insulin had an earlier onset of action (31.7 +/- 12 vs. 77.8 +/- 3 min, P < 0.05), earlier peak (44.2 +/- 10 vs. 159.2 +/- 68 min, P < 0.05), and a shorter duration of action (85.1 +/- 25 vs. 319.2 +/- 45 min, P < 0.05) compared with subcutaneous insulin.",Dose-response relationship of oral insulin spray in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),min,319.2,45735,DB00030,Insulin Regular
,15920051,maximum metabolic effect,"The maximum metabolic effect (1.7 +/- 1.0, 3.09 +/- 1.7, and 4.6 +/- 1.5 mg . kg(-1) . min(-1), P < 0.05) and the GIR-AUC(0-120) (amount of glucose infused from 0 to 120 min) (106.7 +/- 74.3, 162.9 +/- 116.1, and 254 +/- 123 mg/kg) increased in a dose-dependent relationship for the three doses.",Dose-response relationship of oral insulin spray in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[mg] / [kg·min],1.7,45736,DB00030,Insulin Regular
,15920051,maximum metabolic effect,"The maximum metabolic effect (1.7 +/- 1.0, 3.09 +/- 1.7, and 4.6 +/- 1.5 mg . kg(-1) . min(-1), P < 0.05) and the GIR-AUC(0-120) (amount of glucose infused from 0 to 120 min) (106.7 +/- 74.3, 162.9 +/- 116.1, and 254 +/- 123 mg/kg) increased in a dose-dependent relationship for the three doses.",Dose-response relationship of oral insulin spray in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[mg] / [kg·min],3.09,45737,DB00030,Insulin Regular
,15920051,maximum metabolic effect,"The maximum metabolic effect (1.7 +/- 1.0, 3.09 +/- 1.7, and 4.6 +/- 1.5 mg . kg(-1) . min(-1), P < 0.05) and the GIR-AUC(0-120) (amount of glucose infused from 0 to 120 min) (106.7 +/- 74.3, 162.9 +/- 116.1, and 254 +/- 123 mg/kg) increased in a dose-dependent relationship for the three doses.",Dose-response relationship of oral insulin spray in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[mg] / [kg·min],4.6,45738,DB00030,Insulin Regular
,15920051,AUC(0-120),"The maximum metabolic effect (1.7 +/- 1.0, 3.09 +/- 1.7, and 4.6 +/- 1.5 mg . kg(-1) . min(-1), P < 0.05) and the GIR-AUC(0-120) (amount of glucose infused from 0 to 120 min) (106.7 +/- 74.3, 162.9 +/- 116.1, and 254 +/- 123 mg/kg) increased in a dose-dependent relationship for the three doses.",Dose-response relationship of oral insulin spray in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[mg] / [kg],106.7,45739,DB00030,Insulin Regular
,15920051,AUC(0-120),"The maximum metabolic effect (1.7 +/- 1.0, 3.09 +/- 1.7, and 4.6 +/- 1.5 mg . kg(-1) . min(-1), P < 0.05) and the GIR-AUC(0-120) (amount of glucose infused from 0 to 120 min) (106.7 +/- 74.3, 162.9 +/- 116.1, and 254 +/- 123 mg/kg) increased in a dose-dependent relationship for the three doses.",Dose-response relationship of oral insulin spray in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[mg] / [kg],162.9,45740,DB00030,Insulin Regular
,15920051,AUC(0-120),"The maximum metabolic effect (1.7 +/- 1.0, 3.09 +/- 1.7, and 4.6 +/- 1.5 mg . kg(-1) . min(-1), P < 0.05) and the GIR-AUC(0-120) (amount of glucose infused from 0 to 120 min) (106.7 +/- 74.3, 162.9 +/- 116.1, and 254 +/- 123 mg/kg) increased in a dose-dependent relationship for the three doses.",Dose-response relationship of oral insulin spray in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15920051/),[mg] / [kg],254,45741,DB00030,Insulin Regular
,27689406,MCR,GLP-1 had a significantly higher MCR (83.9 ± 14.1 mL/min/kg) compared to GCG (40.7 ± 14.3 mL/min/kg) and Ex-4 (10.1 ± 2.5 mL/min/kg) (p < .01 and p < .001 respectively).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),[ml] / [kg·min],83.9,45742,DB00030,Insulin Regular
,27689406,MCR,GLP-1 had a significantly higher MCR (83.9 ± 14.1 mL/min/kg) compared to GCG (40.7 ± 14.3 mL/min/kg) and Ex-4 (10.1 ± 2.5 mL/min/kg) (p < .01 and p < .001 respectively).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),[ml] / [kg·min],40.7,45743,DB00030,Insulin Regular
,27689406,MCR,GLP-1 had a significantly higher MCR (83.9 ± 14.1 mL/min/kg) compared to GCG (40.7 ± 14.3 mL/min/kg) and Ex-4 (10.1 ± 2.5 mL/min/kg) (p < .01 and p < .001 respectively).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),[ml] / [kg·min],10.1,45744,DB00030,Insulin Regular
,27689406,half-life,Ex-4 had a statistically significant longer half-life (35.1 ± 7.4 min) compared to both GCG (3.2 ± 1.7 min) and GLP-1 (1.2 ± 0.4 min) (p < .01 for both GCG and GLP-1).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),min,35.1,45745,DB00030,Insulin Regular
,27689406,half-life,Ex-4 had a statistically significant longer half-life (35.1 ± 7.4 min) compared to both GCG (3.2 ± 1.7 min) and GLP-1 (1.2 ± 0.4 min) (p < .01 for both GCG and GLP-1).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),min,3.2,45746,DB00030,Insulin Regular
,27689406,half-life,Ex-4 had a statistically significant longer half-life (35.1 ± 7.4 min) compared to both GCG (3.2 ± 1.7 min) and GLP-1 (1.2 ± 0.4 min) (p < .01 for both GCG and GLP-1).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),min,1.2,45747,DB00030,Insulin Regular
,27689406,volume of distribution,Ex-4 had a statistically significant higher volume of distribution (429.7 ± 164.9 mL/kg) compared to both GCG (146.8 ± 49.6 mL/kg) and GLP-1 (149.7 ± 53.5 mL/kg) (p < .01 for both GCG and GLP-1).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),[ml] / [kg],429.7,45748,DB00030,Insulin Regular
,27689406,volume of distribution,Ex-4 had a statistically significant higher volume of distribution (429.7 ± 164.9 mL/kg) compared to both GCG (146.8 ± 49.6 mL/kg) and GLP-1 (149.7 ± 53.5 mL/kg) (p < .01 for both GCG and GLP-1).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),[ml] / [kg],146.8,45749,DB00030,Insulin Regular
,27689406,volume of distribution,Ex-4 had a statistically significant higher volume of distribution (429.7 ± 164.9 mL/kg) compared to both GCG (146.8 ± 49.6 mL/kg) and GLP-1 (149.7 ± 53.5 mL/kg) (p < .01 for both GCG and GLP-1).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),[ml] / [kg],149.7,45750,DB00030,Insulin Regular
,27689406,half-life,Peptide X3 had a statistically significant longer half-life (21.3 ± 3.5 min) compared to both X1 (3.9 ± 0.4 min) and X2 (16.1 ± 2.8 min) (p < .001 for both X1 and X2).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),min,21.3,45751,DB00030,Insulin Regular
,27689406,half-life,Peptide X3 had a statistically significant longer half-life (21.3 ± 3.5 min) compared to both X1 (3.9 ± 0.4 min) and X2 (16.1 ± 2.8 min) (p < .001 for both X1 and X2).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),min,3.9,45752,DB00030,Insulin Regular
,27689406,half-life,Peptide X3 had a statistically significant longer half-life (21.3 ± 3.5 min) compared to both X1 (3.9 ± 0.4 min) and X2 (16.1 ± 2.8 min) (p < .001 for both X1 and X2).,Measuring the Pharmacokinetic Properties of Drugs with a Novel Surgical Rat Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27689406/),min,16.1,45753,DB00030,Insulin Regular
,23792547,zeta potential,The zeta potential was in the range between - 16.48 ± 2.02 and 30.52 ± 3.20 mV.,Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),mv,- 16.48,46120,DB00030,Insulin Regular
,23792547,zeta potential,The zeta potential was in the range between - 16.48 ± 2.02 and 30.52 ± 3.20 mV.,Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),mv,30.52,46121,DB00030,Insulin Regular
,23792547,percentage entrapment efficiency (EE%),The percentage entrapment efficiency (EE%) was 81.4 ± 1.8% to 92.7 ± 1.4%.,Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),%,81.4,46122,DB00030,Insulin Regular
,23792547,percentage entrapment efficiency (EE%),The percentage entrapment efficiency (EE%) was 81.4 ± 1.8% to 92.7 ± 1.4%.,Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),%,92.7,46123,DB00030,Insulin Regular
,23792547,AUC,"Based on in vivo hypoglycemic results, bioavailability parameters like AUC, AUMC, Cmax, Tmax, MRT, t1/2 and relative bioavailability were found to be 2218.88 μIU/mL/h, 381630.3 μIU/mL/h, 41.88 μIU/mL, 36 h, 83.24h, and 52.79 h respectively.",Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),[μiu] / [h·ml],2218.88,46124,DB00030,Insulin Regular
,23792547,t1/2,"Based on in vivo hypoglycemic results, bioavailability parameters like AUC, AUMC, Cmax, Tmax, MRT, t1/2 and relative bioavailability were found to be 2218.88 μIU/mL/h, 381630.3 μIU/mL/h, 41.88 μIU/mL, 36 h, 83.24h, and 52.79 h respectively.",Optimization and charaterization of repaglinide biodegradable polymeric nanoparticle loaded transdermal patchs: in vitro and in vivo studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792547/),h,52.79,46125,DB00030,Insulin Regular
,31276900,IC50(insulin),Ebselen is the most potent inhibitor (IC50(insulin) = 14 nM).,Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31276900/),nM,14,46523,DB00030,Insulin Regular
,22583576,encapsulation efficiency,Insulin-loaded FA-PEG-PLGA NPs (size ∼260 nm; insulin loading ∼6.5% [w/w]; encapsulation efficiency: 87.0 ± 1.92%) were prepared by double-emulsion solvent evaporation method.,Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22583576/),%,87.0,46653,DB00030,Insulin Regular
,11318075,maximum glucose infusion rate (GIRmax),"The mean (+/- SEM) maximum glucose infusion rate (GIRmax) was 8+/-0.6 mg/(min x kg) for the 85/15 preparation, 7+/-0.6 mg/(min x kg) for NPH, and 9+/-0.6 mg/(min x kg) for the 70/30 preparation, with time to peak GIR (tmax(GIR)) occurring at 313, 360, and 272 minutes, respectively.",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),[mg] / [kg·min],8,47444,DB00030,Insulin Regular
,11318075,maximum glucose infusion rate (GIRmax),"The mean (+/- SEM) maximum glucose infusion rate (GIRmax) was 8+/-0.6 mg/(min x kg) for the 85/15 preparation, 7+/-0.6 mg/(min x kg) for NPH, and 9+/-0.6 mg/(min x kg) for the 70/30 preparation, with time to peak GIR (tmax(GIR)) occurring at 313, 360, and 272 minutes, respectively.",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),[mg] / [kg·min],7,47445,DB00030,Insulin Regular
,11318075,maximum glucose infusion rate (GIRmax),"The mean (+/- SEM) maximum glucose infusion rate (GIRmax) was 8+/-0.6 mg/(min x kg) for the 85/15 preparation, 7+/-0.6 mg/(min x kg) for NPH, and 9+/-0.6 mg/(min x kg) for the 70/30 preparation, with time to peak GIR (tmax(GIR)) occurring at 313, 360, and 272 minutes, respectively.",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),[mg] / [kg·min],9,47446,DB00030,Insulin Regular
,11318075,time to peak GIR (tmax(GIR)),"The mean (+/- SEM) maximum glucose infusion rate (GIRmax) was 8+/-0.6 mg/(min x kg) for the 85/15 preparation, 7+/-0.6 mg/(min x kg) for NPH, and 9+/-0.6 mg/(min x kg) for the 70/30 preparation, with time to peak GIR (tmax(GIR)) occurring at 313, 360, and 272 minutes, respectively.",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),min,313,47447,DB00030,Insulin Regular
,11318075,time to peak GIR (tmax(GIR)),"The mean (+/- SEM) maximum glucose infusion rate (GIRmax) was 8+/-0.6 mg/(min x kg) for the 85/15 preparation, 7+/-0.6 mg/(min x kg) for NPH, and 9+/-0.6 mg/(min x kg) for the 70/30 preparation, with time to peak GIR (tmax(GIR)) occurring at 313, 360, and 272 minutes, respectively.",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),min,360,47448,DB00030,Insulin Regular
,11318075,time to peak GIR (tmax(GIR)),"The mean (+/- SEM) maximum glucose infusion rate (GIRmax) was 8+/-0.6 mg/(min x kg) for the 85/15 preparation, 7+/-0.6 mg/(min x kg) for NPH, and 9+/-0.6 mg/(min x kg) for the 70/30 preparation, with time to peak GIR (tmax(GIR)) occurring at 313, 360, and 272 minutes, respectively.",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),min,272,47449,DB00030,Insulin Regular
,11318075,Time to peak insulin levels,"Time to peak insulin levels did not differ significantly for the 3 preparations, but maximum serum insulin concentration (Cmax(ins)) was significantly different between the groups (70/30 premix: 54+/-2.2 microU/mL; 85/15 premix: 44+/-2.4 microU/mL; NPH: 35+/-1.7 microU/mL).",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),[μu] / [ml],54,47450,DB00030,Insulin Regular
,11318075,maximum serum insulin concentration (Cmax(ins)),"Time to peak insulin levels did not differ significantly for the 3 preparations, but maximum serum insulin concentration (Cmax(ins)) was significantly different between the groups (70/30 premix: 54+/-2.2 microU/mL; 85/15 premix: 44+/-2.4 microU/mL; NPH: 35+/-1.7 microU/mL).",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),[μu] / [ml],54,47451,DB00030,Insulin Regular
,11318075,maximum serum insulin concentration (Cmax(ins)),"Time to peak insulin levels did not differ significantly for the 3 preparations, but maximum serum insulin concentration (Cmax(ins)) was significantly different between the groups (70/30 premix: 54+/-2.2 microU/mL; 85/15 premix: 44+/-2.4 microU/mL; NPH: 35+/-1.7 microU/mL).",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),[μu] / [ml],44,47452,DB00030,Insulin Regular
,11318075,maximum serum insulin concentration (Cmax(ins)),"Time to peak insulin levels did not differ significantly for the 3 preparations, but maximum serum insulin concentration (Cmax(ins)) was significantly different between the groups (70/30 premix: 54+/-2.2 microU/mL; 85/15 premix: 44+/-2.4 microU/mL; NPH: 35+/-1.7 microU/mL).",Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11318075/),[μu] / [ml],35,47453,DB00030,Insulin Regular
,24588963,EC50,"From a library of synthesized compounds, 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methyl pyridin-2-yl)-benzamide (19e) was identified as a potent glucokinase activator with assays demonstrating an EC50 of 315nM and the induction of a 2.23 fold increase in glucose uptake.",Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588963/),nM,315,47626,DB00030,Insulin Regular
,11553186,C(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),[pM] / [l],971,47820,DB00030,Insulin Regular
,11553186,C(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),[pM] / [l],659,47821,DB00030,Insulin Regular
,11553186,T(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),min,46.9,47822,DB00030,Insulin Regular
,11553186,T(max),"Insulin C(max) was significantly higher (971 +/- 217 vs. 659 +/- 141 pmol/l, P < 0.001) and T(max) was significantly shorter (46.9 +/- 27 vs. 94.7 +/- 50.1 min, P = 0.002) with insulin lispro.",Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11553186/),min,94.7,47823,DB00030,Insulin Regular
,16958825,maximal increase in insulin secretion,The maximal increase in insulin secretion was 9.98 mIU/L and the maximal decrease in plasma glucose was 19.33 mg/dL.,Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16958825/),[miu] / [l],9.98,48107,DB00030,Insulin Regular
,25106135,area under the curve (AUC),"Respective dextran 10-insulin and Exubera exposures were similar producing near identical area under the curve (AUC), 7,728 ± 1,516 and 6,237 ± 2,621; concentration maximums (C max), 126 and 121 (μU/mL), and concentration-time maximums, 20 and 14 min, respectively.",Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25106135/),,"7,728",48259,DB00030,Insulin Regular
,25106135,area under the curve (AUC),"Respective dextran 10-insulin and Exubera exposures were similar producing near identical area under the curve (AUC), 7,728 ± 1,516 and 6,237 ± 2,621; concentration maximums (C max), 126 and 121 (μU/mL), and concentration-time maximums, 20 and 14 min, respectively.",Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25106135/),,"6,237",48260,DB00030,Insulin Regular
,25106135,concentration maximums (C max),"Respective dextran 10-insulin and Exubera exposures were similar producing near identical area under the curve (AUC), 7,728 ± 1,516 and 6,237 ± 2,621; concentration maximums (C max), 126 and 121 (μU/mL), and concentration-time maximums, 20 and 14 min, respectively.",Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25106135/),[μu] / [ml],126,48261,DB00030,Insulin Regular
,25106135,concentration maximums (C max),"Respective dextran 10-insulin and Exubera exposures were similar producing near identical area under the curve (AUC), 7,728 ± 1,516 and 6,237 ± 2,621; concentration maximums (C max), 126 and 121 (μU/mL), and concentration-time maximums, 20 and 14 min, respectively.",Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25106135/),[μu] / [ml],121,48262,DB00030,Insulin Regular
,25106135,concentration-time maximums,"Respective dextran 10-insulin and Exubera exposures were similar producing near identical area under the curve (AUC), 7,728 ± 1,516 and 6,237 ± 2,621; concentration maximums (C max), 126 and 121 (μU/mL), and concentration-time maximums, 20 and 14 min, respectively.",Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25106135/),min,20,48263,DB00030,Insulin Regular
,25106135,concentration-time maximums,"Respective dextran 10-insulin and Exubera exposures were similar producing near identical area under the curve (AUC), 7,728 ± 1,516 and 6,237 ± 2,621; concentration maximums (C max), 126 and 121 (μU/mL), and concentration-time maximums, 20 and 14 min, respectively.",Biologic comparison of inhaled insulin formulations: Exubera™ and novel spray-dried engineered particles of dextran-10. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25106135/),min,14,48264,DB00030,Insulin Regular
,14512131,area under the curve from 0 to 360 minutes,"Values for mean serum insulin area under the curve from 0 to 360 minutes were 8218, 8244, and 8404 microU/mL x min for the 0-, 3-, and 10-second durations of breath holding, respectively.",Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512131/),[μu] / [min·ml],8218,48828,DB00030,Insulin Regular
,14512131,area under the curve from 0 to 360 minutes,"Values for mean serum insulin area under the curve from 0 to 360 minutes were 8218, 8244, and 8404 microU/mL x min for the 0-, 3-, and 10-second durations of breath holding, respectively.",Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512131/),[μu] / [min·ml],8244,48829,DB00030,Insulin Regular
,14512131,area under the curve from 0 to 360 minutes,"Values for mean serum insulin area under the curve from 0 to 360 minutes were 8218, 8244, and 8404 microU/mL x min for the 0-, 3-, and 10-second durations of breath holding, respectively.",Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512131/),[μu] / [min·ml],8404,48830,DB00030,Insulin Regular
,14512131,maximum insulin concentrations,"Mean maximum insulin concentrations were a respective 44.9, 44.2, and 45.5 microU/mL.",Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512131/),[μu] / [ml],44.9,48831,DB00030,Insulin Regular
,14512131,maximum insulin concentrations,"Mean maximum insulin concentrations were a respective 44.9, 44.2, and 45.5 microU/mL.",Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512131/),[μu] / [ml],44.2,48832,DB00030,Insulin Regular
,14512131,maximum insulin concentrations,"Mean maximum insulin concentrations were a respective 44.9, 44.2, and 45.5 microU/mL.",Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512131/),[μu] / [ml],45.5,48833,DB00030,Insulin Regular
,14512131,area over the curve,"Values for mean plasma glucose area over the curve and below baseline from 0 to 360 minutes were a respective 3512, 4033, and 3708 mg/dL x min.",Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512131/),[mg] / [dl·min],3512,48834,DB00030,Insulin Regular
,14512131,area over the curve,"Values for mean plasma glucose area over the curve and below baseline from 0 to 360 minutes were a respective 3512, 4033, and 3708 mg/dL x min.",Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512131/),[mg] / [dl·min],4033,48835,DB00030,Insulin Regular
,14512131,area over the curve,"Values for mean plasma glucose area over the curve and below baseline from 0 to 360 minutes were a respective 3512, 4033, and 3708 mg/dL x min.",Effects of different durations of breath holding after inhalation of insulin using the AERx insulin diabetes management system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14512131/),[mg] / [dl·min],3708,48836,DB00030,Insulin Regular
,20920436,area under the curve from time 0 to 480 minutes (AUC(0-480)),"No significant pharmacokinetic differences were observed between healthy subjects and CLD subjects [geometric mean (% coefficient of variation) area under the curve from time 0 to 480 minutes (AUC(0-480)): 26,710 (34.8) and 31,477 (28.8) ng/ml·min, respectively].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [min·ml],"26,710",49155,DB00030,Insulin Regular
,20920436,area under the curve from time 0 to 480 minutes (AUC(0-480)),"No significant pharmacokinetic differences were observed between healthy subjects and CLD subjects [geometric mean (% coefficient of variation) area under the curve from time 0 to 480 minutes (AUC(0-480)): 26,710 (34.8) and 31,477 (28.8) ng/ml·min, respectively].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [min·ml],"31,477",49156,DB00030,Insulin Regular
,20920436,C(max),"Maximum observed drug concentration (C(max)) and AUC(0-480) were higher in DNP subjects than in subjects with normal renal function [C(max): 159.9 (59.4) ng/ml versus 147.0 (44.3) ng/ml; AUC(0-480): 36,869 (47.2) ng/ml·min versus 30,474 (31.8) ng/ml·min].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [ml],159.9,49157,DB00030,Insulin Regular
,20920436,C(max),"Maximum observed drug concentration (C(max)) and AUC(0-480) were higher in DNP subjects than in subjects with normal renal function [C(max): 159.9 (59.4) ng/ml versus 147.0 (44.3) ng/ml; AUC(0-480): 36,869 (47.2) ng/ml·min versus 30,474 (31.8) ng/ml·min].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [ml],147.0,49158,DB00030,Insulin Regular
,20920436,AUC(0-480),"Maximum observed drug concentration (C(max)) and AUC(0-480) were higher in DNP subjects than in subjects with normal renal function [C(max): 159.9 (59.4) ng/ml versus 147.0 (44.3) ng/ml; AUC(0-480): 36,869 (47.2) ng/ml·min versus 30,474 (31.8) ng/ml·min].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [min·ml],"36,869",49159,DB00030,Insulin Regular
,20920436,AUC(0-480),"Maximum observed drug concentration (C(max)) and AUC(0-480) were higher in DNP subjects than in subjects with normal renal function [C(max): 159.9 (59.4) ng/ml versus 147.0 (44.3) ng/ml; AUC(0-480): 36,869 (47.2) ng/ml·min versus 30,474 (31.8) ng/ml·min].",Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20920436/),[ng] / [min·ml],"30,474",49160,DB00030,Insulin Regular
,16352683,half-life,The estimated half-life of CJC-1295 was 5.8-8.1 d.,"Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16352683/),d,5.8-8.1,49990,DB00030,Insulin Regular
,10923219,maximum serum insulin (Cmax ins),"The pharmacokinetic profile of insulin aspart differed significantly from that of human insulin with a higher mean maximum serum insulin (Cmax ins), 881 +/- 321 (SD) pmol/l versus 422 +/- 193 pmol/l for human insulin (P < 0.001); and with a shorter median serum insulin tmax ins, 40.0 min (interquartile range: 40-50 min) versus 75.0 min (interquartile range: 60-120 min) for human insulin, (P < 0.001).",Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923219/),[pM] / [l],881,50241,DB00030,Insulin Regular
,10923219,maximum serum insulin (Cmax ins),"The pharmacokinetic profile of insulin aspart differed significantly from that of human insulin with a higher mean maximum serum insulin (Cmax ins), 881 +/- 321 (SD) pmol/l versus 422 +/- 193 pmol/l for human insulin (P < 0.001); and with a shorter median serum insulin tmax ins, 40.0 min (interquartile range: 40-50 min) versus 75.0 min (interquartile range: 60-120 min) for human insulin, (P < 0.001).",Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923219/),[pM] / [l],422,50242,DB00030,Insulin Regular
,10923219,tmax ins,"The pharmacokinetic profile of insulin aspart differed significantly from that of human insulin with a higher mean maximum serum insulin (Cmax ins), 881 +/- 321 (SD) pmol/l versus 422 +/- 193 pmol/l for human insulin (P < 0.001); and with a shorter median serum insulin tmax ins, 40.0 min (interquartile range: 40-50 min) versus 75.0 min (interquartile range: 60-120 min) for human insulin, (P < 0.001).",Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923219/),min,40.0,50243,DB00030,Insulin Regular
,10923219,tmax ins,"The pharmacokinetic profile of insulin aspart differed significantly from that of human insulin with a higher mean maximum serum insulin (Cmax ins), 881 +/- 321 (SD) pmol/l versus 422 +/- 193 pmol/l for human insulin (P < 0.001); and with a shorter median serum insulin tmax ins, 40.0 min (interquartile range: 40-50 min) versus 75.0 min (interquartile range: 60-120 min) for human insulin, (P < 0.001).",Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10923219/),min,75.0,50244,DB00030,Insulin Regular
,32508643,maximum concentration (Cmax),"The maximum concentration (Cmax) and time to peak (Tmax) of the rh-aFGF hydrogel were 909.2 pg/cm2 and 0.5 h, respectively.",Validation of a Double-Sandwich Enzyme-Linked Immunoassay for Pharmacokinetic Study of an rh-aFGF Hydrogel in Rat Skin and Serum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32508643/),[pg] / [cm2],909.2,50361,DB00030,Insulin Regular
,32508643,time to peak (Tmax),"The maximum concentration (Cmax) and time to peak (Tmax) of the rh-aFGF hydrogel were 909.2 pg/cm2 and 0.5 h, respectively.",Validation of a Double-Sandwich Enzyme-Linked Immunoassay for Pharmacokinetic Study of an rh-aFGF Hydrogel in Rat Skin and Serum. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32508643/),h,0.5,50362,DB00030,Insulin Regular
,32508643,relative bioavailability (F),The relative bioavailability (F) of the rh-aFGF hydrogel was 120% compared with that of rh-aFGF-Ai.,Validation of a Double-Sandwich Enzyme-Linked Immunoassay for Pharmacokinetic Study of an rh-aFGF Hydrogel in Rat Skin and Serum. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32508643/),%,120,50363,DB00030,Insulin Regular
,26259978,time,"The jet injector advanced this time to 147.9 ± 14.4 min [difference 44.6 (95% confidence interval 4.3, 84.8); P = 0.03], except in 3 patients who failed to reach this endpoint.",Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26259978/),min,147.9,51462,DB00030,Insulin Regular
exceeded,26259978,time advantage,The time advantage exceeded 1.5 h in patients with a BMI above the median.,Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26259978/),h,1.5,51463,DB00030,Insulin Regular
,26259978,time to peak insulin levels,"Jet injection also reduced the hyperglycaemic burden during the first 2 h (2042 ± 37.2 vs 2168 ± 26.1 mmol/min; P = 0.01) and the time to peak insulin levels (40.5 ± 3.2 vs 76.8 ± 7.7 min; P < 0.001), but did not increase the risk for hypoglycaemia.",Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26259978/),min,40.5,51464,DB00030,Insulin Regular
,26259978,time to peak insulin levels,"Jet injection also reduced the hyperglycaemic burden during the first 2 h (2042 ± 37.2 vs 2168 ± 26.1 mmol/min; P = 0.01) and the time to peak insulin levels (40.5 ± 3.2 vs 76.8 ± 7.7 min; P < 0.001), but did not increase the risk for hypoglycaemia.",Insulin administered by needle-free jet injection corrects marked hyperglycaemia faster in overweight or obese patients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26259978/),min,76.8,51465,DB00030,Insulin Regular
,23278690,half-life (t(1/2) ),"The half-life (t(1/2) ) was 24.3 (range 17.3-41.3), 28.8 (range 19.6-54.3) and 23.6 (range 17.4-36.8) min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,24.3,51940,DB00030,Insulin Regular
,23278690,half-life (t(1/2) ),"The half-life (t(1/2) ) was 24.3 (range 17.3-41.3), 28.8 (range 19.6-54.3) and 23.6 (range 17.4-36.8) min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,28.8,51941,DB00030,Insulin Regular
,23278690,half-life (t(1/2) ),"The half-life (t(1/2) ) was 24.3 (range 17.3-41.3), 28.8 (range 19.6-54.3) and 23.6 (range 17.4-36.8) min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,23.6,51942,DB00030,Insulin Regular
,23278690,area under the curve per dose (AUC/D),"The area under the curve per dose (AUC/D) was determined to be 51.2 ± 19.5, 52.3 ± 12.5 and 51.6 ± 6.7 pm × min/kg for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),[min·pm] / [kg],51.2,51943,DB00030,Insulin Regular
,23278690,area under the curve per dose (AUC/D),"The area under the curve per dose (AUC/D) was determined to be 51.2 ± 19.5, 52.3 ± 12.5 and 51.6 ± 6.7 pm × min/kg for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),[min·pm] / [kg],52.3,51944,DB00030,Insulin Regular
,23278690,area under the curve per dose (AUC/D),"The area under the curve per dose (AUC/D) was determined to be 51.2 ± 19.5, 52.3 ± 12.5 and 51.6 ± 6.7 pm × min/kg for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),[min·pm] / [kg],51.6,51945,DB00030,Insulin Regular
,23278690,steady state plasma concentration (C(ss) ),"The steady state plasma concentration (C(ss) ) was 57.5 ± 27.1, 54.3 ± 10.3 and 55.1 ± 8.0 pm (mean ± SD) for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),pm,57.5,51946,DB00030,Insulin Regular
,23278690,steady state plasma concentration (C(ss) ),"The steady state plasma concentration (C(ss) ) was 57.5 ± 27.1, 54.3 ± 10.3 and 55.1 ± 8.0 pm (mean ± SD) for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),pm,54.3,51947,DB00030,Insulin Regular
,23278690,steady state plasma concentration (C(ss) ),"The steady state plasma concentration (C(ss) ) was 57.5 ± 27.1, 54.3 ± 10.3 and 55.1 ± 8.0 pm (mean ± SD) for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),pm,55.1,51948,DB00030,Insulin Regular
,23278690,Time to steady state (T(ss) ),"Time to steady state (T(ss) ) was 110 ± 36, 98 ± 48 and 90 ± 27 min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,110,51949,DB00030,Insulin Regular
,23278690,Time to steady state (T(ss) ),"Time to steady state (T(ss) ) was 110 ± 36, 98 ± 48 and 90 ± 27 min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,98,51950,DB00030,Insulin Regular
,23278690,Time to steady state (T(ss) ),"Time to steady state (T(ss) ) was 110 ± 36, 98 ± 48 and 90 ± 27 min for U200, U100 and U20, respectively.",Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23278690/),min,90,51951,DB00030,Insulin Regular
,17663820,maximal concentration (Cmax),The maximal concentration (Cmax) of insulin was (22.1 +/- 8.0) mIU/L vs (118.6 +/- 25.2) mIU/L (tested vs reference preparation); the time for reaching Cmax (Tmax) was (255.8 +/- 142.2) min vs (115.5 +/- 43.4) min.,"[Pharmacodynamics, pharmacokinetics and bioavailability of insulin enteric-coated soft capsules]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17663820/),[miu] / [l],22.1,52408,DB00030,Insulin Regular
,17663820,maximal concentration (Cmax),The maximal concentration (Cmax) of insulin was (22.1 +/- 8.0) mIU/L vs (118.6 +/- 25.2) mIU/L (tested vs reference preparation); the time for reaching Cmax (Tmax) was (255.8 +/- 142.2) min vs (115.5 +/- 43.4) min.,"[Pharmacodynamics, pharmacokinetics and bioavailability of insulin enteric-coated soft capsules]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17663820/),[miu] / [l],118.6,52409,DB00030,Insulin Regular
,17663820,time for reaching Cmax (Tmax),The maximal concentration (Cmax) of insulin was (22.1 +/- 8.0) mIU/L vs (118.6 +/- 25.2) mIU/L (tested vs reference preparation); the time for reaching Cmax (Tmax) was (255.8 +/- 142.2) min vs (115.5 +/- 43.4) min.,"[Pharmacodynamics, pharmacokinetics and bioavailability of insulin enteric-coated soft capsules]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17663820/),min,255.8,52410,DB00030,Insulin Regular
,17663820,time for reaching Cmax (Tmax),The maximal concentration (Cmax) of insulin was (22.1 +/- 8.0) mIU/L vs (118.6 +/- 25.2) mIU/L (tested vs reference preparation); the time for reaching Cmax (Tmax) was (255.8 +/- 142.2) min vs (115.5 +/- 43.4) min.,"[Pharmacodynamics, pharmacokinetics and bioavailability of insulin enteric-coated soft capsules]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17663820/),min,115.5,52411,DB00030,Insulin Regular
,17663820,maximal GIR (GIRmax),The maximal GIR (GIRmax) were (3.56 +/- 0.85) mg.kg(-1).,"[Pharmacodynamics, pharmacokinetics and bioavailability of insulin enteric-coated soft capsules]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17663820/),[mg] / [kg],3.56,52412,DB00030,Insulin Regular
,17663820,time for reaching GIRmax (T(GIRmax)),min(-1); the time for reaching GIRmax (T(GIRmax)) was (166.3 +/- 75.9) min vs (148.0 +/- 40.8) min.,"[Pharmacodynamics, pharmacokinetics and bioavailability of insulin enteric-coated soft capsules]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17663820/),min,166.3,52413,DB00030,Insulin Regular
,17663820,time for reaching GIRmax (T(GIRmax)),min(-1); the time for reaching GIRmax (T(GIRmax)) was (166.3 +/- 75.9) min vs (148.0 +/- 40.8) min.,"[Pharmacodynamics, pharmacokinetics and bioavailability of insulin enteric-coated soft capsules]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17663820/),min,148.0,52414,DB00030,Insulin Regular
,17663820,relative bioavailability,The relative bioavailability and bioefficacy of insulin enteric-coated soft capsules were (7.42 +/- 3.25)% and (24.78 +/- 0.08)%.,"[Pharmacodynamics, pharmacokinetics and bioavailability of insulin enteric-coated soft capsules]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17663820/),%,7.42,52415,DB00030,Insulin Regular
,17663820,bioefficacy,The relative bioavailability and bioefficacy of insulin enteric-coated soft capsules were (7.42 +/- 3.25)% and (24.78 +/- 0.08)%.,"[Pharmacodynamics, pharmacokinetics and bioavailability of insulin enteric-coated soft capsules]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17663820/),%,24.78,52416,DB00030,Insulin Regular
,30074791,"oral bioavailability, F","Compound 15w demonstrated good pharmacokinetics (oral bioavailability, F = 56%) in vivo and has an inhibitory potency against sphingomyelin synthase activity when Institute of Cancer Research mice are provided with an oral dose of this compound.",Discovery of 4-Benzyloxybenzo[ d]isoxazole-3-amine Derivatives as Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors that Reduce Chronic Inflammation in db/ db Mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30074791/),%,56,53301,DB00030,Insulin Regular
,21610201,terminal elimination t(1/2),TAK-875 was eliminated slowly with a mean terminal elimination t(1/2) of approximately 28.1 to 36.6 hours.,"Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21610201/),h,28.1 to 36.6,53622,DB00030,Insulin Regular
,29138048,Zeta potential,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),mv,24.35-34.37,53939,DB00030,Insulin Regular
,29138048,polydispersity,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),,0.365-0.512,53940,DB00030,Insulin Regular
,29138048,entra,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,70.60-86.52,53941,DB00030,Insulin Regular
,29138048,loading capacity,"By optimizing preparation conditions, nanoparticles with expected size (157.3-197.7 nm), Zeta potential (24.35-34.37 mV), polydispersity index (0.365-0.512), entrapment efficiency (70.60-86.52%) and loading capacity (30.92-56.81%), proper morphology and desirable release pattern were obtained.",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,30.92-56.81,53942,DB00030,Insulin Regular
,29138048,relative bioavailability,"In animal model, oral administration of glycyl-glycine and alanyl-alanine conjugate nanoparticles of trimethyl chitosan demonstrated reasonable increase in Serum insulin level with relative bioavailability of 17.19% and 15.46% for glycyl-glycine and alanyl-alanine conjugate nanoparticles, respectively, and reduction in Serum glucose level compared with trimethyl chitosan nanoparticles (p < 0.05).",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,17.19,53943,DB00030,Insulin Regular
,29138048,relative bioavailability,"In animal model, oral administration of glycyl-glycine and alanyl-alanine conjugate nanoparticles of trimethyl chitosan demonstrated reasonable increase in Serum insulin level with relative bioavailability of 17.19% and 15.46% for glycyl-glycine and alanyl-alanine conjugate nanoparticles, respectively, and reduction in Serum glucose level compared with trimethyl chitosan nanoparticles (p < 0.05).",In-vitro and in-vivo cytotoxicity and efficacy evaluation of novel glycyl-glycine and alanyl-alanine conjugates of chitosan and trimethyl chitosan nano-particles as carriers for oral insulin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29138048/),%,15.46,53944,DB00030,Insulin Regular
,29383973,relative bioavailability,INS-LCNPs demonstrated approximately 20% relative bioavailability compared with subcutaneously administered INS.,"Insulin- and quercetin-loaded liquid crystalline nanoparticles: implications on oral bioavailability, antidiabetic and antioxidant efficacy. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29383973/),%,20,54059,DB00030,Insulin Regular
,32680576,bioavailability,"In vivo pharmacokinetic results showed that the bioavailability of ORLN-conjugated insulin was approximately 28.7% relative to that of the group subcutaneously administered with an aqueous solution of insulin, indicating enhanced oral absorption.","""Oil-soluble"" reversed lipid nanoparticles for oral insulin delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32680576/),%,28.7,54273,DB00030,Insulin Regular
,25124362,AUCGIR,"No pronounced differences were observed in the glucose-lowering effect of IDeg [area under the glucose infusion rate (GIR) curve 0-24 h after a single dose (AUCGIR,0-24h,SD) and maximum GIR after a single dose (GIRmax,SD)] when injected in the thigh, abdomen or deltoid (AUCGIR,0-24h,SD 2,572, 2,833 and 2,960 mg/kg, respectively).",Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25124362/),mg,"2,572",54697,DB00030,Insulin Regular
,25124362,AUCGIR,"No pronounced differences were observed in the glucose-lowering effect of IDeg [area under the glucose infusion rate (GIR) curve 0-24 h after a single dose (AUCGIR,0-24h,SD) and maximum GIR after a single dose (GIRmax,SD)] when injected in the thigh, abdomen or deltoid (AUCGIR,0-24h,SD 2,572, 2,833 and 2,960 mg/kg, respectively).",Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25124362/),mg,"2,833",54698,DB00030,Insulin Regular
,25124362,AUCGIR,"No pronounced differences were observed in the glucose-lowering effect of IDeg [area under the glucose infusion rate (GIR) curve 0-24 h after a single dose (AUCGIR,0-24h,SD) and maximum GIR after a single dose (GIRmax,SD)] when injected in the thigh, abdomen or deltoid (AUCGIR,0-24h,SD 2,572, 2,833 and 2,960 mg/kg, respectively).",Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25124362/),mg,"2,960",54699,DB00030,Insulin Regular
,19764836,ATBF,ATBF increased from day 0 to day 2 after catheter insertion (2.6 +/- 0.6 to 4.5 +/- 0.8 mL/100 g/min; P = 0.030).,Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764836/),[ml] / [100·g·min],2.6,55143,DB00030,Insulin Regular
,19764836,ATBF,ATBF increased from day 0 to day 2 after catheter insertion (2.6 +/- 0.6 to 4.5 +/- 0.8 mL/100 g/min; P = 0.030).,Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764836/),[ml] / [100·g·min],4.5,55144,DB00030,Insulin Regular
,19764836,Time to peak plasma insulin aspart concentration,Time to peak plasma insulin aspart concentration after bolus administration decreased with catheter wear-time from 55 +/- 3 min on day 0 to 45 +/- 4 min on day 4 (P = 0.019).,Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764836/),min,55,55145,DB00030,Insulin Regular
,19764836,Time to peak plasma insulin aspart concentration,Time to peak plasma insulin aspart concentration after bolus administration decreased with catheter wear-time from 55 +/- 3 min on day 0 to 45 +/- 4 min on day 4 (P = 0.019).,Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19764836/),min,45,55146,DB00030,Insulin Regular
,16563883,flow rate,"The isocratic mobile phase consisted of acetonitrile-10 mmol/l sodium phosphate buffer (pH 4.5) (65:35, v/v) was delivered at a flow rate of 1 ml/min to a Kromasil C(18) reversed-phase column (250 mm x 4.6 mm, 5 microm).","Quantitative determination of MCC-555, a novel insulin sensitizer in beagle dog plasma by high-performance liquid chromatography with fluorescence detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16563883/),[ml] / [min],1,55338,DB00030,Insulin Regular
,23018469,elimination half-life,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),h,3.75,55343,DB00030,Insulin Regular
,23018469,elimination half-life,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),h,4.00,55344,DB00030,Insulin Regular
,23018469,time to maximum concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),h,2.00,55345,DB00030,Insulin Regular
,23018469,time to maximum concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),h,3.00,55346,DB00030,Insulin Regular
,23018469,maximum concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[μg] / [ml],1.42,55347,DB00030,Insulin Regular
,23018469,maximum concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[μg] / [ml],1.21,55348,DB00030,Insulin Regular
,23018469,concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[μg] / [ml],0.53,55349,DB00030,Insulin Regular
,23018469,concentration,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[μg] / [ml],0.56,55350,DB00030,Insulin Regular
,23018469,area under the plasma concentration-time curve from time zero to 12 h,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[h·μg] / [ml],6.42,55351,DB00030,Insulin Regular
,23018469,area under the plasma concentration-time curve from time zero to 12 h,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[h·μg] / [ml],6.73,55352,DB00030,Insulin Regular
,23018469,apparent total oral clearance,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[l] / [h],105.39,55353,DB00030,Insulin Regular
,23018469,apparent total oral clearance,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),[l] / [h],98.38,55354,DB00030,Insulin Regular
,23018469,apparent volume of distribution,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),l,550.51,55355,DB00030,Insulin Regular
,23018469,apparent volume of distribution,"The pharmacokinetic parameters detected for PCOS versus T2DM patients, reported as median, were, respectively: elimination half-life 3.75 versus 4.00 h; time to maximum concentration 2.00 versus 3.00 h; maximum concentration 1.42 versus 1.21 μg/mL; mean concentration 0.53 versus 0.56 μg/mL; area under the plasma concentration-time curve from time zero to 12 h 6.42 versus 6.73 μg·h/mL; apparent total oral clearance 105.39 versus 98.38 L/h; apparent volume of distribution after oral administration 550.51 versus 490.98 L; and fluctuation (maximum-minimum concentration variation) of 179.56 versus 181.73 %.",Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018469/),l,490.98,55356,DB00030,Insulin Regular
,15359571,Mon,"Monomeric content of hGH recovered from SR-hGH was 97.4% by SEC analysis, and its purity was 96% by RP-HPLC analysis.",Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359571/),%,97.4,55510,DB00030,Insulin Regular
,15359571,Cmax,Delayed absorption of hGH was observed with Cmax of 69.5+/-8.0 ng/ml and Tmax between 10 and 12 h.,Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359571/),[ng] / [ml],69.5,55511,DB00030,Insulin Regular
,15359571,Tmax,Delayed absorption of hGH was observed with Cmax of 69.5+/-8.0 ng/ml and Tmax between 10 and 12 h.,Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359571/),h,10 and 12,55512,DB00030,Insulin Regular
,25137036,AUC,"There were also significant differences in AUC of insulin (48,418±22,707 vs. 26,473±8,273 pmol/L, P=0.003) and insulinogenic index (0.48±0.22 vs. 0.28±0.08, P=0.004).","Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137036/),[pM] / [l],"48,418",56581,DB00030,Insulin Regular
,25137036,AUC,"There were also significant differences in AUC of insulin (48,418±22,707 vs. 26,473±8,273 pmol/L, P=0.003) and insulinogenic index (0.48±0.22 vs. 0.28±0.08, P=0.004).","Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137036/),[pM] / [l],"26,473",56582,DB00030,Insulin Regular
,25137036,insulinogenic index,"There were also significant differences in AUC of insulin (48,418±22,707 vs. 26,473±8,273 pmol/L, P=0.003) and insulinogenic index (0.48±0.22 vs. 0.28±0.08, P=0.004).","Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137036/),,0.48,56583,DB00030,Insulin Regular
,25137036,insulinogenic index,"There were also significant differences in AUC of insulin (48,418±22,707 vs. 26,473±8,273 pmol/L, P=0.003) and insulinogenic index (0.48±0.22 vs. 0.28±0.08, P=0.004).","Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25137036/),,0.28,56584,DB00030,Insulin Regular
,16025254,t(1/2),"During GLP-1 infusion, candoxatril doubled C-terminal immunoreactivity, improving the pharmacokinetics (t(1/2) 2.3+/-0.1 to 8.8+/-1.2 min; metabolic clearance rate [MCR] 20.4+/-3.4 to 4.8+/-0.4 ml.kg(-1).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),min,2.3,56674,DB00030,Insulin Regular
,16025254,t(1/2),"During GLP-1 infusion, candoxatril doubled C-terminal immunoreactivity, improving the pharmacokinetics (t(1/2) 2.3+/-0.1 to 8.8+/-1.2 min; metabolic clearance rate [MCR] 20.4+/-3.4 to 4.8+/-0.4 ml.kg(-1).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),min,8.8,56675,DB00030,Insulin Regular
,16025254,metabolic clearance rate [MCR],"During GLP-1 infusion, candoxatril doubled C-terminal immunoreactivity, improving the pharmacokinetics (t(1/2) 2.3+/-0.1 to 8.8+/-1.2 min; metabolic clearance rate [MCR] 20.4+/-3.4 to 4.8+/-0.4 ml.kg(-1).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[ml] / [kg],20.4,56676,DB00030,Insulin Regular
,16025254,metabolic clearance rate [MCR],"During GLP-1 infusion, candoxatril doubled C-terminal immunoreactivity, improving the pharmacokinetics (t(1/2) 2.3+/-0.1 to 8.8+/-1.2 min; metabolic clearance rate [MCR] 20.4+/-3.4 to 4.8+/-0.4 ml.kg(-1).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[ml] / [kg],4.8,56677,DB00030,Insulin Regular
,16025254,t(1/2),"min(-1); p<0.01), but had no effect upon intact GLP-1 (t(1/2) 1.4+/-0.1 to 1.6+/-0.1 min; MCR 47.9+/-8.0 to 38.8+/-5.0 ml.kg(-1).min(-1)).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),min,1.4,56678,DB00030,Insulin Regular
,16025254,t(1/2),"min(-1); p<0.01), but had no effect upon intact GLP-1 (t(1/2) 1.4+/-0.1 to 1.6+/-0.1 min; MCR 47.9+/-8.0 to 38.8+/-5.0 ml.kg(-1).min(-1)).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),min,1.6,56679,DB00030,Insulin Regular
,16025254,MCR,"min(-1); p<0.01), but had no effect upon intact GLP-1 (t(1/2) 1.4+/-0.1 to 1.6+/-0.1 min; MCR 47.9+/-8.0 to 38.8+/-5.0 ml.kg(-1).min(-1)).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[ml] / [kg·min],47.9,56680,DB00030,Insulin Regular
,16025254,MCR,"min(-1); p<0.01), but had no effect upon intact GLP-1 (t(1/2) 1.4+/-0.1 to 1.6+/-0.1 min; MCR 47.9+/-8.0 to 38.8+/-5.0 ml.kg(-1).min(-1)).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[ml] / [kg·min],38.8,56681,DB00030,Insulin Regular
,16025254,DeltaAUC(min,"Insulin responses to intravenous glucose were unaffected by candoxatril, but glucose tolerance was improved (DeltaAUC(min 27-87) 118+/-5 to 74+/-14 min.mmol.l(-1); glucose elimination rate [k] 6.6+/-0.5 to 8.6+/-0.5%; p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[mM·min] / [l],27,56682,DB00030,Insulin Regular
,16025254,DeltaAUC(min,"Insulin responses to intravenous glucose were unaffected by candoxatril, but glucose tolerance was improved (DeltaAUC(min 27-87) 118+/-5 to 74+/-14 min.mmol.l(-1); glucose elimination rate [k] 6.6+/-0.5 to 8.6+/-0.5%; p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[mM·min] / [l],118,56683,DB00030,Insulin Regular
,16025254,DeltaAUC(min,"Insulin responses to intravenous glucose were unaffected by candoxatril, but glucose tolerance was improved (DeltaAUC(min 27-87) 118+/-5 to 74+/-14 min.mmol.l(-1); glucose elimination rate [k] 6.6+/-0.5 to 8.6+/-0.5%; p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[mM·min] / [l],74,56684,DB00030,Insulin Regular
,16025254,glucose elimination rate [k],"Insulin responses to intravenous glucose were unaffected by candoxatril, but glucose tolerance was improved (DeltaAUC(min 27-87) 118+/-5 to 74+/-14 min.mmol.l(-1); glucose elimination rate [k] 6.6+/-0.5 to 8.6+/-0.5%; p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),%,6.6,56685,DB00030,Insulin Regular
,16025254,glucose elimination rate [k],"Insulin responses to intravenous glucose were unaffected by candoxatril, but glucose tolerance was improved (DeltaAUC(min 27-87) 118+/-5 to 74+/-14 min.mmol.l(-1); glucose elimination rate [k] 6.6+/-0.5 to 8.6+/-0.5%; p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),%,8.6,56686,DB00030,Insulin Regular
,16025254,t(1/2),"When candoxatril was co-administered with valine pyrrolidide (a DPP-IV inhibitor), changes in C-terminal GLP-1 pharmacokinetics mirrored those seen when candoxatril alone was administered (t(1/2) 2.7+/-0.3 and 7.7+/-0.8 min; MCR 17.3+/-2.6 and 6.5+/-0.8 ml.kg(-1).min(-1) for valine pyrrolidide without and with candoxatril, respectively).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),min,2.7,56687,DB00030,Insulin Regular
,16025254,t(1/2),"When candoxatril was co-administered with valine pyrrolidide (a DPP-IV inhibitor), changes in C-terminal GLP-1 pharmacokinetics mirrored those seen when candoxatril alone was administered (t(1/2) 2.7+/-0.3 and 7.7+/-0.8 min; MCR 17.3+/-2.6 and 6.5+/-0.8 ml.kg(-1).min(-1) for valine pyrrolidide without and with candoxatril, respectively).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),min,7.7,56688,DB00030,Insulin Regular
,16025254,MCR,"When candoxatril was co-administered with valine pyrrolidide (a DPP-IV inhibitor), changes in C-terminal GLP-1 pharmacokinetics mirrored those seen when candoxatril alone was administered (t(1/2) 2.7+/-0.3 and 7.7+/-0.8 min; MCR 17.3+/-2.6 and 6.5+/-0.8 ml.kg(-1).min(-1) for valine pyrrolidide without and with candoxatril, respectively).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[ml] / [kg·min],17.3,56689,DB00030,Insulin Regular
,16025254,MCR,"When candoxatril was co-administered with valine pyrrolidide (a DPP-IV inhibitor), changes in C-terminal GLP-1 pharmacokinetics mirrored those seen when candoxatril alone was administered (t(1/2) 2.7+/-0.3 and 7.7+/-0.8 min; MCR 17.3+/-2.6 and 6.5+/-0.8 ml.kg(-1).min(-1) for valine pyrrolidide without and with candoxatril, respectively).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[ml] / [kg·min],6.5,56690,DB00030,Insulin Regular
,16025254,t(1/2),"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),min,2.8,56691,DB00030,Insulin Regular
,16025254,t(1/2),"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),min,7.5,56692,DB00030,Insulin Regular
,16025254,MCR,"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[ml] / [kg·min],18.3,56693,DB00030,Insulin Regular
,16025254,MCR,"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[ml] / [kg·min],9.4,56694,DB00030,Insulin Regular
,16025254,glucose deltaAUC,"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[mM·min] / [l],103,56695,DB00030,Insulin Regular
,16025254,glucose deltaAUC,"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[mM·min] / [l],62,56696,DB00030,Insulin Regular
,16025254,k,"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),%,6.8,56697,DB00030,Insulin Regular
,16025254,k,"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),%,11.4,56698,DB00030,Insulin Regular
,16025254,deltaAUC,"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[min·pM] / [l],"3,680",56699,DB00030,Insulin Regular
,16025254,deltaAUC,"However, intact GLP-1 pharmacokinetics were improved (t(1/2) 2.8+/-0.3 and 7.5+/-0.6 min; MCR 18.3+/-0.6 and 9.4+/-0.9 ml.kg(-1).min(-1); p<0.02), potentiating the antihyperglycaemic/insulinotropic effects of GLP-1 (glucose deltaAUC(min 27- 87) 103+/-8 to 62+/-14 min.mmol.l(-1); k 6.8+/-0.4 to 11.4+/-1.4%; insulin deltaAUC(min 27-87) 3,680+/-738 to 7,201+/-1,183 min.pmol.l(-1); p<0.05).",Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16025254/),[min·pM] / [l],"7,201",56700,DB00030,Insulin Regular
,17311892,initial half-life,"s-Ghrelin initial half-life was 24 +/- 2 min and terminal half-life 146 +/- 36 min, respectively.",Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17311892/),min,24,57438,DB00030,Insulin Regular
,17311892,terminal half-life,"s-Ghrelin initial half-life was 24 +/- 2 min and terminal half-life 146 +/- 36 min, respectively.",Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17311892/),min,146,57439,DB00030,Insulin Regular
,17311892,Mean residence time (MRT),Mean residence time (MRT) of ghrelin was 93 +/- 16 min.,Constant intravenous ghrelin infusion in healthy young men: clinical pharmacokinetics and metabolic effects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17311892/),min,93,57440,DB00030,Insulin Regular
,19236441,area under the curve (AUC)(0-4 h,"Insulin area under the curve (AUC)(0-4 h) was similar for both test periods; 656; interquartile range (IQR): 518-1755 (normal tissue) vs. 602; IQR: 382-1436 (lipohypertrophic tissue), z = 1.7, p = 0.09.",Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236441/),,656,58059,DB00030,Insulin Regular
,19236441,area under the curve (AUC)(0-4 h,"Insulin area under the curve (AUC)(0-4 h) was similar for both test periods; 656; interquartile range (IQR): 518-1755 (normal tissue) vs. 602; IQR: 382-1436 (lipohypertrophic tissue), z = 1.7, p = 0.09.",Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236441/),,602,58060,DB00030,Insulin Regular
,19236441,time to maximal insulin concentration (Time(max),There was also no difference in the median time to maximal insulin concentration (Time(max) 2 h; IQR: 2-3 h; z = 0.6; p = 0.6).,Lipohypertrophy: does it matter in daily life? A study using a continuous glucose monitoring system. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236441/),h,2,58061,DB00030,Insulin Regular
,25559205,IC50,"A stepwise optimization by combination of active fragments led to discovery of compound 6f and 6k, two structures with IGF-1R IC50 of 20 nM and 10 nM, respectively.",Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559205/),nM,20,58480,DB00030,Insulin Regular
,25559205,IC50,"A stepwise optimization by combination of active fragments led to discovery of compound 6f and 6k, two structures with IGF-1R IC50 of 20 nM and 10 nM, respectively.",Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559205/),nM,10,58481,DB00030,Insulin Regular
,24353417,zeta potential,"Developed SLNs showed homogeneous spherical shapes, small size (76.8 nm), zeta potential (7.87 mV), encapsulation efficiency (58%), and drug loading (4.2%).","Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353417/),m,7.87,58796,DB00030,Insulin Regular
,24353417,en,"Developed SLNs showed homogeneous spherical shapes, small size (76.8 nm), zeta potential (7.87 mV), encapsulation efficiency (58%), and drug loading (4.2%).","Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24353417/),%,58,58797,DB00030,Insulin Regular
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mg] / [l·min],758,58897,DB00030,Insulin Regular
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mg] / [l·min],780,58898,DB00030,Insulin Regular
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mu] / [l·min],2327,58899,DB00030,Insulin Regular
,16142016,AUC,Analysis of the insulin and glucose concentrations throughout the meal test revealed that AUC for glucose (758 +/- 19 vs 780 +/- 28 mg/Lxmin; P = 0.02) was significantly lower after repaglinide than glimepiride administration despite similar AUC for insulin (2327 +/- 269 vs 2148 +/- 292 mU/Lxmin; P = 0.105).,Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16142016/),[mu] / [l·min],2148,58900,DB00030,Insulin Regular
,21177764,time on study,Median time on study was 104 days (range 17-300).,Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21177764/),d,104,60784,DB00030,Insulin Regular
,23933302,Entrapment efficiency,"Entrapment efficiency of insulin increased significantly when the thiolated chitosan was employed (95.14±2.96%), in comparison to the insulin SNEDDS (80.38±1.22%).",Combining two technologies: multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23933302/),%,95.14,60972,DB00030,Insulin Regular
,23933302,Entrapment efficiency,"Entrapment efficiency of insulin increased significantly when the thiolated chitosan was employed (95.14±2.96%), in comparison to the insulin SNEDDS (80.38±1.22%).",Combining two technologies: multifunctional polymers and self-nanoemulsifying drug delivery system (SNEDDS) for oral insulin administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23933302/),%,80.38,60973,DB00030,Insulin Regular
greater,27242314,residence time,"The in vivo fluorescence images of mice injected with rhodamine B isothiocyanate-labelled nanogel suspension showed fluorescence intensity up to 96h after intravenous injection, indicating that the in vivo residence time of the nanogel was greater than 96h.","In vivo residence duration of human growth hormone loaded in nanogels comprising cinnamoyl alginate, cinnamoyl Pluronic F127 and cinnamoyl poly(ethylene glycol). ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27242314/),h,96,61121,DB00030,Insulin Regular
,18192544,area under the curve(0-t'),"AIR insulin exposure was reduced 34 and 41% (both P < 0.01) in asthmatic subjects (area under the curve(0-t'), 24.0 and 21.1 nmol x min x l(-1) in mild and moderate asthma subjects, respectively) compared with healthy subjects (35.2 nmol x min x l(-1)), respectively.","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),[min·nM] / [l],24.0,62244,DB00030,Insulin Regular
,18192544,area under the curve(0-t'),"AIR insulin exposure was reduced 34 and 41% (both P < 0.01) in asthmatic subjects (area under the curve(0-t'), 24.0 and 21.1 nmol x min x l(-1) in mild and moderate asthma subjects, respectively) compared with healthy subjects (35.2 nmol x min x l(-1)), respectively.","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),[min·nM] / [l],21.1,62245,DB00030,Insulin Regular
,18192544,area under the curve(0-t'),"AIR insulin exposure was reduced 34 and 41% (both P < 0.01) in asthmatic subjects (area under the curve(0-t'), 24.0 and 21.1 nmol x min x l(-1) in mild and moderate asthma subjects, respectively) compared with healthy subjects (35.2 nmol x min x l(-1)), respectively.","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),[min·nM] / [l],35.2,62246,DB00030,Insulin Regular
,18192544,G(tot),"Glucodynamic (G) effects were similar in healthy and mildly asthmatic subjects (G(tot) = 38.7 and 23.4 g, respectively; P = 0.16) and were reduced in moderately asthmatic subjects (G(tot) = 10.7 g).","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),g,38.7,62247,DB00030,Insulin Regular
,18192544,G(tot),"Glucodynamic (G) effects were similar in healthy and mildly asthmatic subjects (G(tot) = 38.7 and 23.4 g, respectively; P = 0.16) and were reduced in moderately asthmatic subjects (G(tot) = 10.7 g).","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),g,23.4,62248,DB00030,Insulin Regular
,18192544,G(tot),"Glucodynamic (G) effects were similar in healthy and mildly asthmatic subjects (G(tot) = 38.7 and 23.4 g, respectively; P = 0.16) and were reduced in moderately asthmatic subjects (G(tot) = 10.7 g).","AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18192544/),g,10.7,62249,DB00030,Insulin Regular
,20357371,maximal glucose infusion rates,"Increases in glucose flux revealed no discernible peak and were modest with maximal glucose infusion rates of 9.4, 6.6, 5.5, and 2.8 mumol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively.",Dose-response effects of insulin glargine in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357371/),[μM] / [kg·min],9.4,62311,DB00030,Insulin Regular
,20357371,maximal glucose infusion rates,"Increases in glucose flux revealed no discernible peak and were modest with maximal glucose infusion rates of 9.4, 6.6, 5.5, and 2.8 mumol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively.",Dose-response effects of insulin glargine in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357371/),[μM] / [kg·min],6.6,62312,DB00030,Insulin Regular
,20357371,maximal glucose infusion rates,"Increases in glucose flux revealed no discernible peak and were modest with maximal glucose infusion rates of 9.4, 6.6, 5.5, and 2.8 mumol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively.",Dose-response effects of insulin glargine in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357371/),[μM] / [kg·min],5.5,62313,DB00030,Insulin Regular
,20357371,maximal glucose infusion rates,"Increases in glucose flux revealed no discernible peak and were modest with maximal glucose infusion rates of 9.4, 6.6, 5.5, and 2.8 mumol/kg/min for the 2.0, 1.5, 1.0, and 0.5 units/kg doses, respectively.",Dose-response effects of insulin glargine in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357371/),[μM] / [kg·min],2.8,62314,DB00030,Insulin Regular
less,27232339,half-life,"However, its clinical benefits are limited by its short half-life, which is less than 2 min because of its small size and rapid enzymatic inactivation by dipeptidyl peptidase IV.","Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27232339/),min,2,62329,DB00030,Insulin Regular
,27232339,half-life,The half-life of GLP-1-IgG2σ-Fc in cynomolgus monkeys was approximately 57.1 ± 4.5 h.,"Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27232339/),h,57.1,62330,DB00030,Insulin Regular
,19176244,relative bioavailability,Oral administration of insulin-loaded NPs demonstrated a significant hypoglycemic action for at least 10h in diabetic rats and the corresponding relative bioavailability of insulin was found to be 15.1+/-0.9%.,In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19176244/),%,15.1,62905,DB00030,Insulin Regular
,19055616,In-Cl,The mean of In-Cl was 44.5 +/- 17.9 ml/min/1.73 m(2).,Validation of plasma clearance of 51Cr-EDTA in adult renal transplant recipients: comparison with inulin renal clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19055616/),[1.73·min·ml] / [m(2],44.5,63838,DB00030,Insulin Regular
,22612529,bioavailability,"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),%,55,64209,DB00030,Insulin Regular
,22612529,t(1/2),"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),h,3.5,64210,DB00030,Insulin Regular
,22612529,T(max),"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),h,3.6,64211,DB00030,Insulin Regular
,22612529,C(max),"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),[ng] / [ml],2131,64212,DB00030,Insulin Regular
,22612529,AUC(0-∞),"After oral administration, mean bioavailability was 55%, t(1/2) was 3.5 h, T(max) was 3.6 h, C(max) was 2131 ng/mL, and AUC(0-∞) was 15 556 ng/mL · h.",Pharmacokinetics of pioglitazone in lean and obese cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22612529/),[ng] / [h·ml],15 556,64213,DB00030,Insulin Regular
,19129748,half-life,Dapagliflozin exhibited dose-proportional plasma concentrations with a half-life of approximately 17 h.,"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19129748/),h,17,64241,DB00030,Insulin Regular
,16168194,area under the glucose curve (AUC),The negative area under the glucose curve (AUC) (mean [standard error of the mean (SEM)]) was -1.42 (0.09) mmol min/L in cases and -1.76 (0.09) in controls (P = 0.004).,The glucose response to an oral fat tolerance test in young men with a paternal history of premature myocardial infarction: possible early indication of insulin resistance. The EARS 2 study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16168194/),[mM·min] / [l],1.42,65710,DB00030,Insulin Regular
,16168194,area under the glucose curve (AUC),The negative area under the glucose curve (AUC) (mean [standard error of the mean (SEM)]) was -1.42 (0.09) mmol min/L in cases and -1.76 (0.09) in controls (P = 0.004).,The glucose response to an oral fat tolerance test in young men with a paternal history of premature myocardial infarction: possible early indication of insulin resistance. The EARS 2 study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16168194/),,1.76,65711,DB00030,Insulin Regular
,16168194,Peak height,Peak height (mean [SEM]) was -0.65 (0.02) mmol/L in cases and -0.73 (0.02) in controls (P = 0.007).,The glucose response to an oral fat tolerance test in young men with a paternal history of premature myocardial infarction: possible early indication of insulin resistance. The EARS 2 study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16168194/),[mM] / [l],-,65712,DB00030,Insulin Regular
,16168194,Peak height,Peak height (mean [SEM]) was -0.65 (0.02) mmol/L in cases and -0.73 (0.02) in controls (P = 0.007).,The glucose response to an oral fat tolerance test in young men with a paternal history of premature myocardial infarction: possible early indication of insulin resistance. The EARS 2 study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16168194/),[mM] / [l],0.65,65713,DB00030,Insulin Regular
,16168194,Peak height,Peak height (mean [SEM]) was -0.65 (0.02) mmol/L in cases and -0.73 (0.02) in controls (P = 0.007).,The glucose response to an oral fat tolerance test in young men with a paternal history of premature myocardial infarction: possible early indication of insulin resistance. The EARS 2 study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16168194/),,0.73,65714,DB00030,Insulin Regular
,16168194,AUC,Insulin AUC (mean [SEM]) was 161 (10) mU min/L in cases and 148 (10) in controls (P = 0.34).,The glucose response to an oral fat tolerance test in young men with a paternal history of premature myocardial infarction: possible early indication of insulin resistance. The EARS 2 study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16168194/),[min·mu] / [l],161,65715,DB00030,Insulin Regular
,16168194,AUC,Insulin AUC (mean [SEM]) was 161 (10) mU min/L in cases and 148 (10) in controls (P = 0.34).,The glucose response to an oral fat tolerance test in young men with a paternal history of premature myocardial infarction: possible early indication of insulin resistance. The EARS 2 study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16168194/),,148,65716,DB00030,Insulin Regular
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],50.8,65727,DB00030,Insulin Regular
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],100.3,65728,DB00030,Insulin Regular
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],177.69,65729,DB00030,Insulin Regular
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],246.2,65730,DB00030,Insulin Regular
,20590742,C(max),"The insulin C(max) values were found to be 50.8 +/- 26.0 mU/L for placebo, 100.3 +/- 66.7 with 10 mg IN-105, 177.69 +/- 150.3 with 15 mg IN-105, 246.2 +/- 245.2 with 20 mg IN-105 and 352.5 +/- 279.3 mU/L with 30 mg of IN-105.",A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20590742/),[mu] / [l],352.5,65731,DB00030,Insulin Regular
,32263103,bioavailability,A mild and prolonged hypoglycaemic effect is achieved in both normal and diabetic rats for a duration of at least 20 h with pharmacological bioavailability as high as about 9-10%.,Glucan microparticles thickened with thermosensitive gels as potential carriers for oral delivery of insulin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32263103/),%,9-10,65786,DB00030,Insulin Regular
,28656605,maximum concentration,Mean serum concentrations of somapacitan increased in a dose-dependent but nonlinear manner: maximum concentration ranged from 21.8 ng/mL (0.02 mg/kg dose) to 458.4 ng/mL (0.16 mg/kg dose).,"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28656605/),[ng] / [ml],21.8,67055,DB00030,Insulin Regular
,28656605,maximum concentration,Mean serum concentrations of somapacitan increased in a dose-dependent but nonlinear manner: maximum concentration ranged from 21.8 ng/mL (0.02 mg/kg dose) to 458.4 ng/mL (0.16 mg/kg dose).,"Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28656605/),[ng] / [ml],458.4,67056,DB00030,Insulin Regular
,25227138,area under the curve,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[h·μg·∙] / [ml],"2,174.4",68858,DB00030,Insulin Regular
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[h·μg·∙] / [ml],"3,128",68859,DB00030,Insulin Regular
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),h,23.7,68860,DB00030,Insulin Regular
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),h,8.87,68861,DB00030,Insulin Regular
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[ml] / [h],13.9,68862,DB00030,Insulin Regular
,25227138,biological half-life,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[ml] / [h],151.1,68863,DB00030,Insulin Regular
,25227138,clearance,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[ml] / [h],13.9,68864,DB00030,Insulin Regular
,25227138,clearance,"In the case of the rat and rabbit study, the β-HPC area under the curve, biological half-life, and clearance were 2,174.4 versus 3,128 μg ∙ h/ml, 23.7 versus 8.87 h, and 13.9 versus 151.1 ml/h in the rats versus the rabbits, respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[ml] / [h],151.1,68865,DB00030,Insulin Regular
,25227138,time of maximal concentration,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),h,0.58,68866,DB00030,Insulin Regular
,25227138,time of maximal concentration,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),h,1.53,68867,DB00030,Insulin Regular
,25227138,maximal concentration,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[μg] / [ml],62.4,68868,DB00030,Insulin Regular
,25227138,maximal concentration,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),[μg] / [ml],221.4,68869,DB00030,Insulin Regular
,25227138,absorption rate constant,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),1/[h],0.02,68870,DB00030,Insulin Regular
,25227138,absorption rate constant,"The values for the time of maximal concentration were 0.58 versus 1.53 h, for the maximal concentration, they were 62.4 versus 221.4 μg/ml, and for the absorption rate constant 0.02 versus 2.40 h(-1), respectively.",Pharmacokinetic and pharmacological effects of β-hydroxyphosphocarnitine in animal models. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25227138/),1/[h],2.40,68871,DB00030,Insulin Regular
,33754315,AUC0-168 h,"AUC0-168 h of IGF-I was increased in the moderate impairment group (1.35 [1.09-1.66]), severe impairment group (1.40 [1.10-1.78]), and requiring hemodialysis group (1.24 [1.01-1.52]), compared with the normal function group.","Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,1.35,69510,DB00030,Insulin Regular
,33754315,AUC0-168 h,"AUC0-168 h of IGF-I was increased in the moderate impairment group (1.35 [1.09-1.66]), severe impairment group (1.40 [1.10-1.78]), and requiring hemodialysis group (1.24 [1.01-1.52]), compared with the normal function group.","Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,1.40,69511,DB00030,Insulin Regular
,33754315,AUC0-168 h,"AUC0-168 h of IGF-I was increased in the moderate impairment group (1.35 [1.09-1.66]), severe impairment group (1.40 [1.10-1.78]), and requiring hemodialysis group (1.24 [1.01-1.52]), compared with the normal function group.","Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,1.24,69512,DB00030,Insulin Regular
,33754315,AUC0-168 h,"In the hepatic impairment trial, somapacitan AUC0-168 h was significantly higher in the moderate impairment group compared with the normal hepatic function group (4.69 [2.92-7.52]).","Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,4.69,69513,DB00030,Insulin Regular
,33754315,AUC0-168 h,IGF-I AUC0-168 h was lower in both hepatic impairment groups (0.85 [0.67-1.08] for the mild impairment group and 0.75 [0.60-0.95] for the moderate impairment group) compared with the normal function group.,"Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,0.85,69514,DB00030,Insulin Regular
,33754315,AUC0-168 h,IGF-I AUC0-168 h was lower in both hepatic impairment groups (0.85 [0.67-1.08] for the mild impairment group and 0.75 [0.60-0.95] for the moderate impairment group) compared with the normal function group.,"Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33754315/),,0.75,69515,DB00030,Insulin Regular
,31819423,particle,"The mean particle size, PDI, and ZP values of INS-SLNs, LP-INS-SLNs, and DP-INS-SLNs ranged from 618.5 to 973.0 nm, 0.227 to 0.734, and -17.0 to -23.7 mV, respectively.",Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31819423/),m,0,70834,DB00030,Insulin Regular
,31819423,PDI,"The mean particle size, PDI, and ZP values of INS-SLNs, LP-INS-SLNs, and DP-INS-SLNs ranged from 618.5 to 973.0 nm, 0.227 to 0.734, and -17.0 to -23.7 mV, respectively.",Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31819423/),m,0,70835,DB00030,Insulin Regular
,31819423,encapsulation efficiency (,"The encapsulation efficiency (%EE) and drug loading (%DL) of INS-SLNs, LP-INS-SLNs, and DP-INS-SLNs ranged from 59.03% to 67.42% and from 1.62% to 1.82%, respectively.",Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31819423/),%,59,70836,DB00030,Insulin Regular
,31819423,encapsulation efficiency (,"The encapsulation efficiency (%EE) and drug loading (%DL) of INS-SLNs, LP-INS-SLNs, and DP-INS-SLNs ranged from 59.03% to 67.42% and from 1.62% to 1.82%, respectively.",Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31819423/),%,67.42,70837,DB00030,Insulin Regular
,31819423,availability (PA),"The pharmacological availability (PA) and BA of orally administered LP-INS-SLNs, which were the most effective SLNs, were 13.1% and 15.7% relative to s.c. administration, respectively.",Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31819423/),%,13.1,70838,DB00030,Insulin Regular
,31819423,BA,"The pharmacological availability (PA) and BA of orally administered LP-INS-SLNs, which were the most effective SLNs, were 13.1% and 15.7% relative to s.c. administration, respectively.",Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31819423/),%,15.7,70839,DB00030,Insulin Regular
,12518253,glucose concentrations,Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mM] / [l],3.2,71255,DB00030,Insulin Regular
,12518253,glucose concentrations,Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mM] / [l],3.5,71256,DB00030,Insulin Regular
,12518253,glucose concentrations,Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mM] / [l],3.4,71257,DB00030,Insulin Regular
,12518253,t min,For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,59.3,71258,DB00030,Insulin Regular
,12518253,t min,For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,63.5,71259,DB00030,Insulin Regular
,12518253,C-peptide,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],225,71260,DB00030,Insulin Regular
,12518253,C-peptide,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],309,71261,DB00030,Insulin Regular
,12518253,C-peptide concentrations,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],117,71262,DB00030,Insulin Regular
,12518253,C-peptide concentrations,"After 40 min a lower C-peptide was determined for aspart (225 +/- 21 pmol/l versus lispro 309 +/- 33 pmol/l; p = 0.031), whereas minimal C-peptide concentrations were reached in both groups after 105 min (lispro 117 +/- 21 pmol/l versus aspart 105 +/- 18 pmol/l).",Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[pM] / [l],105,71263,DB00030,Insulin Regular
,12518253,maximal concentration,The maximal concentration of insulin was detected in both groups after 40 min (lispro 20.8 +/- 1.1 mU/l versus aspart 24.6 +/- 1.3 mU/l; p = 0.032).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mu] / [l],20.8,71264,DB00030,Insulin Regular
,12518253,maximal concentration,The maximal concentration of insulin was detected in both groups after 40 min (lispro 20.8 +/- 1.1 mU/l versus aspart 24.6 +/- 1.3 mU/l; p = 0.032).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),[mu] / [l],24.6,71265,DB00030,Insulin Regular
,12518253,t max,For insulin t max was 33.0 +/- 2.6 min in the aspart versus 33.3 +/- 2.6 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,33.0,71266,DB00030,Insulin Regular
,12518253,t max,For insulin t max was 33.0 +/- 2.6 min in the aspart versus 33.3 +/- 2.6 min in the lispro group (ns).,Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12518253/),min,33.3,71267,DB00030,Insulin Regular
,16443873,Cmax,"Before smoking cessation, maximum insulin concentration (Cmax) and area under the curve (AUC) for insulin concentration time (AUC-Insulin(0-360)) with inhaled insulin were higher, and time to Cmax (t(max)) shorter, in smokers than nonsmokers (Cmax 26.8 vs.",The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16443873/),,26.8,71293,DB00030,Insulin Regular
,16443873,AUC-Insulin(0-360),"9.7 microU/ml; AUC-Insulin(0-360) 2,583 vs. 1,645 microU x ml(-1) x min(-1); t(max) 20 vs. 53 min, respectively; all P < 0.05), whereas with subcutaneous insulin, systemic exposure was unchanged (AUC-Insulin(0-360) 2,324 vs. 2,269 microU x ml(-1) x min(-1); P = NS).",The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16443873/),[μu] / [min·ml],"2,583",71294,DB00030,Insulin Regular
,16443873,AUC-Insulin(0-360),"9.7 microU/ml; AUC-Insulin(0-360) 2,583 vs. 1,645 microU x ml(-1) x min(-1); t(max) 20 vs. 53 min, respectively; all P < 0.05), whereas with subcutaneous insulin, systemic exposure was unchanged (AUC-Insulin(0-360) 2,324 vs. 2,269 microU x ml(-1) x min(-1); P = NS).",The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16443873/),[μu] / [min·ml],"1,645",71295,DB00030,Insulin Regular
,16443873,t(max),"9.7 microU/ml; AUC-Insulin(0-360) 2,583 vs. 1,645 microU x ml(-1) x min(-1); t(max) 20 vs. 53 min, respectively; all P < 0.05), whereas with subcutaneous insulin, systemic exposure was unchanged (AUC-Insulin(0-360) 2,324 vs. 2,269 microU x ml(-1) x min(-1); P = NS).",The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16443873/),min,20,71296,DB00030,Insulin Regular
,16443873,t(max),"9.7 microU/ml; AUC-Insulin(0-360) 2,583 vs. 1,645 microU x ml(-1) x min(-1); t(max) 20 vs. 53 min, respectively; all P < 0.05), whereas with subcutaneous insulin, systemic exposure was unchanged (AUC-Insulin(0-360) 2,324 vs. 2,269 microU x ml(-1) x min(-1); P = NS).",The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16443873/),min,53,71297,DB00030,Insulin Regular
,16443873,AUC-Insulin(0-360),"9.7 microU/ml; AUC-Insulin(0-360) 2,583 vs. 1,645 microU x ml(-1) x min(-1); t(max) 20 vs. 53 min, respectively; all P < 0.05), whereas with subcutaneous insulin, systemic exposure was unchanged (AUC-Insulin(0-360) 2,324 vs. 2,269 microU x ml(-1) x min(-1); P = NS).",The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16443873/),[μu] / [min·ml],"2,324",71298,DB00030,Insulin Regular
,16443873,AUC-Insulin(0-360),"9.7 microU/ml; AUC-Insulin(0-360) 2,583 vs. 1,645 microU x ml(-1) x min(-1); t(max) 20 vs. 53 min, respectively; all P < 0.05), whereas with subcutaneous insulin, systemic exposure was unchanged (AUC-Insulin(0-360) 2,324 vs. 2,269 microU x ml(-1) x min(-1); P = NS).",The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16443873/),[μu] / [min·ml],"2,269",71299,DB00030,Insulin Regular
,30217957,EC50,"In in vitro studies, DS-8500a increased intracellular cAMP in a concentration-dependent manner in human, rat, and mouse GPR119-expressing Chinese hamster ovary (CHO)-K1 cells, with EC50 values of 51.5, 98.4, and 108.1 nmol/l, respectively.","DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30217957/),[nM] / [l],51.5,71551,DB00030,Insulin Regular
,30217957,EC50,"In in vitro studies, DS-8500a increased intracellular cAMP in a concentration-dependent manner in human, rat, and mouse GPR119-expressing Chinese hamster ovary (CHO)-K1 cells, with EC50 values of 51.5, 98.4, and 108.1 nmol/l, respectively.","DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30217957/),[nM] / [l],98.4,71552,DB00030,Insulin Regular
,30217957,EC50,"In in vitro studies, DS-8500a increased intracellular cAMP in a concentration-dependent manner in human, rat, and mouse GPR119-expressing Chinese hamster ovary (CHO)-K1 cells, with EC50 values of 51.5, 98.4, and 108.1 nmol/l, respectively.","DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30217957/),[nM] / [l],108.1,71553,DB00030,Insulin Regular
,26425883,relative bioavailability,The relative bioavailability was about 3%.,Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26425883/),%,3,71623,DB00030,Insulin Regular
,15357011,Cmax,"The estimated Cmax, Tmax, CLt/F (apparent clearance), V/F(apparent volume of distribution), and half-life of metformin were 1.42 +/- 0.07 microg/mL, 2.59 +/- 0.18 h, 66.12 +/- 4.6 L/h, 26.63 L, and 1.54 h respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),[μg] / [ml],1.42,72024,DB00030,Insulin Regular
,15357011,half-life,"The estimated Cmax, Tmax, CLt/F (apparent clearance), V/F(apparent volume of distribution), and half-life of metformin were 1.42 +/- 0.07 microg/mL, 2.59 +/- 0.18 h, 66.12 +/- 4.6 L/h, 26.63 L, and 1.54 h respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),h,1.54,72025,DB00030,Insulin Regular
,15357011,concentration at half-maximum inhibition IC50,"The mean concentration at half-maximum inhibition IC50, kin, and kout, were 2.26 microg/mL, 83.26 h(-1), and 0.68 h(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),[μg] / [ml],2.26,72026,DB00030,Insulin Regular
,15357011,concentration at half-maximum inhibition IC50,"The mean concentration at half-maximum inhibition IC50, kin, and kout, were 2.26 microg/mL, 83.26 h(-1), and 0.68 h(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),1/[h],83.26,72027,DB00030,Insulin Regular
,15357011,kin,"The mean concentration at half-maximum inhibition IC50, kin, and kout, were 2.26 microg/mL, 83.26 h(-1), and 0.68 h(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),1/[h],83.26,72028,DB00030,Insulin Regular
,15357011,kout,"The mean concentration at half-maximum inhibition IC50, kin, and kout, were 2.26 microg/mL, 83.26 h(-1), and 0.68 h(-1), respectively.",Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15357011/),1/[h],0.68,72029,DB00030,Insulin Regular
,11594240,absolute bioavailability,"It is well-absorbed, with a mean absolute bioavailability of 83% and reaching maximum concentrations in around 1.5 hours.",Pharmacokinetics and clinical efficacy of pioglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11594240/),%,83,72504,DB00030,Insulin Regular
,11594240,half-life,The half-life is about 9 hours but two active metabolites mainly contribute to the extended glucose-lowering effects.,Pharmacokinetics and clinical efficacy of pioglitazone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11594240/),h,9,72505,DB00030,Insulin Regular
,11978199,percent minimum blood glucose levels,"The percent minimum blood glucose levels, compared with the glucose levels before the administration, for pulmonary deliver ed insulin at the doses of 20, 10, 5, and 2.5 U/kg were 6.5 %, 16.6 %, 24.6 %, and 57.0 %, respectively.",Hypoglycemic efficacy of pulmonary delivered insulin dry powder aerosol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978199/),,16,72875,DB00030,Insulin Regular
,11978199,percent minimum blood glucose levels,"The percent minimum blood glucose levels, compared with the glucose levels before the administration, for pulmonary deliver ed insulin at the doses of 20, 10, 5, and 2.5 U/kg were 6.5 %, 16.6 %, 24.6 %, and 57.0 %, respectively.",Hypoglycemic efficacy of pulmonary delivered insulin dry powder aerosol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978199/),,24,72876,DB00030,Insulin Regular
,11978199,percent minimum blood glucose levels,"The percent minimum blood glucose levels, compared with the glucose levels before the administration, for pulmonary deliver ed insulin at the doses of 20, 10, 5, and 2.5 U/kg were 6.5 %, 16.6 %, 24.6 %, and 57.0 %, respectively.",Hypoglycemic efficacy of pulmonary delivered insulin dry powder aerosol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11978199/),,57,72877,DB00030,Insulin Regular
,32729820,half-life,"The half-life of JY09 was ~ 9.3 days, and the peak concentration was reached at ~ 60 - 72 hours.","Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32729820/),d,9.3,72891,DB00030,Insulin Regular
,32729820,half-life,"JY09 has a long half-life of ~ 9.3 days, with an acceptable safety profile.","Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32729820/),d,9.3,72892,DB00030,Insulin Regular
<,30350477,time,"The median time (range) to an increase in PG of >1.1 mmol/L (20 mg/dL) was <20 (18-19.5) minutes with 0.03 mg dasiglucagon and, with higher doses, the median times ranged from 9 to 15 minutes (commercial glucagon 13-14 minutes).",Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30350477/),min,20,72970,DB00030,Insulin Regular
,30350477,times,"The median time (range) to an increase in PG of >1.1 mmol/L (20 mg/dL) was <20 (18-19.5) minutes with 0.03 mg dasiglucagon and, with higher doses, the median times ranged from 9 to 15 minutes (commercial glucagon 13-14 minutes).",Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30350477/),min,9 to 15,72971,DB00030,Insulin Regular
,28303726,T-INSmax,"The difference between the two test days for these endpoints did not differ between jet injection and conventional administration (T-INSmax: 7.3 ± 1.9 vs 22.3 ± 6.3 min, P = .074; T-GIRmax: 24.0 ± 3.5 vs 27.3 ± 6.6 min, P = .66).",Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28303726/),min,7.3,74711,DB00030,Insulin Regular
,28303726,T-INSmax,"The difference between the two test days for these endpoints did not differ between jet injection and conventional administration (T-INSmax: 7.3 ± 1.9 vs 22.3 ± 6.3 min, P = .074; T-GIRmax: 24.0 ± 3.5 vs 27.3 ± 6.6 min, P = .66).",Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28303726/),min,22.3,74712,DB00030,Insulin Regular
,28303726,T-GIRmax,"The difference between the two test days for these endpoints did not differ between jet injection and conventional administration (T-INSmax: 7.3 ± 1.9 vs 22.3 ± 6.3 min, P = .074; T-GIRmax: 24.0 ± 3.5 vs 27.3 ± 6.6 min, P = .66).",Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28303726/),min,24.0,74713,DB00030,Insulin Regular
,28303726,T-GIRmax,"The difference between the two test days for these endpoints did not differ between jet injection and conventional administration (T-INSmax: 7.3 ± 1.9 vs 22.3 ± 6.3 min, P = .074; T-GIRmax: 24.0 ± 3.5 vs 27.3 ± 6.6 min, P = .66).",Pharmacokinetic and Pharmacodynamic Variability of Insulin When Administered by Jet Injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28303726/),min,27.3,74714,DB00030,Insulin Regular
,19609743,clearance rates,"The PK analysis showed a linear relationship between plasma AUC and dose, a large systemic volume of distribution, as well as high clearance rates of 8-10 mL/kg/min.",Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19609743/),[ml] / [kg·min],8-10,74786,DB00030,Insulin Regular
,15386480,systemic clearance,"After intravenous administration the systemic clearance and volume of distribution of ragaglitazar in rats were 139+/-30 ml/h/kg and 463+/-51 ml/kg, respectively (mean+/-SD).","Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386480/),[ml] / [h·kg],139,75013,DB00030,Insulin Regular
,15386480,volume of distribution,"After intravenous administration the systemic clearance and volume of distribution of ragaglitazar in rats were 139+/-30 ml/h/kg and 463+/-51 ml/kg, respectively (mean+/-SD).","Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386480/),[ml] / [kg],463,75014,DB00030,Insulin Regular
,15386480,elimination half-life (t1/2),Plasma concentrations declined mono-exponentially following intravenous administration and elimination half-life (t1/2) was about 2.6 h and not significantly different (p > 0.05) from the value from oral administration.,"Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386480/),h,2.6,75015,DB00030,Insulin Regular
,15386480,Mean residence time (MRT),Mean residence time (MRT) values for ragaglitazar were found to be 4.15+/-0.52 h (3.5 to 4.6 h).,"Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386480/),h,4.15,75016,DB00030,Insulin Regular
,15386480,Absolute oral bioavailability,Absolute oral bioavailability of ragaglitazar across the doses tested was in the range of 68%-93%.,"Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386480/),%,68,75017,DB00030,Insulin Regular
,15386480,Absolute oral bioavailability,Absolute oral bioavailability of ragaglitazar across the doses tested was in the range of 68%-93%.,"Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15386480/),%,93,75018,DB00030,Insulin Regular
,24876617,root mean,SC pramlintide PK root mean square error values range from 1.98 to 10.66 pmol/L.,A model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24876617/),[pM] / [l],1.98 to 10.66,75693,DB00030,Insulin Regular
,15120482,plasma half-life,The plasma half-life of OXA was 27.1+/-9.5 min.,Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15120482/),min,27.1,75933,DB00030,Insulin Regular
,21724838,AUC(0)(-),"Mean values for IGF1 AUC(0)(-)(168 h)/168 h and C(max) were higher for GH than for NNC126-0083, although the difference was not statistically significant for cohort's 0.06 mg protein/kg.","Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724838/),h,168,76851,DB00030,Insulin Regular
,19539098,post,The mean (SD) postprandial glucose excursion AUC at 120 minutes after the meal was significantly reduced in the group that used the device compared with the group that did not (104 [65] vs 155 [56] mg/dL/h; P < 0.005).,"Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mg] / [dl·h],104,77439,DB00030,Insulin Regular
,19539098,T(max),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,45,77440,DB00030,Insulin Regular
,19539098,T(max),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,78,77441,DB00030,Insulin Regular
,19539098,time to half-maximum concentration (T(50%max)),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,20,77442,DB00030,Insulin Regular
,19539098,time to half-maximum concentration (T(50%max)),"Use of the device was associated with significant reductions in mean (SD) T(max) (45 [28] vs 78 [35] minutes) and time to half-maximum concentration (T(50%max)) (20 [11] vs 28 [10] minutes; both, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),min,28,77443,DB00030,Insulin Regular
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],21,77444,DB00030,Insulin Regular
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],33,77445,DB00030,Insulin Regular
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],60,77446,DB00030,Insulin Regular
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],55,77447,DB00030,Insulin Regular
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],80,77448,DB00030,Insulin Regular
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],90,77449,DB00030,Insulin Regular
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],93,77450,DB00030,Insulin Regular
,19539098,AUC,"Insulin AUC increased significantly in the group that used the device compared with the group that did not at 30 (21 [6] vs 33 [16] mU/L/h), 60 (55 [12] vs 80 [28] mU/L/h), and 90 (93 [19] vs 118 [31] mU/L/h) minutes after administration (all, P < 0.05).","Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [h·l],118,77451,DB00030,Insulin Regular
,19539098,Cmax,Cmax also increased significantly (118 [35] vs 86 [16] mU/L [38%]; P < 0.05).,"Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [l],118,77452,DB00030,Insulin Regular
,19539098,Cmax,Cmax also increased significantly (118 [35] vs 86 [16] mU/L [38%]; P < 0.05).,"Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539098/),[mu] / [l],86,77453,DB00030,Insulin Regular
,29551575,renal clearance,"Insulin treated diabetic animals showed higher renal clearance compared to control (vehicle + GAB: 0.25 [0.18-0.30] L/h·kg; DM + GAB + insulin: 0.55 [0.45-1.43] L/h·kg), which was attributed to the diabetes-induced glomerular hyperfiltration.","The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551575/),[l] / [h·kg],0.25,77927,DB00030,Insulin Regular
,29551575,renal clearance,"Insulin treated diabetic animals showed higher renal clearance compared to control (vehicle + GAB: 0.25 [0.18-0.30] L/h·kg; DM + GAB + insulin: 0.55 [0.45-1.43] L/h·kg), which was attributed to the diabetes-induced glomerular hyperfiltration.","The role of organic cation transporter 2 inhibitor cimetidine, experimental diabetes mellitus and metformin on gabapentin pharmacokinetics in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29551575/),[l] / [h·kg],0.55,77928,DB00030,Insulin Regular
,27245553,half maximal inhibitory concentration (IC50),"The in vitro inhibition assays on metformin transport were carried out and showed that the half maximal inhibitory concentration (IC50) of rabeprazole on OCT2-mediated metformin transport was 26.0 μM, whereas the IC50 on MATE1-mediated metformin transport inhibition was 4.6 μM.",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),μM,26.0,78035,DB00030,Insulin Regular
,27245553,IC50,"The in vitro inhibition assays on metformin transport were carried out and showed that the half maximal inhibitory concentration (IC50) of rabeprazole on OCT2-mediated metformin transport was 26.0 μM, whereas the IC50 on MATE1-mediated metformin transport inhibition was 4.6 μM.",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),μM,4.6,78036,DB00030,Insulin Regular
,27245553,AUC0-12,"The AUC0-12 of metformin plus rabeprazole were 28,276 ± 5187 ng/ml·h, which was significantly higher than AUC0-12 of metformin plus placebo (24,691 ± 3129 ng/ml·h).",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),[ng] / [h·ml],"28,276",78037,DB00030,Insulin Regular
,27245553,AUC0-12,"The AUC0-12 of metformin plus rabeprazole were 28,276 ± 5187 ng/ml·h, which was significantly higher than AUC0-12 of metformin plus placebo (24,691 ± 3129 ng/ml·h).",The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27245553/),[ng] / [h·ml],"24,691",78038,DB00030,Insulin Regular
,16132341,relative bioavailabilities F(rel),"In both animal models significant concentrations of human insulin were detected, with relative bioavailabilities F(rel) of 2.8 up to 8.3%.",Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide): bioavailability and nasal tolerability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132341/),,2.8,78447,DB00030,Insulin Regular
,16132341,relative bioavailabilities F(rel),"In both animal models significant concentrations of human insulin were detected, with relative bioavailabilities F(rel) of 2.8 up to 8.3%.",Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide): bioavailability and nasal tolerability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132341/),%,8.3,78448,DB00030,Insulin Regular
,16132341,relative bioavailability F(rel),"The more hydrophobic, lactic acid grafted polyester were more effective at a threefold higher polymer concentration, increasing the relative bioavailability F(rel) of a 5 IU/kg dose from 2.8 to 5.7%.",Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide): bioavailability and nasal tolerability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132341/),%,2.8,78449,DB00030,Insulin Regular
,16132341,relative bioavailability F(rel),"The more hydrophobic, lactic acid grafted polyester were more effective at a threefold higher polymer concentration, increasing the relative bioavailability F(rel) of a 5 IU/kg dose from 2.8 to 5.7%.",Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide): bioavailability and nasal tolerability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16132341/),%,5.7,78450,DB00030,Insulin Regular
,11955805,T(max),"The capsules containing insulin formulated with sodium salicylate (50 mg) and prepared by either physical mixing or wet granulation using 10% polyvinyl pyrollidone gave almost the same results producing a maximum reduction in plasma glucose level (C(max)) of 81.53+/-8.21 and 79.59+/-5.75%, T(max) of 6 and 5 h, area under the curve (AUC) of 69.37+/-48.64 and 57.98+/-23.15% reduction hour (% red.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),h,6,78533,DB00030,Insulin Regular
,11955805,T(max),"The capsules containing insulin formulated with sodium salicylate (50 mg) and prepared by either physical mixing or wet granulation using 10% polyvinyl pyrollidone gave almost the same results producing a maximum reduction in plasma glucose level (C(max)) of 81.53+/-8.21 and 79.59+/-5.75%, T(max) of 6 and 5 h, area under the curve (AUC) of 69.37+/-48.64 and 57.98+/-23.15% reduction hour (% red.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),h,5,78534,DB00030,Insulin Regular
,11955805,area under the curve (AUC),"The capsules containing insulin formulated with sodium salicylate (50 mg) and prepared by either physical mixing or wet granulation using 10% polyvinyl pyrollidone gave almost the same results producing a maximum reduction in plasma glucose level (C(max)) of 81.53+/-8.21 and 79.59+/-5.75%, T(max) of 6 and 5 h, area under the curve (AUC) of 69.37+/-48.64 and 57.98+/-23.15% reduction hour (% red.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),%,69.37,78535,DB00030,Insulin Regular
,11955805,area under the curve (AUC),"The capsules containing insulin formulated with sodium salicylate (50 mg) and prepared by either physical mixing or wet granulation using 10% polyvinyl pyrollidone gave almost the same results producing a maximum reduction in plasma glucose level (C(max)) of 81.53+/-8.21 and 79.59+/-5.75%, T(max) of 6 and 5 h, area under the curve (AUC) of 69.37+/-48.64 and 57.98+/-23.15% reduction hour (% red.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),%,57.98,78536,DB00030,Insulin Regular
,11955805,AUC,Formulation of insulin with sodium salicylate in PEG 4000 produced a lower AUC of 37.30+/-10.36% red. h and RH of 4.69+/-1.3%.,Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),%·h·red,37.30,78537,DB00030,Insulin Regular
,11955805,T(max),It produced 25% reduction in plasma glucose levels of the hyperglycemic beagle dogs at T(max) of 4 h and the largest AUC of 100.10+/-25.72% red.,Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),h,4,78538,DB00030,Insulin Regular
,11955805,RH,"h, resulting in the highest RH of 12.59+/-3.23%.",Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycemia of diabetic beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11955805/),%,12,78539,DB00030,Insulin Regular
,28452143,Ki,"ZY15557 is a potent, competitive and long acting inhibitor of DPP-4 (Ki 5.53 nM; Koff 3.2 × 10-4 ·s-1 , half-life 35.8 min).","ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452143/),nM,5.53,78932,DB00030,Insulin Regular
,28452143,Koff,"ZY15557 is a potent, competitive and long acting inhibitor of DPP-4 (Ki 5.53 nM; Koff 3.2 × 10-4 ·s-1 , half-life 35.8 min).","ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452143/),1/[s],3.2 × 10-4,78933,DB00030,Insulin Regular
,28452143,half-life,"ZY15557 is a potent, competitive and long acting inhibitor of DPP-4 (Ki 5.53 nM; Koff 3.2 × 10-4 ·s-1 , half-life 35.8 min).","ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452143/),min,35.8,78934,DB00030,Insulin Regular
up to,28452143,half-life,Allometric scaling predicts a half-life for ZY15557 in humans of up to 60 h.,"ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28452143/),h,60,78935,DB00030,Insulin Regular
,22943970,terminal t(½),"DA-1229 reached a peak at 3.0 to 5.5 hours after a single oral dose and the concentrations declined, with a terminal t(½) from 32.5 to 39.8 hours.","Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943970/),h,32.5 to 39.8,79772,DB00030,Insulin Regular
,15926116,AUC,"At steady state (90 - 120 min), insulin glulisine and RHI had equivalent glucose utilization (GIR-AUC (SS), 209 [corrected] mg . kg (-1) for glulisine, 214 [corrected] mg . kg (-1) for RHI) and infusion rates (GIR (SS), 7.0 and 7.2 [corrected] mg . kg (-1) . [corrected] min (-1) . kg (-1)).","A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926116/),-1·kg·mg,209,79940,DB00030,Insulin Regular
,15926116,AUC,"At steady state (90 - 120 min), insulin glulisine and RHI had equivalent glucose utilization (GIR-AUC (SS), 209 [corrected] mg . kg (-1) for glulisine, 214 [corrected] mg . kg (-1) for RHI) and infusion rates (GIR (SS), 7.0 and 7.2 [corrected] mg . kg (-1) . [corrected] min (-1) . kg (-1)).","A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926116/),-1·kg·mg,214,79941,DB00030,Insulin Regular
,15926116,in,"At steady state (90 - 120 min), insulin glulisine and RHI had equivalent glucose utilization (GIR-AUC (SS), 209 [corrected] mg . kg (-1) for glulisine, 214 [corrected] mg . kg (-1) for RHI) and infusion rates (GIR (SS), 7.0 and 7.2 [corrected] mg . kg (-1) . [corrected] min (-1) . kg (-1)).","A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926116/),-1·kg·mg,7.0,79942,DB00030,Insulin Regular
,15926116,in,"At steady state (90 - 120 min), insulin glulisine and RHI had equivalent glucose utilization (GIR-AUC (SS), 209 [corrected] mg . kg (-1) for glulisine, 214 [corrected] mg . kg (-1) for RHI) and infusion rates (GIR (SS), 7.0 and 7.2 [corrected] mg . kg (-1) . [corrected] min (-1) . kg (-1)).","A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926116/),-1·kg·mg,7.2,79943,DB00030,Insulin Regular
,15926116,total glucose disposal (,"Both insulins also presented equal total glucose disposal (GIR-AUC (0 - clamp end), 995 and 1050 [corrected] mg . kg (-1)) and onset of activity within 20 min.","A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926116/),-1·kg·mg,99,79944,DB00030,Insulin Regular
,15926116,total glucose disposal (,"Both insulins also presented equal total glucose disposal (GIR-AUC (0 - clamp end), 995 and 1050 [corrected] mg . kg (-1)) and onset of activity within 20 min.","A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926116/),-1·kg·mg,105,79945,DB00030,Insulin Regular
,26161618,progression-free survival,The 15 patients with NSCLC with treatment duration longer than two weeks with single agent AXL1717 in third or fourth line of therapy showed a median progression-free survival of 31 weeks and overall survival of 60 weeks.,A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26161618/),weeks,31,80098,DB00030,Insulin Regular
,26161618,overall survival,The 15 patients with NSCLC with treatment duration longer than two weeks with single agent AXL1717 in third or fourth line of therapy showed a median progression-free survival of 31 weeks and overall survival of 60 weeks.,A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26161618/),weeks,60,80099,DB00030,Insulin Regular
,14703957,time of maximum concentration tmax,"Plasma insulin concentrations increased faster (time of maximum concentration tmax 20 vs 40 minutes, p = 0.01) and were higher (standardized maximum concentration Cmax/D 13.6 vs 6.1 microU/ml/U, p = 0.01) after lispro-insulin compared to regular insulin.",Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703957/),min,20,80585,DB00030,Insulin Regular
,14703957,time of maximum concentration tmax,"Plasma insulin concentrations increased faster (time of maximum concentration tmax 20 vs 40 minutes, p = 0.01) and were higher (standardized maximum concentration Cmax/D 13.6 vs 6.1 microU/ml/U, p = 0.01) after lispro-insulin compared to regular insulin.",Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703957/),min,40,80586,DB00030,Insulin Regular
,14703957,standardized maximum concentration Cmax/D,"Plasma insulin concentrations increased faster (time of maximum concentration tmax 20 vs 40 minutes, p = 0.01) and were higher (standardized maximum concentration Cmax/D 13.6 vs 6.1 microU/ml/U, p = 0.01) after lispro-insulin compared to regular insulin.",Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703957/),[μu] / [ml·u],13.6,80587,DB00030,Insulin Regular
,14703957,standardized maximum concentration Cmax/D,"Plasma insulin concentrations increased faster (time of maximum concentration tmax 20 vs 40 minutes, p = 0.01) and were higher (standardized maximum concentration Cmax/D 13.6 vs 6.1 microU/ml/U, p = 0.01) after lispro-insulin compared to regular insulin.",Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703957/),[μu] / [ml·u],6.1,80588,DB00030,Insulin Regular
,12772412,AUC,"The level of blood Insulin was as follows: (3,954.47 +/- 644.47) mU/L, AUC = (1,264.87 +/- 148.00) mU.L-1.min-1 x 10(-3) in i.v. group; (740.44 +/- 94.16) mU/L, AUC = (298.02 +/- 63) mU.L-1.min-1 x 10(-3) in SGC group; (908.18 +/- 201.19) mU/L, AUC = (596.92 +/- 84.00) mU.L-1.min-1 x 10(-3) in Azone group.",[Functional and pathological study of intranasal absorption of insulin aided by azone]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12772412/),[mu] / [(10)^3·l·min],"1,264.87",81043,DB00030,Insulin Regular
,12772412,AUC,"The level of blood Insulin was as follows: (3,954.47 +/- 644.47) mU/L, AUC = (1,264.87 +/- 148.00) mU.L-1.min-1 x 10(-3) in i.v. group; (740.44 +/- 94.16) mU/L, AUC = (298.02 +/- 63) mU.L-1.min-1 x 10(-3) in SGC group; (908.18 +/- 201.19) mU/L, AUC = (596.92 +/- 84.00) mU.L-1.min-1 x 10(-3) in Azone group.",[Functional and pathological study of intranasal absorption of insulin aided by azone]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12772412/),[mu] / [l],740.44,81044,DB00030,Insulin Regular
,12772412,AUC,"The level of blood Insulin was as follows: (3,954.47 +/- 644.47) mU/L, AUC = (1,264.87 +/- 148.00) mU.L-1.min-1 x 10(-3) in i.v. group; (740.44 +/- 94.16) mU/L, AUC = (298.02 +/- 63) mU.L-1.min-1 x 10(-3) in SGC group; (908.18 +/- 201.19) mU/L, AUC = (596.92 +/- 84.00) mU.L-1.min-1 x 10(-3) in Azone group.",[Functional and pathological study of intranasal absorption of insulin aided by azone]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12772412/),[mu] / [(10)^3·l·min],298.02,81045,DB00030,Insulin Regular
,12772412,AUC,"The level of blood Insulin was as follows: (3,954.47 +/- 644.47) mU/L, AUC = (1,264.87 +/- 148.00) mU.L-1.min-1 x 10(-3) in i.v. group; (740.44 +/- 94.16) mU/L, AUC = (298.02 +/- 63) mU.L-1.min-1 x 10(-3) in SGC group; (908.18 +/- 201.19) mU/L, AUC = (596.92 +/- 84.00) mU.L-1.min-1 x 10(-3) in Azone group.",[Functional and pathological study of intranasal absorption of insulin aided by azone]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12772412/),[mu] / [(10)^3·l·min],596.92,81046,DB00030,Insulin Regular
,12772412,bioavailability,The bioavailability was 23.56% and 47.19% respectively.,[Functional and pathological study of intranasal absorption of insulin aided by azone]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12772412/),%,23.56,81047,DB00030,Insulin Regular
,12772412,bioavailability,The bioavailability was 23.56% and 47.19% respectively.,[Functional and pathological study of intranasal absorption of insulin aided by azone]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12772412/),%,47.19,81048,DB00030,Insulin Regular
,12859957,t(1/2),"This dose yielded glucose-lowering profiles with t(1/2) values at the range of 50-70h, turning catabolic STZ-rats into anabolic ones over a period of 2-3 days.",Suspensions of pro-drug insulin greatly prolong normoglycemic patterns in diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12859957/),h,50-70,83074,DB00030,Insulin Regular
,24771009,half-life,"The results showed that the half-life of rolGLP-1 in db/db mice was 68.2 h, which is longer than that of native GLP-1.","Pharmacokinetics, pharmacodynamics, and cytotoxicity of recombinant orally-administrated long-lasting GLP-1 and its therapeutic effect on db/db mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24771009/),h,68.2,83094,DB00030,Insulin Regular
,26064170,C max,"The C max⁡ and the time to reach C max⁡ (t max⁡) of curcumin in plasma were 3.14 ± 0.9 μg/mL and 5 minutes (10 mg/kg, i.v.) and 0.06 ± 0.01 μg/mL and 14 minutes (500 mg/kg, p.o.).",Curcumin Pharmacokinetic and Pharmacodynamic Evidences in Streptozotocin-Diabetic Rats Support the Antidiabetic Activity to Be via Metabolite(s). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26064170/),[μg] / [ml],3.14,83253,DB00030,Insulin Regular
,26064170,C max,"The C max⁡ and the time to reach C max⁡ (t max⁡) of curcumin in plasma were 3.14 ± 0.9 μg/mL and 5 minutes (10 mg/kg, i.v.) and 0.06 ± 0.01 μg/mL and 14 minutes (500 mg/kg, p.o.).",Curcumin Pharmacokinetic and Pharmacodynamic Evidences in Streptozotocin-Diabetic Rats Support the Antidiabetic Activity to Be via Metabolite(s). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26064170/),[μg] / [ml],0.06,83254,DB00030,Insulin Regular
,26064170,time to reach C max⁡ (t max⁡),"The C max⁡ and the time to reach C max⁡ (t max⁡) of curcumin in plasma were 3.14 ± 0.9 μg/mL and 5 minutes (10 mg/kg, i.v.) and 0.06 ± 0.01 μg/mL and 14 minutes (500 mg/kg, p.o.).",Curcumin Pharmacokinetic and Pharmacodynamic Evidences in Streptozotocin-Diabetic Rats Support the Antidiabetic Activity to Be via Metabolite(s). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26064170/),min,5,83255,DB00030,Insulin Regular
,26064170,time to reach C max⁡ (t max⁡),"The C max⁡ and the time to reach C max⁡ (t max⁡) of curcumin in plasma were 3.14 ± 0.9 μg/mL and 5 minutes (10 mg/kg, i.v.) and 0.06 ± 0.01 μg/mL and 14 minutes (500 mg/kg, p.o.).",Curcumin Pharmacokinetic and Pharmacodynamic Evidences in Streptozotocin-Diabetic Rats Support the Antidiabetic Activity to Be via Metabolite(s). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26064170/),min,14,83256,DB00030,Insulin Regular
,26064170,elimination half-time,The elimination half-time was 8.64 ± 2.31 (i.v.) and 32.70 ± 12.92 (p.o.) minutes.,Curcumin Pharmacokinetic and Pharmacodynamic Evidences in Streptozotocin-Diabetic Rats Support the Antidiabetic Activity to Be via Metabolite(s). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26064170/),min,8.64,83257,DB00030,Insulin Regular
,26064170,elimination half-time,The elimination half-time was 8.64 ± 2.31 (i.v.) and 32.70 ± 12.92 (p.o.) minutes.,Curcumin Pharmacokinetic and Pharmacodynamic Evidences in Streptozotocin-Diabetic Rats Support the Antidiabetic Activity to Be via Metabolite(s). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26064170/),min,32.70,83258,DB00030,Insulin Regular
,26064170,oral bioavailability,The oral bioavailability was about 0.47%.,Curcumin Pharmacokinetic and Pharmacodynamic Evidences in Streptozotocin-Diabetic Rats Support the Antidiabetic Activity to Be via Metabolite(s). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26064170/),%,0.47,83259,DB00030,Insulin Regular
,25524950,area under the curve (AUC0-24h),"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [24·h·kg],"1,058",83346,DB00030,Insulin Regular
,25524950,area under the curve (AUC0-24h),"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [24·h·kg],995,83347,DB00030,Insulin Regular
,25524950,AUC0-12h,"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [12·h·kg],357,83348,DB00030,Insulin Regular
,25524950,AUC0-12h,"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [12·h·kg],593,83349,DB00030,Insulin Regular
,25524950,AUC12-24h,"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [24·h·kg],700,83350,DB00030,Insulin Regular
,25524950,AUC12-24h,"The 24-h glucose infusion rate area under the curve (AUC0-24h) was similar in the evening and morning studies (1,058 ± 571 and 995 ± 691 mg/kg × 24 h, P = 0.503), but the first 12 h (AUC0-12h) was lower with evening versus morning glargine (357 ± 244 vs. 593 ± 374 mg/kg × 12 h, P = 0.004), whereas the opposite occurred for the second 12 h (AUC12-24h 700 ± 396 vs. 403 ± 343 mg/kg × 24 h, P = 0.002).",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mg] / [24·h·kg],403,83351,DB00030,Insulin Regular
,25524950,AUC0-24h,"Plasma glucagon levels (AUC0-24h 1,533 ± 656 vs. 1,120 ± 344 ng/L/h, P = 0.027) and lipolysis (free fatty acid AUC0-24h 7.5 ± 1.6 vs.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[ng] / [h·l],"1,533",83352,DB00030,Insulin Regular
,25524950,AUC0-24h,"Plasma glucagon levels (AUC0-24h 1,533 ± 656 vs. 1,120 ± 344 ng/L/h, P = 0.027) and lipolysis (free fatty acid AUC0-24h 7.5 ± 1.6 vs.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[ng] / [h·l],"1,120",83353,DB00030,Insulin Regular
,25524950,AUC0-24h,"Plasma glucagon levels (AUC0-24h 1,533 ± 656 vs. 1,120 ± 344 ng/L/h, P = 0.027) and lipolysis (free fatty acid AUC0-24h 7.5 ± 1.6 vs.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),,7.5,83354,DB00030,Insulin Regular
,25524950,AUC0-24h,"8.9 ± 1.9 mmol/L/h, P = 0.005; β-OH-butyrate AUC0-24h 6.8 ± 4.7 vs. 17.0 ± 11.9 mmol/L/h, P = 0.005; glycerol, P < 0.020) were overall more suppressed after evening versus morning glargine administration.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mM] / [h·l],6.8,83355,DB00030,Insulin Regular
,25524950,AUC0-24h,"8.9 ± 1.9 mmol/L/h, P = 0.005; β-OH-butyrate AUC0-24h 6.8 ± 4.7 vs. 17.0 ± 11.9 mmol/L/h, P = 0.005; glycerol, P < 0.020) were overall more suppressed after evening versus morning glargine administration.",Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25524950/),[mM] / [h·l],17.0,83356,DB00030,Insulin Regular
,20940337,clearance,"Typical values were clearance, 43.4 L/h; volume of distribution in the central compartment, 5.0 L; intercompartmental clearance, 23.9 L/h; volume of distribution in the peripheral compartment 30.7 L; TI first-order absorption rate constant, 2.35 h⁻¹; and first-order absorption rate constants associated with subcutaneously administered insulin, 0.63 and 1.04 h⁻¹, respectively.",Population pharmacokinetic model of human insulin following different routes of administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940337/),[l] / [h],43.4,83852,DB00030,Insulin Regular
,20940337,volume of distribution in the central compartment,"Typical values were clearance, 43.4 L/h; volume of distribution in the central compartment, 5.0 L; intercompartmental clearance, 23.9 L/h; volume of distribution in the peripheral compartment 30.7 L; TI first-order absorption rate constant, 2.35 h⁻¹; and first-order absorption rate constants associated with subcutaneously administered insulin, 0.63 and 1.04 h⁻¹, respectively.",Population pharmacokinetic model of human insulin following different routes of administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940337/),l,5.0,83853,DB00030,Insulin Regular
,20940337,intercompartmental clearance,"Typical values were clearance, 43.4 L/h; volume of distribution in the central compartment, 5.0 L; intercompartmental clearance, 23.9 L/h; volume of distribution in the peripheral compartment 30.7 L; TI first-order absorption rate constant, 2.35 h⁻¹; and first-order absorption rate constants associated with subcutaneously administered insulin, 0.63 and 1.04 h⁻¹, respectively.",Population pharmacokinetic model of human insulin following different routes of administration. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940337/),[l] / [h],23.9,83854,DB00030,Insulin Regular
,20940337,volume of distribution in the peripheral compartment,"Typical values were clearance, 43.4 L/h; volume of distribution in the central compartment, 5.0 L; intercompartmental clearance, 23.9 L/h; volume of distribution in the peripheral compartment 30.7 L; TI first-order absorption rate constant, 2.35 h⁻¹; and first-order absorption rate constants associated with subcutaneously administered insulin, 0.63 and 1.04 h⁻¹, respectively.",Population pharmacokinetic model of human insulin following different routes of administration. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940337/),l,30.7,83855,DB00030,Insulin Regular
,20940337,first-order absorption rate constant,"Typical values were clearance, 43.4 L/h; volume of distribution in the central compartment, 5.0 L; intercompartmental clearance, 23.9 L/h; volume of distribution in the peripheral compartment 30.7 L; TI first-order absorption rate constant, 2.35 h⁻¹; and first-order absorption rate constants associated with subcutaneously administered insulin, 0.63 and 1.04 h⁻¹, respectively.",Population pharmacokinetic model of human insulin following different routes of administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940337/),h⁻¹,2.35,83856,DB00030,Insulin Regular
,20940337,first-order absorption rate constants,"Typical values were clearance, 43.4 L/h; volume of distribution in the central compartment, 5.0 L; intercompartmental clearance, 23.9 L/h; volume of distribution in the peripheral compartment 30.7 L; TI first-order absorption rate constant, 2.35 h⁻¹; and first-order absorption rate constants associated with subcutaneously administered insulin, 0.63 and 1.04 h⁻¹, respectively.",Population pharmacokinetic model of human insulin following different routes of administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940337/),h⁻¹,0.63,83857,DB00030,Insulin Regular
,20940337,first-order absorption rate constants,"Typical values were clearance, 43.4 L/h; volume of distribution in the central compartment, 5.0 L; intercompartmental clearance, 23.9 L/h; volume of distribution in the peripheral compartment 30.7 L; TI first-order absorption rate constant, 2.35 h⁻¹; and first-order absorption rate constants associated with subcutaneously administered insulin, 0.63 and 1.04 h⁻¹, respectively.",Population pharmacokinetic model of human insulin following different routes of administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940337/),h⁻¹,1.04,83858,DB00030,Insulin Regular
more,34293397,half-life,Further pharmacokinetic test in cynomolgus monkeys exhibited that the half-life of AX18 was more than 6 days.,Design and evaluation of GLP-1 receptor G-protein biased agonist with prolonged efficacy on diabetes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34293397/),d,6,84106,DB00030,Insulin Regular
<,33258802,half-life (t1/2,"GLP-1 has a short half-life (t1/2 < 2 min) due to degrading enzyme dipeptidyl peptidase-IV and rapid kidney clearance, which limits its clinical application as a therapeutic reagent.",Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33258802/),min,2,84207,DB00030,Insulin Regular
,26006182,elimination half-life,Amlodipine elimination half-life during the first MARS™ session was calculated at 7.6 h.,Mixed amlodipine/valsartan overdose treated by the molecular adsorbent recirculating system (MARS™). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006182/),h,7.6,84289,DB00030,Insulin Regular
,12077738,Maximum serum glucose concentration (C(max)),"Maximum serum glucose concentration (C(max)) was lower for BIAsp 30 compared with BHI 30(t=0) (14.0 +/- 2.4 v 16.5 +/- 2.8 mmol/L, P <.0001), and time to maximal serum glucose concentration (t(max)) was approximately 20 minutes shorter for BIAsp 30, irrespective of timing of BHI 30 injection (P <.0001).",Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12077738/),[mM] / [l],14.0,84326,DB00030,Insulin Regular
,12077738,Maximum serum glucose concentration (C(max)),"Maximum serum glucose concentration (C(max)) was lower for BIAsp 30 compared with BHI 30(t=0) (14.0 +/- 2.4 v 16.5 +/- 2.8 mmol/L, P <.0001), and time to maximal serum glucose concentration (t(max)) was approximately 20 minutes shorter for BIAsp 30, irrespective of timing of BHI 30 injection (P <.0001).",Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12077738/),[mM] / [l],16.5,84327,DB00030,Insulin Regular
,12077738,time to maximal serum glucose concentration (t(max)),"Maximum serum glucose concentration (C(max)) was lower for BIAsp 30 compared with BHI 30(t=0) (14.0 +/- 2.4 v 16.5 +/- 2.8 mmol/L, P <.0001), and time to maximal serum glucose concentration (t(max)) was approximately 20 minutes shorter for BIAsp 30, irrespective of timing of BHI 30 injection (P <.0001).",Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12077738/),min,20,84328,DB00030,Insulin Regular
,12475773,half-life (t(1/2)),"We demonstrate that the half-life (t(1/2)) of glibenclamide in the blood is increased in Hnf-1alpha(-/-) mice compared with wild-type littermates (3.9 +/- 1.3 vs. 1.5 +/- 1.8 min, P <or= 0.05).","Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12475773/),min,3.9,84408,DB00030,Insulin Regular
,12475773,half-life (t(1/2)),"We demonstrate that the half-life (t(1/2)) of glibenclamide in the blood is increased in Hnf-1alpha(-/-) mice compared with wild-type littermates (3.9 +/- 1.3 vs. 1.5 +/- 1.8 min, P <or= 0.05).","Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12475773/),min,1.5,84409,DB00030,Insulin Regular
,20508081,G(tot),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg],2512.7,84501,DB00030,Insulin Regular
,20508081,G(tot),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg],1291.9,84502,DB00030,Insulin Regular
,20508081,R(max),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg·min],3.740,84503,DB00030,Insulin Regular
,20508081,R(max),"Least-square (LS) mean estimates for G(tot) and R(max) were 2512.7 mg/kg and 3.740 mg/min per kg respectively for ILPS, and 1291.9 mg/kg and 1.793 mg/min per kg respectively for glargine.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[mg] / [kg·min],1.793,84504,DB00030,Insulin Regular
,20508081,area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[min·pM] / [l],77 150,84505,DB00030,Insulin Regular
,20508081,area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[min·pM] / [l],53 111,84506,DB00030,Insulin Regular
,20508081,maximum serum insulin concentration (C(max)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[pM] / [l],119,84507,DB00030,Insulin Regular
,20508081,maximum serum insulin concentration (C(max)),"ILPS administration resulted in significantly greater exposure compared with glargine (area under the baseline-corrected serum concentration versus time curve from time 0 to 24 h (AUC(0-24)): 77 150 vs 53 111 pmol min/l; maximum serum insulin concentration (C(max)): 119 vs 68 pmol/l; ILPS versus glargine respectively), but the intrasubject variabilities for AUC and C(max) were comparable.",Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20508081/),[pM] / [l],68,84508,DB00030,Insulin Regular
,11935150,half-life,"Following s. c. administration the half-life of NN2211 was found to be 12.6 +/- 1.1 h, with a subsequent accumulation index after a daily dose for seven days of 1.4-1.5.","The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935150/),h,12.6,85080,DB00030,Insulin Regular
,11935150,accumulation index,"Following s. c. administration the half-life of NN2211 was found to be 12.6 +/- 1.1 h, with a subsequent accumulation index after a daily dose for seven days of 1.4-1.5.","The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11935150/),,1.4-1.5,85081,DB00030,Insulin Regular
,19293342,area under the curve for 0 to 24 hours,Results are given as mean +/- SEM: The area under the curve for 0 to 24 hours is approximately twice as high without food (27.8 +/- 4.1) than with food (13.7 +/- 1.2; P = .002).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),,27.8,85728,DB00030,Insulin Regular
,19293342,area under the curve for 0 to 24 hours,Results are given as mean +/- SEM: The area under the curve for 0 to 24 hours is approximately twice as high without food (27.8 +/- 4.1) than with food (13.7 +/- 1.2; P = .002).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),,13.7,85729,DB00030,Insulin Regular
,19293342,maximum observed ARD-07 concentration relative to dose administration (C(max)),The maximum observed ARD-07 concentration relative to dose administration (C(max)) is more than twice as high without food (10.6 +/- 1.6 ng/mL) than with food (4.4 +/- 0.5 ng/mL; P = .001).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],10.6,85730,DB00030,Insulin Regular
,19293342,maximum observed ARD-07 concentration relative to dose administration (C(max)),The maximum observed ARD-07 concentration relative to dose administration (C(max)) is more than twice as high without food (10.6 +/- 1.6 ng/mL) than with food (4.4 +/- 0.5 ng/mL; P = .001).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],4.4,85731,DB00030,Insulin Regular
,19293342,C(max),C(max) of growth hormone occurs at a significantly (P = .001) later stage with food (C(max) = 13.0 +/- 3.5 ng/mL) than without food (37.1 +/- 5.3 ng/mL).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],13.0,85732,DB00030,Insulin Regular
,19293342,C(max),C(max) of growth hormone occurs at a significantly (P = .001) later stage with food (C(max) = 13.0 +/- 3.5 ng/mL) than without food (37.1 +/- 5.3 ng/mL).,Effect of food on the pharmacokinetics and pharmacodynamics of an oral ghrelin agonist (ARD-07) in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19293342/),[ng] / [ml],37.1,85733,DB00030,Insulin Regular
,20924141,maximal glucose infusion rate (GIR(max)),Pharmacodynamic parameter estimates were 15.1 mg/min/kg for maximal glucose infusion rate (GIR(max)) and 88.0 mIU/L for SC(50) for diabetic patients and 62.9 mIU/L for healthy subjects.,Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20924141/),[mg] / [kg·min],15.1,85753,DB00030,Insulin Regular
,20924141,SC(50),Pharmacodynamic parameter estimates were 15.1 mg/min/kg for maximal glucose infusion rate (GIR(max)) and 88.0 mIU/L for SC(50) for diabetic patients and 62.9 mIU/L for healthy subjects.,Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20924141/),[miu] / [l],88.0,85754,DB00030,Insulin Regular
,20924141,SC(50),Pharmacodynamic parameter estimates were 15.1 mg/min/kg for maximal glucose infusion rate (GIR(max)) and 88.0 mIU/L for SC(50) for diabetic patients and 62.9 mIU/L for healthy subjects.,Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20924141/),[miu] / [l],62.9,85755,DB00030,Insulin Regular
,21251179,half-life,"The half-life of LY was approximately 90 h, with C(max) occurring between 24 and 48 h in most subjects.","LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251179/),h,90,86059,DB00030,Insulin Regular
,21251179,C(max),"The half-life of LY was approximately 90 h, with C(max) occurring between 24 and 48 h in most subjects.","LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21251179/),h,24 and 48,86060,DB00030,Insulin Regular
,30257345,IC50,Compound 1 was tested in the enzymatic assay showing an IC50 = 9.6 ± 0.5 μM and compound 2 showed about a 50% of inhibition of PTP-1B at 20 μM.,"Synthesis and evaluation of thiazolidine-2,4-dione/benzazole derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B): Antihyperglycemic activity with molecular docking study. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30257345/),μM,9.6,87336,DB00030,Insulin Regular
,27282159,half-life,"The half-life of plasma DPP-4 inhibition with saxagliptin 5 mg is ~27 h, which supports a once-daily dosing regimen.","Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27282159/),h,27,87472,DB00030,Insulin Regular
,30860869,half-lives,"The enhanced half-lives of xGLP159 and xGLP296 in SD rats (5.1 and 5.8 h, respectively) resulted in prolonged anti-db/db durations in db/db mice.",The chronic administration of two novel long-acting Xenopus glucagon-like peptide-1 analogs xGLP159 and xGLP296 potently improved systemic metabolism and glycemic control in rodent models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30860869/),h,5.1,88340,DB00030,Insulin Regular
,30860869,half-lives,"The enhanced half-lives of xGLP159 and xGLP296 in SD rats (5.1 and 5.8 h, respectively) resulted in prolonged anti-db/db durations in db/db mice.",The chronic administration of two novel long-acting Xenopus glucagon-like peptide-1 analogs xGLP159 and xGLP296 potently improved systemic metabolism and glycemic control in rodent models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30860869/),h,5.8,88341,DB00030,Insulin Regular
,23003329,AUC-PG(0-5h),"AUC-PG(0-5h) was similar with either bolus for 40-g (iBolus vs. tBolus, 585.5±127.5 vs. 689.2±180.7 mg/dL·h) or 100-g (752.1±237.7 vs. 760.0±263.2 mg/dL·h) CHO meals.",Evaluation of a novel continuous glucose monitoring-based method for mealtime insulin dosing--the iBolus--in subjects with type 1 diabetes using continuous subcutaneous insulin infusion therapy: a randomized controlled trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23003329/),[mg] / [dl·h],585.5,88358,DB00030,Insulin Regular
,23003329,AUC-PG(0-5h),"AUC-PG(0-5h) was similar with either bolus for 40-g (iBolus vs. tBolus, 585.5±127.5 vs. 689.2±180.7 mg/dL·h) or 100-g (752.1±237.7 vs. 760.0±263.2 mg/dL·h) CHO meals.",Evaluation of a novel continuous glucose monitoring-based method for mealtime insulin dosing--the iBolus--in subjects with type 1 diabetes using continuous subcutaneous insulin infusion therapy: a randomized controlled trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23003329/),[mg] / [dl·h],689.2,88359,DB00030,Insulin Regular
,23003329,AUC-PG(0-5h),"AUC-PG(0-5h) was similar with either bolus for 40-g (iBolus vs. tBolus, 585.5±127.5 vs. 689.2±180.7 mg/dL·h) or 100-g (752.1±237.7 vs. 760.0±263.2 mg/dL·h) CHO meals.",Evaluation of a novel continuous glucose monitoring-based method for mealtime insulin dosing--the iBolus--in subjects with type 1 diabetes using continuous subcutaneous insulin infusion therapy: a randomized controlled trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23003329/),[mg] / [dl·h],752.1,88360,DB00030,Insulin Regular
,23003329,AUC-PG(0-5h),"AUC-PG(0-5h) was similar with either bolus for 40-g (iBolus vs. tBolus, 585.5±127.5 vs. 689.2±180.7 mg/dL·h) or 100-g (752.1±237.7 vs. 760.0±263.2 mg/dL·h) CHO meals.",Evaluation of a novel continuous glucose monitoring-based method for mealtime insulin dosing--the iBolus--in subjects with type 1 diabetes using continuous subcutaneous insulin infusion therapy: a randomized controlled trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23003329/),[mg] / [dl·h],760.0,88361,DB00030,Insulin Regular
,31891874,flow rate,"Phenomenex Aqua 5μ 125A (250 × 4.6 mm) column was utilized to separate PSTi8 and IS with a mobile phase consists of MeOH-0.1 % formic acid (1:1, v/v) using 0.4 mL/min flow rate.",LC-ESI-MS/MS assay development and validation of a novel antidiabetic peptide PSTi8 in mice plasma using SPE: An application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31891874/),[ml] / [min],0.4,90537,DB00030,Insulin Regular
>,31891874,extraction recovery,SPE using medium anion exchange cartridge (Oasis MAX) was used for the extraction of analyte and IS from the mice plasma and the extraction recovery was found to be >55 %.,LC-ESI-MS/MS assay development and validation of a novel antidiabetic peptide PSTi8 in mice plasma using SPE: An application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31891874/),%,55,90538,DB00030,Insulin Regular
,31891874,absolute bioavailability,The absolute bioavailability of PSTi8 was 52.74 ± 13.50 %.,LC-ESI-MS/MS assay development and validation of a novel antidiabetic peptide PSTi8 in mice plasma using SPE: An application to pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31891874/),%,52.74,90539,DB00030,Insulin Regular
,24286115,area under the glucose concentration-time curve for 0-240 min,"In this small pilot study, the devices were similar in glucose excursion (median [quartile 1, quartile 3], InsuJet vs. FlexPen, 9.4 [4.8, 12.8] vs. 8.1 [5.4, 10.6] mmol/L; P=0.43), in the area under the glucose concentration-time curve for 0-240 min corrected for baseline glucose level (InsuJet vs. FlexPen, 1,230 [623, 2,012] vs. 1,175 [91, 1,774] mmol · min/L; P=0.4), and in insulin absorption over the 240-min period.",A pilot study to examine the tolerability and device preference in type 1 diabetes of insulin aspart administered by InsuJet compared with subcutaneous injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24286115/),[mM·min] / [l],"1,230",91465,DB00030,Insulin Regular
,24286115,area under the glucose concentration-time curve for 0-240 min,"In this small pilot study, the devices were similar in glucose excursion (median [quartile 1, quartile 3], InsuJet vs. FlexPen, 9.4 [4.8, 12.8] vs. 8.1 [5.4, 10.6] mmol/L; P=0.43), in the area under the glucose concentration-time curve for 0-240 min corrected for baseline glucose level (InsuJet vs. FlexPen, 1,230 [623, 2,012] vs. 1,175 [91, 1,774] mmol · min/L; P=0.4), and in insulin absorption over the 240-min period.",A pilot study to examine the tolerability and device preference in type 1 diabetes of insulin aspart administered by InsuJet compared with subcutaneous injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24286115/),[mM·min] / [l],"1,175",91466,DB00030,Insulin Regular
,22162541,apparent terminal half-life,"MK-5046 exposure increased dose proportionally, and MK-5046 was eliminated with an apparent terminal half-life of 1.5 to 3.5 hours.","Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22162541/),h,1.5 to 3.5,91764,DB00030,Insulin Regular
,19446153,AUC(0-infinity),"After administration of exenatide 5 microg, the geometric mean (SE) exenatide AUC(0-infinity) and C(max) were 339.5 (39.6) pg * h/mL and 85.1 (11.5) pg/mL, respectively (n = 12).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[h·pg] / [ml],339.5,92060,DB00030,Insulin Regular
,19446153,C(max),"After administration of exenatide 5 microg, the geometric mean (SE) exenatide AUC(0-infinity) and C(max) were 339.5 (39.6) pg * h/mL and 85.1 (11.5) pg/mL, respectively (n = 12).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[pg] / [ml],85.1,92061,DB00030,Insulin Regular
,19446153,AUC(0-infinity)),"The exenatide AUC appeared to be dose dependent, although exenatide was not quantifiable in all patients at the 2.5-microg dose; after administration of exenatide 2.5-microg, the geometric mean AUC(0-infinity)) was 159.2 (23.1) pg * h/mL (n = 6) and the geometric mean C(max) was 56.3 (10.1) pg/mL (n = 9).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[h·pg] / [ml],159.2,92062,DB00030,Insulin Regular
,19446153,C(max),"The exenatide AUC appeared to be dose dependent, although exenatide was not quantifiable in all patients at the 2.5-microg dose; after administration of exenatide 2.5-microg, the geometric mean AUC(0-infinity)) was 159.2 (23.1) pg * h/mL (n = 6) and the geometric mean C(max) was 56.3 (10.1) pg/mL (n = 9).","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[pg] / [ml],56.3,92063,DB00030,Insulin Regular
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],-3465.6,92064,DB00030,Insulin Regular
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],-,92065,DB00030,Insulin Regular
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],4422.2,92066,DB00030,Insulin Regular
,19446153,AUC(15-360min),"Both exenatide doses were associated with significant reductions in postprandial plasma glucose excursions compared with placebo (P < 0.01); the incremental mean (SE) AUC(15-360min) was -3465.6 (1587.3) mg * min/dL for exenatide 2.5 pg, -4422.2 (2434.4) mg * min/dL for exenatide 5 microg, and 3457.4 (1615.5) mg * min/dL for placebo.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[mg·min] / [dl],3457.4,92067,DB00030,Insulin Regular
,19446153,AUC(15-180min),"The 2 exenatide doses were also associated with significant reductions in postprandial plasma glucagon concentrations compared with placebo (P < 0.01); the respective incremental mean values for AUC(15-180min) were 125.5 (658.4), -1403.8 (632.1), and 1843.1 (540.6) pg * min/mL.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[min·pg] / [ml],125.5,92068,DB00030,Insulin Regular
,19446153,AUC(15-180min),"The 2 exenatide doses were also associated with significant reductions in postprandial plasma glucagon concentrations compared with placebo (P < 0.01); the respective incremental mean values for AUC(15-180min) were 125.5 (658.4), -1403.8 (632.1), and 1843.1 (540.6) pg * min/mL.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[min·pg] / [ml],-1403.8,92069,DB00030,Insulin Regular
,19446153,AUC(15-180min),"The 2 exenatide doses were also associated with significant reductions in postprandial plasma glucagon concentrations compared with placebo (P < 0.01); the respective incremental mean values for AUC(15-180min) were 125.5 (658.4), -1403.8 (632.1), and 1843.1 (540.6) pg * min/mL.","Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19446153/),[min·pg] / [ml],1843.1,92070,DB00030,Insulin Regular
,27849380,area under the curve (AUC0-180 min),"At 24 weeks, compared with baseline, saxagliptin + dapagliflozin and saxagliptin + placebo increased mean (95% confidence interval [CI]) C-peptide area under the curve (AUC0-180 min) (40.2 [9.2 to 71.3] ng/mL and 95.4 [63.4 to 127.4] ng/mL, respectively); no change was noted with dapagliflozin + placebo (14.5 [-17.6 to 46.8] ng/mL).",COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27849380/),[ng] / [ml],40.2,92253,DB00030,Insulin Regular
,27849380,area under the curve (AUC0-180 min),"At 24 weeks, compared with baseline, saxagliptin + dapagliflozin and saxagliptin + placebo increased mean (95% confidence interval [CI]) C-peptide area under the curve (AUC0-180 min) (40.2 [9.2 to 71.3] ng/mL and 95.4 [63.4 to 127.4] ng/mL, respectively); no change was noted with dapagliflozin + placebo (14.5 [-17.6 to 46.8] ng/mL).",COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27849380/),[ng] / [ml],95.4,92254,DB00030,Insulin Regular
,27849380,area under the curve (AUC0-180 min),"At 24 weeks, compared with baseline, saxagliptin + dapagliflozin and saxagliptin + placebo increased mean (95% confidence interval [CI]) C-peptide area under the curve (AUC0-180 min) (40.2 [9.2 to 71.3] ng/mL and 95.4 [63.4 to 127.4] ng/mL, respectively); no change was noted with dapagliflozin + placebo (14.5 [-17.6 to 46.8] ng/mL).",COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27849380/),[ng] / [ml],14.5,92255,DB00030,Insulin Regular
,27849380,AUC,"Insulin AUC was reduced from baseline with saxagliptin + dapagliflozin (-1,120.4 [-1,633.9 to -606.9] μU/mL) and dapagliflozin + placebo (-1,018.6 [-1550.5 to -486.8] μU/mL) but increased with saxagliptin + placebo (661.2 [131.1 to 1,191.3] μU/mL).",COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27849380/),[μu] / [ml],661.2,92256,DB00030,Insulin Regular
,18405788,T(max),"On day 14, the median T(max) was ~1 hour and the mean t(1/2) was 12.5 to 21.1 hours across all alogliptin doses.","Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18405788/),h,1,92959,DB00030,Insulin Regular
,18405788,t(1/2),"On day 14, the median T(max) was ~1 hour and the mean t(1/2) was 12.5 to 21.1 hours across all alogliptin doses.","Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18405788/),h,12.5 to 21.1,92960,DB00030,Insulin Regular
,25507175,terminal half-life,"The terminal half-life of IDeg is about 25 hours, which reflects a mean prolongation by factor 2 compared to Insulin glargin (lGlar).",[Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25507175/),h,25,93293,DB00030,Insulin Regular
,31468636,maximal concentration,The pharmacokinetic variables were: maximal concentration: 15.76 ± 7.88 μM (NAR150) and 48.45 ± 7.88 μM (NAR600); time to peak: 3.17 ± 0.74 hours (NAR150) and 2.41 ± 0.74 hours (NAR600); area under the 24-hour concentration-time curve: 67.61 ± 24.36 μM × h (NAR150) and 199.05 ± 24.36 μM × h (NAR600); and apparent oral clearance: 10.21 ± 2.34 L/h (NAR150) and 13.70 ± 2.34 L/h (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),μM,15.76,93595,DB00030,Insulin Regular
,31468636,maximal concentration,The pharmacokinetic variables were: maximal concentration: 15.76 ± 7.88 μM (NAR150) and 48.45 ± 7.88 μM (NAR600); time to peak: 3.17 ± 0.74 hours (NAR150) and 2.41 ± 0.74 hours (NAR600); area under the 24-hour concentration-time curve: 67.61 ± 24.36 μM × h (NAR150) and 199.05 ± 24.36 μM × h (NAR600); and apparent oral clearance: 10.21 ± 2.34 L/h (NAR150) and 13.70 ± 2.34 L/h (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),μM,48.45,93596,DB00030,Insulin Regular
,31468636,time to peak,The pharmacokinetic variables were: maximal concentration: 15.76 ± 7.88 μM (NAR150) and 48.45 ± 7.88 μM (NAR600); time to peak: 3.17 ± 0.74 hours (NAR150) and 2.41 ± 0.74 hours (NAR600); area under the 24-hour concentration-time curve: 67.61 ± 24.36 μM × h (NAR150) and 199.05 ± 24.36 μM × h (NAR600); and apparent oral clearance: 10.21 ± 2.34 L/h (NAR150) and 13.70 ± 2.34 L/h (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),h,3.17,93597,DB00030,Insulin Regular
,31468636,time to peak,The pharmacokinetic variables were: maximal concentration: 15.76 ± 7.88 μM (NAR150) and 48.45 ± 7.88 μM (NAR600); time to peak: 3.17 ± 0.74 hours (NAR150) and 2.41 ± 0.74 hours (NAR600); area under the 24-hour concentration-time curve: 67.61 ± 24.36 μM × h (NAR150) and 199.05 ± 24.36 μM × h (NAR600); and apparent oral clearance: 10.21 ± 2.34 L/h (NAR150) and 13.70 ± 2.34 L/h (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),h,2.41,93598,DB00030,Insulin Regular
,31468636,area under the 24-hour concentration-time curve,The pharmacokinetic variables were: maximal concentration: 15.76 ± 7.88 μM (NAR150) and 48.45 ± 7.88 μM (NAR600); time to peak: 3.17 ± 0.74 hours (NAR150) and 2.41 ± 0.74 hours (NAR600); area under the 24-hour concentration-time curve: 67.61 ± 24.36 μM × h (NAR150) and 199.05 ± 24.36 μM × h (NAR600); and apparent oral clearance: 10.21 ± 2.34 L/h (NAR150) and 13.70 ± 2.34 L/h (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),h·μM,67.61,93599,DB00030,Insulin Regular
,31468636,area under the 24-hour concentration-time curve,The pharmacokinetic variables were: maximal concentration: 15.76 ± 7.88 μM (NAR150) and 48.45 ± 7.88 μM (NAR600); time to peak: 3.17 ± 0.74 hours (NAR150) and 2.41 ± 0.74 hours (NAR600); area under the 24-hour concentration-time curve: 67.61 ± 24.36 μM × h (NAR150) and 199.05 ± 24.36 μM × h (NAR600); and apparent oral clearance: 10.21 ± 2.34 L/h (NAR150) and 13.70 ± 2.34 L/h (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),h·μM,199.05,93600,DB00030,Insulin Regular
,31468636,apparent oral clearance,The pharmacokinetic variables were: maximal concentration: 15.76 ± 7.88 μM (NAR150) and 48.45 ± 7.88 μM (NAR600); time to peak: 3.17 ± 0.74 hours (NAR150) and 2.41 ± 0.74 hours (NAR600); area under the 24-hour concentration-time curve: 67.61 ± 24.36 μM × h (NAR150) and 199.05 ± 24.36 μM × h (NAR600); and apparent oral clearance: 10.21 ± 2.34 L/h (NAR150) and 13.70 ± 2.34 L/h (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),[l] / [h],10.21,93601,DB00030,Insulin Regular
,31468636,apparent oral clearance,The pharmacokinetic variables were: maximal concentration: 15.76 ± 7.88 μM (NAR150) and 48.45 ± 7.88 μM (NAR600); time to peak: 3.17 ± 0.74 hours (NAR150) and 2.41 ± 0.74 hours (NAR600); area under the 24-hour concentration-time curve: 67.61 ± 24.36 μM × h (NAR150) and 199.05 ± 24.36 μM × h (NAR600); and apparent oral clearance: 10.21 ± 2.34 L/h (NAR150) and 13.70 ± 2.34 L/h (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),[l] / [h],13.70,93602,DB00030,Insulin Regular
,31468636,half-life,Naringenin half-life was 3.0 hours (NAR150) and 2.65 hours (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),h,3.0,93603,DB00030,Insulin Regular
,31468636,half-life,Naringenin half-life was 3.0 hours (NAR150) and 2.65 hours (NAR600).,"Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),h,2.65,93604,DB00030,Insulin Regular
,31468636,serum concentrations,"After NAR300 ingestion, serum concentrations were 10.67 ± 5.74 μM (4 hours) and 0.35 ± 0.30 μM (24 hours).","Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),μM,10.67,93605,DB00030,Insulin Regular
,31468636,serum concentrations,"After NAR300 ingestion, serum concentrations were 10.67 ± 5.74 μM (4 hours) and 0.35 ± 0.30 μM (24 hours).","Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),μ,0.35,93606,DB00030,Insulin Regular
,31468636,serum concentrations,"After NAR900 ingestion, serum concentrations were 43.11 ± 5.26 μM (4 hours) and 0.24 ± 0.30 μM (24 hours).","Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),μM,43.11,93607,DB00030,Insulin Regular
,31468636,serum concentrations,"After NAR900 ingestion, serum concentrations were 43.11 ± 5.26 μM (4 hours) and 0.24 ± 0.30 μM (24 hours).","Safety and pharmacokinetics of naringenin: A randomized, controlled, single-ascending-dose clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468636/),μ,0.24,93608,DB00030,Insulin Regular
,16484515,apparent volume of distribution,The mean apparent volume of distribution after administration of a single subcutaneous dose is 28.3 L.,Exenatide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),l,28.3,93631,DB00030,Insulin Regular
,16484515,terminal half-life,The terminal half-life of the drug is 2.4 hours.,Exenatide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),h,2.4,93632,DB00030,Insulin Regular
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,65,93633,DB00030,Insulin Regular
,16484515,bioavailability,"Based on animal studies, the bioavailability of exenatide after subcutaneous injection has been estimated to be between 65% and 75%.",Exenatide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16484515/),%,75,93634,DB00030,Insulin Regular
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.97,93783,DB00030,Insulin Regular
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.86,93784,DB00030,Insulin Regular
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.75,93785,DB00030,Insulin Regular
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.56,93786,DB00030,Insulin Regular
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.45,93787,DB00030,Insulin Regular
,11875364,oral clearances,"The mean oral clearances of tolbutamide were 0.97 (95% confidence interval [CI] 0.89-1.05), 0.86 (95% CI 0.79-0.93), 0.75 (95% CI 0.69-0.81), 0.56 (95% CI 0.51-0.61), 0.45 (95% CI 0.41-0.49) and 0.15 (95% CI 0.14-0.16) l/h in carriers of CYP2C9 genotypes 1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3, respectively.",Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11875364/),[l] / [h],0.15,93788,DB00030,Insulin Regular
,17953788,maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),[μM] / [l],146,93834,DB00030,Insulin Regular
,17953788,maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),[μM] / [l],303,93835,DB00030,Insulin Regular
,17953788,maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),[μM] / [l],81,93836,DB00030,Insulin Regular
,17953788,maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),[μM] / [l],179,93837,DB00030,Insulin Regular
,17953788,time to reach maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),h,1.17,93838,DB00030,Insulin Regular
,17953788,time to reach maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),h,2.29,93839,DB00030,Insulin Regular
,17953788,time to reach maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),h,1.38,93840,DB00030,Insulin Regular
,17953788,time to reach maximum concentration,"Concerning AA, only CIT, ornithine (ORN) and arginine (ARG) plasma concentrations were affected (maximum concentration 146 (sem 8) to 303 (sem 11) micromol/l (ARG) and 81 (sem 4) to 179 (sem 10) micromol/l (ORN); time to reach maximum concentration 1.17 (sem 0.26) to 2.29 (sem 0.20) h (ARG) and 1.38 (sem 0.25) to 1.79 (sem 0.11) h (ORN) according to CIT dose).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),h,1.79,93841,DB00030,Insulin Regular
<,17953788,urinary excretion,"Even at high doses, urinary excretion of CIT remained low ( < 5 %).",Dose-ranging effects of citrulline administration on plasma amino acids and hormonal patterns in healthy subjects: the Citrudose pharmacokinetic study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17953788/),%,5,93842,DB00030,Insulin Regular
,18310929,weight,The mean weight of SDMP was 1.03+/-0.04 mg.,Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310929/),,1.03,93856,DB00030,Insulin Regular
,18310929,"time when minimum plasma glucose level appeared, T(min)","The time when minimum plasma glucose level appeared, T(min), was 1.38+/-0.2 h for 1.0 IU study and 1.38+/-0.1 h for 2.0 IU study and clear dose-dependent hypoglycemic effect of insulin was observed in the dose range.",Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310929/),h,1.38,93857,DB00030,Insulin Regular
,18310929,"time when minimum plasma glucose level appeared, T(min)","The time when minimum plasma glucose level appeared, T(min), was 1.38+/-0.2 h for 1.0 IU study and 1.38+/-0.1 h for 2.0 IU study and clear dose-dependent hypoglycemic effect of insulin was observed in the dose range.",Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310929/),h,1.38,93858,DB00030,Insulin Regular
,18310929,relative pharmacological availabilities,"By comparing the area above the plasma glucose level vs. time curve (AAC) between insulin SDMP and subcutaneous (s.c.) injection solution, the relative pharmacological availabilities were 99% (1.0 IU) and 90% (2.0 IU), respectively.",Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310929/),%,99,93859,DB00030,Insulin Regular
,18310929,relative pharmacological availabilities,"By comparing the area above the plasma glucose level vs. time curve (AAC) between insulin SDMP and subcutaneous (s.c.) injection solution, the relative pharmacological availabilities were 99% (1.0 IU) and 90% (2.0 IU), respectively.",Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310929/),iu,1.0,93860,DB00030,Insulin Regular
,18310929,relative pharmacological availabilities,"By comparing the area above the plasma glucose level vs. time curve (AAC) between insulin SDMP and subcutaneous (s.c.) injection solution, the relative pharmacological availabilities were 99% (1.0 IU) and 90% (2.0 IU), respectively.",Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310929/),%,90,93861,DB00030,Insulin Regular
,18310929,relative pharmacological availabilities,"By comparing the area above the plasma glucose level vs. time curve (AAC) between insulin SDMP and subcutaneous (s.c.) injection solution, the relative pharmacological availabilities were 99% (1.0 IU) and 90% (2.0 IU), respectively.",Antihyperglycemic effect of insulin from self-dissolving micropiles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18310929/),iu,2.0,93862,DB00030,Insulin Regular
,22136324,time to peak insulin concentration,"Co-injection of lispro+rHuPH20 accelerated pharmacokinetics relative to lispro alone (time to peak insulin concentration, 43 vs. 74 min; P=0.0045) with increased exposure in the first hour (184% of control; P<0.0001) and reduced exposure after 2 h (67% of control; P=0.0001).",Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136324/),min,43,94352,DB00030,Insulin Regular
,22136324,time to peak insulin concentration,"Co-injection of lispro+rHuPH20 accelerated pharmacokinetics relative to lispro alone (time to peak insulin concentration, 43 vs. 74 min; P=0.0045) with increased exposure in the first hour (184% of control; P<0.0001) and reduced exposure after 2 h (67% of control; P=0.0001).",Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136324/),min,74,94353,DB00030,Insulin Regular
>,22136324,area under the curve for 0-4 h,"These accelerated pharmacokinetics improved both total hyperglycemic excursions (area under the curve for 0-4 h >140 mg/dL, 56% of control; P=0.048) and hypoglycemic excursions (area under the curve for 0-8 h <70 mg/dL, 34% of control; P=0.033), allowing over three times as many patients to reach the American Diabetes Association's target of peak PPG <180 mg/dL without requiring glucose treatment for hypoglycemia.",Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136324/),[mg] / [dl],140,94354,DB00030,Insulin Regular
<,22136324,area under the curve for 0-8 h,"These accelerated pharmacokinetics improved both total hyperglycemic excursions (area under the curve for 0-4 h >140 mg/dL, 56% of control; P=0.048) and hypoglycemic excursions (area under the curve for 0-8 h <70 mg/dL, 34% of control; P=0.033), allowing over three times as many patients to reach the American Diabetes Association's target of peak PPG <180 mg/dL without requiring glucose treatment for hypoglycemia.",Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136324/),[mg] / [dl],70,94355,DB00030,Insulin Regular
,21877761,time to reach the maximum plasma concentration,Ipragliflozin was rapidly absorbed with a median time to reach the maximum plasma concentration of 1.3 hours after the last dose.,"Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877761/),h,1.3,94547,DB00030,Insulin Regular
,21877761,elimination half-life,The mean elimination half-life was 12 hours following the last dose.,"Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21877761/),h,12,94548,DB00030,Insulin Regular
,30731237,en,CuMPs were formulated and characterized for size (12.71 ± 4.20 μm) and encapsulation efficiency (85.10 ± 2.33%) with 28% drug loading.,Dramatic improvement in pharmacokinetic and pharmacodynamic effects of sustain release curcumin microparticles demonstrated in experimental type 1 diabetes model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30731237/),,85,94687,DB00030,Insulin Regular
up to,21154170,t1/2,"Pharmacokinetic studies demonstrated a t1/2 in humans of up to 90 h, making dulaglutide an ideal candidate for once-weekly dosing.","Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21154170/),h,90,95331,DB00030,Insulin Regular
,15133532,terminal half-life (t(1/2)),The mean terminal half-life (t(1/2)) of RPR749 and RPR772 were similar (approximately 16.4 hours).,"Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15133532/),h,16.4,96826,DB00030,Insulin Regular
<,15527823,half-life,The short half-life (<2 min) in blood was subsequently associated with modest and inconsistent neuroprotection.,"Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15527823/),min,2,97069,DB00030,Insulin Regular
,29101821,duration of action,"When compared to the PD data that have been reported for regular insulin in healthy cats, insulin aspart had a more rapid onset (IM: 10 min [10-21.25 min], SC: 12.5 min [10-18.75 min]) and shorter duration of action (IM: 182.5 ± 34.33 min, SC: 159.38 ± 41.87 min).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),min,182.5,97437,DB00030,Insulin Regular
,29101821,duration of action,"When compared to the PD data that have been reported for regular insulin in healthy cats, insulin aspart had a more rapid onset (IM: 10 min [10-21.25 min], SC: 12.5 min [10-18.75 min]) and shorter duration of action (IM: 182.5 ± 34.33 min, SC: 159.38 ± 41.87 min).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),min,159.38,97438,DB00030,Insulin Regular
,29101821,maximum plasma insulin aspart concentration,"The onset of action (P = 0.795), time to peak action (P = 0.499), duration of action (P = 0.301), and total metabolic effect (P = 0.603) did not differ with route of administration; however, SC administration did result in a higher maximum plasma insulin aspart concentration (IM: 1,265.17 pmol/L [999.69-1,433.89 pmol/L], SC: 3,278.19 pmol/L [2,485.29-4,132.01 pmol/L], P = 0.000) and larger area under the insulin aspart vs time curve (IM: 82,662 ± 30,565 pmol/L, SC: 135,060 ± 39,026 pmol/L, P = 0.010).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),[pM] / [l],"1,265.17",97439,DB00030,Insulin Regular
,29101821,maximum plasma insulin aspart concentration,"The onset of action (P = 0.795), time to peak action (P = 0.499), duration of action (P = 0.301), and total metabolic effect (P = 0.603) did not differ with route of administration; however, SC administration did result in a higher maximum plasma insulin aspart concentration (IM: 1,265.17 pmol/L [999.69-1,433.89 pmol/L], SC: 3,278.19 pmol/L [2,485.29-4,132.01 pmol/L], P = 0.000) and larger area under the insulin aspart vs time curve (IM: 82,662 ± 30,565 pmol/L, SC: 135,060 ± 39,026 pmol/L, P = 0.010).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),[pM] / [l],"3,278.19",97440,DB00030,Insulin Regular
,29101821,area under the insulin aspart vs time curve,"The onset of action (P = 0.795), time to peak action (P = 0.499), duration of action (P = 0.301), and total metabolic effect (P = 0.603) did not differ with route of administration; however, SC administration did result in a higher maximum plasma insulin aspart concentration (IM: 1,265.17 pmol/L [999.69-1,433.89 pmol/L], SC: 3,278.19 pmol/L [2,485.29-4,132.01 pmol/L], P = 0.000) and larger area under the insulin aspart vs time curve (IM: 82,662 ± 30,565 pmol/L, SC: 135,060 ± 39,026 pmol/L, P = 0.010).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),[pM] / [l],"82,662",97441,DB00030,Insulin Regular
,29101821,area under the insulin aspart vs time curve,"The onset of action (P = 0.795), time to peak action (P = 0.499), duration of action (P = 0.301), and total metabolic effect (P = 0.603) did not differ with route of administration; however, SC administration did result in a higher maximum plasma insulin aspart concentration (IM: 1,265.17 pmol/L [999.69-1,433.89 pmol/L], SC: 3,278.19 pmol/L [2,485.29-4,132.01 pmol/L], P = 0.000) and larger area under the insulin aspart vs time curve (IM: 82,662 ± 30,565 pmol/L, SC: 135,060 ± 39,026 pmol/L, P = 0.010).",Pharmacodynamics and pharmacokinetics of insulin aspart assessed by use of the isoglycemic clamp method in healthy cats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29101821/),[pM] / [l],"135,060",97442,DB00030,Insulin Regular
,22758791,onset of action,"For single-site 0.8 U/kg, median (range) onset of action was 3.5 h (0.5-10 h), time to glucose nadir was 14 h (5 to >24 h), and duration of action was >24 h (16 to >24 h).",Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22758791/),h,3.5,98187,DB00030,Insulin Regular
,22758791,time to glucose nadir,"For single-site 0.8 U/kg, median (range) onset of action was 3.5 h (0.5-10 h), time to glucose nadir was 14 h (5 to >24 h), and duration of action was >24 h (16 to >24 h).",Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22758791/),h,14,98188,DB00030,Insulin Regular
>,22758791,duration of action,"For single-site 0.8 U/kg, median (range) onset of action was 3.5 h (0.5-10 h), time to glucose nadir was 14 h (5 to >24 h), and duration of action was >24 h (16 to >24 h).",Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22758791/),h,24,98189,DB00030,Insulin Regular
,17460786,time-to-peak plasma concentration,Its pharmacokinetic profile is characterized by a mean time-to-peak plasma concentration of 24.1 hours and an elimination half-life of approximately 24 hours.,"Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460786/),h,24.1,98845,DB00030,Insulin Regular
,17460786,elimination half-life,Its pharmacokinetic profile is characterized by a mean time-to-peak plasma concentration of 24.1 hours and an elimination half-life of approximately 24 hours.,"Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17460786/),h,24,98846,DB00030,Insulin Regular
,25212606,MTDs,The MTDs were established to be 400 mg once daily and 150 mg twice daily.,"A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212606/),mg,400,98957,DB00030,Insulin Regular
,25212606,half-life,"OSI-906 was rapidly absorbed with a half-life of 5 hours, and steady-state plasma concentrations were achieved by day 8.","A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25212606/),h,5,98958,DB00030,Insulin Regular
,25460544,Bioavailability,Bioavailability of leuprolide following pulmonary administration was 75% higher compared to subcutaneously administered leuprolide.,Effect of protease inhibitors on pulmonary bioavailability of therapeutic proteins and peptides in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25460544/),%,75,100120,DB00030,Insulin Regular
,12419651,bioavailability,The average bioavailability of IBS by buccal delivery versus subcutaneous injection is 29.2%.,Hypoglycaemic effect of a novel insulin buccal formulation on rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12419651/),%,29.2,100842,DB00030,Insulin Regular
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],43.1,102014,DB00030,Insulin Regular
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],45.9,102015,DB00030,Insulin Regular
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],29.0,102016,DB00030,Insulin Regular
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],33.1,102017,DB00030,Insulin Regular
,19477256,absolute bioavailability,Nasal administration of Amioca/Carbopol 974P powders without heat treatment resulted in an absolute bioavailability in rabbits of 8.2+/-3.0% for insulin.,Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,8.2,102369,DB00030,Insulin Regular
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,26.4,102370,DB00030,Insulin Regular
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,36.5,102371,DB00030,Insulin Regular
,19477256,bioavailability,"Due to the difference in water-absorbing capacity (which opened the tight junctions of the nasal mucosa), elasticity and plasticity (which reduced mucociliairy clearance and prolonged residence time) heat treatment at 120 degrees C improved the bioavailability: 26.4+/-21.9, 36.5+/-11.0 and 19.3+/-17.3% after heat treatment during 30 min, 1 h and 4 h, respectively.",Influence of heat treatment on spray-dried mixtures of Amioca starch and Carbopol 974P used as carriers for nasal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19477256/),%,19.3,102372,DB00030,Insulin Regular
,10963823,peak,"Subcutaneous single injections (0.025 and 0.05 U/kg body weight (BW)) of insulin aspart produced a significantly earlier peak of exogenous insulin level in comparison with human insulin (30.8+/-13.8 versus 61.3+/-14. 6 min, P<0.9001 for 0.025 U/kg; and 39.2+/-18.8 versus 99.2+/-53.8 min, P<0.005 for 0.05 U/kg).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),min,30,102449,DB00030,Insulin Regular
,10963823,peak,"Subcutaneous single injections (0.025 and 0.05 U/kg body weight (BW)) of insulin aspart produced a significantly earlier peak of exogenous insulin level in comparison with human insulin (30.8+/-13.8 versus 61.3+/-14. 6 min, P<0.9001 for 0.025 U/kg; and 39.2+/-18.8 versus 99.2+/-53.8 min, P<0.005 for 0.05 U/kg).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),min,61.3,102450,DB00030,Insulin Regular
,10963823,peak,"Subcutaneous single injections (0.025 and 0.05 U/kg body weight (BW)) of insulin aspart produced a significantly earlier peak of exogenous insulin level in comparison with human insulin (30.8+/-13.8 versus 61.3+/-14. 6 min, P<0.9001 for 0.025 U/kg; and 39.2+/-18.8 versus 99.2+/-53.8 min, P<0.005 for 0.05 U/kg).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),min,39.2,102451,DB00030,Insulin Regular
,10963823,peak,"Subcutaneous single injections (0.025 and 0.05 U/kg body weight (BW)) of insulin aspart produced a significantly earlier peak of exogenous insulin level in comparison with human insulin (30.8+/-13.8 versus 61.3+/-14. 6 min, P<0.9001 for 0.025 U/kg; and 39.2+/-18.8 versus 99.2+/-53.8 min, P<0.005 for 0.05 U/kg).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),min,99.2,102452,DB00030,Insulin Regular
,10963823,peak serum level,"The peak serum level of insulin aspart was higher than that of human insulin (23.0+/-6.0 versus 9.9+/-3.1 microU/ml for 0.025 U/kg; and 30.9+/-9.2 versus 13.3+/-4.1 microU/ml for 0.05 U/kg, P<0.0001).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),[μu] / [ml],23.0,102453,DB00030,Insulin Regular
,10963823,peak serum level,"The peak serum level of insulin aspart was higher than that of human insulin (23.0+/-6.0 versus 9.9+/-3.1 microU/ml for 0.025 U/kg; and 30.9+/-9.2 versus 13.3+/-4.1 microU/ml for 0.05 U/kg, P<0.0001).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),[μu] / [ml],9.9,102454,DB00030,Insulin Regular
,10963823,peak serum level,"The peak serum level of insulin aspart was higher than that of human insulin (23.0+/-6.0 versus 9.9+/-3.1 microU/ml for 0.025 U/kg; and 30.9+/-9.2 versus 13.3+/-4.1 microU/ml for 0.05 U/kg, P<0.0001).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),[μu] / [ml],30.9,102455,DB00030,Insulin Regular
,10963823,peak serum level,"The peak serum level of insulin aspart was higher than that of human insulin (23.0+/-6.0 versus 9.9+/-3.1 microU/ml for 0.025 U/kg; and 30.9+/-9.2 versus 13.3+/-4.1 microU/ml for 0.05 U/kg, P<0.0001).","Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10963823/),[μu] / [ml],13.3,102456,DB00030,Insulin Regular
,24800725,Trough pasireotide concentrations,"Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group).","Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800725/),[ng] / [ml],2.48,103977,DB00030,Insulin Regular
,24800725,Trough pasireotide concentrations,"Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group).","Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800725/),[ng] / [ml],4.16,103978,DB00030,Insulin Regular
,24800725,Trough pasireotide concentrations,"Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group).","Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800725/),[ng] / [ml],3.10,103979,DB00030,Insulin Regular
,24800725,Trough pasireotide concentrations,"Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group).","Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800725/),[ng] / [ml],6.42,103980,DB00030,Insulin Regular
,24800725,Trough pasireotide concentrations,"Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group).","Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800725/),[ng] / [ml],6.62,103981,DB00030,Insulin Regular
,24800725,Trough pasireotide concentrations,"Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group).","Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800725/),[ng] / [ml],7.12,103982,DB00030,Insulin Regular
,24800725,Trough pasireotide concentrations,"Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group).","Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800725/),[ng] / [ml],9.51,103983,DB00030,Insulin Regular
,24800725,Trough pasireotide concentrations,"Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group).","Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800725/),[ng] / [ml],11.7,103984,DB00030,Insulin Regular
,24800725,Trough pasireotide concentrations,"Trough pasireotide concentrations (ng/mL) 28 days after each injection were: 2.48, 4.16, and 3.10 (20 mg group); 6.42, 6.62, and 7.12 (40 mg group); and 9.51, 11.7, and 13.0 (60 mg group).","Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24800725/),[ng] / [ml],13.0,103985,DB00030,Insulin Regular
,21129323,peak plasma glucagon levels,"The relative error in the control algorithm's online estimate of the instantaneous plasma insulin level was also higher during episodes ending in hypoglycemia (50 versus 30%, p=.003), as were the peak plasma glucagon levels (183 versus 116 pg/ml, p=.007, normal range 50-150 pg/ml) and mean plasma glucagon levels (142 versus 75 pg/ml, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[pg] / [ml],183,104428,DB00030,Insulin Regular
,21129323,peak plasma glucagon levels,"The relative error in the control algorithm's online estimate of the instantaneous plasma insulin level was also higher during episodes ending in hypoglycemia (50 versus 30%, p=.003), as were the peak plasma glucagon levels (183 versus 116 pg/ml, p=.007, normal range 50-150 pg/ml) and mean plasma glucagon levels (142 versus 75 pg/ml, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[pg] / [ml],116,104429,DB00030,Insulin Regular
,21129323,rate of,"The rate of BG descent was also significantly greater during episodes ending in hypoglycemia (1.5 versus 1.0 mg/dl/min, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[mg] / [dl·min],1.5,104430,DB00030,Insulin Regular
,21129323,rate of,"The rate of BG descent was also significantly greater during episodes ending in hypoglycemia (1.5 versus 1.0 mg/dl/min, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[mg] / [dl·min],1.0,104431,DB00030,Insulin Regular
,21129323,descent,"The rate of BG descent was also significantly greater during episodes ending in hypoglycemia (1.5 versus 1.0 mg/dl/min, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[mg] / [dl·min],1.5,104432,DB00030,Insulin Regular
,21129323,descent,"The rate of BG descent was also significantly greater during episodes ending in hypoglycemia (1.5 versus 1.0 mg/dl/min, p=.02).",Efficacy determinants of subcutaneous microdose glucagon during closed-loop control. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21129323/),[mg] / [dl·min],1.0,104433,DB00030,Insulin Regular
,15561487,available energy,"Orally ingested cellobiose was well fermented in human large intestine, and its available energy was estimated to be about 2 kcal/g.",Bioavailability of cellobiose by tolerance test and breath hydrogen excretion in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561487/),[kcal] / [g],2,104567,DB00030,Insulin Regular
,29777569,clearance (CL,"As expected, HWL-066 revealed a lower clearance (CL = 0.23 L-1 hr-1 kg-1 ), higher maximum concentration (Cmax = 5907.47 μg/L), and longer half-life (T1/2 = 3.50 hr), resulting in a 2.8-fold higher exposure than GW9508.","Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777569/),1/[h·kg·l],0.23,104632,DB00030,Insulin Regular
,29777569,maximum concentration (Cmax,"As expected, HWL-066 revealed a lower clearance (CL = 0.23 L-1 hr-1 kg-1 ), higher maximum concentration (Cmax = 5907.47 μg/L), and longer half-life (T1/2 = 3.50 hr), resulting in a 2.8-fold higher exposure than GW9508.","Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777569/),[μg] / [l],5907.47,104633,DB00030,Insulin Regular
,29777569,half-life (T1/2,"As expected, HWL-066 revealed a lower clearance (CL = 0.23 L-1 hr-1 kg-1 ), higher maximum concentration (Cmax = 5907.47 μg/L), and longer half-life (T1/2 = 3.50 hr), resulting in a 2.8-fold higher exposure than GW9508.","Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29777569/),h,3.50,104634,DB00030,Insulin Regular
,31622690,polydispersity index,"The optimized IN-Z-CSA/CS0.2% nanocomposites exhibited an average size of 311.32±6.98 nm, a low polydispersity index (0.227±0.01), a negative zeta potential (43.77±1.36 mV), an encapsulation efficiency of 89.6±0.9%, and a loading capacity of 6.8±0.4%.",Chitosan coating of zein-carboxymethylated short-chain amylose nanocomposites improves oral bioavailability of insulin in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622690/),,0.227,105510,DB00030,Insulin Regular
,31622690,zeta potential,"The optimized IN-Z-CSA/CS0.2% nanocomposites exhibited an average size of 311.32±6.98 nm, a low polydispersity index (0.227±0.01), a negative zeta potential (43.77±1.36 mV), an encapsulation efficiency of 89.6±0.9%, and a loading capacity of 6.8±0.4%.",Chitosan coating of zein-carboxymethylated short-chain amylose nanocomposites improves oral bioavailability of insulin in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622690/),mv,43.77,105511,DB00030,Insulin Regular
,31622690,encapsulation efficiency,"The optimized IN-Z-CSA/CS0.2% nanocomposites exhibited an average size of 311.32±6.98 nm, a low polydispersity index (0.227±0.01), a negative zeta potential (43.77±1.36 mV), an encapsulation efficiency of 89.6±0.9%, and a loading capacity of 6.8±0.4%.",Chitosan coating of zein-carboxymethylated short-chain amylose nanocomposites improves oral bioavailability of insulin in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622690/),%,89.6,105512,DB00030,Insulin Regular
,31622690,loading capacity,"The optimized IN-Z-CSA/CS0.2% nanocomposites exhibited an average size of 311.32±6.98 nm, a low polydispersity index (0.227±0.01), a negative zeta potential (43.77±1.36 mV), an encapsulation efficiency of 89.6±0.9%, and a loading capacity of 6.8±0.4%.",Chitosan coating of zein-carboxymethylated short-chain amylose nanocomposites improves oral bioavailability of insulin in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622690/),%,6.8,105513,DB00030,Insulin Regular
,31622690,relative bioavailability,"Additionally, in pharmacological studies, orally administered IN-Z-CSA/CS0.2% nanocomposites had a stronger hypoglycemic effect with a relative bioavailability of 15.19% compared with that of IN-Z-CSA1.0% nanocomposites.",Chitosan coating of zein-carboxymethylated short-chain amylose nanocomposites improves oral bioavailability of insulin in vitro and in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31622690/),%,15.19,105514,DB00030,Insulin Regular
,24097863,M,The MTD was 700 mg twice weekly when BIIB021 was dosed for 3 weeks out of each 4-week course.,"A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24097863/),mg,700,105693,DB00030,Insulin Regular
,24097863,Cmax,Cmax occurred at approximately 90 minutes and t1/2 was approximately 1 hour across dosing cohorts of 25 to 800 mg BIIB021 twice weekly.,"A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24097863/),min,90,105694,DB00030,Insulin Regular
,24097863,t1/2,Cmax occurred at approximately 90 minutes and t1/2 was approximately 1 hour across dosing cohorts of 25 to 800 mg BIIB021 twice weekly.,"A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24097863/),h,1,105695,DB00030,Insulin Regular
,28889219,run time,Sample preparation by protein precipitation and ion exchange solid phase extraction was followed by UPLC on an XBridge™ BEH300 C18 column at 40 °C in a run time of only 5.5 min.,A validated UPLC-MS/MS method coupled with protein precipitation and ion exchange solid phase extraction for the quantitation of porcine relaxin B29 in dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889219/),min,5.5,106054,DB00030,Insulin Regular
,28889219,m/,"Detection was performed on a Qtrap 6500 mass spectrometer using ESI in the positive ion mode with MRM of the transitions at m/z 831.7 [M+7H]7+ → 505.4 and m/z 1162.4 [M+5H]5+ → 226 for pRLX B29 and internal standard (recombinant human insulin), respectively.",A validated UPLC-MS/MS method coupled with protein precipitation and ion exchange solid phase extraction for the quantitation of porcine relaxin B29 in dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889219/),,831.7,106055,DB00030,Insulin Regular
,28889219,m/,"Detection was performed on a Qtrap 6500 mass spectrometer using ESI in the positive ion mode with MRM of the transitions at m/z 831.7 [M+7H]7+ → 505.4 and m/z 1162.4 [M+5H]5+ → 226 for pRLX B29 and internal standard (recombinant human insulin), respectively.",A validated UPLC-MS/MS method coupled with protein precipitation and ion exchange solid phase extraction for the quantitation of porcine relaxin B29 in dog plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28889219/),,7,106056,DB00030,Insulin Regular
,21127194,AUC(0-7d),"At 9 mg/kg/wk the mean AUC(0-7d) (21,000 μg h/mL) exceeded the target (16,000 μg h/mL).",Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21127194/),[h·μg] / [ml],"21,000",106230,DB00030,Insulin Regular
,21127194,AUC(0-7d),"At 9 mg/kg/wk the mean AUC(0-7d) (21,000 μg h/mL) exceeded the target (16,000 μg h/mL).",Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21127194/),[h·μg] / [ml],"16,000",106231,DB00030,Insulin Regular
,21127194,AUC(021d),"At 16 mg/kg q3W, the mean AUC(021d) (70,000 μg h/mL) exceeded the target (59,400 μg h/mL).",Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21127194/),[h·μg] / [ml],"70,000",106232,DB00030,Insulin Regular
,21127194,AUC(021d),"At 16 mg/kg q3W, the mean AUC(021d) (70,000 μg h/mL) exceeded the target (59,400 μg h/mL).",Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21127194/),[h·μg] / [ml],"59,400",106233,DB00030,Insulin Regular
,30326527,AUC,"Serum insulin AUC was lower (p<0.05) following the HIGH (34,158±8,786 pmol·min·L-1) compared to the LOW (40,738±9,276 pmol·min·L-1) trial.",Altering Physical Activity Influences Insulin Responses to Glucose Ingestion in Healthy Adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326527/),[min·pM] / [l],"34,158",106537,DB00030,Insulin Regular
,30326527,AUC,"Serum insulin AUC was lower (p<0.05) following the HIGH (34,158±8,786 pmol·min·L-1) compared to the LOW (40,738±9,276 pmol·min·L-1) trial.",Altering Physical Activity Influences Insulin Responses to Glucose Ingestion in Healthy Adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30326527/),[min·pM] / [l],"40,738",106538,DB00030,Insulin Regular
,25625650,half-life,"With a half-life of approximately 12 h, once daily dosing might be feasible; however, significant effects on appetite and weight loss may necessitate dosage or dosing frequency reductions.",Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25625650/),h,12,107005,DB00030,Insulin Regular
,19476477,peak insulin concentrations (C(max)),"Following inhalation of TI, peak insulin concentrations (C(max)) were achieved approximately 2 h earlier than with RHI (12-17 min for TI vs. 134 min for RHI).",Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476477/),min,12-17,107164,DB00030,Insulin Regular
,19476477,peak insulin concentrations (C(max)),"Following inhalation of TI, peak insulin concentrations (C(max)) were achieved approximately 2 h earlier than with RHI (12-17 min for TI vs. 134 min for RHI).",Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476477/),min,134,107165,DB00030,Insulin Regular
,19476477,relative bioavailability,"RHI, TI at doses of 25, 50 and 100 U showed a relative bioavailability of 25, 23 and 21%, respectively.",Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476477/),%,25,107166,DB00030,Insulin Regular
,19476477,relative bioavailability,"RHI, TI at doses of 25, 50 and 100 U showed a relative bioavailability of 25, 23 and 21%, respectively.",Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476477/),%,23,107167,DB00030,Insulin Regular
,19476477,relative bioavailability,"RHI, TI at doses of 25, 50 and 100 U showed a relative bioavailability of 25, 23 and 21%, respectively.",Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476477/),%,21,107168,DB00030,Insulin Regular
,19476477,bioeffect,"The maximum bioeffect, as measured by the glucose infusion rate, occurred approximately 2 h earlier for all three TI doses (42, 50 and 58 min, respectively) than for s.c. RHI (171 min).",Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476477/),min,42,107169,DB00030,Insulin Regular
,19476477,bioeffect,"The maximum bioeffect, as measured by the glucose infusion rate, occurred approximately 2 h earlier for all three TI doses (42, 50 and 58 min, respectively) than for s.c. RHI (171 min).",Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476477/),min,50,107170,DB00030,Insulin Regular
,19476477,bioeffect,"The maximum bioeffect, as measured by the glucose infusion rate, occurred approximately 2 h earlier for all three TI doses (42, 50 and 58 min, respectively) than for s.c. RHI (171 min).",Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476477/),min,58,107171,DB00030,Insulin Regular
,19476477,bioeffect,"The maximum bioeffect, as measured by the glucose infusion rate, occurred approximately 2 h earlier for all three TI doses (42, 50 and 58 min, respectively) than for s.c. RHI (171 min).",Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19476477/),min,171,107172,DB00030,Insulin Regular
,16388405,bioavailability,"A single administration of 100 U/kg of insulin-magnetite-PLGA microparticles to fasted mice resulted in a reduction of blood glucose levels of up to 43.8% in the presence of an external magnetic field for 20 h (bioavailability = 2.77 +/- 0.46 and 0.87 +/- 0.29% based on glucose and ELISA assay, respectively), significantly higher than similarly dosed mice without a magnetic field (bioavailability = 0.66 +/- 0.56 and 0.30 +/- 0.06%, based on glucose and ELISA assay, respectively).",Magnetically responsive polymeric microparticles for oral delivery of protein drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388405/),%,2.77,107361,DB00030,Insulin Regular
,16388405,bioavailability,"A single administration of 100 U/kg of insulin-magnetite-PLGA microparticles to fasted mice resulted in a reduction of blood glucose levels of up to 43.8% in the presence of an external magnetic field for 20 h (bioavailability = 2.77 +/- 0.46 and 0.87 +/- 0.29% based on glucose and ELISA assay, respectively), significantly higher than similarly dosed mice without a magnetic field (bioavailability = 0.66 +/- 0.56 and 0.30 +/- 0.06%, based on glucose and ELISA assay, respectively).",Magnetically responsive polymeric microparticles for oral delivery of protein drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388405/),%,0.87,107362,DB00030,Insulin Regular
,16388405,bioavailability,"A single administration of 100 U/kg of insulin-magnetite-PLGA microparticles to fasted mice resulted in a reduction of blood glucose levels of up to 43.8% in the presence of an external magnetic field for 20 h (bioavailability = 2.77 +/- 0.46 and 0.87 +/- 0.29% based on glucose and ELISA assay, respectively), significantly higher than similarly dosed mice without a magnetic field (bioavailability = 0.66 +/- 0.56 and 0.30 +/- 0.06%, based on glucose and ELISA assay, respectively).",Magnetically responsive polymeric microparticles for oral delivery of protein drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388405/),%,0.66,107363,DB00030,Insulin Regular
,16388405,bioavailability,"A single administration of 100 U/kg of insulin-magnetite-PLGA microparticles to fasted mice resulted in a reduction of blood glucose levels of up to 43.8% in the presence of an external magnetic field for 20 h (bioavailability = 2.77 +/- 0.46 and 0.87 +/- 0.29% based on glucose and ELISA assay, respectively), significantly higher than similarly dosed mice without a magnetic field (bioavailability = 0.66 +/- 0.56 and 0.30 +/- 0.06%, based on glucose and ELISA assay, respectively).",Magnetically responsive polymeric microparticles for oral delivery of protein drugs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16388405/),%,0.30,107364,DB00030,Insulin Regular
,33768488,systemic clearance,"Teprotumumab pharmacokinetics was linear in patients with TED, with low systemic clearance (0.334 L/day), low volume of distribution (3.9 and 4.2 L for the central and peripheral compartment, respectively), and a long elimination half-life (19.9 days).","Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768488/),[l] / [d],0.334,107486,DB00030,Insulin Regular
,33768488,volume of distribution,"Teprotumumab pharmacokinetics was linear in patients with TED, with low systemic clearance (0.334 L/day), low volume of distribution (3.9 and 4.2 L for the central and peripheral compartment, respectively), and a long elimination half-life (19.9 days).","Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768488/),l,3.9,107487,DB00030,Insulin Regular
,33768488,volume of distribution,"Teprotumumab pharmacokinetics was linear in patients with TED, with low systemic clearance (0.334 L/day), low volume of distribution (3.9 and 4.2 L for the central and peripheral compartment, respectively), and a long elimination half-life (19.9 days).","Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768488/),l,4.2,107488,DB00030,Insulin Regular
,33768488,elimination half-life,"Teprotumumab pharmacokinetics was linear in patients with TED, with low systemic clearance (0.334 L/day), low volume of distribution (3.9 and 4.2 L for the central and peripheral compartment, respectively), and a long elimination half-life (19.9 days).","Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768488/),d,19.9,107489,DB00030,Insulin Regular
,33768488,steady-state area under the concentration-time curve,"Model-predicted mean (± standard deviation) steady-state area under the concentration-time curve, peak, and trough concentrations in patients with TED were 131 (± 30.9) mg∙h/mL, 643 (± 130) µg/mL, and 157 (± 50.6) µg/mL, respectively.","Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768488/),[mg∙h] / [ml],131,107490,DB00030,Insulin Regular
,33768488,peak,"Model-predicted mean (± standard deviation) steady-state area under the concentration-time curve, peak, and trough concentrations in patients with TED were 131 (± 30.9) mg∙h/mL, 643 (± 130) µg/mL, and 157 (± 50.6) µg/mL, respectively.","Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768488/),[μg] / [ml],643,107491,DB00030,Insulin Regular
,33768488,trough concentrations,"Model-predicted mean (± standard deviation) steady-state area under the concentration-time curve, peak, and trough concentrations in patients with TED were 131 (± 30.9) mg∙h/mL, 643 (± 130) µg/mL, and 157 (± 50.6) µg/mL, respectively.","Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768488/),[μg] / [ml],157,107492,DB00030,Insulin Regular
,29511780,Cmax,"PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr.",Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),[ng] / [ml],491.7,107564,DB00030,Insulin Regular
,29511780,AUC0-∞,"PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr.",Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),[h·ng] / [ml],4256.1,107565,DB00030,Insulin Regular
,29511780,Tmax,"PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr.",Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),h,2.9,107566,DB00030,Insulin Regular
,29511780,t1/2,"PK parameters expressed in mean (SD) were Cmax 491.7 (135.9) ng/mL; AUC0-∞ 4256.1 (509.9) ng· hr/mL, Tmax 2.9 (1.0) hr and t1/2 10.4 (3.0) hr.",Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),h,10.4,107567,DB00030,Insulin Regular
,29511780,AUC,The mean average (SD) AUC of plasma insulin over 2 h of standardised meal was 47.9 (24.9) μIU/mL.,Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511780/),[μiu] / [ml],47.9,107568,DB00030,Insulin Regular
,20513326,C(max),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [ml],22,107661,DB00030,Insulin Regular
,20513326,C(max),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [ml],27,107662,DB00030,Insulin Regular
,20513326,C(max),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [ml],56,107663,DB00030,Insulin Regular
,20513326,C(max),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [ml],62,107664,DB00030,Insulin Regular
,20513326,C(max),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [ml],84,107665,DB00030,Insulin Regular
,20513326,AUC((0-45 min)),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [min·ml],491,107666,DB00030,Insulin Regular
,20513326,AUC((0-45 min)),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [min·ml],592,107667,DB00030,Insulin Regular
,20513326,AUC((0-45 min)),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [min·ml],1231,107668,DB00030,Insulin Regular
,20513326,AUC((0-45 min)),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [min·ml],1310,107669,DB00030,Insulin Regular
,20513326,AUC((0-45 min)),"A dose response (slope of the natural log response versus dose) was demonstrated by baseline-adjusted C(max) of 22, 27, 56, 62, and 84 microU/ml for the 25, 35, 50, 70, and 100 U doses (p < .0001), respectively, and by baseline-adjusted AUC((0-45 min)) values of 491, 592, 1231, 1310, and 1894 microU/ml/min (p < .0001).","Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20513326/),[μu] / [min·ml],1894,107670,DB00030,Insulin Regular
,17929148,peak concentrations,Testing the microspheres in healthy volunteers showed an increase (over 7-8 days) in hGH serum concentrations (peak concentrations: 1-2.5 ng/ml).,Preclinical and clinical in vitro in vivo correlation of an hGH dextran microsphere formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17929148/),[ng] / [ml],1-2.5,107704,DB00030,Insulin Regular
,27500713,Tmax,"ID versus SC injection demonstrated significantly shorter Tmax (median 35 vs. 87.5 min [P < 0.001]), while the Cmax did not significantly differ (median 80 vs. 55 μU/mL [P = 0.085]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),min,35,108741,DB00030,Insulin Regular
,27500713,Tmax,"ID versus SC injection demonstrated significantly shorter Tmax (median 35 vs. 87.5 min [P < 0.001]), while the Cmax did not significantly differ (median 80 vs. 55 μU/mL [P = 0.085]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),min,87.5,108742,DB00030,Insulin Regular
,27500713,Cmax,"ID versus SC injection demonstrated significantly shorter Tmax (median 35 vs. 87.5 min [P < 0.001]), while the Cmax did not significantly differ (median 80 vs. 55 μU/mL [P = 0.085]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [ml],80,108743,DB00030,Insulin Regular
,27500713,Cmax,"ID versus SC injection demonstrated significantly shorter Tmax (median 35 vs. 87.5 min [P < 0.001]), while the Cmax did not significantly differ (median 80 vs. 55 μU/mL [P = 0.085]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [ml],55,108744,DB00030,Insulin Regular
,27500713,area under the curve (AUC; 360 min),"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],9914,108745,DB00030,Insulin Regular
,27500713,area under the curve (AUC; 360 min),"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],"10,936",108746,DB00030,Insulin Regular
,27500713,AUC,"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],3821,108747,DB00030,Insulin Regular
,27500713,AUC,"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],2534,108748,DB00030,Insulin Regular
,27500713,AUC,"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],2054,108749,DB00030,Insulin Regular
,27500713,AUC,"Median insulin area under the curve (AUC; 360 min) did not differ between the groups (9914 vs. 10,936 μU/mL/min [p = 0.077]), yet 0-60 min insulin AUC was higher with ID versus SC injection (mean ± SD 3821 ± 1429 vs. 2534 ± 737 μU/mL/min [p = 0.01]) and 4-6 h AUC was lower with ID versus SC injection (mean ± SD 2054 ± 858 vs. 2929 ± 1412 μU/mL/min [p = 0.02]).",Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),[μu] / [min·ml],2929,108750,DB00030,Insulin Regular
,27500713,relative bioavailability,The relative bioavailability of the ID versus the SC insulin (AUCID/AUCSC) was similar (median 0.91 [95% confidence interval 0.73-1.27]).,Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27500713/),,0.91,108751,DB00030,Insulin Regular
up to,33086102,encapsulation efficiency,"nMIC and nFIB displayed good CsA encapsulation efficiency (up to 4.5 and 2 mg/mL, respectively in aqueous solution), superior to many other solubilization methods, and provided sustained release (>14 and > 7 days for the nMIC and nFIB) without compromising CsA's pharmacological activity.",Drug-Integrating Amphiphilic Nanomaterial Assemblies: 1. Spatiotemporal control of cyclosporine delivery and activity using nanomicelles and nanofibrils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33086102/),[mg] / [ml],4.5,109495,DB00030,Insulin Regular
,33086102,encapsulation efficiency,"nMIC and nFIB displayed good CsA encapsulation efficiency (up to 4.5 and 2 mg/mL, respectively in aqueous solution), superior to many other solubilization methods, and provided sustained release (>14 and > 7 days for the nMIC and nFIB) without compromising CsA's pharmacological activity.",Drug-Integrating Amphiphilic Nanomaterial Assemblies: 1. Spatiotemporal control of cyclosporine delivery and activity using nanomicelles and nanofibrils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33086102/),[mg] / [ml],2,109496,DB00030,Insulin Regular
,28406239,IC50,The IC50 of CMD-05 on DPP-IV inhibitory activity was approximately 12 nM while vildagliptin was 3.5 nM in vitro.,"CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406239/),nM,12,109775,DB00030,Insulin Regular
,28406239,IC50,The IC50 of CMD-05 on DPP-IV inhibitory activity was approximately 12 nM while vildagliptin was 3.5 nM in vitro.,"CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406239/),nM,3.5,109776,DB00030,Insulin Regular
,28406239,half-life,"After oral administration, CMD-05 reached peak concentration at 30 min with half-life of 288 minutes and the inhibitory rate of DPP-IV greater than 50% lasted for 15 h.","CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406239/),min,288,109777,DB00030,Insulin Regular
,28406239,maximum tolerance dose,CMD-05 had a lower cytotoxicity than vildagliptin in vitro and its maximum tolerance dose in mice is beyond 2000 mg/kg.,"CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406239/),[mg] / [kg],2000,109778,DB00030,Insulin Regular
>,25370471,AUC,Levels of phosphorylated serine-473 AKT were suppressed >90% in PRP at 3 hours after dose at the MTD and in tumor at pictilisib doses associated with AUC >20 h·μmol/L.,"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25370471/),[h·μM] / [l],20,110153,DB00030,Insulin Regular
,22978318,terminal elimination half-life,The mean terminal elimination half-life ranged between 3.11 and 5.28 h.,Half-life prolongation of therapeutic proteins by conjugation to ATIII-binding pentasaccharides: a first-in-human study of CarboCarrier® insulin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22978318/),h,3.11 and 5.28,110569,DB00030,Insulin Regular
,30929789,t½λz,The t½λz for metformin was 2.9 hours and for sitagliptin 21 hours.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),h,2.9,110571,DB00030,Insulin Regular
,30929789,t½λz,The t½λz for metformin was 2.9 hours and for sitagliptin 21 hours.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),h,21,110572,DB00030,Insulin Regular
,30929789,Cmax,The Cmax was 442 ± 84 mg/L within 0.9 hours for metformin and 94 ± 14 mg/L within 1.3 hours for sitagliptin.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),[mg] / [l],442,110573,DB00030,Insulin Regular
,30929789,Cmax,The Cmax was 442 ± 84 mg/L within 0.9 hours for metformin and 94 ± 14 mg/L within 1.3 hours for sitagliptin.,Pharmacokinetics of Metformin in Combination With Sitagliptin in Adult Horses After Enteral Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30929789/),[mg] / [l],94,110574,DB00030,Insulin Regular
,20831536,AUC(0-∞),"When group C (CYP2C9*1/*1 and CYP2C19 poor metabolizers) was compared with group A, the AUC(0-∞) and C(max) in group C were significantly higher [83.94 ± 40.41 vs. 16.39 ± 5.10 μg·h/mL (P = 0.000) and 1.50 ± 0.85 vs. 0.45 ± 0.18 μg/mL (P = 0.000)], and the oral clearance was significantly lower [1.17 ± 0.63 vs. 5.38 ± 1.86 L/h (P = 0.000)].",Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831536/),[h·μg] / [ml],83.94,110632,DB00030,Insulin Regular
,20831536,AUC(0-∞),"When group C (CYP2C9*1/*1 and CYP2C19 poor metabolizers) was compared with group A, the AUC(0-∞) and C(max) in group C were significantly higher [83.94 ± 40.41 vs. 16.39 ± 5.10 μg·h/mL (P = 0.000) and 1.50 ± 0.85 vs. 0.45 ± 0.18 μg/mL (P = 0.000)], and the oral clearance was significantly lower [1.17 ± 0.63 vs. 5.38 ± 1.86 L/h (P = 0.000)].",Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831536/),[h·μg] / [ml],16.39,110633,DB00030,Insulin Regular
,20831536,C(max),"When group C (CYP2C9*1/*1 and CYP2C19 poor metabolizers) was compared with group A, the AUC(0-∞) and C(max) in group C were significantly higher [83.94 ± 40.41 vs. 16.39 ± 5.10 μg·h/mL (P = 0.000) and 1.50 ± 0.85 vs. 0.45 ± 0.18 μg/mL (P = 0.000)], and the oral clearance was significantly lower [1.17 ± 0.63 vs. 5.38 ± 1.86 L/h (P = 0.000)].",Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831536/),[h·μg] / [ml],16.39,110634,DB00030,Insulin Regular
,20831536,C(max),"When group C (CYP2C9*1/*1 and CYP2C19 poor metabolizers) was compared with group A, the AUC(0-∞) and C(max) in group C were significantly higher [83.94 ± 40.41 vs. 16.39 ± 5.10 μg·h/mL (P = 0.000) and 1.50 ± 0.85 vs. 0.45 ± 0.18 μg/mL (P = 0.000)], and the oral clearance was significantly lower [1.17 ± 0.63 vs. 5.38 ± 1.86 L/h (P = 0.000)].",Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831536/),[μg] / [ml],1.50,110635,DB00030,Insulin Regular
,20831536,C(max),"When group C (CYP2C9*1/*1 and CYP2C19 poor metabolizers) was compared with group A, the AUC(0-∞) and C(max) in group C were significantly higher [83.94 ± 40.41 vs. 16.39 ± 5.10 μg·h/mL (P = 0.000) and 1.50 ± 0.85 vs. 0.45 ± 0.18 μg/mL (P = 0.000)], and the oral clearance was significantly lower [1.17 ± 0.63 vs. 5.38 ± 1.86 L/h (P = 0.000)].",Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831536/),[μg] / [ml],0.45,110636,DB00030,Insulin Regular
,20831536,oral clearance,"When group C (CYP2C9*1/*1 and CYP2C19 poor metabolizers) was compared with group A, the AUC(0-∞) and C(max) in group C were significantly higher [83.94 ± 40.41 vs. 16.39 ± 5.10 μg·h/mL (P = 0.000) and 1.50 ± 0.85 vs. 0.45 ± 0.18 μg/mL (P = 0.000)], and the oral clearance was significantly lower [1.17 ± 0.63 vs. 5.38 ± 1.86 L/h (P = 0.000)].",Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831536/),[l] / [h],1.17,110637,DB00030,Insulin Regular
,20831536,oral clearance,"When group C (CYP2C9*1/*1 and CYP2C19 poor metabolizers) was compared with group A, the AUC(0-∞) and C(max) in group C were significantly higher [83.94 ± 40.41 vs. 16.39 ± 5.10 μg·h/mL (P = 0.000) and 1.50 ± 0.85 vs. 0.45 ± 0.18 μg/mL (P = 0.000)], and the oral clearance was significantly lower [1.17 ± 0.63 vs. 5.38 ± 1.86 L/h (P = 0.000)].",Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831536/),[l] / [h],5.38,110638,DB00030,Insulin Regular
,20831536,half-life,"The half-life of gliclazide was also significantly prolonged in group C subjects when compared with that of group A (33.47 ± 12.39 vs. 19.34 ± 10.45 h), but the difference was not significant (P = 0.052).",Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831536/),h,33.47,110639,DB00030,Insulin Regular
,20831536,half-life,"The half-life of gliclazide was also significantly prolonged in group C subjects when compared with that of group A (33.47 ± 12.39 vs. 19.34 ± 10.45 h), but the difference was not significant (P = 0.052).",Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20831536/),h,19.34,110640,DB00030,Insulin Regular
,33503847,peak plasma BYL719,"Compared to oral gavage, diet incorporation resulted in a lower peak plasma BYL719 (3.6 vs. 9.2 μM) concentration but similar half-life (~1.5 h).",Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33503847/),μM,3.6,111313,DB00030,Insulin Regular
,33503847,peak plasma BYL719,"Compared to oral gavage, diet incorporation resulted in a lower peak plasma BYL719 (3.6 vs. 9.2 μM) concentration but similar half-life (~1.5 h).",Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33503847/),μM,9.2,111314,DB00030,Insulin Regular
,33503847,half-life,"Compared to oral gavage, diet incorporation resulted in a lower peak plasma BYL719 (3.6 vs. 9.2 μM) concentration but similar half-life (~1.5 h).",Efficacy of Providing the PI3K p110α Inhibitor BYL719 (Alpelisib) to Middle-Aged Mice in Their Diet. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33503847/),h,1.5,111315,DB00030,Insulin Regular
,11469258,Time to maximum insulin concentration in serum (Tmax),"Time to maximum insulin concentration in serum (Tmax) after SC dosing occurred approximately 50-60 minutes with the time to minimum plasma glucose concentration (i.e., maximum hypoglycemic effect), (TGmin), occurring later, at around 100-120 minutes.",Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11469258/),min,50-60,111496,DB00030,Insulin Regular
,11469258,time to minimum plasma,"Time to maximum insulin concentration in serum (Tmax) after SC dosing occurred approximately 50-60 minutes with the time to minimum plasma glucose concentration (i.e., maximum hypoglycemic effect), (TGmin), occurring later, at around 100-120 minutes.",Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11469258/),min,100-120,111497,DB00030,Insulin Regular
,11469258,Tmax,"In contrast, pulmonary delivery led to a significantly earlier Tmax (7-20 minutes) and TGmin (60-70 minutes), parameters that were shown to be largely unaffected by changing the pH or concentration of the insulin.",Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11469258/),min,7-20,111498,DB00030,Insulin Regular
,11469258,TGmin,"In contrast, pulmonary delivery led to a significantly earlier Tmax (7-20 minutes) and TGmin (60-70 minutes), parameters that were shown to be largely unaffected by changing the pH or concentration of the insulin.",Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11469258/),min,60-70,111499,DB00030,Insulin Regular
,14620506,relative bioavailability,The relative bioavailability of insulin formulations containing TDM was higher (0.34-0.84%) than that of formulations containing DMbetaCD (0.19-0.48%).,Pulmonary absorption of insulin mediated by tetradecyl-beta-maltoside and dimethyl-beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620506/),%,0.34-0.84,111908,DB00030,Insulin Regular
,14620506,relative bioavailability,The relative bioavailability of insulin formulations containing TDM was higher (0.34-0.84%) than that of formulations containing DMbetaCD (0.19-0.48%).,Pulmonary absorption of insulin mediated by tetradecyl-beta-maltoside and dimethyl-beta-cyclodextrin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620506/),%,0.19-0.48,111909,DB00030,Insulin Regular
,27686971,progression-free survival,"The median progression-free survival for the linsitinib versus the placebo group was 8.4 months versus 12.4 months (hazard ratio, 1.37; P = .29).",Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),month,8.4,112609,DB00030,Insulin Regular
,27686971,progression-free survival,"The median progression-free survival for the linsitinib versus the placebo group was 8.4 months versus 12.4 months (hazard ratio, 1.37; P = .29).",Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),month,12.4,112610,DB00030,Insulin Regular
,27686971,Overall response rate,Overall response rate (47.7% vs. 75.0%; P = .02) and disease control rate (77.3% vs. 95.5%; P = .03) were also inferior.,Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),%,47.7,112611,DB00030,Insulin Regular
,27686971,Overall response rate,Overall response rate (47.7% vs. 75.0%; P = .02) and disease control rate (77.3% vs. 95.5%; P = .03) were also inferior.,Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),%,75.0,112612,DB00030,Insulin Regular
,27686971,disease control rate,Overall response rate (47.7% vs. 75.0%; P = .02) and disease control rate (77.3% vs. 95.5%; P = .03) were also inferior.,Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),%,77.3,112613,DB00030,Insulin Regular
,27686971,disease control rate,Overall response rate (47.7% vs. 75.0%; P = .02) and disease control rate (77.3% vs. 95.5%; P = .03) were also inferior.,Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686971/),%,95.5,112614,DB00030,Insulin Regular
,20429049,area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min,"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),[mg] / [kg],30.3,112731,DB00030,Insulin Regular
,20429049,area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min,"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),[mg] / [kg],16.2,112732,DB00030,Insulin Regular
,20429049,time to 10% of GIR (max) (GIR (max)-t (10%)),"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),min,9,112733,DB00030,Insulin Regular
,20429049,time to 10% of GIR (max) (GIR (max)-t (10%)),"GLU showed a significantly higher early metabolic effect (area under the glucose infusion rate (GIR) curve in the first 30 min AUC-GIR (0-)30↓ min 30.3 ± 26.4 vs. 16.2 ± 18.4 mg/kg, P = 0.0421) than ASP, an earlier onset of action (time to 10% of GIR (max) (GIR (max)-t (10%)) 9 vs. 17 min, P = 0.0146) and a faster absorption (shorter times to 10% and 20% of INS (max,) P = 0.0005 each).",Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20429049/),min,17,112734,DB00030,Insulin Regular
,22968103,maximal concentration,"The serum concentration of glucose did not change significantly after pentamidine infusion at 7.5mg/kg, while it increased with pentamidine at 15 mg/kg, and the maximal concentration of glucose was 167 ± 36 mg/dl, 30 min after the start of pentamidine infusion.",Effect of cimetidine on pentamidine induced hyperglycemia in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968103/),[mg] / [dl],167,112792,DB00030,Insulin Regular
,22968103,maximal concentration,Cimetidine (50mg/kg) enhanced the pentamidine-induced elevation of glucose concentration and the maximal concentration of glucose was 208 ± 33 mg/dl in the pentamidine 15 mg/kg treated group.,Effect of cimetidine on pentamidine induced hyperglycemia in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22968103/),[mg] / [dl],208,112793,DB00030,Insulin Regular
,24829088,t50,"In RYGB subjects, the glucose drink emptied very rapidly (PE t50 = 3 ± 1 min) and intestinal glucose infusion was associated with higher blood glucose and plasma 3-OMG, but lower plasma GLP-1, GIP, insulin, and GI symptoms than oral glucose (all P < 0.001), and comparable to volunteers.","Rapid gastric and intestinal transit is a major determinant of changes in blood glucose, intestinal hormones, glucose absorption and postprandial symptoms after gastric bypass. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24829088/),min,3,112871,DB00030,Insulin Regular
,19190540,half-life,"Median (range) half-life for IGF-I and IGFBP-3 was 0.79 (0.59-1.42) and 0.87 (0.85-0.94) hours, respectively.",A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19190540/),h,0.79,113305,DB00030,Insulin Regular
,19190540,half-life,"Median (range) half-life for IGF-I and IGFBP-3 was 0.79 (0.59-1.42) and 0.87 (0.85-0.94) hours, respectively.",A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19190540/),h,0.87,113306,DB00030,Insulin Regular
smaller,12433442,polydispersity index,"CS-NPs had a particle size in the range of 250-400 nm and its polydispersity index was smaller than 0.1, positively charged, stable.",Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433442/),,0.1,114762,DB00030,Insulin Regular
up to,12433442,bioavailability,"Above all, after administration of 21 I.U./kg insulin in the CS-NPs, the hypoglycemia was prolonged over 15 h and the average pharmacological bioavailability relative to SC injection of insulin solution was up to 14.9%.",Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12433442/),%,14.9,114763,DB00030,Insulin Regular
,29224132,Time required,Time required for normoglycemia recovery was 19.5 ± 12.0 min.,Treatment of mild-to-moderate hypoglycemia in patients with type 1 diabetes treated with insulin pump therapy: are current recommendations effective? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29224132/),min,19.5,115238,DB00030,Insulin Regular
,11347749,Peak plasma free insulin levels,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),[pM] / [l],359,116769,DB00030,Insulin Regular
,11347749,Peak plasma free insulin levels,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),[pM] / [l],254,116770,DB00030,Insulin Regular
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,85,116771,DB00030,Insulin Regular
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,99,116772,DB00030,Insulin Regular
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),[pM] / [l],213,116773,DB00030,Insulin Regular
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),[pM] / [l],144,116774,DB00030,Insulin Regular
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,118,116775,DB00030,Insulin Regular
,11347749,time to maximal insulin concentrations,Peak plasma free insulin levels with insulin lispro (359 [NP] vs. 254 pmol/l [DC]) were higher and time to maximal insulin concentrations (85 [NP] vs. 99 min [DC]) shorter than with regular insulin (213 [NP] vs. 144 pmol/l [DC]; 118 [NP] vs. 153 min [DC]) in both patient groups.,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,153,116776,DB00030,Insulin Regular
,11347749,Time to maximal metabolic effect,Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]).,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,102,116777,DB00030,Insulin Regular
,11347749,Time to maximal metabolic effect,Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]).,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,191,116778,DB00030,Insulin Regular
,11347749,Time to maximal metabolic effect,Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]).,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,105,116779,DB00030,Insulin Regular
,11347749,Time to maximal metabolic effect,Time to maximal metabolic effect was shorter with insulin lispro than with regular insulin in both patient groups (102 vs. 191 min [NP]; 105 vs. 172 min [DC]).,Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),min,172,116780,DB00030,Insulin Regular
,11347749,overall metabolic effect,"The overall metabolic effect of regular insulin but not of insulin lispro was lower in patients with diabetic nephropathy than in diabetic control patients (967 vs. 1,510 mg/kg, respectively).",Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),,96,116781,DB00030,Insulin Regular
,11347749,overall metabolic effect,"The overall metabolic effect of regular insulin but not of insulin lispro was lower in patients with diabetic nephropathy than in diabetic control patients (967 vs. 1,510 mg/kg, respectively).",Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11347749/),,"1,510",116782,DB00030,Insulin Regular
,31912800,PFS,"In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental versus control arms, respectively [hazard ratio (HR) = 1.88, P = 0.027].","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,3.6,117460,DB00030,Insulin Regular
,31912800,PFS,"In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental versus control arms, respectively [hazard ratio (HR) = 1.88, P = 0.027].","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,7.3,117461,DB00030,Insulin Regular
,31912800,PFS,"In the high IGF-1/HRG+ subgroup (n = 44), median PFS was 4.1 and 7.3 months, respectively (HR = 1.39, P = 0.42).","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,4.1,117462,DB00030,Insulin Regular
,31912800,PFS,"In the high IGF-1/HRG+ subgroup (n = 44), median PFS was 4.1 and 7.3 months, respectively (HR = 1.39, P = 0.42).","Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31912800/),month,7.3,117463,DB00030,Insulin Regular
,25749986,serum minimum concentrations,A maximum tolerated dose was not identified; pre-determined target serum minimum concentrations (60 μg/mL) were achieved with ≥6 mg/kg weekly and ≥10 mg/kg every-2-week dosing.,"Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25749986/),[μg] / [ml],60,117647,DB00030,Insulin Regular
,25749986,terminal elimination half-life,"Cixutumumab terminal elimination half-life is approximately a week (individual range, t1/2 = 4.58-9.33 days based upon 10 mg/kg every 2 weeks).","Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25749986/),week,a,117648,DB00030,Insulin Regular
,25749986,t1/2,"Cixutumumab terminal elimination half-life is approximately a week (individual range, t1/2 = 4.58-9.33 days based upon 10 mg/kg every 2 weeks).","Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25749986/),d,4.58-9.33,117649,DB00030,Insulin Regular
<,22642657,time to maximum concentration (T(max)),"However, the time to maximum concentration (T(max)), which varied widely from < 60 to ≥ 120 min, was not associated with either dosage (r(2) = 0.02; P = 0.51) or body mass index (r(2) = 0.02; P = 0.57).",Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642657/),min,60,117900,DB00030,Insulin Regular
,22642657,time to maximum concentration (T(max)),"However, the time to maximum concentration (T(max)), which varied widely from < 60 to ≥ 120 min, was not associated with either dosage (r(2) = 0.02; P = 0.51) or body mass index (r(2) = 0.02; P = 0.57).",Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642657/),min,120,117901,DB00030,Insulin Regular
≥,22642657,T(max),"Injection of insulin aspart exacerbated delayed hyperinsulinaemia after meal loading, mainly in patients with T(max) ≥ 120 min.",Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22642657/),min,120,117902,DB00030,Insulin Regular
,17309854,IC(50),"DRH-417 emerged from the EORTC-Drug Discovery Committee and NCI 60 cell line in vitro screening programs as a potent antiproliferative agent with differential sensitivity towards certain cancer types such as melanoma, breast and renal cell carcinoma (mean IC(50) = 3 nM).",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),nM,3,118106,DB00030,Insulin Regular
,17309854,maximum tolerated dose (MTD),The maximum tolerated dose (MTD) was established as 0.5 mg/kg given i.p.,Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),[mg] / [kg],0.5,118107,DB00030,Insulin Regular
,17309854,plasma AUC,"At a dose of 0.5 mg kg(-1), the plasma AUC was 540 nM h (197.1 ng h ml(-1)) and the peak plasma concentration (171 nM [62.4 ng ml(-1)]) occurred at 30 min., reaching doses levels well above those needed for in vitro antiproliferative activity.",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),h·nM,540,118108,DB00030,Insulin Regular
,17309854,plasma AUC,"At a dose of 0.5 mg kg(-1), the plasma AUC was 540 nM h (197.1 ng h ml(-1)) and the peak plasma concentration (171 nM [62.4 ng ml(-1)]) occurred at 30 min., reaching doses levels well above those needed for in vitro antiproliferative activity.",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),[h·ng] / [ml],197.1,118109,DB00030,Insulin Regular
,17309854,peak plasma concentration,"At a dose of 0.5 mg kg(-1), the plasma AUC was 540 nM h (197.1 ng h ml(-1)) and the peak plasma concentration (171 nM [62.4 ng ml(-1)]) occurred at 30 min., reaching doses levels well above those needed for in vitro antiproliferative activity.",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),nM,171,118110,DB00030,Insulin Regular
,17309854,peak plasma concentration,"At a dose of 0.5 mg kg(-1), the plasma AUC was 540 nM h (197.1 ng h ml(-1)) and the peak plasma concentration (171 nM [62.4 ng ml(-1)]) occurred at 30 min., reaching doses levels well above those needed for in vitro antiproliferative activity.",Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17309854/),[ng] / [ml],62.4,118111,DB00030,Insulin Regular
,21983605,Lung deposition,"Lung deposition was found to be 50 ± 9% and 24 ± 8% for the F1 and F2 formulations, respectively.",Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21983605/),%,50,118837,DB00030,Insulin Regular
,21983605,Lung deposition,"Lung deposition was found to be 50 ± 9% and 24 ± 8% for the F1 and F2 formulations, respectively.",Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21983605/),%,24,118838,DB00030,Insulin Regular
,21983605,AUC₀₋₃₆₀ ratio,"The insulin AUC₀₋₃₆₀ ratio of F1/F2 was 188%, which was consistent with scintigraphic imaging.",Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21983605/),%,188,118839,DB00030,Insulin Regular
,21983605,T(max),"The two formulations showed interesting pharmacokinetic profiles (T(max) of 26 and 16 min for F1 and F2, respectively) that mimic the physiological insulin secretion pattern.",Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21983605/),min,26,118840,DB00030,Insulin Regular
,21983605,T(max),"The two formulations showed interesting pharmacokinetic profiles (T(max) of 26 and 16 min for F1 and F2, respectively) that mimic the physiological insulin secretion pattern.",Comparative pharmacoscintigraphic and pharmacokinetic evaluation of two new formulations of inhaled insulin in type 1 diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21983605/),min,16,118841,DB00030,Insulin Regular
,31946217,bioavailability,"While the bioavailability for the SC route is found to be slightly higher compared to the ID route (99% vs. 96%), the Tmax for both are almost identical.","In-vivo Intradermal Delivery of Co-57 labeled Vitamin B-12, and Subsequent Comparison with Standard Subcutaneous Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31946217/),%,99,119190,DB00030,Insulin Regular
,31946217,bioavailability,"While the bioavailability for the SC route is found to be slightly higher compared to the ID route (99% vs. 96%), the Tmax for both are almost identical.","In-vivo Intradermal Delivery of Co-57 labeled Vitamin B-12, and Subsequent Comparison with Standard Subcutaneous Administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31946217/),%,96,119191,DB00030,Insulin Regular
,18477263,t(max),"The median (range) t(max) was 60 min (20-120 min) and 75 min (20-360 min) in the EXU with no exposure and EXU passive exposure groups, respectively.",Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477263/),min,60,120100,DB00030,Insulin Regular
,18477263,t(max),"The median (range) t(max) was 60 min (20-120 min) and 75 min (20-360 min) in the EXU with no exposure and EXU passive exposure groups, respectively.",Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18477263/),min,75,120101,DB00030,Insulin Regular
,20200268,half-life,Mean half-life of the active entity was approximately 2 hours; there was no evidence of drug accumulation.,"Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20200268/),h,2,120629,DB00030,Insulin Regular
,27139036,duration of stable disease,"The median duration of stable disease was 6.9 months (range 2.8, 6.9) for all cohorts.","A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27139036/),month,6.9,120691,DB00030,Insulin Regular
,23248408,IC50,"RBx-0128 inhibited human, mouse, and rat plasma DPP-IV activity with IC50 values of 10.6, 18.1, and 56.0 nM respectively, selective over various serine proteases (900-9000-fold).","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),nM,10.6,122131,DB00030,Insulin Regular
,23248408,IC50,"RBx-0128 inhibited human, mouse, and rat plasma DPP-IV activity with IC50 values of 10.6, 18.1, and 56.0 nM respectively, selective over various serine proteases (900-9000-fold).","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),nM,18.1,122132,DB00030,Insulin Regular
,23248408,IC50,"RBx-0128 inhibited human, mouse, and rat plasma DPP-IV activity with IC50 values of 10.6, 18.1, and 56.0 nM respectively, selective over various serine proteases (900-9000-fold).","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),nM,56.0,122133,DB00030,Insulin Regular
,23248408,plasma clearance,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),[ml] / [kg·min],39.3,122134,DB00030,Insulin Regular
,23248408,Cmax,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),[ng] / [ml],790,122135,DB00030,Insulin Regular
,23248408,t1/2,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),h,1.6,122136,DB00030,Insulin Regular
,23248408,tmax,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),h,4.8,122137,DB00030,Insulin Regular
,23248408,Vss,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),[l] / [kg],3.24,122138,DB00030,Insulin Regular
,23248408,Foral,"The effect was sustained till 8 hours (30-35%) at 10 mg/kg with favorable PK profile (plasma clearance: 39.3 ml/min/kg; Cmax 790 ng/ml; t1/2 1.6 hours; tmax 4.8 hours, Vss 3.24 l/kg and Foral 55%) in Wistar rats.","Biological evaluation of RBx-0128, a potent and selective dipeptidyl peptidase-IV inhibitor in type 2 diabetes genetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23248408/),%,55,122139,DB00030,Insulin Regular
,21673460,minimum effective active GLP-1 concentration,"GLP-1 infusion from jugular vein significantly and concentration-dependently enhanced area under the curve (AUC) of the 1st phase insulin, in which the minimum effective active GLP-1 concentration was 6.6 pmol/l.",Dynamics of plasma active GLP-1 versus insulin and glucose concentrations during GLP-1 infusion in rat model of postprandial hyperglycemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21673460/),[pM] / [l],6.6,122239,DB00030,Insulin Regular
,24418334,flow rate,Elute was monitored at 230 nm with a flow rate of 1 mL/min.,Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),[ml] / [min],1,122542,DB00030,Insulin Regular
,24418334,Retention times,Retention times of GPZ and internal standard (gliclazide) were 7.32 and 9.02 min respectively.,Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),min,7.32,122543,DB00030,Insulin Regular
,24418334,Retention times,Retention times of GPZ and internal standard (gliclazide) were 7.32 and 9.02 min respectively.,Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),min,9.02,122544,DB00030,Insulin Regular
,24418334,Maximum plasma drug concentration,"Maximum plasma drug concentration, area under the plasma drug concentration-time curve and elimination half life for GPZ floating microspheres were 2.88±0.29 μg mL(-1), 38.46±2.26 μg h mL(-1) and 13.55±1.36 h respectively.",Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),[μg] / [ml],2.88,122545,DB00030,Insulin Regular
,24418334,area under the plasma drug concentration-time curve,"Maximum plasma drug concentration, area under the plasma drug concentration-time curve and elimination half life for GPZ floating microspheres were 2.88±0.29 μg mL(-1), 38.46±2.26 μg h mL(-1) and 13.55±1.36 h respectively.",Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),[h·μg] / [ml],38.46,122546,DB00030,Insulin Regular
,24418334,elimination half life,"Maximum plasma drug concentration, area under the plasma drug concentration-time curve and elimination half life for GPZ floating microspheres were 2.88±0.29 μg mL(-1), 38.46±2.26 μg h mL(-1) and 13.55±1.36 h respectively.",Development and validation of RP-HPLC method for quantification of glipizide in biological macromolecules. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24418334/),h,13.55,122547,DB00030,Insulin Regular
,26175543,Subcutaneous bioavailability,Subcutaneous bioavailability of BIL was 23%-29%; bioavailability for unconjugated PEG was 78%.,Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26175543/),%,23%-29,123536,DB00030,Insulin Regular
,26175543,bioavailability,Subcutaneous bioavailability of BIL was 23%-29%; bioavailability for unconjugated PEG was 78%.,Disposition of Basal Insulin Peglispro Compared with 20-kDa Polyethylene Glycol in Rats Following a Single Intravenous or Subcutaneous Dose. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26175543/),%,78,123537,DB00030,Insulin Regular
,11725967,area under the curve (AUC),"Insulin suppositories containing sodium salicylate (50 mg) produced a maximum reduction of plasma glucose concentration (Cmax) of 55 +/- 11%, an area under the curve (AUC) of 252 +/- 59% reduction h; and a relative hypoglycemia (RH) of 49 +/- 12% relative to subcutaneous injection of insulin (4 U/kg).",Relative hypoglycemic effect of insulin suppositories in diabetic beagle dogs: optimization of various concentrations of sodium salicylate and polyoxyethylene-9-lauryl ether. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11725967/),%·h·reduction,252,124708,DB00030,Insulin Regular
,11725967,AUC,"Investigation of the influence of insulin suppositories containing different concentrations of the nonionic surfactant POELE (1, 3, 4%) showed that; the suppositories containing the lowest concentration (1%) produced the highest hypoglycemic effect with a Cmax of 68%, AUC of 332 +/- 67% reduction h, and RH of 55 +/- 11%.",Relative hypoglycemic effect of insulin suppositories in diabetic beagle dogs: optimization of various concentrations of sodium salicylate and polyoxyethylene-9-lauryl ether. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11725967/),%,332,124709,DB00030,Insulin Regular
,17535864,Cmax,Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 microg/l; AUC 196.2 and 123.8).,Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535864/),[μg] / [l],35.5,124742,DB00030,Insulin Regular
,17535864,Cmax,Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 microg/l; AUC 196.2 and 123.8).,Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535864/),[μg] / [l],12.0,124743,DB00030,Insulin Regular
,17535864,AUC,Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 microg/l; AUC 196.2 and 123.8).,Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535864/),,196.2,124744,DB00030,Insulin Regular
,17535864,AUC,Serum GH maximal concentration (Cmax) and area under the time-concentration curve (AUC) were higher after i.m. than s.c. administration of 0.033 mg/kg (Cmax 35.5 and 12.0 microg/l; AUC 196.2 and 123.8).,Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535864/),,123.8,124745,DB00030,Insulin Regular
up,20361761,coupling ratio,The lipophilicity and permeability of insulin/DCK (coupling ratio up to 1:10) were also highly increased.,Diabetes correction in pancreatectomized canines by orally absorbable insulin-deoxycholate complex. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20361761/),,1,124915,DB00030,Insulin Regular
,16046313,steady-state plasma glucose,"After rosiglitazone treatment, insulin sensitivity improved with significant fall in steady-state plasma glucose (means +/- SE from 13.5 +/- 0.62 to 9.8 +/- 1.02 mmol/l, P < 0.001).","Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046313/),[mM] / [l],13.5,125699,DB00030,Insulin Regular
,16046313,steady-state plasma glucose,"After rosiglitazone treatment, insulin sensitivity improved with significant fall in steady-state plasma glucose (means +/- SE from 13.5 +/- 0.62 to 9.8 +/- 1.02 mmol/l, P < 0.001).","Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16046313/),[mM] / [l],9.8,125700,DB00030,Insulin Regular
,21262219,IC(50),TS-021 inhibits DPP-IV activity in human plasma with an IC(50) value of 5.34nM.,"(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21262219/),nM,5.34,126112,DB00030,Insulin Regular
,21262219,k(off),"In kinetics experiments, TS-021 had a relatively higher dissociation rate constant, with a k(off) value of 1.09×10(-3)s, despite exhibiting a potent human plasma DPP-IV inhibition activity with a K(i) value of 4.96nM.","(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21262219/),s,1.09×10(-3),126113,DB00030,Insulin Regular
,21262219,K(i),"In kinetics experiments, TS-021 had a relatively higher dissociation rate constant, with a k(off) value of 1.09×10(-3)s, despite exhibiting a potent human plasma DPP-IV inhibition activity with a K(i) value of 4.96nM.","(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21262219/),nM,4.96,126114,DB00030,Insulin Regular
>,24588343,t1/2,"Although GLP-1(9-36)amide was resistant to proteolytic cleavage in dog plasma and bovine serum albumin (t1/2>240 min), the peptide was rapidly metabolized in dog hepatocytes with a t1/2 of 110 min.",Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588343/),min,240,126376,DB00030,Insulin Regular
,24588343,t1/2,"Although GLP-1(9-36)amide was resistant to proteolytic cleavage in dog plasma and bovine serum albumin (t1/2>240 min), the peptide was rapidly metabolized in dog hepatocytes with a t1/2 of 110 min.",Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588343/),min,110,126377,DB00030,Insulin Regular
,24588343,plasma clearance,"Following the administration of a single intravenous bolus dose (20 µg/kg) to male Beagle dogs, GLP-1(9-36)amide exhibited a mean plasma clearance of 15 ml/min/kg and a low steady state distribution volume of 0.05 l/kg, which translated into a short elimination half life of 0.05 h.",Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588343/),[ml] / [kg·min],15,126378,DB00030,Insulin Regular
,24588343,steady state distribution volume,"Following the administration of a single intravenous bolus dose (20 µg/kg) to male Beagle dogs, GLP-1(9-36)amide exhibited a mean plasma clearance of 15 ml/min/kg and a low steady state distribution volume of 0.05 l/kg, which translated into a short elimination half life of 0.05 h.",Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588343/),[l] / [kg],0.05,126379,DB00030,Insulin Regular
,24588343,elimination half life,"Following the administration of a single intravenous bolus dose (20 µg/kg) to male Beagle dogs, GLP-1(9-36)amide exhibited a mean plasma clearance of 15 ml/min/kg and a low steady state distribution volume of 0.05 l/kg, which translated into a short elimination half life of 0.05 h.",Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588343/),h,0.05,126380,DB00030,Insulin Regular
,24588343,maximal plasma concentrations,"Following subcutaneous administration of GLP-1(9-36)amide at 50 µg/kg, systemic exposure of GLP-1(9-36)amide as ascertained from maximal plasma concentrations and area under the plasma concentration-time curve from zero to infinity was 44 ng/ml and 32 ng h/ml, respectively.",Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588343/),[ng] / [ml],44,126381,DB00030,Insulin Regular
,24588343,area under the plasma concentration-time curve from zero to infinity,"Following subcutaneous administration of GLP-1(9-36)amide at 50 µg/kg, systemic exposure of GLP-1(9-36)amide as ascertained from maximal plasma concentrations and area under the plasma concentration-time curve from zero to infinity was 44 ng/ml and 32 ng h/ml, respectively.",Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588343/),[h·ng] / [ml],32,126382,DB00030,Insulin Regular
,24588343,subcutaneous bioavailability,The subcutaneous bioavailability of GLP-1(9-36)amide in dogs was 57%.,Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24588343/),%,57,126383,DB00030,Insulin Regular
,20180657,permeability coefficient,"The permeability coefficient was 4.59, 4.69, 3.38, and 1.43 x 10(-4) cm/h for FD-10, 20, 40, and 70, respectively.",Molecular weight dependence on bioavailability of FITC-dextran after administration of self-dissolving micropile to rat skin. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20180657/),[cm] / [h],4.59,126633,DB00030,Insulin Regular
,20180657,permeability coefficient,"The permeability coefficient was 4.59, 4.69, 3.38, and 1.43 x 10(-4) cm/h for FD-10, 20, 40, and 70, respectively.",Molecular weight dependence on bioavailability of FITC-dextran after administration of self-dissolving micropile to rat skin. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20180657/),[cm] / [h],4.69,126634,DB00030,Insulin Regular
,20180657,permeability coefficient,"The permeability coefficient was 4.59, 4.69, 3.38, and 1.43 x 10(-4) cm/h for FD-10, 20, 40, and 70, respectively.",Molecular weight dependence on bioavailability of FITC-dextran after administration of self-dissolving micropile to rat skin. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20180657/),[cm] / [h],3.38,126635,DB00030,Insulin Regular
,20180657,permeability coefficient,"The permeability coefficient was 4.59, 4.69, 3.38, and 1.43 x 10(-4) cm/h for FD-10, 20, 40, and 70, respectively.",Molecular weight dependence on bioavailability of FITC-dextran after administration of self-dissolving micropile to rat skin. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20180657/),[cm] / [h],1.43 x 10(-4),126636,DB00030,Insulin Regular
,20180657,Bioavailabilities,"Bioavailabilities of FDs from SDMP were 99.4 +/- 6.93%, 88.3 +/- 7.05%, 45.7 +/- 4.77%, and 16.0 +/- 1.15% for FD-10, 20, 40, and 70, and the dependency on molecular weight dependence was clearly observed.",Molecular weight dependence on bioavailability of FITC-dextran after administration of self-dissolving micropile to rat skin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20180657/),%,99.4,126637,DB00030,Insulin Regular
,20180657,Bioavailabilities,"Bioavailabilities of FDs from SDMP were 99.4 +/- 6.93%, 88.3 +/- 7.05%, 45.7 +/- 4.77%, and 16.0 +/- 1.15% for FD-10, 20, 40, and 70, and the dependency on molecular weight dependence was clearly observed.",Molecular weight dependence on bioavailability of FITC-dextran after administration of self-dissolving micropile to rat skin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20180657/),%,88.3,126638,DB00030,Insulin Regular
,20180657,Bioavailabilities,"Bioavailabilities of FDs from SDMP were 99.4 +/- 6.93%, 88.3 +/- 7.05%, 45.7 +/- 4.77%, and 16.0 +/- 1.15% for FD-10, 20, 40, and 70, and the dependency on molecular weight dependence was clearly observed.",Molecular weight dependence on bioavailability of FITC-dextran after administration of self-dissolving micropile to rat skin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20180657/),%,45.7,126639,DB00030,Insulin Regular
,20180657,Bioavailabilities,"Bioavailabilities of FDs from SDMP were 99.4 +/- 6.93%, 88.3 +/- 7.05%, 45.7 +/- 4.77%, and 16.0 +/- 1.15% for FD-10, 20, 40, and 70, and the dependency on molecular weight dependence was clearly observed.",Molecular weight dependence on bioavailability of FITC-dextran after administration of self-dissolving micropile to rat skin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20180657/),%,16.0,126640,DB00030,Insulin Regular
,17625517,AUC(0-t'),"AIR Insulin exposure (the area under the immunoreactive insulin (IRI) concentration vs time curve from time zero until the IRI concentrations returned to the predose baseline value (AUC(0-t'))) and glucodynamic response (total amount of glucose infused (G(tot))) were comparable before and during RV infection (AUC(0-t') 46,300 vs 52,600 pmol min/l, P=0.21; G(tot) 61,800 vs 68,700 mg, P=0.42, respectively).",Effect of upper respiratory tract infection on AIR inhaled insulin pharmacokinetics and glucodynamics in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17625517/),[min·pM] / [l],"46,300",127353,DB00030,Insulin Regular
,17625517,AUC(0-t'),"AIR Insulin exposure (the area under the immunoreactive insulin (IRI) concentration vs time curve from time zero until the IRI concentrations returned to the predose baseline value (AUC(0-t'))) and glucodynamic response (total amount of glucose infused (G(tot))) were comparable before and during RV infection (AUC(0-t') 46,300 vs 52,600 pmol min/l, P=0.21; G(tot) 61,800 vs 68,700 mg, P=0.42, respectively).",Effect of upper respiratory tract infection on AIR inhaled insulin pharmacokinetics and glucodynamics in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17625517/),[min·pM] / [l],"52,600",127354,DB00030,Insulin Regular
,17625517,AUC(0-t'),"AIR Insulin exposure (the area under the immunoreactive insulin (IRI) concentration vs time curve from time zero until the IRI concentrations returned to the predose baseline value (AUC(0-t'))) and glucodynamic response (total amount of glucose infused (G(tot))) were comparable before and during RV infection (AUC(0-t') 46,300 vs 52,600 pmol min/l, P=0.21; G(tot) 61,800 vs 68,700 mg, P=0.42, respectively).",Effect of upper respiratory tract infection on AIR inhaled insulin pharmacokinetics and glucodynamics in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17625517/),,61,127355,DB00030,Insulin Regular
,20540938,IC(50),"RBx-0597 inhibited human, mouse and rat plasma DPP-IV activity with IC(50) values of 32, 31 and 39nM respectively.","RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20540938/),nM,32,127387,DB00030,Insulin Regular
,20540938,IC(50),"RBx-0597 inhibited human, mouse and rat plasma DPP-IV activity with IC(50) values of 32, 31 and 39nM respectively.","RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20540938/),nM,31,127388,DB00030,Insulin Regular
,20540938,IC(50),"RBx-0597 inhibited human, mouse and rat plasma DPP-IV activity with IC(50) values of 32, 31 and 39nM respectively.","RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20540938/),nM,39,127389,DB00030,Insulin Regular
,20540938,plasma clearance,It showed a favourable pharmacokinetic profile (plasma clearance:174ml/min/kg; C(max) 292ng/ml; T(1/2) 0.28h; T(max) 0.75h and V(ss) 4.13L/kg) in Wistar rats with the oral bioavailability (F(oral)) of 65%.,"RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20540938/),[ml] / [kg·min],174,127390,DB00030,Insulin Regular
,20540938,C(max),It showed a favourable pharmacokinetic profile (plasma clearance:174ml/min/kg; C(max) 292ng/ml; T(1/2) 0.28h; T(max) 0.75h and V(ss) 4.13L/kg) in Wistar rats with the oral bioavailability (F(oral)) of 65%.,"RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20540938/),[ng] / [ml],292,127391,DB00030,Insulin Regular
,20540938,T(1/2),It showed a favourable pharmacokinetic profile (plasma clearance:174ml/min/kg; C(max) 292ng/ml; T(1/2) 0.28h; T(max) 0.75h and V(ss) 4.13L/kg) in Wistar rats with the oral bioavailability (F(oral)) of 65%.,"RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20540938/),h,0.28,127392,DB00030,Insulin Regular
,20540938,T(max),It showed a favourable pharmacokinetic profile (plasma clearance:174ml/min/kg; C(max) 292ng/ml; T(1/2) 0.28h; T(max) 0.75h and V(ss) 4.13L/kg) in Wistar rats with the oral bioavailability (F(oral)) of 65%.,"RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20540938/),h,0.75,127393,DB00030,Insulin Regular
,20540938,V(ss),It showed a favourable pharmacokinetic profile (plasma clearance:174ml/min/kg; C(max) 292ng/ml; T(1/2) 0.28h; T(max) 0.75h and V(ss) 4.13L/kg) in Wistar rats with the oral bioavailability (F(oral)) of 65%.,"RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20540938/),[l] / [kg],4.13,127394,DB00030,Insulin Regular
,20540938,oral bioavailability (F(oral)),It showed a favourable pharmacokinetic profile (plasma clearance:174ml/min/kg; C(max) 292ng/ml; T(1/2) 0.28h; T(max) 0.75h and V(ss) 4.13L/kg) in Wistar rats with the oral bioavailability (F(oral)) of 65%.,"RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20540938/),%,65,127395,DB00030,Insulin Regular
,11185675,AUC(0-24),"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[h·ng] / [ml],18.5,127836,DB00030,Insulin Regular
,11185675,AUC(0-24),"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[h·ng] / [ml],19.1,127837,DB00030,Insulin Regular
,11185675,AUC(0-24),"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[ng] / [ml],0.594,127838,DB00030,Insulin Regular
,11185675,C24,"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[ng] / [ml],0.579,127839,DB00030,Insulin Regular
,11185675,C24,"Digoxin AUC(0-24) and C24 values were similar for digoxin 0.375 mg plus matching placebo (18.5 ng.h/mL and 0.579 ng/mL, respectively) and digoxin 0.375 mg plus rosiglitazone (19.1 ng.h/mL and 0.594 ng/mL, respectively).",Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11185675/),[ng] / [ml],0.594,127840,DB00030,Insulin Regular
,26672637,HVs,"Mean annualized HVs for somavaratan administered monthly, twice monthly, or weekly (7.86 ± 2.5, 8.61 ± 2.7, and 7.58 ± 2.5 cm/y, respectively) were similar between groups.","A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672637/),[cm] / [y],7.86,127951,DB00030,Insulin Regular
,26672637,HVs,"Mean annualized HVs for somavaratan administered monthly, twice monthly, or weekly (7.86 ± 2.5, 8.61 ± 2.7, and 7.58 ± 2.5 cm/y, respectively) were similar between groups.","A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672637/),[cm] / [y],8.61,127952,DB00030,Insulin Regular
,26672637,HVs,"Mean annualized HVs for somavaratan administered monthly, twice monthly, or weekly (7.86 ± 2.5, 8.61 ± 2.7, and 7.58 ± 2.5 cm/y, respectively) were similar between groups.","A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26672637/),[cm] / [y],7.58,127953,DB00030,Insulin Regular
,21831337,area under the curve (AUC,"The P dogs exhibited postprandial hyperglycaemia compared with NP dogs (area under the curve (AUC; change from basal over 390 min) of arterial plasma glucose: 86 680 (sem 12 140) and 187 990 (sem 33 990) mg/l in NP and P dogs, respectively; P < 0·05).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[mg] / [l],86 680,128782,DB00030,Insulin Regular
,21831337,area under the curve (AUC,"The P dogs exhibited postprandial hyperglycaemia compared with NP dogs (area under the curve (AUC; change from basal over 390 min) of arterial plasma glucose: 86 680 (sem 12 140) and 187 990 (sem 33 990) mg/l in NP and P dogs, respectively; P < 0·05).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[mg] / [l],187 990,128783,DB00030,Insulin Regular
,21831337,AUC,"Plasma insulin concentrations did not differ significantly between the groups (AUC: 88 230 (sem 16 314) and 69 750 (sem 19 512) pmol/l in NP and P dogs, respectively).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[pM] / [l],88 230,128784,DB00030,Insulin Regular
,21831337,AUC,"Plasma insulin concentrations did not differ significantly between the groups (AUC: 88 230 (sem 16 314) and 69 750 (sem 19 512) pmol/l in NP and P dogs, respectively).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[pM] / [l],69 750,128785,DB00030,Insulin Regular
,21831337,Net hepatic glucose uptake,"Net hepatic glucose uptake totalled 3691 (sem 508) v. 5081 (sem 1145) mg/100 g liver in NP and P dogs, respectively (P = 0·38).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[mg] / [100·g·liver],3691,128786,DB00030,Insulin Regular
,21831337,Net hepatic glucose uptake,"Net hepatic glucose uptake totalled 3691 (sem 508) v. 5081 (sem 1145) mg/100 g liver in NP and P dogs, respectively (P = 0·38).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[mg] / [100·g·liver],5081,128787,DB00030,Insulin Regular
,21831337,AUC of,"The AUC of glucose oxidation by the gut and hindlimb were not different in NP and P dogs, but hepatic glucose oxidation (84 (sem 13) v. 206 (sem 30) mg/100 g liver) and glycogen synthesis (0·4 (sem 0·5) v. 26 (sem 0·7) g/100 g liver) were greater in P dogs (P < 0·05).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[mg] / [100],84,128788,DB00030,Insulin Regular
,21831337,AUC of,"The AUC of glucose oxidation by the gut and hindlimb were not different in NP and P dogs, but hepatic glucose oxidation (84 (sem 13) v. 206 (sem 30) mg/100 g liver) and glycogen synthesis (0·4 (sem 0·5) v. 26 (sem 0·7) g/100 g liver) were greater in P dogs (P < 0·05).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[mg] / [100],206,128789,DB00030,Insulin Regular
,21831337,AUC of,"The AUC of glucose oxidation by the gut and hindlimb were not different in NP and P dogs, but hepatic glucose oxidation (84 (sem 13) v. 206 (sem 30) mg/100 g liver) and glycogen synthesis (0·4 (sem 0·5) v. 26 (sem 0·7) g/100 g liver) were greater in P dogs (P < 0·05).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[g] / [100],0·4,128790,DB00030,Insulin Regular
,21831337,AUC of,"The AUC of glucose oxidation by the gut and hindlimb were not different in NP and P dogs, but hepatic glucose oxidation (84 (sem 13) v. 206 (sem 30) mg/100 g liver) and glycogen synthesis (0·4 (sem 0·5) v. 26 (sem 0·7) g/100 g liver) were greater in P dogs (P < 0·05).",Pregnancy augments hepatic glucose storage in response to a mixed meal. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831337/),[g] / [100],26,128791,DB00030,Insulin Regular
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB00030,Insulin Regular
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB00030,Insulin Regular
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB00030,Insulin Regular
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB00030,Insulin Regular
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB00030,Insulin Regular
,14571692,time course of absorption,"We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),,1.5,129515,DB00030,Insulin Regular
,14571692,time course of absorption,"We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),,2.1,129516,DB00030,Insulin Regular
,14571692,elimination rate constant,"We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),1/[min],0.010,129517,DB00030,Insulin Regular
,14571692,elimination rate constant,"We found statistically significant differences between most of the HI and IAsp pharmacokinetic parameters, including the sigmoidicity of the time course of absorption (1.5 for HI vs. 2.1 for IAsp (unit less), P = 0.0005, Wilcoxon Signed-rank test), elimination rate constant (0.010 min-1 for HI vs. 0.016 min-1 for IAsp (P = 0.002)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),1/[min],0.016,129518,DB00030,Insulin Regular
,14571692,rate of insulin action,"The PD model parameters were mostly not different, except for the rate of insulin action (0.012 min-1 for HI vs. 0.017 min-1 for IAsp (P = 0.03)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),1/[min],0.012,129519,DB00030,Insulin Regular
,14571692,rate of insulin action,"The PD model parameters were mostly not different, except for the rate of insulin action (0.012 min-1 for HI vs. 0.017 min-1 for IAsp (P = 0.03)).",Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14571692/),1/[min],0.017,129520,DB00030,Insulin Regular
,17593235,area under the curve (GIR-AUC),"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),[mg] / [kg],102.3,129535,DB00030,Insulin Regular
,17593235,area under the curve (GIR-AUC),"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),[mg] / [kg],83.1,129536,DB00030,Insulin Regular
,17593235,area under the curve (GIR-AUC),"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),[mg] / [kg],158.0,129537,DB00030,Insulin Regular
,17593235,area under the curve (GIR-AUC),"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),[mg] / [kg],112.3,129538,DB00030,Insulin Regular
,17593235,time to 10% of,"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,1.4,129539,DB00030,Insulin Regular
,17593235,time to 10% of,"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,1.5,129540,DB00030,Insulin Regular
,17593235,time to 10% of,"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,1.4,129541,DB00030,Insulin Regular
,17593235,time to 10% of,"Glulisine showed a greater early metabolic action than lispro [GIR-area under the curve (GIR-AUC) between 0 and 1 h (0.2 U/kg: 102.3 +/- 75.1 vs. 83.1 +/- 72.8 mg/kg, p < 0.05; 0.4 U/kg: 158.0 +/- 100.0 vs. 112.3 +/- 70.8 mg/kg, p < 0.001)], with an earlier time to 10% of total GIR-AUC (0.2 U/kg: 1.4 +/- 0.4 vs. 1.5 +/- 0.4 h; 0.4 U/kg: 1.4 +/- 0.3 vs. 1.5 +/- 0.3 h, p < 0.05).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,1.5,129542,DB00030,Insulin Regular
,17593235,time to 10%,"In accordance with these findings, the time to 10% of total INS-AUC was faster with glulisine compared with lispro at either dose (0.2 U/kg: 0.7 +/- 0.2 vs. 0.8 +/- 0.2 h; 0.4 U/kg: 0.8 +/- 0.2 vs. 0.9 +/- 0.2 h, p < 0.001).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,0.7,129543,DB00030,Insulin Regular
,17593235,time to 10%,"In accordance with these findings, the time to 10% of total INS-AUC was faster with glulisine compared with lispro at either dose (0.2 U/kg: 0.7 +/- 0.2 vs. 0.8 +/- 0.2 h; 0.4 U/kg: 0.8 +/- 0.2 vs. 0.9 +/- 0.2 h, p < 0.001).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,0.8,129544,DB00030,Insulin Regular
,17593235,time to 10%,"In accordance with these findings, the time to 10% of total INS-AUC was faster with glulisine compared with lispro at either dose (0.2 U/kg: 0.7 +/- 0.2 vs. 0.8 +/- 0.2 h; 0.4 U/kg: 0.8 +/- 0.2 vs. 0.9 +/- 0.2 h, p < 0.001).",Insulin glulisine: a faster onset of action compared with insulin lispro. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17593235/),h,0.9,129545,DB00030,Insulin Regular
,24610683,Maximal post-insulin bolus concentration,Maximal post-insulin bolus concentration was 57 mU/L on day 1 InsuPatch versus 47.6 mU/L on day 1 control (p < 0.01).,"Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],57,130150,DB00030,Insulin Regular
,24610683,Maximal post-insulin bolus concentration,Maximal post-insulin bolus concentration was 57 mU/L on day 1 InsuPatch versus 47.6 mU/L on day 1 control (p < 0.01).,"Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],47.6,130151,DB00030,Insulin Regular
,24610683,Maximal insulin concentration,"Maximal insulin concentration was 70.4 mU/L versus 57 mU/L, respectively (p = 0.05).","Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],70.4,130152,DB00030,Insulin Regular
,24610683,Maximal insulin concentration,"Maximal insulin concentration was 70.4 mU/L versus 57 mU/L, respectively (p = 0.05).","Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24610683/),[mu] / [l],57,130153,DB00030,Insulin Regular
,33258391,cumulative amount permeated,"Furthermore, the cumulative amount permeated across cellulose acetate membrane at 30 min was 1.13 and 1.00 IU/cm2 for insulin solution and fast-dissolving film, respectively, demonstrating to be similar.",Sublingual insulin administration: application of hydroxypropyl beta-cyclodextrin and poloxamer188 as permeation enhancers. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33258391/),[iu] / [cm2],1.13,131107,DB00030,Insulin Regular
,33258391,cumulative amount permeated,"Furthermore, the cumulative amount permeated across cellulose acetate membrane at 30 min was 1.13 and 1.00 IU/cm2 for insulin solution and fast-dissolving film, respectively, demonstrating to be similar.",Sublingual insulin administration: application of hydroxypropyl beta-cyclodextrin and poloxamer188 as permeation enhancers. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33258391/),[iu] / [cm2],1.00,131108,DB00030,Insulin Regular
,26617516,Tmax,GABA was rapidly absorbed (Tmax: 0.5 ~ 1 h) with the half-life (t1/2) of 5 h.,Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26617516/),h,0.5 ~ 1,131372,DB00030,Insulin Regular
,26617516,half-life (t1/2),GABA was rapidly absorbed (Tmax: 0.5 ~ 1 h) with the half-life (t1/2) of 5 h.,Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26617516/),h,5,131373,DB00030,Insulin Regular
,20470231,length,"The mean length, diameter of basement, and drug-loaded space from the top of the microneedles were 492.6 +/- 2.4, 290.0 +/- 3.6, and 316.0 +/- 7.3 microm, respectively.",Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),μm,492.6,132067,DB00030,Insulin Regular
,20470231,diameter of basement,"The mean length, diameter of basement, and drug-loaded space from the top of the microneedles were 492.6 +/- 2.4, 290.0 +/- 3.6, and 316.0 +/- 7.3 microm, respectively.",Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),μm,290.0,132068,DB00030,Insulin Regular
,20470231,diameter of basement,"The mean length, diameter of basement, and drug-loaded space from the top of the microneedles were 492.6 +/- 2.4, 290.0 +/- 3.6, and 316.0 +/- 7.3 microm, respectively.",Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),μm,316.0,132069,DB00030,Insulin Regular
,20470231,drug-loaded space,"The mean length, diameter of basement, and drug-loaded space from the top of the microneedles were 492.6 +/- 2.4, 290.0 +/- 3.6, and 316.0 +/- 7.3 microm, respectively.",Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),μm,316.0,132070,DB00030,Insulin Regular
,20470231,insulin content,The insulin content was 1.67 +/- 0.17 IU per patch.,Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),-1·iu,1.67,132071,DB00030,Insulin Regular
,20470231,time when the minimum plasma glucose level was obtained,The time when the minimum plasma glucose level was obtained was 50.0 +/- 8.7 min for two-patch and 82.5 +/- 14.4 min for four-patch studies.,Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),min,50.0,132072,DB00030,Insulin Regular
,20470231,time when the minimum plasma glucose level was obtained,The time when the minimum plasma glucose level was obtained was 50.0 +/- 8.7 min for two-patch and 82.5 +/- 14.4 min for four-patch studies.,Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),min,82.5,132073,DB00030,Insulin Regular
,20470231,relative physiological availabilities,"By comparing the cumulative percentage change in the plasma glucose level between insulin microneedles and solution, the relative physiological availabilities were calculated to be 71.1 +/- 17.8% (for two patches) and 59.3 +/- 4.4% (for four patches).",Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),%,71.1,132074,DB00030,Insulin Regular
,20470231,relative physiological availabilities,"By comparing the cumulative percentage change in the plasma glucose level between insulin microneedles and solution, the relative physiological availabilities were calculated to be 71.1 +/- 17.8% (for two patches) and 59.3 +/- 4.4% (for four patches).",Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),%,59.3,132075,DB00030,Insulin Regular
,20470231,Bioavailabilities,Bioavailabilities of insulin from microneedles were 72.1 +/- 11.6% (for two patches) and 72.4 +/- 8.3% (for four patches).,Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),%,72.1,132076,DB00030,Insulin Regular
,20470231,Bioavailabilities,Bioavailabilities of insulin from microneedles were 72.1 +/- 11.6% (for two patches) and 72.4 +/- 8.3% (for four patches).,Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),%,72.4,132077,DB00030,Insulin Regular
,20470231,recovered percentage,Insulin was stable in dissolving microneedles for 1 month at 4 degrees C; the recovered percentage was 99.2 +/- 13.9%.,Pharmacokinetic and pharmacodynamic evaluation of insulin dissolving microneedles in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20470231/),%,99.2,132078,DB00030,Insulin Regular
,32006325,peak time,"The pharmacokinetics of polyethylene glycolated exenatide was studied in 36 subjects, which showed slow absorption, a mean peak time of 20-40 h, and a mean elimination half-life of 51-64 h.","Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32006325/),h,20-40,132348,DB00030,Insulin Regular
,32006325,elimination half-life,"The pharmacokinetics of polyethylene glycolated exenatide was studied in 36 subjects, which showed slow absorption, a mean peak time of 20-40 h, and a mean elimination half-life of 51-64 h.","Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32006325/),h,51-64,132349,DB00030,Insulin Regular
<,24118909,peak-to-trough,"PK steady state was achieved within 7-10 days and the peak-to-trough fluctuation was <2, translating to a nearly 'peakless' glucose infusion rate at steady state and with a duration of action of at least 24 h.","Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118909/),,2,133044,DB00030,Insulin Regular
,24118909,t1/2,Across dose levels t1/2 ranged from 44.7 to 75.5 h (~2-3 days).,"Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118909/),h,44.7 to 75.5,133045,DB00030,Insulin Regular
,24118909,t1/2,Across dose levels t1/2 ranged from 44.7 to 75.5 h (~2-3 days).,"Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118909/),d,2-3,133046,DB00030,Insulin Regular
,25160589,I max,The drug effect was modeled by using an inhibitory E max model (I max = 0.96 and IC50 = 13.9 nM) to reduce the ability of glucagon to increase the glucose production rate (GPROD).,"A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160589/),,0.96,133560,DB00030,Insulin Regular
,25160589,IC50,The drug effect was modeled by using an inhibitory E max model (I max = 0.96 and IC50 = 13.9 nM) to reduce the ability of glucagon to increase the glucose production rate (GPROD).,"A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160589/),nM,13.9,133561,DB00030,Insulin Regular
,25160589,E max,"In addition, an E max model (E max = 0.79 and EC50 = 575 nM) to increase glucagon secretion by the drug was used to account for the increased glucagon concentrations prechallenge (via compensatory feedback).","A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160589/),,0.79,133562,DB00030,Insulin Regular
,25160589,EC50,"In addition, an E max model (E max = 0.79 and EC50 = 575 nM) to increase glucagon secretion by the drug was used to account for the increased glucagon concentrations prechallenge (via compensatory feedback).","A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160589/),nM,575,133563,DB00030,Insulin Regular
,33159695,"AUCGIR,0-10h","The AUCGIR,0-10h in groups A, B, and C was 1983 ± 650,1682 ± 454, and 1479 ± 440 mg/kg (P = 0.047), respectively, under comparable IAsp exposure.",Oscillations of C-peptide in the euglycemic clamp and their effect on the pharmacodynamic assessment of insulin preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159695/),[mg] / [kg],1983,133761,DB00030,Insulin Regular
,33159695,"AUCGIR,0-10h","The AUCGIR,0-10h in groups A, B, and C was 1983 ± 650,1682 ± 454, and 1479 ± 440 mg/kg (P = 0.047), respectively, under comparable IAsp exposure.",Oscillations of C-peptide in the euglycemic clamp and their effect on the pharmacodynamic assessment of insulin preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159695/),[mg] / [kg],1682,133762,DB00030,Insulin Regular
,33159695,"AUCGIR,0-10h","The AUCGIR,0-10h in groups A, B, and C was 1983 ± 650,1682 ± 454, and 1479 ± 440 mg/kg (P = 0.047), respectively, under comparable IAsp exposure.",Oscillations of C-peptide in the euglycemic clamp and their effect on the pharmacodynamic assessment of insulin preparations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33159695/),[mg] / [kg],1479,133763,DB00030,Insulin Regular
,24399453,elimination half-life,The mean elimination half-life of blonanserin (7.7-11.9 h) was much longer than that of M2 (1.2-1.3 h) but shorter than that of M1 (26.4-31.4 h) after single fasting doses.,The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399453/),h,7.7-11.9,134439,DB00030,Insulin Regular
,24399453,elimination half-life,The mean elimination half-life of blonanserin (7.7-11.9 h) was much longer than that of M2 (1.2-1.3 h) but shorter than that of M1 (26.4-31.4 h) after single fasting doses.,The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399453/),h,1.2-1.3,134440,DB00030,Insulin Regular
,24399453,elimination half-life,The mean elimination half-life of blonanserin (7.7-11.9 h) was much longer than that of M2 (1.2-1.3 h) but shorter than that of M1 (26.4-31.4 h) after single fasting doses.,The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24399453/),h,26.4-31.4,134441,DB00030,Insulin Regular
,18641968,time to early half-maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,33,134613,DB00030,Insulin Regular
,18641968,time to early half-maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,51,134614,DB00030,Insulin Regular
,18641968,time to early half-maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,66,134615,DB00030,Insulin Regular
,18641968,time to maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,136,134616,DB00030,Insulin Regular
,18641968,time to maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,152,134617,DB00030,Insulin Regular
,18641968,time to maximal activity,Subcutaneous injection of 12 IU ultra-fast insulin resulted in a time-action profile characterised by an even more rapid onset of action and maximal metabolic activity than insulin lispro: time to early half-maximal activity was 33 +/- 17 min (mean +/- SD) vs insulin lispro 51 +/- 13 min vs human soluble insulin 66 +/- 15 min (p < 0.05 ultra-fast insulin<insulin lispro<human soluble insulin); time to maximal activity was 136 +/- 56 min vs insulin lispro 152 +/- 30 min vs human soluble insulin 193 +/- 57 min (p < 0.05 ultra-fast insulin and insulin lispro<human soluble insulin).,A novel insulin formulation with a more rapid onset of action. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),min,193,134618,DB00030,Insulin Regular
,18641968,AUC glucose infusion rate [GIR] 0-120 min,The metabolic activity in the first 2 h after injection was higher with ultra-fast insulin and insulin lispro than with human soluble insulin (AUC glucose infusion rate [GIR] 0-120 min: 915 +/- 301 and 781 +/- 174 vs 580 +/- 164 mg/kg; p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],915,134619,DB00030,Insulin Regular
,18641968,AUC glucose infusion rate [GIR] 0-120 min,The metabolic activity in the first 2 h after injection was higher with ultra-fast insulin and insulin lispro than with human soluble insulin (AUC glucose infusion rate [GIR] 0-120 min: 915 +/- 301 and 781 +/- 174 vs 580 +/- 164 mg/kg; p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],781,134620,DB00030,Insulin Regular
,18641968,AUC glucose infusion rate [GIR] 0-120 min,The metabolic activity in the first 2 h after injection was higher with ultra-fast insulin and insulin lispro than with human soluble insulin (AUC glucose infusion rate [GIR] 0-120 min: 915 +/- 301 and 781 +/- 174 vs 580 +/- 164 mg/kg; p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],580,134621,DB00030,Insulin Regular
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],915,134622,DB00030,Insulin Regular
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],6,134623,DB00030,Insulin Regular
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],718,134624,DB00030,Insulin Regular
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],3,134625,DB00030,Insulin Regular
,18641968,AUCGIR 0-120 min,A clear dose-response relationship was observed with the three doses of ultra-fast insulin: AUCGIR 0-120 min 12 IU 915 +/- 301 vs 6 IU 718 +/- 255 vs 3 IU 524 +/- 262 mg/kg (p < 0.05).,A novel insulin formulation with a more rapid onset of action. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641968/),[mg] / [kg],524,134626,DB00030,Insulin Regular
,25220345,half-life,"However, although m67 exhibited a reasonably long half-life (6.4 ± 0.6 days) in cynomolgus macaques and high stability in serum, its administration to three animals did not result in any measurable decrease in the IGF2 concentration likely due to the complexity of the IGF2 interactions in the blood and the relatively low (2mg/kg) dose of the mAb leading to a relatively low maximal blood concentration of 120nM.","A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220345/),d,6.4,134814,DB00030,Insulin Regular
,25220345,maximal blood concentration,"However, although m67 exhibited a reasonably long half-life (6.4 ± 0.6 days) in cynomolgus macaques and high stability in serum, its administration to three animals did not result in any measurable decrease in the IGF2 concentration likely due to the complexity of the IGF2 interactions in the blood and the relatively low (2mg/kg) dose of the mAb leading to a relatively low maximal blood concentration of 120nM.","A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25220345/),nM,120,134815,DB00030,Insulin Regular
,26041408,oral bioavailability,Dose-proportional systemic exposure to canagliflozin has been observed over a wide dose range (50-1600 mg) with an oral bioavailability of 65 %.,"Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),%,65,135780,DB00030,Insulin Regular
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,10.6,135781,DB00030,Insulin Regular
,26041408,half-life,"The half-life of orally administered canagliflozin 100 or 300 mg in healthy participants is 10.6 and 13.1 h, respectively.","Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26041408/),h,13.1,135782,DB00030,Insulin Regular
,29223807,clearance (CL,"Better still, compound 18 revealed a lower clearance (CL = 0.44 L/h/kg), higher maximum concentration (Cmax = 7584.27 μg/L), and longer half-life (T1/2 = 4.16 h), resulting in a >23-fold exposure than compound 1.","Design, synthesis, and biological evaluation of deuterated phenylpropionic acid derivatives as potent and long-acting free fatty acid receptor 1 agonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223807/),[l] / [h·kg],0.44,135991,DB00030,Insulin Regular
,29223807,maximum concentration (Cmax,"Better still, compound 18 revealed a lower clearance (CL = 0.44 L/h/kg), higher maximum concentration (Cmax = 7584.27 μg/L), and longer half-life (T1/2 = 4.16 h), resulting in a >23-fold exposure than compound 1.","Design, synthesis, and biological evaluation of deuterated phenylpropionic acid derivatives as potent and long-acting free fatty acid receptor 1 agonists. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223807/),[μg] / [l],7584.27,135992,DB00030,Insulin Regular
,29223807,half-life (T1/2,"Better still, compound 18 revealed a lower clearance (CL = 0.44 L/h/kg), higher maximum concentration (Cmax = 7584.27 μg/L), and longer half-life (T1/2 = 4.16 h), resulting in a >23-fold exposure than compound 1.","Design, synthesis, and biological evaluation of deuterated phenylpropionic acid derivatives as potent and long-acting free fatty acid receptor 1 agonists. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29223807/),h,4.16,135993,DB00030,Insulin Regular
,20960101,Area Under Curve (AUC(0-clamp end)),"The Area Under Curve (AUC(0-clamp end)) in Glulisine and Lispro groups were 1455.04 ± 381.88 mg/kg and 1356.25 ± 287.30 mg/kg (P > 0.05), respectively.",Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20960101/),[mg] / [kg],1455.04,136301,DB00030,Insulin Regular
,20960101,Area Under Curve (AUC(0-clamp end)),"The Area Under Curve (AUC(0-clamp end)) in Glulisine and Lispro groups were 1455.04 ± 381.88 mg/kg and 1356.25 ± 287.30 mg/kg (P > 0.05), respectively.",Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20960101/),[mg] / [kg],1356.25,136302,DB00030,Insulin Regular
,24667460,plasma peak concentration,"The plasma peak concentration of active GLP-1 was 47.2 pmol/L, and its Tmax was 8.1 min.",Exploratory trial of intranasal administration of glucagon-like peptide-1 in Japanese patients with type 2 diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24667460/),[pM] / [l],47.2,136509,DB00030,Insulin Regular
,24667460,Tmax,"The plasma peak concentration of active GLP-1 was 47.2 pmol/L, and its Tmax was 8.1 min.",Exploratory trial of intranasal administration of glucagon-like peptide-1 in Japanese patients with type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24667460/),min,8.1,136510,DB00030,Insulin Regular
,19581422,half-life,"Despite its abundant presence in plasma, adiponectin is cleared rapidly with a half-life of approximately 75 min.",Systemic fate of the adipocyte-derived factor adiponectin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19581422/),min,75,137101,DB00030,Insulin Regular
,23585663,terminal elimination half-life,"At 0.80 mg/kg, VRS-317 had a mean terminal elimination half-life of 131 hours.","A long-acting human growth hormone with delayed clearance (VRS-317): results of a double-blind, placebo-controlled, single ascending dose study in growth hormone-deficient adults. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23585663/),h,131,137107,DB00030,Insulin Regular
,32513580,ClINS,"At baseline, IVGTT ClINS showed alterations in PROG, especially in second phase (0.88 ± 0.10 l·min-1 in PROG, 0.60 ± 0.06 in NONPROG, 0.54 ± 0.07 in CNT, p ≤ 0.03).",Insulin clearance is altered in women with a history of gestational diabetes progressing to type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32513580/),[l] / [min],0.88,137113,DB00030,Insulin Regular
,32513580,ClINS,"At baseline, IVGTT ClINS showed alterations in PROG, especially in second phase (0.88 ± 0.10 l·min-1 in PROG, 0.60 ± 0.06 in NONPROG, 0.54 ± 0.07 in CNT, p ≤ 0.03).",Insulin clearance is altered in women with a history of gestational diabetes progressing to type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32513580/),,0.60,137114,DB00030,Insulin Regular
,32513580,ClINS,"At baseline, IVGTT ClINS showed alterations in PROG, especially in second phase (0.88 ± 0.10 l·min-1 in PROG, 0.60 ± 0.06 in NONPROG, 0.54 ± 0.07 in CNT, p ≤ 0.03).",Insulin clearance is altered in women with a history of gestational diabetes progressing to type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32513580/),,0.54,137115,DB00030,Insulin Regular
,16123473,maximum insulin concentrations,"For insulin glulisine versus RHI, maximum insulin concentrations (58 vs. 33 microIU/ml, P < 0.05) and initial insulin concentrations (insulin [area under the curve] AUC(0-2h) 5,232 vs. 2,994 microIU.min(-1).","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),[μiu] / [ml],58,137320,DB00030,Insulin Regular
,16123473,maximum insulin concentrations,"For insulin glulisine versus RHI, maximum insulin concentrations (58 vs. 33 microIU/ml, P < 0.05) and initial insulin concentrations (insulin [area under the curve] AUC(0-2h) 5,232 vs. 2,994 microIU.min(-1).","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),[μiu] / [ml],33,137321,DB00030,Insulin Regular
,16123473,[,"For insulin glulisine versus RHI, maximum insulin concentrations (58 vs. 33 microIU/ml, P < 0.05) and initial insulin concentrations (insulin [area under the curve] AUC(0-2h) 5,232 vs. 2,994 microIU.min(-1).","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),[μiu] / [min],"5,232",137322,DB00030,Insulin Regular
,16123473,area under the curve],"For insulin glulisine versus RHI, maximum insulin concentrations (58 vs. 33 microIU/ml, P < 0.05) and initial insulin concentrations (insulin [area under the curve] AUC(0-2h) 5,232 vs. 2,994 microIU.min(-1).","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),[μiu] / [min],"5,232",137323,DB00030,Insulin Regular
,16123473,AUC(0-2h),"For insulin glulisine versus RHI, maximum insulin concentrations (58 vs. 33 microIU/ml, P < 0.05) and initial insulin concentrations (insulin [area under the curve] AUC(0-2h) 5,232 vs. 2,994 microIU.min(-1).","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),[μiu] / [min],"5,232",137324,DB00030,Insulin Regular
,16123473,AUC(0-2h),"For insulin glulisine versus RHI, maximum insulin concentrations (58 vs. 33 microIU/ml, P < 0.05) and initial insulin concentrations (insulin [area under the curve] AUC(0-2h) 5,232 vs. 2,994 microIU.min(-1).","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),[μiu] / [min],"2,994",137325,DB00030,Insulin Regular
,16123473,time to maximum insulin concentration,"Both time to maximum insulin concentration (54 vs. 66 min) and mean residence time (88 vs. 137 min, P < 0.05) were shorter with insulin glulisine versus RHI.","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),min,54,137326,DB00030,Insulin Regular
,16123473,time to maximum insulin concentration,"Both time to maximum insulin concentration (54 vs. 66 min) and mean residence time (88 vs. 137 min, P < 0.05) were shorter with insulin glulisine versus RHI.","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),min,66,137327,DB00030,Insulin Regular
,16123473,mean residence time,"Both time to maximum insulin concentration (54 vs. 66 min) and mean residence time (88 vs. 137 min, P < 0.05) were shorter with insulin glulisine versus RHI.","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),min,88,137328,DB00030,Insulin Regular
,16123473,mean residence time,"Both time to maximum insulin concentration (54 vs. 66 min) and mean residence time (88 vs. 137 min, P < 0.05) were shorter with insulin glulisine versus RHI.","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),min,137,137329,DB00030,Insulin Regular
,16123473,glucose AUC(0-6h),"Postprandial glucose excursions after insulin glulisine were lower than after RHI (glucose AUC(0-6h) 641 vs. 801 mg.h(-1).dl(-1), P < 0.05).","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),[mg] / [dl·h],641,137330,DB00030,Insulin Regular
,16123473,glucose AUC(0-6h),"Postprandial glucose excursions after insulin glulisine were lower than after RHI (glucose AUC(0-6h) 641 vs. 801 mg.h(-1).dl(-1), P < 0.05).","Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16123473/),[mg] / [dl·h],801,137331,DB00030,Insulin Regular
,29403789,flow rate,The elute was monitored with the UV-vis detector at 210 nm with a flow rate of 1 mL/min.,Development and validation of analytical method for the estimation of nateglinide in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403789/),[ml] / [min],1,138169,DB00030,Insulin Regular
,29403789,retention times,The retention times of nateglinide and internal standard (gliclazide) were 9.608 min and 11.821 min respectively.,Development and validation of analytical method for the estimation of nateglinide in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403789/),min,9.608,138170,DB00030,Insulin Regular
,29403789,retention times,The retention times of nateglinide and internal standard (gliclazide) were 9.608 min and 11.821 min respectively.,Development and validation of analytical method for the estimation of nateglinide in rabbit plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403789/),min,11.821,138171,DB00030,Insulin Regular
>,12392732,LogD,"Compounds 4c and 4d (ACD LogD values >or=2.9) displayed extended plasma elimination half-lives in dogs, primarily due to high volumes of distribution, but showed weak GH secretagogue activities in rats (ED(50)s>10 mg/kg).",Discovery and biological characterization of capromorelin analogues with extended half-lives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392732/),,2.9,138762,DB00030,Insulin Regular
>,12392732,ED(50)s,"Compounds 4c and 4d (ACD LogD values >or=2.9) displayed extended plasma elimination half-lives in dogs, primarily due to high volumes of distribution, but showed weak GH secretagogue activities in rats (ED(50)s>10 mg/kg).",Discovery and biological characterization of capromorelin analogues with extended half-lives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392732/),[mg] / [kg],10,138763,DB00030,Insulin Regular
,12392732,LogD,"A less lipophilic derivative 4 (ACD LogD=1.6) exhibited a shorter canine half-life, but stimulated GH secretion in two animal species.",Discovery and biological characterization of capromorelin analogues with extended half-lives. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392732/),,1.6,138764,DB00030,Insulin Regular
,27489211,tmax,"TV-1106 demonstrated relatively slow absorption (median tmax , 10-30 hours) and a mean elimination half-life of 26-36 hours.","Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV-1106, a Long-Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27489211/),h,10-30,139017,DB00030,Insulin Regular
,27489211,elimination half-life,"TV-1106 demonstrated relatively slow absorption (median tmax , 10-30 hours) and a mean elimination half-life of 26-36 hours.","Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV-1106, a Long-Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27489211/),h,26-36,139018,DB00030,Insulin Regular
,30721709,oral bioavailability,"Finally, according to pharmacokinetic analyses, insulin-loaded DC-LIPs show a significant hypoglycemic effect with an oral bioavailability of 16.1% in rats with type I diabetes.",A Delivery System for Oral Administration of Proteins/Peptides Through Bile Acid Transport Channels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30721709/),%,16.1,139019,DB00030,Insulin Regular
,15900936,transdermal absorption,Mean +/- SD transdermal absorption was 20 +/- 14% of oral absorption.,Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900936/),%,20,139037,DB00030,Insulin Regular
,15900936,Elimination half-life,Elimination half-life was variable (16.8 +/- 12 hours orally and 15.5 +/- 15.3 hours transdermally).,Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900936/),h,16.8,139038,DB00030,Insulin Regular
,15900936,Elimination half-life,Elimination half-life was variable (16.8 +/- 12 hours orally and 15.5 +/- 15.3 hours transdermally).,Evaluation of transdermal application of glipizide in a pluronic lecithin gel to healthy cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900936/),h,15.5,139039,DB00030,Insulin Regular
,12453973,bioavailability,INH showed a bioavailability (0-8 h postdosing) of 16% and biopotency of 13% relative to SC.,Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12453973/),%,16,139650,DB00030,Insulin Regular
,12453973,biopotency,INH showed a bioavailability (0-8 h postdosing) of 16% and biopotency of 13% relative to SC.,Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12453973/),%,13,139651,DB00030,Insulin Regular
,12453973,time to peak insulin concentration (T(max),INH exhibited a shorter time to peak insulin concentration (T(max) [mean +/- SD] 76 +/- 51 vs. 193 +/- 66 min) and shorter time to peak metabolic effect (T(GIRmax) 170 +/- 53 vs. 244 +/- 75 min) compared with SC (P < 0.001).,Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12453973/),min,76,139652,DB00030,Insulin Regular
,12453973,time to peak insulin concentration (T(max),INH exhibited a shorter time to peak insulin concentration (T(max) [mean +/- SD] 76 +/- 51 vs. 193 +/- 66 min) and shorter time to peak metabolic effect (T(GIRmax) 170 +/- 53 vs. 244 +/- 75 min) compared with SC (P < 0.001).,Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12453973/),min,193,139653,DB00030,Insulin Regular
,12453973,time to peak metabolic effect (T(GIRmax),INH exhibited a shorter time to peak insulin concentration (T(max) [mean +/- SD] 76 +/- 51 vs. 193 +/- 66 min) and shorter time to peak metabolic effect (T(GIRmax) 170 +/- 53 vs. 244 +/- 75 min) compared with SC (P < 0.001).,Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12453973/),min,170,139654,DB00030,Insulin Regular
,12453973,time to peak metabolic effect (T(GIRmax),INH exhibited a shorter time to peak insulin concentration (T(max) [mean +/- SD] 76 +/- 51 vs. 193 +/- 66 min) and shorter time to peak metabolic effect (T(GIRmax) 170 +/- 53 vs. 244 +/- 75 min) compared with SC (P < 0.001).,Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12453973/),min,244,139655,DB00030,Insulin Regular
,32243177,half-life,"However, its extremely short half-life of 1-2 min hampers any direct clinical application.",Ferritin-Displayed GLP-1 with Improved Pharmacological Activities and Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32243177/),min,1-2,140039,DB00030,Insulin Regular
,32243177,half-life,The half-life of the GLP-HFt nanocage was approximately 52 h in mice after subcutaneous injection.,Ferritin-Displayed GLP-1 with Improved Pharmacological Activities and Pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32243177/),h,52,140040,DB00030,Insulin Regular
,24465043,Cmax,The mean (SD) Cmax for repaglinide with the test and reference formulations were 20.0 (5.1) and 18.7 (8.7) ng/mL.,"Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),[ng] / [ml],20.0,140190,DB00030,Insulin Regular
,24465043,Cmax,The mean (SD) Cmax for repaglinide with the test and reference formulations were 20.0 (5.1) and 18.7 (8.7) ng/mL.,"Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),[ng] / [ml],18.7,140191,DB00030,Insulin Regular
,24465043,AUC0-t,The AUC0-t for the test formulation was 46.3 (15.1) and AUC0-∞ was 47.9 (16.5) ng(•)h/mL.,"Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),,46.3,140192,DB00030,Insulin Regular
,24465043,AUC0-∞,The AUC0-t for the test formulation was 46.3 (15.1) and AUC0-∞ was 47.9 (16.5) ng(•)h/mL.,"Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),[)h·ng(] / [ml],47.9,140193,DB00030,Insulin Regular
,24465043,Tmax,"The mean (SD) Tmax values with the test and reference formulations were 1.2 (0.7) hours and 1.5 (0.8) hours and the mean (SD) values t1/2 values were 1.0 (0.3), and 0.9 (0.3) hours, respectively.","Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),h,1.2,140194,DB00030,Insulin Regular
,24465043,Tmax,"The mean (SD) Tmax values with the test and reference formulations were 1.2 (0.7) hours and 1.5 (0.8) hours and the mean (SD) values t1/2 values were 1.0 (0.3), and 0.9 (0.3) hours, respectively.","Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),h,1.5,140195,DB00030,Insulin Regular
,24465043,t1/2,"The mean (SD) Tmax values with the test and reference formulations were 1.2 (0.7) hours and 1.5 (0.8) hours and the mean (SD) values t1/2 values were 1.0 (0.3), and 0.9 (0.3) hours, respectively.","Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),h,1.0,140196,DB00030,Insulin Regular
,24465043,t1/2,"The mean (SD) Tmax values with the test and reference formulations were 1.2 (0.7) hours and 1.5 (0.8) hours and the mean (SD) values t1/2 values were 1.0 (0.3), and 0.9 (0.3) hours, respectively.","Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting, Healthy Chinese Male Volunteers: An Open-Label, Randomized-Sequence, 2-Period Crossover Study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24465043/),h,0.9,140197,DB00030,Insulin Regular
,27540687,surface area,Highest surface area (304.3921 m2/g) was observed in case of calcined sample.,"pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540687/),[m2] / [g],304.3921,142531,DB00030,Insulin Regular
,27540687,Adsorption pore width,Adsorption pore width of final coated sample was highest (64.7844 nm) compared with others.,"pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540687/),nm,64.7844,142532,DB00030,Insulin Regular
,27540687,entrapment efficiency,The entrapment efficiency of insulin was found to be 39.39%.,"pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540687/),%,39.39,142533,DB00030,Insulin Regular
,27540687,relative bioavailability,This novel formulation has shown 73.10% relative bioavailability of insulin.,"pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27540687/),%,73.10,142534,DB00030,Insulin Regular
,29055774,oral bioavailability,Further pharmacokinetic studies disclose an oral bioavailability of 15.9% in type I diabetic rats after loading freeze-dried DNPs into enteric-coated capsules.,Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055774/),%,15.9,142970,DB00030,Insulin Regular
,34120651,AUC,"Day 1, for AUC values of remogliflozin etabonate and its metabolites were all very close to 1, indicating no accumulation in plasma concentrations of remogliflozin etabonate and its metabolites.",Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34120651/),,1,143294,DB00030,Insulin Regular
,11025411,half-life,"In this report, we found that IGF-1 had a half-life of 4.5 min in blood, could remain intact for 20 min, and entered brain and spinal cord linearly.",Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11025411/),min,4.5,143312,DB00030,Insulin Regular
,11025411,influx rate,"In the brain, IGF-1 had an influx rate of 0.4 microl/g x min after intravenous (iv) bolus injection as determined by multiple-time regression analysis.",Interactions of IGF-1 with the blood-brain barrier in vivo and in situ. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11025411/),[μl] / [g·min],0.4,143313,DB00030,Insulin Regular
,17381499,bioavailability,Acarbose reduced the overall 6-h appearance of exogenous glucose (bioavailability) by 22 +/- 7% (mean +/-se) and the 6-h cumulative (13)CO(2) excretion by 30 +/- 6%.,Low-dose acarbose does not delay digestion of starch but reduces its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17381499/),,22,143965,DB00030,Insulin Regular
,20804443,forced expiratory volume in 1 second (FEV(1)),"Insulin pharmacokinetics were evaluated in an open-label, single-dose, hyperinsulinemic-euglycemic glucose clamp study in 19 nondiabetic, nonsmoking healthy subjects (mean age [±SD] = 50.9 ± 14.1 years, body mass index = 29.1 ± 3.5 kg/m(2), forced expiratory volume in 1 second (FEV(1)) = 3.52 ± 1.02 L) and 17 nondiabetic subjects with mild-to-moderate COPD (mean age = 60.0 ± 9.0 years, body mass index = 28.5 ± 5 kg/m(2), FEV(1) = 2.56 ± 0.83 L).",Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20804443/),l,3.52,144199,DB00030,Insulin Regular
,20804443,peak insulin (C(max)),"For the COPD and non-COPD groups, respectively, mean peak insulin (C(max)) was 34.7 µU/mL and 39.5 µU/mL (p = 0.29), median t(max) was 15 and 12 min (p = 0.24), and mean insulin exposure from time 0 to 240 min (AUC(0-240)) was 2037 µU/mL · min and 2279 µU/mL · min (p = 0.47).",Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20804443/),[µu] / [ml],34.7,144200,DB00030,Insulin Regular
,20804443,peak insulin (C(max)),"For the COPD and non-COPD groups, respectively, mean peak insulin (C(max)) was 34.7 µU/mL and 39.5 µU/mL (p = 0.29), median t(max) was 15 and 12 min (p = 0.24), and mean insulin exposure from time 0 to 240 min (AUC(0-240)) was 2037 µU/mL · min and 2279 µU/mL · min (p = 0.47).",Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20804443/),[µu] / [ml],39.5,144201,DB00030,Insulin Regular
,20804443,t(max),"For the COPD and non-COPD groups, respectively, mean peak insulin (C(max)) was 34.7 µU/mL and 39.5 µU/mL (p = 0.29), median t(max) was 15 and 12 min (p = 0.24), and mean insulin exposure from time 0 to 240 min (AUC(0-240)) was 2037 µU/mL · min and 2279 µU/mL · min (p = 0.47).",Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20804443/),min,15,144202,DB00030,Insulin Regular
,20804443,t(max),"For the COPD and non-COPD groups, respectively, mean peak insulin (C(max)) was 34.7 µU/mL and 39.5 µU/mL (p = 0.29), median t(max) was 15 and 12 min (p = 0.24), and mean insulin exposure from time 0 to 240 min (AUC(0-240)) was 2037 µU/mL · min and 2279 µU/mL · min (p = 0.47).",Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20804443/),min,12,144203,DB00030,Insulin Regular
,20804443,insulin,"For the COPD and non-COPD groups, respectively, mean peak insulin (C(max)) was 34.7 µU/mL and 39.5 µU/mL (p = 0.29), median t(max) was 15 and 12 min (p = 0.24), and mean insulin exposure from time 0 to 240 min (AUC(0-240)) was 2037 µU/mL · min and 2279 µU/mL · min (p = 0.47).",Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20804443/),[µu] / [min·ml],2037,144204,DB00030,Insulin Regular
,20804443,exposure from time 0 to 240 min (AUC(0-240)),"For the COPD and non-COPD groups, respectively, mean peak insulin (C(max)) was 34.7 µU/mL and 39.5 µU/mL (p = 0.29), median t(max) was 15 and 12 min (p = 0.24), and mean insulin exposure from time 0 to 240 min (AUC(0-240)) was 2037 µU/mL · min and 2279 µU/mL · min (p = 0.47).",Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20804443/),[µu] / [min·ml],2037,144205,DB00030,Insulin Regular
,20804443,exposure from time 0 to 240 min (AUC(0-240)),"For the COPD and non-COPD groups, respectively, mean peak insulin (C(max)) was 34.7 µU/mL and 39.5 µU/mL (p = 0.29), median t(max) was 15 and 12 min (p = 0.24), and mean insulin exposure from time 0 to 240 min (AUC(0-240)) was 2037 µU/mL · min and 2279 µU/mL · min (p = 0.47).",Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20804443/),[µu] / [min·ml],2279,144206,DB00030,Insulin Regular
,17083451,plasma concentration,The mean plasma concentration of KET during the 1.5 mg/kg/h KET CRI was 235 ng/mL.,Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[ng] / [ml],235,144216,DB00030,Insulin Regular
,17083451,elimination half-lives (t1/2alpha,"The KET median elimination half-lives (t1/2alpha and t1/2beta) were 2.3 and 67.4 min, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),min,2.3,144217,DB00030,Insulin Regular
,17083451,t1/2beta,"The KET median elimination half-lives (t1/2alpha and t1/2beta) were 2.3 and 67.4 min, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),min,67.4,144218,DB00030,Insulin Regular
,17083451,area under the KET,"The area under the KET plasma concentration-time curve (AUC), elimination was 76.0 microg.min/mL.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[min·μg] / [ml],76.0,144219,DB00030,Insulin Regular
,17083451,"plasma concentration-time curve (AUC), elimination","The area under the KET plasma concentration-time curve (AUC), elimination was 76.0 microg.min/mL.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[min·μg] / [ml],76.0,144220,DB00030,Insulin Regular
,17083451,C1,"Volumes of C1 and C2 were 0.24 and 0.79 L/kg, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[l] / [kg],0.24,144221,DB00030,Insulin Regular
,17083451,C2,"Volumes of C1 and C2 were 0.24 and 0.79 L/kg, respectively.",Pharmacodynamic effects and pharmacokinetic profile of a long-term continuous rate infusion of racemic ketamine in healthy conscious horses. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17083451/),[l] / [kg],0.79,144222,DB00030,Insulin Regular
,21355718,time to maximum insulin concentration,"Microneedle ID delivery resulted in more rapid absorption of IL, with decreased time to maximum insulin concentration (ID vs. SC: 36.0-46.4 vs. 64.3 min, P < 0.05) and higher fractional availability at early postinjection times.",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,36.0-46.4,144273,DB00030,Insulin Regular
,21355718,time to maximum insulin concentration,"Microneedle ID delivery resulted in more rapid absorption of IL, with decreased time to maximum insulin concentration (ID vs. SC: 36.0-46.4 vs. 64.3 min, P < 0.05) and higher fractional availability at early postinjection times.",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,64.3,144274,DB00030,Insulin Regular
,21355718,time to maximum,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,106-112,144275,DB00030,Insulin Regular
,21355718,time to maximum,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,130,144276,DB00030,Insulin Regular
,21355718,early half-maximal,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,29-35,144277,DB00030,Insulin Regular
,21355718,early half-maximal,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,42,144278,DB00030,Insulin Regular
,21355718,time to late half-maximal,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,271-287,144279,DB00030,Insulin Regular
,21355718,time to late half-maximal,"ID produced more rapid effects on glucose uptake with shorter times to maximal and early half-maximal glucose infusion rates (GIRs) (ID vs. SC: time to maximum GIR, 106-112 vs. 130 min, P < 0.05; early half-maximal GIR, 29-35 vs. 42 min), increased early GIR area under the curve (AUC), and faster offset of insulin action (shorter time to late half-maximal GIR: 271-287 vs. 309 min).",Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21355718/),min,309,144280,DB00030,Insulin Regular
,15738706,fractional insulin loss rate,The model had a fractional insulin loss rate of 0.112 +/- 0.063 min(1) and a distribution volume of 15.6 +/- 4.0 L.,Pharmacokinetics of intravenous insulin delivery in humans with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15738706/),min(1),0.112,144650,DB00030,Insulin Regular
,15738706,distribution volume,The model had a fractional insulin loss rate of 0.112 +/- 0.063 min(1) and a distribution volume of 15.6 +/- 4.0 L.,Pharmacokinetics of intravenous insulin delivery in humans with type 1 diabetes. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15738706/),l,15.6,144651,DB00030,Insulin Regular
,22237261,progression-free survival,The median progression-free survival was 39 days (range 21-432+ days).,A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237261/),d,39,145181,DB00030,Insulin Regular
,26446475,half-life,"The half-life of glipizide did not change, and reached 3.8±0.7 and 3.7±1.8 h in the MODY and control subjects, respectively.",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,3.8,146051,DB00030,Insulin Regular
,26446475,half-life,"The half-life of glipizide did not change, and reached 3.8±0.7 and 3.7±1.8 h in the MODY and control subjects, respectively.",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,3.7,146052,DB00030,Insulin Regular
,26446475,t1/2,"The half-life of glibenclamide was increased only in some MODY subjects (t1/2 9.5±6.7 and 5.0±1.4 h, respectively).",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,9.5,146053,DB00030,Insulin Regular
,26446475,t1/2,"The half-life of glibenclamide was increased only in some MODY subjects (t1/2 9.5±6.7 and 5.0±1.4 h, respectively).",Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26446475/),h,5.0,146054,DB00030,Insulin Regular
,33576936,t1/2,"After 6 consecutive weeks of administration, the t1/2 in the 165 μg, 330 μg, and 660 µg dose groups was 55.67 ± 11.03 h, 56.99 ± 21.37 h, and 54.81 ± 13.87 h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),h,55.67,146410,DB00030,Insulin Regular
,33576936,t1/2,"After 6 consecutive weeks of administration, the t1/2 in the 165 μg, 330 μg, and 660 µg dose groups was 55.67 ± 11.03 h, 56.99 ± 21.37 h, and 54.81 ± 13.87 h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),h,56.99,146411,DB00030,Insulin Regular
,33576936,t1/2,"After 6 consecutive weeks of administration, the t1/2 in the 165 μg, 330 μg, and 660 µg dose groups was 55.67 ± 11.03 h, 56.99 ± 21.37 h, and 54.81 ± 13.87 h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),h,54.81,146412,DB00030,Insulin Regular
,33576936,Cavg,"The Cavg was 4.22 ± 0.78 ng/ml, 6.03 ± 1.43 ng/ml, and 10.50 ± 3.06 ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ng] / [ml],4.22,146413,DB00030,Insulin Regular
,33576936,Cavg,"The Cavg was 4.22 ± 0.78 ng/ml, 6.03 ± 1.43 ng/ml, and 10.50 ± 3.06 ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ng] / [ml],6.03,146414,DB00030,Insulin Regular
,33576936,Cavg,"The Cavg was 4.22 ± 0.78 ng/ml, 6.03 ± 1.43 ng/ml, and 10.50 ± 3.06 ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ng] / [ml],10.50,146415,DB00030,Insulin Regular
,33576936,AUCss,"AUCss was 708.59 ± 131.87 h•ng/ml, 1012.63 ± 240.79 h•ng/ml, and 1763.81 ± 514.50 h•ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[h·ng] / [ml],708.59,146416,DB00030,Insulin Regular
,33576936,AUCss,"AUCss was 708.59 ± 131.87 h•ng/ml, 1012.63 ± 240.79 h•ng/ml, and 1763.81 ± 514.50 h•ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[h·ng] / [ml],1012.63,146417,DB00030,Insulin Regular
,33576936,AUCss,"AUCss was 708.59 ± 131.87 h•ng/ml, 1012.63 ± 240.79 h•ng/ml, and 1763.81 ± 514.50 h•ng/ml, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[h·ng] / [ml],1763.81,146418,DB00030,Insulin Regular
,33576936,accumulation index,"The accumulation index was 1.15 ± 0.07, 1.17 ± 0.11, and 1.14 ± 0.07.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),,1.15,146419,DB00030,Insulin Regular
,33576936,accumulation index,"The accumulation index was 1.15 ± 0.07, 1.17 ± 0.11, and 1.14 ± 0.07.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),,1.17,146420,DB00030,Insulin Regular
,33576936,accumulation index,"The accumulation index was 1.15 ± 0.07, 1.17 ± 0.11, and 1.14 ± 0.07.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),,1.14,146421,DB00030,Insulin Regular
,33576936,CLss/F,"The CLss/F was 241.25 ± 51.13 ml/h, 341.53 ± 73.62 ml/h, and 450.06 ± 313.76 ml/h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ml] / [h],241.25,146422,DB00030,Insulin Regular
,33576936,CLss/F,"The CLss/F was 241.25 ± 51.13 ml/h, 341.53 ± 73.62 ml/h, and 450.06 ± 313.76 ml/h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ml] / [h],341.53,146423,DB00030,Insulin Regular
,33576936,CLss/F,"The CLss/F was 241.25 ± 51.13 ml/h, 341.53 ± 73.62 ml/h, and 450.06 ± 313.76 ml/h, respectively.","Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33576936/),[ml] / [h],450.06,146424,DB00030,Insulin Regular
,19295505,concentration ratio,The average umbilical cord/maternal plasma glyburide concentration ratio at the time of delivery was 0.7 +/- 0.4.,Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19295505/),,0.7,146720,DB00030,Insulin Regular
,17252192,Vd,"Parametric and nonparametric estimates of Vd for RBC and sucrose were similar and were 0.14+/-0.01, 0.15 0.005 and 0.35+/-0.01 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.14,147798,DB00030,Insulin Regular
,17252192,Vd,"Parametric and nonparametric estimates of Vd for RBC and sucrose were similar and were 0.14+/-0.01, 0.15 0.005 and 0.35+/-0.01 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.15,147799,DB00030,Insulin Regular
,17252192,Vd,"Parametric and nonparametric estimates of Vd for RBC and sucrose were similar and were 0.14+/-0.01, 0.15 0.005 and 0.35+/-0.01 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.005,147800,DB00030,Insulin Regular
,17252192,Vd,"Parametric and nonparametric estimates of Vd for RBC and sucrose were similar and were 0.14+/-0.01, 0.15 0.005 and 0.35+/-0.01 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.35,147801,DB00030,Insulin Regular
,17252192,water,"The parametric estimate for water, 1.04+/-0.05 ml/g was greater than the nonparametric estimate, 0.89+/-0.02 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],1.04,147802,DB00030,Insulin Regular
,17252192,water,"The parametric estimate for water, 1.04+/-0.05 ml/g was greater than the nonparametric estimate, 0.89+/-0.02 ml/g.",Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.89,147803,DB00030,Insulin Regular
,17252192,Vd,The multiple indicator dilution method Vd of tolbutamide of 0.75+0.08 ml/g was similar to the reported value of 0.73+/-0.04 ml/g estimated by tissue partitioning studies.,Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.75,147804,DB00030,Insulin Regular
,17252192,Vd,The multiple indicator dilution method Vd of tolbutamide of 0.75+0.08 ml/g was similar to the reported value of 0.73+/-0.04 ml/g estimated by tissue partitioning studies.,Characterization of the physiological spaces and distribution of tolbutamide in the perfused rat pancreas. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17252192/),[ml] / [g],0.73,147805,DB00030,Insulin Regular
,24152122,half-lives,"2. The half-lives against phase I metabolism were measured as 75.3 ± 20.9 min and over 120 min in rat and human liver microsomes, respectively.","Preclinical pharmacokinetic characterization of 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl) acetic acid, a novel DGAT-1 inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152122/),min,75.3,147811,DB00030,Insulin Regular
,24152122,half-lives,"2. The half-lives against phase I metabolism were measured as 75.3 ± 20.9 min and over 120 min in rat and human liver microsomes, respectively.","Preclinical pharmacokinetic characterization of 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl) acetic acid, a novel DGAT-1 inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152122/),min,over,147812,DB00030,Insulin Regular
,24152122,half-lives,"2. The half-lives against phase I metabolism were measured as 75.3 ± 20.9 min and over 120 min in rat and human liver microsomes, respectively.","Preclinical pharmacokinetic characterization of 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl) acetic acid, a novel DGAT-1 inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152122/),min,120,147813,DB00030,Insulin Regular
<,24152122,permeability,"In Caco-2 cell monolayers, extremely low permeability (<0.13 × 10⁻⁶cm/s) was seen in the absorptive direction, predicting limited intestinal absorption of KR-69232.","Preclinical pharmacokinetic characterization of 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl) acetic acid, a novel DGAT-1 inhibitor. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152122/),[cm] / [s],0.13 × 10⁻⁶,147814,DB00030,Insulin Regular
<,24152122,bioavailability,"Following oral administration, it exhibited low bioavailability (<10%) and was absorbed slowly (T(max), 3.8-5.2 h) over the dose range.","Preclinical pharmacokinetic characterization of 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl) acetic acid, a novel DGAT-1 inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152122/),%,10,147815,DB00030,Insulin Regular
,24152122,T(max),"Following oral administration, it exhibited low bioavailability (<10%) and was absorbed slowly (T(max), 3.8-5.2 h) over the dose range.","Preclinical pharmacokinetic characterization of 2-(4-(4-(5-(2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamido)-1H-benzo[d]imidazol-2-yl)phenyl)cyclohexyl) acetic acid, a novel DGAT-1 inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24152122/),h,3.8-5.2,147816,DB00030,Insulin Regular
,31069935,onset of appearance,"Least squares mean (± SE) onset of appearance was 3.3 ± 0.3 minutes for faster aspart, which was 1.2 minutes earlier than for IAsp (95% confidence interval [CI] -1.8;-0.5; P = .001).",Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31069935/),min,3.3,147884,DB00030,Insulin Regular
,34100220,time to maximum glucagon concentration,"The mean (standard deviation) time to maximum glucagon concentration in plasma was 11 (5) min, and the mean elimination half-life of glucagon in plasma was 19 (7) min.",Pharmacokinetics of Intraperitoneally Delivered Glucagon in Pigs: A Hypothesis of First Pass Metabolism. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100220/),min,11,148233,DB00030,Insulin Regular
,34100220,elimination half-life,"The mean (standard deviation) time to maximum glucagon concentration in plasma was 11 (5) min, and the mean elimination half-life of glucagon in plasma was 19 (7) min.",Pharmacokinetics of Intraperitoneally Delivered Glucagon in Pigs: A Hypothesis of First Pass Metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100220/),min,19,148234,DB00030,Insulin Regular
,20919907,elimination half-life (t1/2),"Mean±SD elimination half-life (t1/2) of metformin was 11.7±5.2 hours, maxima plasma concentration was 748±269 ng/mL at 54±32 minutes, mean area under the curve was 355±92 microg.h/mL, and apparent clearance was 90.6±28.1 mL/min/kg.",Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),h,11.7,148625,DB00030,Insulin Regular
,20919907,maxima plasma concentration,"Mean±SD elimination half-life (t1/2) of metformin was 11.7±5.2 hours, maxima plasma concentration was 748±269 ng/mL at 54±32 minutes, mean area under the curve was 355±92 microg.h/mL, and apparent clearance was 90.6±28.1 mL/min/kg.",Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),[ng] / [ml],748,148626,DB00030,Insulin Regular
,20919907,area under the curve,"Mean±SD elimination half-life (t1/2) of metformin was 11.7±5.2 hours, maxima plasma concentration was 748±269 ng/mL at 54±32 minutes, mean area under the curve was 355±92 microg.h/mL, and apparent clearance was 90.6±28.1 mL/min/kg.",Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),[h·μg] / [ml],355,148627,DB00030,Insulin Regular
,20919907,apparent clearance,"Mean±SD elimination half-life (t1/2) of metformin was 11.7±5.2 hours, maxima plasma concentration was 748±269 ng/mL at 54±32 minutes, mean area under the curve was 355±92 microg.h/mL, and apparent clearance was 90.6±28.1 mL/min/kg.",Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),[ml] / [kg·min],90.6,148628,DB00030,Insulin Regular
,20919907,Css,The Css was 122±22 ng/mL.,Pharmacokinetics of metformin after enteral administration in insulin-resistant ponies. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20919907/),[ng] / [ml],122,148629,DB00030,Insulin Regular
,12039708,half-life,"However, its very short half-life (1.5-5 min) in plasma represents a major limitation for its use in the clinical setting.",The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12039708/),min,1.5-5,148745,DB00030,Insulin Regular
,21492190,maximum plasma concentration,"The maximum plasma concentration was 509.1 ± 413.5 ng/mL achieved at 1.88 ± 1.39 h following oral administration of the first dose, and 448.1 ± 303.5 ng/mL achieved at 2.83 ± 1.81 h (mean ± SD) following the eleventh dose.",Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492190/),[ng] / [ml],509.1,148916,DB00030,Insulin Regular
,21492190,maximum plasma concentration,"The maximum plasma concentration was 509.1 ± 413.5 ng/mL achieved at 1.88 ± 1.39 h following oral administration of the first dose, and 448.1 ± 303.5 ng/mL achieved at 2.83 ± 1.81 h (mean ± SD) following the eleventh dose.",Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492190/),[ng] / [ml],448.1,148917,DB00030,Insulin Regular
,21492190,Apparent elimination half-life,"Apparent elimination half-life was 9.94 ± 4.57 and 9.63 ± 5.33 h after the first and eleventh dose, respectively.",Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492190/),h,9.94,148918,DB00030,Insulin Regular
,21492190,Apparent elimination half-life,"Apparent elimination half-life was 9.94 ± 4.57 and 9.63 ± 5.33 h after the first and eleventh dose, respectively.",Pharmacokinetics of pioglitazone after multiple oral dose administration in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21492190/),h,9.63,148919,DB00030,Insulin Regular
,26762368,peak plasma insulin concentrations,"Jejunal feeding resulted in higher peak plasma insulin concentrations than did gastric feeding (392 ± 53 compared with 326 ± 54 pmol/L, respectively; P < 0.05).","Jejunal feeding is followed by a greater rise in plasma cholecystokinin, peptide YY, glucagon-like peptide 1, and glucagon-like peptide 2 concentrations compared with gastric feeding in vivo in humans: a randomized trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26762368/),[pM] / [l],392,148980,DB00030,Insulin Regular
,26762368,peak plasma insulin concentrations,"Jejunal feeding resulted in higher peak plasma insulin concentrations than did gastric feeding (392 ± 53 compared with 326 ± 54 pmol/L, respectively; P < 0.05).","Jejunal feeding is followed by a greater rise in plasma cholecystokinin, peptide YY, glucagon-like peptide 1, and glucagon-like peptide 2 concentrations compared with gastric feeding in vivo in humans: a randomized trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26762368/),[pM] / [l],326,148981,DB00030,Insulin Regular
,15047601,peak arterial concentration,"In contrast, subcutaneous insulin was associated with a delayed and lower peak arterial concentration (55 +/- 8 microU/ml at 64 min), requiring 6 h to return to baseline.",Inhalation of insulin in dogs: assessment of insulin levels and comparison to subcutaneous injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15047601/),[μu] / [ml],55,149465,DB00030,Insulin Regular
,20655382,drop,The droplet sizes of the microemulsions were 161.7±24.7nm with PDI of 0.447±0.076 and insulin entrapment of ∼85%.,"Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655382/),nm,161.7,151112,DB00030,Insulin Regular
,20655382,PDI,The droplet sizes of the microemulsions were 161.7±24.7nm with PDI of 0.447±0.076 and insulin entrapment of ∼85%.,"Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655382/),,0.447,151113,DB00030,Insulin Regular
,20655382,entrapment,The droplet sizes of the microemulsions were 161.7±24.7nm with PDI of 0.447±0.076 and insulin entrapment of ∼85%.,"Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655382/),%,∼85,151114,DB00030,Insulin Regular
,12242461,t(1/2),"GIP was rapidly degraded by dipeptidylpeptidase IV and plasma (t(1/2) 2.3 and 6.2 h, respectively) whereas Ac-GIP and pGlu-GIP remained intact even after 24 h.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),h,2.3,151330,DB00030,Insulin Regular
,12242461,t(1/2),"GIP was rapidly degraded by dipeptidylpeptidase IV and plasma (t(1/2) 2.3 and 6.2 h, respectively) whereas Ac-GIP and pGlu-GIP remained intact even after 24 h.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),h,6.2,151331,DB00030,Insulin Regular
,12242461,EC(50),"Both Ac-GIP and pGlu-GIP were extremely potent ( p<0.001) at stimulating cAMP production (EC(50) values 1.9 and 2.7 nmol/l, respectively), almost a tenfold increase compared to native GIP (18.2 nmol/l).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[nM] / [l],1.9,151332,DB00030,Insulin Regular
,12242461,EC(50),"Both Ac-GIP and pGlu-GIP were extremely potent ( p<0.001) at stimulating cAMP production (EC(50) values 1.9 and 2.7 nmol/l, respectively), almost a tenfold increase compared to native GIP (18.2 nmol/l).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[nM] / [l],2.7,151333,DB00030,Insulin Regular
,12242461,EC(50),"Both Ac-GIP and pGlu-GIP were extremely potent ( p<0.001) at stimulating cAMP production (EC(50) values 1.9 and 2.7 nmol/l, respectively), almost a tenfold increase compared to native GIP (18.2 nmol/l).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[nM] / [l],18.2,151334,DB00030,Insulin Regular
,12242461,AUC,"This antihyperglycaemic effect was coupled to a raised ( p<0.001) and more prolonged insulin response after administration of Ac-GIP and pGlu-GIP (AUC, 644+/-54 and 576+/-51 ng.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),ng,644,151335,DB00030,Insulin Regular
,12242461,AUC,"This antihyperglycaemic effect was coupled to a raised ( p<0.001) and more prolonged insulin response after administration of Ac-GIP and pGlu-GIP (AUC, 644+/-54 and 576+/-51 ng.","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),ng,576,151336,DB00030,Insulin Regular
,12242461,AUC,"ml(-1) x min, respectively) compared with native GIP (AUC, 257+/-29 ng.ml(-1) x min).","Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12242461/),[min·ng] / [ml],257,151337,DB00030,Insulin Regular
,16027400,AUC(0-12),"Total mycophenolic acid AUC(0-12) mcg x h/mL before day 60 was 62.1-67.8, declining to 33.6-64.7 thereafter (P = .61).",Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·mcg] / [ml],62.1-67.8,151954,DB00030,Insulin Regular
,16027400,AUC(0-12),"Total mycophenolic acid AUC(0-12) mcg x h/mL before day 60 was 62.1-67.8, declining to 33.6-64.7 thereafter (P = .61).",Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·mcg] / [ml],33.6-64.7,151955,DB00030,Insulin Regular
,16027400,total trough concentrations,Median total trough concentrations were 1.16-2.90 mcg/mL.,Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[mcg] / [ml],1.16-2.90,151956,DB00030,Insulin Regular
,16027400,Unbound AUC(0-12),Unbound AUC(0-12) was 412-673 ng x h/mL and did not change over time (P = .30).,Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·ng] / [ml],412-673,151957,DB00030,Insulin Regular
,19234324,duration of action,"The median duration of action of the insulin was approximately 14 hours, with a range from 10 to more than 24 hours.",Pharmacokinetics and pharmacodynamics of porcine insulin zinc suspension in eight diabetic dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19234324/),h,14,152872,DB00030,Insulin Regular
,19863477,half-life,"Albiglutide sc had a median half-life of 5.3 days, plasma apparent systemic clearance of 68.7 mL/h, and apparent volume of distribution of 12.6 L.","Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19863477/),d,5.3,153331,DB00030,Insulin Regular
,19863477,plasma apparent systemic clearance,"Albiglutide sc had a median half-life of 5.3 days, plasma apparent systemic clearance of 68.7 mL/h, and apparent volume of distribution of 12.6 L.","Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19863477/),[ml] / [h],68.7,153332,DB00030,Insulin Regular
,19863477,apparent volume of distribution,"Albiglutide sc had a median half-life of 5.3 days, plasma apparent systemic clearance of 68.7 mL/h, and apparent volume of distribution of 12.6 L.","Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19863477/),l,12.6,153333,DB00030,Insulin Regular
,15080773,elimination half life (t(1/2)),"Acylated ghrelin disappeared more rapidly from plasma than total ghrelin, with elimination half life (t(1/2)) of 9-13 and 27-31 min respectively.","Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080773/),min,9-13,153522,DB00030,Insulin Regular
,15080773,elimination half life (t(1/2)),"Acylated ghrelin disappeared more rapidly from plasma than total ghrelin, with elimination half life (t(1/2)) of 9-13 and 27-31 min respectively.","Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080773/),min,27-31,153523,DB00030,Insulin Regular
,15080773,"peak plasma concentration (C(max,0-90 min)","Both the low and high doses of ghrelin strongly stimulated GH release (peak plasma concentration (C(max,0-90 min)): 124.2+/-63.9 and 153.2+/-52.2 ng/ml for 1 and 5 microg/kg ghrelin respectively).","Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080773/),[ng] / [ml],124.2,153524,DB00030,Insulin Regular
,15080773,"peak plasma concentration (C(max,0-90 min)","Both the low and high doses of ghrelin strongly stimulated GH release (peak plasma concentration (C(max,0-90 min)): 124.2+/-63.9 and 153.2+/-52.2 ng/ml for 1 and 5 microg/kg ghrelin respectively).","Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080773/),[ng] / [ml],153.2,153525,DB00030,Insulin Regular
,11699836,area under the curve (AUC),"Of the bile salts/acids studied, incorporation of 100 mg of deoxycholic acid (DCA), sodium cholate (NaC), or sodium deoxycholate (NaDC) with insulin (10 U/Kg) showed that suppositories containing NaDC produced the highest area under the curve (AUC) and relative hypoglycemia (RH) of 290 +/- 83 mg%h and 28% +/- 8.1%, respectively.",Effect of different bile salts on the relative hypoglycemia of witepsol W35 suppositories containing insulin in diabetic Beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699836/),mg%h,290,153737,DB00030,Insulin Regular
,11699836,AUC,"A combination of NaDC (100 mg) and NaC (50 mg) produced an AUC of 252 +/- 13mg%h and an RH of 49% +/- 2.6%, which were higher than produced by either of its individual components (NaC 50 mg or NaDC 100 mg) when used alone or when compared with an equivalent amount of NaDC (150 mg).",Effect of different bile salts on the relative hypoglycemia of witepsol W35 suppositories containing insulin in diabetic Beagle dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699836/),mg%h,252,153738,DB00030,Insulin Regular
,26076191,bioavailability,"The relative octreotide bioavailability of depot variants vs. octreotide IR ranged from 0.68 (90% confidence interval [CI] 0.61, 0.76) to 0.91 (90% CI 0.81, 1.02) and, vs. octreotide LAR, was approximately four- to five-fold greater: 3.97 (90% CI 3.35, 4.71) to 5.27 ng ml(-1) h (90% CI 4.43, 6.27).",Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26076191/),[h·ng] / [ml],3.,153960,DB00030,Insulin Regular
,26076191,bioavailability,"The relative octreotide bioavailability of depot variants vs. octreotide IR ranged from 0.68 (90% confidence interval [CI] 0.61, 0.76) to 0.91 (90% CI 0.81, 1.02) and, vs. octreotide LAR, was approximately four- to five-fold greater: 3.97 (90% CI 3.35, 4.71) to 5.27 ng ml(-1) h (90% CI 4.43, 6.27).",Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26076191/),[h·ng] / [ml],5.27,153961,DB00030,Insulin Regular
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],47.7,154308,DB00030,Insulin Regular
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],83.1,154309,DB00030,Insulin Regular
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],569,154310,DB00030,Insulin Regular
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],911,154311,DB00030,Insulin Regular
,24232127,C(0),"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],2.6,154312,DB00030,Insulin Regular
,24232127,C(0),"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],4.6,154313,DB00030,Insulin Regular
,24232127,maximum serum concentration,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],9.2,154314,DB00030,Insulin Regular
,24232127,maximum serum concentration,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],20.3,154315,DB00030,Insulin Regular
,24232127,apparent oral clearance,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·l] / [kg],0.26,154316,DB00030,Insulin Regular
,24232127,apparent oral clearance,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·l] / [kg],0.13,154317,DB00030,Insulin Regular
,24086950,elimination half-life,"Following subcutaneous administration in humans, lixisenatide displays linear pharmacokinetics and an absorption-dependent elimination half-life of 2-3 hours.",Lixisenatide for the treatment of type 2 diabetes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086950/),h,2-3,154900,DB00030,Insulin Regular
,17588259,insulin-loading capacity,The insulin-loading capacity was 62%.,Development and characterization of chitosan succinate microspheres for the improved oral bioavailability of insulin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17588259/),%,62,154994,DB00030,Insulin Regular
,15170368,"k(a,L)","The best estimate for k(a,L) was found to be 0.020-0.032 h(-1), effectively unchanged across doses (0.3-1.8 IU/kg), formulations (powder vs liquid) and subjects (healthy vs diabetic), suggesting passive diffusive absorption of insulin from the lung.",Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15170368/),1/[h],0.020-0.032,155135,DB00030,Insulin Regular
,15170368,k(,"In contrast, the values for k(mm,L) were much larger (0.5-1.6 h(-1)) and decreased with increasing inhaled dose.",Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15170368/),1/[h],0.5-1.6,155136,DB00030,Insulin Regular
,15170368,absolute bioavailability,"As a result, the absolute bioavailability ranged from 1.5% to 4.8%.",Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15170368/),%,1.5,155137,DB00030,Insulin Regular
,15170368,absolute bioavailability,"As a result, the absolute bioavailability ranged from 1.5% to 4.8%.",Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15170368/),%,4.8,155138,DB00030,Insulin Regular
,28110155,half-life,PEGylation resulted in long exposure to RO5046013 with a half-life of 140-200h.,First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28110155/),h,140-200,155975,DB00030,Insulin Regular
,23013357,Duration of action,"Duration of action was similar for detemir [23.0 (range 2.25-32) h] and NPL [22.0 (9.5-32) h], p = 0.55.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),h,23.0,157003,DB00030,Insulin Regular
,23013357,Duration of action,"Duration of action was similar for detemir [23.0 (range 2.25-32) h] and NPL [22.0 (9.5-32) h], p = 0.55.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),h,22.0,157004,DB00030,Insulin Regular
,23013357,"area under the curve, AUC","Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],1326,157005,DB00030,Insulin Regular
,23013357,"area under the curve, AUC","Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],1841,157006,DB00030,Insulin Regular
,23013357,AUC,"Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],784,157007,DB00030,Insulin Regular
,23013357,AUC,"Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],1392,157008,DB00030,Insulin Regular
,23013357,AUC,"Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],455,157009,DB00030,Insulin Regular
,23013357,AUC,"Using glucose infusion rate (GIR) parameters, detemir showed a flatter pharmacodynamic profile versus NPL: area under the curve, AUC(GIR) ((0-32)) = 1326 vs. 1841 mg/kg, p < 0.01 (detemir vs. NPL, respectively); AUC(GIR) ((0-12)) = 784 vs. 1392 mg/kg, p < 0.05; AUC(GIR) ((12-32)) = 455 vs. 274 mg/kg, p = 0.051; GIR(late) (12-32)/GIR(early) (0-12) ratio = 0.33 vs. 0.04, p < 0.001.",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg],274,157010,DB00030,Insulin Regular
,23013357,GIR(max),"Detemir also showed a lower and later peak of action than NPL [GIR(max) 2.0 vs. 3.2 mg/kg/min, p < 0.01; T(max) 9.1 (95% confidence interval: 3.0-14.7) vs. 7.0 h (1.8-15.2)].",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg·min],2.0,157011,DB00030,Insulin Regular
,23013357,GIR(max),"Detemir also showed a lower and later peak of action than NPL [GIR(max) 2.0 vs. 3.2 mg/kg/min, p < 0.01; T(max) 9.1 (95% confidence interval: 3.0-14.7) vs. 7.0 h (1.8-15.2)].",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),[mg] / [kg·min],3.2,157012,DB00030,Insulin Regular
,23013357,T(max),"Detemir also showed a lower and later peak of action than NPL [GIR(max) 2.0 vs. 3.2 mg/kg/min, p < 0.01; T(max) 9.1 (95% confidence interval: 3.0-14.7) vs. 7.0 h (1.8-15.2)].",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),h,9.1,157013,DB00030,Insulin Regular
,23013357,T(max),"Detemir also showed a lower and later peak of action than NPL [GIR(max) 2.0 vs. 3.2 mg/kg/min, p < 0.01; T(max) 9.1 (95% confidence interval: 3.0-14.7) vs. 7.0 h (1.8-15.2)].",A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013357/),h,7.0,157014,DB00030,Insulin Regular
,28605468,half-life,X358 exhibited dose-proportional PK with a half-life of 21 days.,Attenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28605468/),d,21,157142,DB00030,Insulin Regular
,16403822,half-life,The IGF-I half-life in four subjects after a dose of 0.5 mg/kg rhIGF-I/rhIGFBP-3 was estimated to be 21+/- 4 h.,Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16403822/),h,21,157405,DB00030,Insulin Regular
,29257872,AUCbrain,"SC insulin (2.4 IU) achieved therapeutically relevant concentrations in the brain (AUCbrain = 2537 h·μIU/mL) but dramatically increased plasma insulin (AUCplasma = 520 351 h·*μIU/mL), resulting in severe hypoglycemia and in some cases death.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],2537,157792,DB00030,Insulin Regular
,29257872,AUCplasma,"SC insulin (2.4 IU) achieved therapeutically relevant concentrations in the brain (AUCbrain = 2537 h·μIU/mL) but dramatically increased plasma insulin (AUCplasma = 520 351 h·*μIU/mL), resulting in severe hypoglycemia and in some cases death.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],520 351,157793,DB00030,Insulin Regular
,29257872,AUCbrain,"IN administration of the same dose resulted in similar insulin levels in the brain (AUCbrain = 3442 h·μIU/mL) but substantially lower plasma concentrations (AUCplasma = 354 h·μIU/mL), amounting to a ∼ 2000-fold increase in the AUCbrain:plasma ratio relative to SC.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],3442,157794,DB00030,Insulin Regular
,29257872,AUCplasma,"IN administration of the same dose resulted in similar insulin levels in the brain (AUCbrain = 3442 h·μIU/mL) but substantially lower plasma concentrations (AUCplasma = 354 h·μIU/mL), amounting to a ∼ 2000-fold increase in the AUCbrain:plasma ratio relative to SC.",Pharmacokinetics of Intranasal versus Subcutaneous Insulin in the Mouse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29257872/),[h·μiu] / [ml],354,157795,DB00030,Insulin Regular
,20167039,NE release into the extravascular compartment (NE(2)),"Within 1 week of starting the HFD, NE release into the extravascular compartment (NE(2)) increased from 3.44+/-0.59 microg/mL to 4.87+/-0.80 microg/mL (P<.01) and this increase was maintained over the next 5 weeks of the HFD (NE(2) at week 6 was 4.66+/-0.97 microg/mL).",Serial changes in norepinephrine kinetics associated with feeding dogs a high-fat diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167039/),[μg] / [ml],3.44,158366,DB00030,Insulin Regular
,20167039,NE release into the extravascular compartment (NE(2)),"Within 1 week of starting the HFD, NE release into the extravascular compartment (NE(2)) increased from 3.44+/-0.59 microg/mL to 4.87+/-0.80 microg/mL (P<.01) and this increase was maintained over the next 5 weeks of the HFD (NE(2) at week 6 was 4.66+/-0.97 microg/mL).",Serial changes in norepinephrine kinetics associated with feeding dogs a high-fat diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167039/),[μg] / [ml],4.87,158367,DB00030,Insulin Regular
,20167039,NE(2),"Within 1 week of starting the HFD, NE release into the extravascular compartment (NE(2)) increased from 3.44+/-0.59 microg/mL to 4.87+/-0.80 microg/mL (P<.01) and this increase was maintained over the next 5 weeks of the HFD (NE(2) at week 6 was 4.66+/-0.97 microg/mL).",Serial changes in norepinephrine kinetics associated with feeding dogs a high-fat diet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20167039/),[μg] / [ml],4.66,158368,DB00030,Insulin Regular
,19344673,Total uptake,"Total uptake (1,072,270, 1,182,498; 1,481,060; ng/ml/min), serum half-life (48.8; 34.0; 30.0 min) and relative bioavailability (1.0, 1.1; 1.4;) of mouse [D-Leu-4]OB3 were similar when the peptide was given by ip, sc, or im injection, respectively.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),[ng] / [min·ml],"1,072,270",158610,DB00030,Insulin Regular
,19344673,Total uptake,"Total uptake (1,072,270, 1,182,498; 1,481,060; ng/ml/min), serum half-life (48.8; 34.0; 30.0 min) and relative bioavailability (1.0, 1.1; 1.4;) of mouse [D-Leu-4]OB3 were similar when the peptide was given by ip, sc, or im injection, respectively.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),[ng] / [min·ml],"1,182,498",158611,DB00030,Insulin Regular
,19344673,Total uptake,"Total uptake (1,072,270, 1,182,498; 1,481,060; ng/ml/min), serum half-life (48.8; 34.0; 30.0 min) and relative bioavailability (1.0, 1.1; 1.4;) of mouse [D-Leu-4]OB3 were similar when the peptide was given by ip, sc, or im injection, respectively.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),[ng] / [min·ml],"1,481,060",158612,DB00030,Insulin Regular
,19344673,serum half-life,"Total uptake (1,072,270, 1,182,498; 1,481,060; ng/ml/min), serum half-life (48.8; 34.0; 30.0 min) and relative bioavailability (1.0, 1.1; 1.4;) of mouse [D-Leu-4]OB3 were similar when the peptide was given by ip, sc, or im injection, respectively.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),min,48.8,158613,DB00030,Insulin Regular
,19344673,serum half-life,"Total uptake (1,072,270, 1,182,498; 1,481,060; ng/ml/min), serum half-life (48.8; 34.0; 30.0 min) and relative bioavailability (1.0, 1.1; 1.4;) of mouse [D-Leu-4]OB3 were similar when the peptide was given by ip, sc, or im injection, respectively.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),min,34.0,158614,DB00030,Insulin Regular
,19344673,serum half-life,"Total uptake (1,072,270, 1,182,498; 1,481,060; ng/ml/min), serum half-life (48.8; 34.0; 30.0 min) and relative bioavailability (1.0, 1.1; 1.4;) of mouse [D-Leu-4]OB3 were similar when the peptide was given by ip, sc, or im injection, respectively.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),min,30.0,158615,DB00030,Insulin Regular
,19344673,relative bioavailability,"Total uptake (1,072,270, 1,182,498; 1,481,060; ng/ml/min), serum half-life (48.8; 34.0; 30.0 min) and relative bioavailability (1.0, 1.1; 1.4;) of mouse [D-Leu-4]OB3 were similar when the peptide was given by ip, sc, or im injection, respectively.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),,1.0,158616,DB00030,Insulin Regular
,19344673,relative bioavailability,"Total uptake (1,072,270, 1,182,498; 1,481,060; ng/ml/min), serum half-life (48.8; 34.0; 30.0 min) and relative bioavailability (1.0, 1.1; 1.4;) of mouse [D-Leu-4]OB3 were similar when the peptide was given by ip, sc, or im injection, respectively.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),,1.1,158617,DB00030,Insulin Regular
,19344673,relative bioavailability,"Total uptake (1,072,270, 1,182,498; 1,481,060; ng/ml/min), serum half-life (48.8; 34.0; 30.0 min) and relative bioavailability (1.0, 1.1; 1.4;) of mouse [D-Leu-4]OB3 were similar when the peptide was given by ip, sc, or im injection, respectively.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),,1.4,158618,DB00030,Insulin Regular
,19344673,Total uptake,"Total uptake and relative bioavailability were enhanced following intranasal delivery (4,336,963 ng/ml/min and 4.0, respectively), and serum half-life was 41.1 min.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),[ng] / [min·ml],"4,336,963",158619,DB00030,Insulin Regular
,19344673,relative bioavailability,"Total uptake and relative bioavailability were enhanced following intranasal delivery (4,336,963 ng/ml/min and 4.0, respectively), and serum half-life was 41.1 min.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),,4.0,158620,DB00030,Insulin Regular
,19344673,serum half-life,"Total uptake and relative bioavailability were enhanced following intranasal delivery (4,336,963 ng/ml/min and 4.0, respectively), and serum half-life was 41.1 min.","Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19344673/),min,41.1,158621,DB00030,Insulin Regular
,16027230,minimum effective dose (MED),A single oral dose of vildagliptin in Zucker rats produced a rapid and dose-related inhibition of DPP-4: the minimum effective dose (MED) was 0.3 mg/kg.,Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027230/),[mg] / [kg],0.3,158988,DB00030,Insulin Regular
,27442605,V,"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),l,63.4,159028,DB00030,Insulin Regular
,27442605,maximum rate [Vm],"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),[mg] / [h],9.57,159029,DB00030,Insulin Regular
,27442605,Michaelis constant [Km],"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),[mg] / [l],1.97,159030,DB00030,Insulin Regular
,27442605,elimination half-life,Predicted elimination half-life decreased from 20 h over time until there was first order elimination with a half-life 9 h.,Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),h,20,159031,DB00030,Insulin Regular
,27442605,half-life,Predicted elimination half-life decreased from 20 h over time until there was first order elimination with a half-life 9 h.,Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),h,9,159032,DB00030,Insulin Regular
,15638870,area under the curve (AUC),"The women with pGDM had higher fasting glucose concentrations than controls (5.1; 4.9-5.3 vs. 4.8; 4.4-5.1 mmol/l, median; interquartile range, P = 0.04) and greater circulating glucose area under the curve (AUC) following the oral glucose load (930; 818-1015 vs. 668; 584-737 min x mmol/l, P = 0.0007).",Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15638870/),[mM·min] / [l],930,159911,DB00030,Insulin Regular
,15638870,area under the curve (AUC),"The women with pGDM had higher fasting glucose concentrations than controls (5.1; 4.9-5.3 vs. 4.8; 4.4-5.1 mmol/l, median; interquartile range, P = 0.04) and greater circulating glucose area under the curve (AUC) following the oral glucose load (930; 818-1015 vs. 668; 584-737 min x mmol/l, P = 0.0007).",Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15638870/),[mM·min] / [l],668,159912,DB00030,Insulin Regular
,15638870,AUC,"The initial (0-30 min) insulin response was decreased in the pGDM women (AUC 3981; 2783-4795 vs. 6167; 5009-8145 min x pmol/l, P = 0.05).",Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15638870/),[min·pM] / [l],3981,159913,DB00030,Insulin Regular
,15638870,AUC,"The initial (0-30 min) insulin response was decreased in the pGDM women (AUC 3981; 2783-4795 vs. 6167; 5009-8145 min x pmol/l, P = 0.05).",Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15638870/),[min·pM] / [l],6167,159914,DB00030,Insulin Regular
,15638870,AUC,"The initial (0-30 min) GLP-1 response was reduced in the pGDM women (AUC 816; 663-984 vs. 1163; 872-2024 min x pmol/l, P = 0.02).",Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15638870/),[min·pM] / [l],816,159915,DB00030,Insulin Regular
,15638870,AUC,"The initial (0-30 min) GLP-1 response was reduced in the pGDM women (AUC 816; 663-984 vs. 1163; 872-2024 min x pmol/l, P = 0.02).",Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15638870/),[min·pM] / [l],1163,159916,DB00030,Insulin Regular
,33197556,droplet size,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,24.28,160257,DB00030,Insulin Regular
,33197556,polydispersity index,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,0.17,160258,DB00030,Insulin Regular
,33197556,zeta potential,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,0.17,160259,DB00030,Insulin Regular
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,-,160260,DB00030,Insulin Regular
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,1.28,160261,DB00030,Insulin Regular
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4 loaded self-nanoemulsifying system were found as 24.28 ± 0.43 nm, 0.17 ± 0.01, -1.28 ± 3.61 mV, 79.60 ± 3.30 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),m,79.60,160262,DB00030,Insulin Regular
,33197556,droplet size,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,20.25,160263,DB00030,Insulin Regular
,33197556,polydispersity index,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,0.11,160264,DB00030,Insulin Regular
,33197556,zeta potential,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,0.11,160265,DB00030,Insulin Regular
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,-,160266,DB00030,Insulin Regular
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),mv,1.85,160267,DB00030,Insulin Regular
,33197556,viscosity,"The mean droplet size, polydispersity index, zeta potential and viscosity of exendin-4/chymostatin loaded self-nanoemulsifying system were found as 20.25 ± 0.35 nm, 0.11 ± 0.02, -1.85 ± 2.49 mV, 100.02 ± 7.65 m.",Evaluation of the hypoglycemic effect of exendin-4's new oral self-nanoemulsifying system in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33197556/),m,100.02,160268,DB00030,Insulin Regular
,25537835,total daily dose,"Eleven children (six male; age range 3.75-6.96 years, HbA1c 7.6% ± 1.3% [60 ± 14 mmol/mol], BMI standard deviation score 1.0 ± 0.8, duration of diabetes 2.2 ± 1.0 years, total daily dose 12.9 [10.6-16.5] U, fasting C-peptide concentration 5 [5-17.1] pmol/l; mean ± SD or median [interquartile range]) participated in the study.",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),u,12.9,160532,DB00030,Insulin Regular
,25537835,t max,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),min,59.2,160533,DB00030,Insulin Regular
,25537835,t max,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),min,61.6,160534,DB00030,Insulin Regular
,25537835,I,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),[1] / [kg·min],1.98 × 10(-2),160535,DB00030,Insulin Regular
,25537835,I,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),[1] / [kg·min],1.89 × 10(-2),160536,DB00030,Insulin Regular
,25537835,ins c,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),[pM] / [l],34,160537,DB00030,Insulin Regular
,25537835,ins c,"No differences between standard and diluted insulin were observed in terms of t max (59.2 ± 14.4 vs 61.6 ± 8.7) min for standard vs diluted, p = 0.59; MCR I (1.98 × 10(-2) ± 0.99 × 10(-2) vs 1.89 × 10(-2) ± 0.82 × 10(-2) 1/kg/min, p = 0.47), and ins c (34 [1-72] vs 23 [3-65] pmol/l, p = 0.66).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),[pM] / [l],23,160538,DB00030,Insulin Regular
,25537835,t max,"However, t max showed less intersubject variability following administration of diluted aspart (SD 14.4 vs 8.7 min, p = 0.047).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),min,14.4,160539,DB00030,Insulin Regular
,25537835,t max,"However, t max showed less intersubject variability following administration of diluted aspart (SD 14.4 vs 8.7 min, p = 0.047).",Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25537835/),min,8.7,160540,DB00030,Insulin Regular
,18793592,maximum GIR,"The maximum GIR were 10.20 mg/kg/min and 9.72 mg/kg/min for Jusline Regular and Humulin Regular, respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],10.20,160730,DB00030,Insulin Regular
,18793592,maximum GIR,"The maximum GIR were 10.20 mg/kg/min and 9.72 mg/kg/min for Jusline Regular and Humulin Regular, respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],9.72,160731,DB00030,Insulin Regular
,18793592,maximum GIR,"The maximum GIR were 7.09 mg/kg/min and 7.91 mg/kg/min for Jusline NPH and Humulin NPH, respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],7.09,160732,DB00030,Insulin Regular
,18793592,maximum GIR,"The maximum GIR were 7.09 mg/kg/min and 7.91 mg/kg/min for Jusline NPH and Humulin NPH, respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],7.91,160733,DB00030,Insulin Regular
,18793592,maximum GIR,"The maximum GIR and tGIRmax were 6.39 mg/kg/min and 6.63 mg/kg/ min for Jusline Premixed Regular/NPH (30/70) and Humulin Premixed Regular/NPH (30/70), respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [kg·min],6.39,160734,DB00030,Insulin Regular
,18793592,tGIRmax,"The maximum GIR and tGIRmax were 6.39 mg/kg/min and 6.63 mg/kg/ min for Jusline Premixed Regular/NPH (30/70) and Humulin Premixed Regular/NPH (30/70), respectively.",Bioequivalence of Jusline following subcutaneous administration in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18793592/),[mg] / [·kg·min],6.63,160735,DB00030,Insulin Regular
,11535549,half-lives,"Serum tamoxifen and N-desmethyltamoxifen half-lives were 9 and 13 days, respectively.",Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11535549/),d,9,161392,DB00030,Insulin Regular
,11535549,half-lives,"Serum tamoxifen and N-desmethyltamoxifen half-lives were 9 and 13 days, respectively.",Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11535549/),d,13,161393,DB00030,Insulin Regular
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],15.8,162229,DB00030,Insulin Regular
,11055323,plasma concentrations,This steroid sulfate did not accumulate; plasma concentrations 12 hours after the 3beta-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 microg/L respectively.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[μg] / [l],16.3,162230,DB00030,Insulin Regular
,11055323,time to peak plasma level,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.2,162231,DB00030,Insulin Regular
,11055323,half life,The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 hours; the mean half life was 2.17 hours.,Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),h,2.17,162232,DB00030,Insulin Regular
,11055323,apparent clearance,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),[l] / [h],172,162233,DB00030,Insulin Regular
,11055323,apparent mean volume of distribution,"The apparent clearance averaged 172 L/h, and the apparent mean volume of distribution was 540 L.",Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11055323/),l,540,162234,DB00030,Insulin Regular
,12071338,clearance rates,Untreated type 1 patients eliminated antipyrine rapidly and insulin treatment normalised antipyrine elimination (clearance rates 89.5 +/- 20.3 versus 58.8 +/- 17.2 ml/min.; P<0.001).,"Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071338/),[ml] / [min],89.5,164975,DB00030,Insulin Regular
,12071338,clearance rates,Untreated type 1 patients eliminated antipyrine rapidly and insulin treatment normalised antipyrine elimination (clearance rates 89.5 +/- 20.3 versus 58.8 +/- 17.2 ml/min.; P<0.001).,"Diabetes and elimination of antipyrine in man: an analysis of 298 patients classified by type of diabetes, age, sex, duration of disease and liver involvement. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071338/),[ml] / [min],58.8,164976,DB00030,Insulin Regular
,24272966,Tmax,D-ribose was absorbed rapidly with mean Tmax ranging between 18 and 30 minutes.,"Evaluation of D-ribose pharmacokinetics, dose proportionality, food effect, and pharmacodynamics after oral solution administration in healthy male and female subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24272966/),min,18 and 30,165125,DB00030,Insulin Regular
,34102842,IC50,"The inhibitory effects of polymeric micelles on the hOCT1 isoform were the most pronounced, with the lowest IC50 values ranging from 0.106 to 0.280 mg/mL.",mPEG2k-PCLx Polymeric Micelles Influence Pharmacokinetics and Hypoglycemic Efficacy of Metformin through Inhibition of Organic Cation Transporters in Rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34102842/),[mg] / [ml],0.106 to 0.280,165940,DB00030,Insulin Regular
,16198656,area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity),Their respective values for area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity) and elimination half-life (t1/2) were 0.46+/-0.13 microg.h/mL versus 0.57+/- 0.11 microg.h/mL (P=.569) and 2.09+/-0.22 hours versus 2.24+/- 0.27 hours (P=.721).,"CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198656/),[h·μg] / [ml],0.46,166060,DB00030,Insulin Regular
,16198656,elimination half-life (t1/2),Their respective values for area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity) and elimination half-life (t1/2) were 0.46+/-0.13 microg.h/mL versus 0.57+/- 0.11 microg.h/mL (P=.569) and 2.09+/-0.22 hours versus 2.24+/- 0.27 hours (P=.721).,"CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198656/),h,2.09,166061,DB00030,Insulin Regular
,16198656,elimination half-life (t1/2),Their respective values for area under the plasma concentration-time curve from time 0 to infinity (AUC0-infinity) and elimination half-life (t1/2) were 0.46+/-0.13 microg.h/mL versus 0.57+/- 0.11 microg.h/mL (P=.569) and 2.09+/-0.22 hours versus 2.24+/- 0.27 hours (P=.721).,"CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198656/),h,2.24,166062,DB00030,Insulin Regular
,17634080,AUC(0-24 h),GH AUC(0-24 h) was greater for patients (387.91 +/- 134.13 microg h/l) than healthy subjects (225.35 +/- 59.63 microg h/l) and the 90% confidence interval (CI) for the estimated patient : healthy subject ratio (1.40-2.07) was not within the acceptance interval (0.67-1.50).,"Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],387.91,167860,DB00030,Insulin Regular
,17634080,AUC(0-24 h),GH AUC(0-24 h) was greater for patients (387.91 +/- 134.13 microg h/l) than healthy subjects (225.35 +/- 59.63 microg h/l) and the 90% confidence interval (CI) for the estimated patient : healthy subject ratio (1.40-2.07) was not within the acceptance interval (0.67-1.50).,"Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],225.35,167861,DB00030,Insulin Regular
,17634080,AUC(18-24 h),"GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],3.03,167862,DB00030,Insulin Regular
,17634080,AUC(18-24 h),"GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],6.37,167863,DB00030,Insulin Regular
,17634080,AUC(18-24 h),"GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],2.86,167864,DB00030,Insulin Regular
,17634080,AUC(18-24 h),"GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),[h·μg] / [l],1.09,167865,DB00030,Insulin Regular
,17634080,"terminal half-life (t(1/2,z))","GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),h,2.28,167866,DB00030,Insulin Regular
,17634080,"terminal half-life (t(1/2,z))","GH AUC(18-24 h) for patients and healthy subjects (3.03 +/- 2.71 microg h/l and 6.37 +/- 4.21 microg h/l) returned approximately to baseline (2.86 +/- 3.91 microg h/l and 1.09 +/- 1.43 microg h/l); terminal half-life (t(1/2,z)) was shorter for patients (2.28 +/- 00.43 h vs. 3.23 +/- 00.75 h).","Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17634080/),h,3.23,167867,DB00030,Insulin Regular
,26603258,MTD,The MTD was 2.5 mg/day (MTD with twice daily dosing undefined).,"First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26603258/),[mg] / [d],2.5,168046,DB00030,Insulin Regular
,26603258,OR rate,Responses were not associated withPIK3CAmutations (OR rate: 5% wild-type vs. 6% mutant).,"First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26603258/),%,5,168047,DB00030,Insulin Regular
,26603258,OR rate,Responses were not associated withPIK3CAmutations (OR rate: 5% wild-type vs. 6% mutant).,"First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26603258/),%,6,168048,DB00030,Insulin Regular
,26603258,MTD,"Although the MTD of GSK458 was 2.5 mg once daily, twice-daily dosing may increase duration of target inhibition.","First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26603258/),mg,2.5,168049,DB00030,Insulin Regular
,17442688,t(max),The t(max) for parent drug was observed between 0.5 and 1.5 hours postdose.,Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442688/),h,0.5 and 1.5,168109,DB00030,Insulin Regular
,26826263,delta glucose concentration,"During the 4-hour feeding period, DSF compared with SF resulted in a lower mean delta glucose concentration in the 3- to 4-hour period (0.3 ± 1.0 and 2.4 ± 1.5 mmol/L; P < .001).","Improved Glucose Profile in Patients With Type 2 Diabetes With a New, High-Protein, Diabetes-Specific Tube Feed During 4 Hours of Continuous Feeding. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26826263/),[mM] / [l],0.3,169636,DB00030,Insulin Regular
,26826263,delta glucose concentration,"During the 4-hour feeding period, DSF compared with SF resulted in a lower mean delta glucose concentration in the 3- to 4-hour period (0.3 ± 1.0 and 2.4 ± 1.5 mmol/L; P < .001).","Improved Glucose Profile in Patients With Type 2 Diabetes With a New, High-Protein, Diabetes-Specific Tube Feed During 4 Hours of Continuous Feeding. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26826263/),[mM] / [l],2.4,169637,DB00030,Insulin Regular
,28211608,ED50,"A single oral dose of 55P0251 improved glucose tolerance in mice with an ED50 between 1.5 and 2 mg/kg (reductions in areas under the curve, 1 mg/kg, -18%; 5 mg/kg, -30%; 27 mg/kg, -47%).","Preclinical characterization of 55P0251, a novel compound that amplifies glucose-stimulated insulin secretion and counteracts hyperglycaemia in rodents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28211608/),[mg] / [kg],1.5 and 2,171488,DB00030,Insulin Regular
,28211608,plasma half-life,"Pharmacokinetic studies revealed attractive attributes, including a plasma half-life of approximately 3 hours and a bioavailability of approximately 58% in rats.","Preclinical characterization of 55P0251, a novel compound that amplifies glucose-stimulated insulin secretion and counteracts hyperglycaemia in rodents. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28211608/),h,3,171489,DB00030,Insulin Regular
,28211608,bioavailability,"Pharmacokinetic studies revealed attractive attributes, including a plasma half-life of approximately 3 hours and a bioavailability of approximately 58% in rats.","Preclinical characterization of 55P0251, a novel compound that amplifies glucose-stimulated insulin secretion and counteracts hyperglycaemia in rodents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28211608/),%,58,171490,DB00030,Insulin Regular
,15089057,bioavailability,A five-fold higher bioavailability (approximately 60%) was observed from a S-cosolvent formulation containing propylene glycol (PG)+20 mg/g HPMC as compared to that (approximately 12%) of a neat polyethylene glycol (PEG) 400 formulation.,Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089057/),%,60,171620,DB00030,Insulin Regular
,15089057,bioavailability,A five-fold higher bioavailability (approximately 60%) was observed from a S-cosolvent formulation containing propylene glycol (PG)+20 mg/g HPMC as compared to that (approximately 12%) of a neat polyethylene glycol (PEG) 400 formulation.,Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089057/),%,12,171621,DB00030,Insulin Regular
,15089057,oral bioavailability,"A S-SEDDS formulation composed of 30% w/w Cremophor (surfactant), 9% PEG 400, 5% DMA, 18% Pluronic L44, 20% HPMC, and other minor components showed an oral bioavailability of approximately 76%, comparable to that of a neat tween formulation (bioavailability: approximately 68%).",Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089057/),%,76,171622,DB00030,Insulin Regular
,15089057,bioavailability,"A S-SEDDS formulation composed of 30% w/w Cremophor (surfactant), 9% PEG 400, 5% DMA, 18% Pluronic L44, 20% HPMC, and other minor components showed an oral bioavailability of approximately 76%, comparable to that of a neat tween formulation (bioavailability: approximately 68%).",Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15089057/),%,68,171623,DB00030,Insulin Regular
,24900321,IC50,Compound 3 inhibits DGAT-1 with an IC50 of 19 nM and shows high selectivity versus a broad panel of off-target pharmacologic end points.,"Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24900321/),nM,19,171683,DB00030,Insulin Regular
,25327540,Ki,"ZYDPLA1 is a potent, competitive and long acting inhibitor of DPP-4 (Ki 0.0027 μM; Koff 2.3 × 10(-4 ) s(-1) ).","Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25327540/),μM,0.0027,171731,DB00030,Insulin Regular
,25327540,Koff,"ZYDPLA1 is a potent, competitive and long acting inhibitor of DPP-4 (Ki 0.0027 μM; Koff 2.3 × 10(-4 ) s(-1) ).","Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25327540/),1/[s],2.3 × 10(-4 ),171732,DB00030,Insulin Regular
,25327540,half-life,Allometric scaling predicted a half-life in humans of 53 to 166 h.,"Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25327540/),h,53 to 166,171733,DB00030,Insulin Regular
,32265061,Tmax,Oral DJT1116PG was rapidly absorbed with a Tmax of 0.75-1.5 h and a t½ of 12-16.2 h.,"A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265061/),h,0.75-1.5,172534,DB00030,Insulin Regular
,32265061,t½,Oral DJT1116PG was rapidly absorbed with a Tmax of 0.75-1.5 h and a t½ of 12-16.2 h.,"A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265061/),h,12-16.2,172535,DB00030,Insulin Regular
,15735188,area under curve above fasting [DeltaAUC] glucose,"As expected, a significant fall in plasma glucose was observed over the exercise period (area under curve above fasting [DeltaAUC] glucose: -0.39 +/- 0.11 vs. -1.30 +/- 0.16 mmol . l(-1) . h(-1); nonexercise vs. exercise; P = 0.001), but insulin levels did not differ significantly on the two occasions (DeltaAUC insulin: -2.1 +/- 3.9 vs.",Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735188/),[mM] / [h·l],-,173639,DB00030,Insulin Regular
,15735188,area under curve above fasting [DeltaAUC] glucose,"As expected, a significant fall in plasma glucose was observed over the exercise period (area under curve above fasting [DeltaAUC] glucose: -0.39 +/- 0.11 vs. -1.30 +/- 0.16 mmol . l(-1) . h(-1); nonexercise vs. exercise; P = 0.001), but insulin levels did not differ significantly on the two occasions (DeltaAUC insulin: -2.1 +/- 3.9 vs.",Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735188/),[mM] / [h·l],0.39,173640,DB00030,Insulin Regular
,15735188,area under curve above fasting [DeltaAUC] glucose,"As expected, a significant fall in plasma glucose was observed over the exercise period (area under curve above fasting [DeltaAUC] glucose: -0.39 +/- 0.11 vs. -1.30 +/- 0.16 mmol . l(-1) . h(-1); nonexercise vs. exercise; P = 0.001), but insulin levels did not differ significantly on the two occasions (DeltaAUC insulin: -2.1 +/- 3.9 vs.",Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735188/),[mM] / [h·l],1.30,173641,DB00030,Insulin Regular
,19481772,area under the curve (AUC),"When galactose was ingested alone, the area under the curve (AUC) of [(13)C(6)]glucose and [(13)C(3)]glucose was 7.28 +/- 0.39 and 3.52 +/- 0.05 mmol/L per 4 hours, respectively.",Contribution of galactose and fructose to glucose homeostasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481772/),[mM] / [4·h·l],7.28,173702,DB00030,Insulin Regular
,19481772,area under the curve (AUC),"When galactose was ingested alone, the area under the curve (AUC) of [(13)C(6)]glucose and [(13)C(3)]glucose was 7.28 +/- 0.39 and 3.52 +/- 0.05 mmol/L per 4 hours, respectively.",Contribution of galactose and fructose to glucose homeostasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481772/),[mM] / [4·h·l],3.52,173703,DB00030,Insulin Regular
,19481772,AUC,"The AUC of [(13)C(3)]glucose after fructose and fructose plus glucose ingestion was 20.21 +/- 2.41 and 6.25 +/- 0.34 mmol/L per 4 hours, respectively.",Contribution of galactose and fructose to glucose homeostasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481772/),[mM] / [4·h·l],20.21,173704,DB00030,Insulin Regular
,19481772,AUC,"The AUC of [(13)C(3)]glucose after fructose and fructose plus glucose ingestion was 20.21 +/- 2.41 and 6.25 +/- 0.34 mmol/L per 4 hours, respectively.",Contribution of galactose and fructose to glucose homeostasis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481772/),[mM] / [4·h·l],6.25,173705,DB00030,Insulin Regular
,18538760,IC(50),"Alogliptin potently inhibited human DPP-4 in vitro (mean IC(50), ~ 6.9 nM) and exhibited > 10,000-fold selectivity for DPP-4 over the closely related serine proteases DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidase, and tryptase (IC(50) > 100,000 nM).","Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18538760/),nM,6.9,174390,DB00030,Insulin Regular
>,18538760,IC(50),"Alogliptin potently inhibited human DPP-4 in vitro (mean IC(50), ~ 6.9 nM) and exhibited > 10,000-fold selectivity for DPP-4 over the closely related serine proteases DPP-2, DPP-8, DPP-9, fibroblast activation protein/seprase, prolyl endopeptidase, and tryptase (IC(50) > 100,000 nM).","Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18538760/),nM,"100,000",174391,DB00030,Insulin Regular
,18538760,Absolute oral bioavailability,"Absolute oral bioavailability of alogliptin in rats, dogs, and monkeys was 45%, 86%, and 72% to 88%, respectively.","Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18538760/),%,45,174392,DB00030,Insulin Regular
,18538760,Absolute oral bioavailability,"Absolute oral bioavailability of alogliptin in rats, dogs, and monkeys was 45%, 86%, and 72% to 88%, respectively.","Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18538760/),%,86,174393,DB00030,Insulin Regular
,18538760,Absolute oral bioavailability,"Absolute oral bioavailability of alogliptin in rats, dogs, and monkeys was 45%, 86%, and 72% to 88%, respectively.","Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18538760/),%,72,174394,DB00030,Insulin Regular
,18538760,Absolute oral bioavailability,"Absolute oral bioavailability of alogliptin in rats, dogs, and monkeys was 45%, 86%, and 72% to 88%, respectively.","Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18538760/),%,88,174395,DB00030,Insulin Regular
,18538760,plasma concentration (EC(50)),"From E(max) modeling, 50% inhibition of DPP-4 activity was observed at a mean alogliptin plasma concentration (EC(50)) of 3.4 to 5.6 ng/ml (10.0 to 16.5 nM) in rats, dogs, and monkeys.","Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18538760/),[ng] / [ml],3.4 to 5.6,174396,DB00030,Insulin Regular
,18538760,plasma concentration (EC(50)),"From E(max) modeling, 50% inhibition of DPP-4 activity was observed at a mean alogliptin plasma concentration (EC(50)) of 3.4 to 5.6 ng/ml (10.0 to 16.5 nM) in rats, dogs, and monkeys.","Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18538760/),nM,10.0 to 16.5,174397,DB00030,Insulin Regular
,18455249,serum half-life,"In six week-old mice, the maximum concentration of mouse [D-Leu-4]OB3 was reached in 10 min, and the serum half-life was approximately 52.5 min.","The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18455249/),min,52.5,175043,DB00030,Insulin Regular
,18455249,serum half-life,"In 25 week-old mice, however, mouse [D-Leu-4]OB3 peaked in 5 min, and the serum half-life was approximately 30.6 min.","The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18455249/),min,30.6,175044,DB00030,Insulin Regular
,18455249,Bioavailability,Bioavailability of mouse [D-Leu-4]OB3 was approximately 20% greater in six week-old mice than in 25 week-old mice.,"The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18455249/),%,20,175045,DB00030,Insulin Regular
,14743580,plasma half-life,"The rise in plasma triglycerides was mitigated during infusion of the cholesterol-enriched solution (323.8 +/- 27.5 vs. 202.0 +/- 18.9 mg.dL-1, p < 0.001), plasma half-life was reduced (41.6 +/- 5.4 vs. 29.3 +/- 5.1 min, p < 0.05), and total-body clearance was enhanced (0.96 +/- 0.1 vs. 1.52 +/- 0.2 ml.b.w.(.)min-1, p < 0.02).",Cholesterol improves the utilization of parenteral lipid emulsions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743580/),min,41.6,176042,DB00030,Insulin Regular
,14743580,plasma half-life,"The rise in plasma triglycerides was mitigated during infusion of the cholesterol-enriched solution (323.8 +/- 27.5 vs. 202.0 +/- 18.9 mg.dL-1, p < 0.001), plasma half-life was reduced (41.6 +/- 5.4 vs. 29.3 +/- 5.1 min, p < 0.05), and total-body clearance was enhanced (0.96 +/- 0.1 vs. 1.52 +/- 0.2 ml.b.w.(.)min-1, p < 0.02).",Cholesterol improves the utilization of parenteral lipid emulsions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743580/),min,29.3,176043,DB00030,Insulin Regular
,14743580,total-body clearance,"The rise in plasma triglycerides was mitigated during infusion of the cholesterol-enriched solution (323.8 +/- 27.5 vs. 202.0 +/- 18.9 mg.dL-1, p < 0.001), plasma half-life was reduced (41.6 +/- 5.4 vs. 29.3 +/- 5.1 min, p < 0.05), and total-body clearance was enhanced (0.96 +/- 0.1 vs. 1.52 +/- 0.2 ml.b.w.(.)min-1, p < 0.02).",Cholesterol improves the utilization of parenteral lipid emulsions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743580/),[b·ml·w] / [min],0.96,176044,DB00030,Insulin Regular
,14743580,total-body clearance,"The rise in plasma triglycerides was mitigated during infusion of the cholesterol-enriched solution (323.8 +/- 27.5 vs. 202.0 +/- 18.9 mg.dL-1, p < 0.001), plasma half-life was reduced (41.6 +/- 5.4 vs. 29.3 +/- 5.1 min, p < 0.05), and total-body clearance was enhanced (0.96 +/- 0.1 vs. 1.52 +/- 0.2 ml.b.w.(.)min-1, p < 0.02).",Cholesterol improves the utilization of parenteral lipid emulsions. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14743580/),[b·ml·w] / [min],1.52,176045,DB00030,Insulin Regular
,15950411,t(1/2),It was observed that t(1/2) values varied between 0.53 and 1.31h.,A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15950411/),h,0.53 and 1.31,177406,DB00030,Insulin Regular
,16720652,maximal serum GH concentration,The observed maximal serum GH concentration was approximately doubled after LB03002 (6.1 +/- 3.2 and 4.5 +/- 2.2 microg/liter at first and fifth doses) compared with daily GH (2.7 +/- 2.2 microg/liter).,"Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720652/),[μg] / [l],6.1,178369,DB00030,Insulin Regular
,16720652,maximal serum GH concentration,The observed maximal serum GH concentration was approximately doubled after LB03002 (6.1 +/- 3.2 and 4.5 +/- 2.2 microg/liter at first and fifth doses) compared with daily GH (2.7 +/- 2.2 microg/liter).,"Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720652/),[μg] / [l],4.5,178370,DB00030,Insulin Regular
,16720652,maximal serum GH concentration,The observed maximal serum GH concentration was approximately doubled after LB03002 (6.1 +/- 3.2 and 4.5 +/- 2.2 microg/liter at first and fifth doses) compared with daily GH (2.7 +/- 2.2 microg/liter).,"Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16720652/),[μg] / [l],2.7,178371,DB00030,Insulin Regular
,16542056,apparent terminal half-life,The apparent terminal half-life of MK-0767 averaged approximately 36 hours following single and multiple doses.,A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16542056/),h,36,178545,DB00030,Insulin Regular
,15486008,clearance of glucose,The clearance of glucose was 0.42 litre min(-1) (0.60 litre min(-1) is normal) while the other five parameters in the kinetic model were similar to those obtained in healthy volunteers.,Volume kinetics of glucose 2.5% solution and insulin resistance after abdominal hysterectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15486008/),[l] / [min],0.42,178719,DB00030,Insulin Regular
,15486008,glucose uptake,"The glucose uptake during clamping was 3.9 mg kg(-1) min(-1) (7.0 is normal), which, during the second day after hysterectomy, correlated with the dehydration of the intracellular space (r=0.77; P<0.002) and with the protein catabolism as indicated by the urinary excretion of 3-methylhistidine (r=-0.76, P<0.002).",Volume kinetics of glucose 2.5% solution and insulin resistance after abdominal hysterectomy. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15486008/),[mg] / [kg·min],3.9,178720,DB00030,Insulin Regular
,29709796,time to onset of action,"Median time to onset of action was delayed with glargine compared to detemir (4.0 h [3.3-5.8 h] vs 0.6 h [0.6-1.2 h], P = 0.002).",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,4.0,178947,DB00030,Insulin Regular
,29709796,time to onset of action,"Median time to onset of action was delayed with glargine compared to detemir (4.0 h [3.3-5.8 h] vs 0.6 h [0.6-1.2 h], P = 0.002).",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,0.6,178948,DB00030,Insulin Regular
,29709796,time to peak,"There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] vs 4.3 h [2.9-7.4 h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] vs 10.8 h [8.8-14.8 h], P = 0.21) between glargine and detemir, respectively.",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,6.3,178949,DB00030,Insulin Regular
,29709796,time to peak,"There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] vs 4.3 h [2.9-7.4 h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] vs 10.8 h [8.8-14.8 h], P = 0.21) between glargine and detemir, respectively.",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,4.3,178950,DB00030,Insulin Regular
,29709796,duration of action,"There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] vs 4.3 h [2.9-7.4 h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] vs 10.8 h [8.8-14.8 h], P = 0.21) between glargine and detemir, respectively.",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,16.3,178951,DB00030,Insulin Regular
,29709796,duration of action,"There was no difference in time to peak (median [range] = 6.3 h [5.0-21.3 h] vs 4.3 h [2.9-7.4 h], P = 0.15) or duration of action (16.3 h [6.1-20.1 h] vs 10.8 h [8.8-14.8 h], P = 0.21) between glargine and detemir, respectively.",Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29709796/),h,10.8,178952,DB00030,Insulin Regular
,31548064,half-life,"After bolus administration, human FGF21 circulated with a half-life of 194 min, and its constant infusion increased total plasma concentration 117-fold over levels in excipient-infused cows.","Fibroblast growth factor-21 (FGF21) administration to early-lactating dairy cows. Pharmacokinetics, whole-animal performance, and lipid metabolism. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31548064/),min,194,178974,DB00030,Insulin Regular
,23668634,time to maximum plasma concentration [Cmax;Tmax],"In both populations, RE was rapidly absorbed and converted to remogliflozin (time to maximum plasma concentration [Cmax;Tmax] approximately 1 h).","First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668634/),h,1,179101,DB00030,Insulin Regular
,23668634,T½,RE was rapidly eliminated (mean T½ of ~25 min; mean plasma T½ for remogliflozin was 120 min) and was independent of dose.,"First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668634/),min,25,179102,DB00030,Insulin Regular
,23668634,plasma T½,RE was rapidly eliminated (mean T½ of ~25 min; mean plasma T½ for remogliflozin was 120 min) and was independent of dose.,"First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23668634/),min,120,179103,DB00030,Insulin Regular
,15199095,Apparent,Apparent exendin-4 elimination rate constants for healthy and diabetic subjects were similar (0.0386 +/- 0.0192 and 0.0460 +/- 0.0145 min(-1)).,Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199095/),1/[min],0.0386,179397,DB00030,Insulin Regular
,15199095,elimination rate constants,Apparent exendin-4 elimination rate constants for healthy and diabetic subjects were similar (0.0386 +/- 0.0192 and 0.0460 +/- 0.0145 min(-1)).,Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199095/),1/[min],0.0386,179398,DB00030,Insulin Regular
,15199095,elimination rate constants,Apparent exendin-4 elimination rate constants for healthy and diabetic subjects were similar (0.0386 +/- 0.0192 and 0.0460 +/- 0.0145 min(-1)).,Exendin-4 pharmacodynamics: insights from the hyperglycemic clamp technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199095/),1/[min],0.0460,179399,DB00030,Insulin Regular
,26344384,oral bioavailability,The oral bioavailability of HWH-10d in monkeys is 57.8%.,Determination of a novel dipeptidyl peptidase IV inhibitor in monkey plasma by HPLC-MS/MS and its application in a pharmacokinetics study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26344384/),%,57.8,179851,DB00030,Insulin Regular
,22699287,half-life,"Clearance of gevokizumab was consistent with that for a human IgG(2), with a half-life of 22 days.",Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22699287/),d,22,180123,DB00030,Insulin Regular
,16946406,area under the IGF-1 concentration curve (AUC),"Relative to the predose 24-hr period, area under the IGF-1 concentration curve (AUC) tended to be lower (P = 0.062) with Compound 1 (.79 +/- 130 ng/ml x hr) than controls (543 +/- 330 ng/ml x hr).",Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16946406/),[ng] / [h·ml],.79,180393,DB00030,Insulin Regular
,16946406,area under the IGF-1 concentration curve (AUC),"Relative to the predose 24-hr period, area under the IGF-1 concentration curve (AUC) tended to be lower (P = 0.062) with Compound 1 (.79 +/- 130 ng/ml x hr) than controls (543 +/- 330 ng/ml x hr).",Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16946406/),[ng] / [h·ml],543,180394,DB00030,Insulin Regular
,16946406,AUC,"GHRH treatment increased the IGF-1 AUC (1210 +/- 160 ng/ml x hr, P = 0.049 vs. controls and P = 0.001 vs. Compound 1).",Inhibition of dipeptidyl-peptidase IV does not increase circulating IGF-1 concentrations in growing pigs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16946406/),[ng] / [h·ml],1210,180395,DB00030,Insulin Regular
>or=,12699438,serum peak GH concentration,"Nine of the 83 patients (11%) responded with a serum peak GH concentration >or= 5 micro g/l after the first and/or last NN703 administration, whereas no patient responded after placebo administration.",Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12699438/),[μg] / [l],5,182886,DB00030,Insulin Regular
,12699438,serum peak GH concentration,"Mean serum peak GH concentration after GHRH administration was 2.1 micro g/l (+/-0.3, SEM), which was higher than that after the first NN703 administration (1.32 +/- 0.3, P < 0.05).",Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12699438/),[μg] / [l],2.1,182887,DB00030,Insulin Regular
,12699438,serum peak GH concentration,"Mean serum peak GH concentration after GHRH administration was 2.1 micro g/l (+/-0.3, SEM), which was higher than that after the first NN703 administration (1.32 +/- 0.3, P < 0.05).",Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12699438/),[μg] / [l],1.32,182888,DB00030,Insulin Regular
>or=,12699438,peak GH response,Eleven per cent of the GHD adult patients responded with a peak GH response >or= 5 micro g/l after the first and/or last administration of oral NN703.,Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12699438/),[μg] / [l],5,182889,DB00030,Insulin Regular
,22184397,trough concentration,"Mean trough concentration (± standard deviation) at 9 mg/kg was 106 ± 57 μg/mL, which exceeded the effective trough concentration of 60 μg/mL observed in xenograft models.",Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22184397/),[μg] / [ml],106,182960,DB00030,Insulin Regular
,22184397,effective trough concentration,"Mean trough concentration (± standard deviation) at 9 mg/kg was 106 ± 57 μg/mL, which exceeded the effective trough concentration of 60 μg/mL observed in xenograft models.",Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22184397/),[μg] / [ml],60,182961,DB00030,Insulin Regular
,32535242,recoveries,The recoveries and matrix effects of five analytes ranged from 81.1% to 113%.,Network pharmacology strategy for revealing the pharmacological mechanism of pharmacokinetic target components of San-Ye-Tang-Zhi-Qing formula for the treatment of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32535242/),%,81.1,183436,DB00030,Insulin Regular
,32535242,matrix effects,The recoveries and matrix effects of five analytes ranged from 81.1% to 113%.,Network pharmacology strategy for revealing the pharmacological mechanism of pharmacokinetic target components of San-Ye-Tang-Zhi-Qing formula for the treatment of type 2 diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32535242/),%,113,183437,DB00030,Insulin Regular
,18704955,circulating half-lives,"These analogs had higher metabolic stabilities in rat plasma, liver and kidney homogenates, and extended pharmacokinetic profiles with the greater circulating half-lives (26.6, 64.5, and 105.5 min for Lys(34)-PEG(2,5,10 K)-GLP-1s, respectively, vs. 8.5 min for GLP-1, at elimination phases after i.p. injections) in ICR mice.",Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704955/),min,26.6,183657,DB00030,Insulin Regular
,18704955,circulating half-lives,"These analogs had higher metabolic stabilities in rat plasma, liver and kidney homogenates, and extended pharmacokinetic profiles with the greater circulating half-lives (26.6, 64.5, and 105.5 min for Lys(34)-PEG(2,5,10 K)-GLP-1s, respectively, vs. 8.5 min for GLP-1, at elimination phases after i.p. injections) in ICR mice.",Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704955/),min,64.5,183658,DB00030,Insulin Regular
,18704955,circulating half-lives,"These analogs had higher metabolic stabilities in rat plasma, liver and kidney homogenates, and extended pharmacokinetic profiles with the greater circulating half-lives (26.6, 64.5, and 105.5 min for Lys(34)-PEG(2,5,10 K)-GLP-1s, respectively, vs. 8.5 min for GLP-1, at elimination phases after i.p. injections) in ICR mice.",Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704955/),min,105.5,183659,DB00030,Insulin Regular
,18704955,circulating half-lives,"These analogs had higher metabolic stabilities in rat plasma, liver and kidney homogenates, and extended pharmacokinetic profiles with the greater circulating half-lives (26.6, 64.5, and 105.5 min for Lys(34)-PEG(2,5,10 K)-GLP-1s, respectively, vs. 8.5 min for GLP-1, at elimination phases after i.p. injections) in ICR mice.",Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704955/),min,8.5,183660,DB00030,Insulin Regular
,22369880,oral bioavailability,"The highest oral bioavailability of approximately 8.5% and 11.0% could be observed with subcutaneous insulin as reference for SGC-liposomes in non-diabetic and diabetic rats, respectively.","Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369880/),%,8.5,184243,DB00030,Insulin Regular
,22369880,oral bioavailability,"The highest oral bioavailability of approximately 8.5% and 11.0% could be observed with subcutaneous insulin as reference for SGC-liposomes in non-diabetic and diabetic rats, respectively.","Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369880/),%,11.0,184244,DB00030,Insulin Regular
,21994429,durations of action,Both formulations produced relatively long durations of action (18.3 to 21.5 h).,Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21994429/),h,18.3 to 21.5,184718,DB00030,Insulin Regular
,32180731,total excretion,"The total excretion of four metabolites in urine, bile, and feces was approximately 35.0% within 24 h, and the metabolites were mainly excreted through the urine.","Pharmacokinetics, Tissue Distribution and Excretion of Paeonol and Its Major Metabolites in Rats Provide a Further Insight Into Paeonol Effectiveness. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32180731/),%,35.0,184731,DB00030,Insulin Regular
,26008194,polydispersity index,Ultra small (˜10 nm) nanoparticles with polydispersity index of 0.299 were obtained.,Oral insulin delivery using deoxycholic acid conjugated PEGylated polyhydroxybutyrate co-polymeric nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008194/),,0.299,185403,DB00030,Insulin Regular
,10859151,absolute bioavailability,"The absorption of rosiglitazone was rapid and essentially complete, with absolute bioavailability estimated to be approximately 99% after oral tablet dosing and approximately 95% after oral solution dosing, and clearance was primarily metabolic.","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),%,99,185723,DB00030,Insulin Regular
,10859151,absolute bioavailability,"The absorption of rosiglitazone was rapid and essentially complete, with absolute bioavailability estimated to be approximately 99% after oral tablet dosing and approximately 95% after oral solution dosing, and clearance was primarily metabolic.","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),%,95,185724,DB00030,Insulin Regular
,10859151,time to maximal concentration of radio,"The time to maximal concentration of radioactivity and the elimination half-life for two metabolites in plasma were significantly longer than for rosiglitazone itself (4-6 h versus 0. 5-1 h, and ca. 5 days versus 3-7 h).","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),h,4-6,185725,DB00030,Insulin Regular
,10859151,time to maximal concentration of radio,"The time to maximal concentration of radioactivity and the elimination half-life for two metabolites in plasma were significantly longer than for rosiglitazone itself (4-6 h versus 0. 5-1 h, and ca. 5 days versus 3-7 h).","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),d,5,185726,DB00030,Insulin Regular
,10859151,elimination half-life,"The time to maximal concentration of radioactivity and the elimination half-life for two metabolites in plasma were significantly longer than for rosiglitazone itself (4-6 h versus 0. 5-1 h, and ca. 5 days versus 3-7 h).","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),d,5,185727,DB00030,Insulin Regular
,10859151,elimination half-life,"The time to maximal concentration of radioactivity and the elimination half-life for two metabolites in plasma were significantly longer than for rosiglitazone itself (4-6 h versus 0. 5-1 h, and ca. 5 days versus 3-7 h).","Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859151/),h,3-7,185728,DB00030,Insulin Regular
,19260251,C(max),"When comparing before and after capsicum intake, the results showed the insulin levels were maintained The pharmacokinetic parameters of capsaicin shown as C(max), T(max), AUC(0-t), T1/2 are 2.47 +/- 0.13 ng/ml, 47.08 +/- 1.99 min, 103.6 +/- 11.3 ng x min/ml, and 24.87 +/- 4.97 min, respectively.",Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260251/),[ng] / [ml],2.47,185798,DB00030,Insulin Regular
,19260251,T(max),"When comparing before and after capsicum intake, the results showed the insulin levels were maintained The pharmacokinetic parameters of capsaicin shown as C(max), T(max), AUC(0-t), T1/2 are 2.47 +/- 0.13 ng/ml, 47.08 +/- 1.99 min, 103.6 +/- 11.3 ng x min/ml, and 24.87 +/- 4.97 min, respectively.",Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260251/),min,47.08,185799,DB00030,Insulin Regular
,19260251,T(max),"When comparing before and after capsicum intake, the results showed the insulin levels were maintained The pharmacokinetic parameters of capsaicin shown as C(max), T(max), AUC(0-t), T1/2 are 2.47 +/- 0.13 ng/ml, 47.08 +/- 1.99 min, 103.6 +/- 11.3 ng x min/ml, and 24.87 +/- 4.97 min, respectively.",Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260251/),[min·ng] / [ml],103.6,185800,DB00030,Insulin Regular
,19260251,AUC(0-t),"When comparing before and after capsicum intake, the results showed the insulin levels were maintained The pharmacokinetic parameters of capsaicin shown as C(max), T(max), AUC(0-t), T1/2 are 2.47 +/- 0.13 ng/ml, 47.08 +/- 1.99 min, 103.6 +/- 11.3 ng x min/ml, and 24.87 +/- 4.97 min, respectively.",Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260251/),[min·ng] / [ml],103.6,185801,DB00030,Insulin Regular
,19260251,T1/2,"When comparing before and after capsicum intake, the results showed the insulin levels were maintained The pharmacokinetic parameters of capsaicin shown as C(max), T(max), AUC(0-t), T1/2 are 2.47 +/- 0.13 ng/ml, 47.08 +/- 1.99 min, 103.6 +/- 11.3 ng x min/ml, and 24.87 +/- 4.97 min, respectively.",Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19260251/),min,24.87,185802,DB00030,Insulin Regular
,29100735,half-life (T1/2,"As expected, GPU-028 revealed a longer half-life (T1/2 = 1.66 h), lower clearance (CL = 0.97 L/h/kg) and higher maximum plasma concentration (Cmax = 2035.23 μg/L), resulting in a 4-fold higher exposure than TUG-891.","Improving metabolic stability with deuterium: The discovery of GPU-028, a potent free fatty acid receptor 4 agonists. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29100735/),h,1.66,185944,DB00030,Insulin Regular
,29100735,clearance (CL,"As expected, GPU-028 revealed a longer half-life (T1/2 = 1.66 h), lower clearance (CL = 0.97 L/h/kg) and higher maximum plasma concentration (Cmax = 2035.23 μg/L), resulting in a 4-fold higher exposure than TUG-891.","Improving metabolic stability with deuterium: The discovery of GPU-028, a potent free fatty acid receptor 4 agonists. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29100735/),[l] / [h·kg],0.97,185945,DB00030,Insulin Regular
,29100735,maximum plasma concentration (Cmax,"As expected, GPU-028 revealed a longer half-life (T1/2 = 1.66 h), lower clearance (CL = 0.97 L/h/kg) and higher maximum plasma concentration (Cmax = 2035.23 μg/L), resulting in a 4-fold higher exposure than TUG-891.","Improving metabolic stability with deuterium: The discovery of GPU-028, a potent free fatty acid receptor 4 agonists. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29100735/),[μg] / [l],2035.23,185946,DB00030,Insulin Regular
,17292977,ED(50),The ED(50) values of AC3174 for glucose lowering (60 minute post-dose) were 1.2 microg/kg in db/db mice and 1.3 microg/kg in C57BL/6 mice.,"Biological activity of AC3174, a peptide analog of exendin-4. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17292977/),[μg] / [kg],1.2,186269,DB00030,Insulin Regular
,17292977,ED(50),The ED(50) values of AC3174 for glucose lowering (60 minute post-dose) were 1.2 microg/kg in db/db mice and 1.3 microg/kg in C57BL/6 mice.,"Biological activity of AC3174, a peptide analog of exendin-4. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17292977/),[μg] / [kg],1.3,186270,DB00030,Insulin Regular
,17292977,half-life,"In rats, the in vivo half-life of AC3174 was 42-43 min following SC administration.","Biological activity of AC3174, a peptide analog of exendin-4. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17292977/),min,42-43,186271,DB00030,Insulin Regular
<,31848295,oral bioavailability,"However, silvestrol has suboptimal drug-like properties, including a bulky structure, poor oral bioavailability (<2%), sensitivity to MDR1 efflux, and pulmonary toxicity in dogs.",Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31848295/),%,2,186412,DB00030,Insulin Regular
,31848295,oral bioavailability,Pharmacokinetic analysis confirmed that Roc had 50% oral bioavailability.,Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31848295/),%,50,186413,DB00030,Insulin Regular
,21498786,area under the curve(0-32 h),"The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05).","Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21498786/),[mg] / [kg],"1,538",187655,DB00030,Insulin Regular
,21498786,area under the curve(0-32 h),"The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05).","Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21498786/),[mg] / [kg],"1,081",187656,DB00030,Insulin Regular
,21498786,area under the curve(0-32 h),"The glucose infusion rate area under the curve(0-32 h) was greater for glargine than for detemir and NPH (1,538 ± 688; 1,081 ± 785; and 1,170 ± 703 mg/kg, respectively; P < 0.05).","Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21498786/),[mg] / [kg],"1,170",187657,DB00030,Insulin Regular
,15509750,half-life,[125I]Abeta(1-40) was eliminated from rat brain to circulating blood with a half-life of 48.8 min and a half-saturation concentration of 8.15 nm.,Brain insulin impairs amyloid-beta(1-40) clearance from the brain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509750/),min,48.8,187899,DB00030,Insulin Regular
,15509750,half-saturation concentration,[125I]Abeta(1-40) was eliminated from rat brain to circulating blood with a half-life of 48.8 min and a half-saturation concentration of 8.15 nm.,Brain insulin impairs amyloid-beta(1-40) clearance from the brain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15509750/),nm,8.15,187900,DB00030,Insulin Regular
,25036533,half-life,"For liraglutide 1.8 mg, mean half-life was 12 h, and clearance was 1.7 L/h.","Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036533/),h,12,188363,DB00030,Insulin Regular
,25036533,clearance,"For liraglutide 1.8 mg, mean half-life was 12 h, and clearance was 1.7 L/h.","Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25036533/),[l] / [h],1.7,188364,DB00030,Insulin Regular
,21748299,area under the curve,"This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg·min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-naïve, advanced NSCLC.",Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21748299/),[mg·min] / [ml],6,188919,DB00030,Insulin Regular
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,0.8,189294,DB00030,Insulin Regular
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,0.5,189295,DB00030,Insulin Regular
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,1,189296,DB00030,Insulin Regular
,11118018,Onset of action,"Onset of action (defined as reduction of IV insulin >50%) was earlier with NPH (0.8 +/- 0.2 h), CSII (0.5 +/- 0.1 h), and ultralente (1 +/- 0.2 h) versus glargine (1.5 +/- 0.3 h) (P < 0.05) (mean +/- SE).","Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11118018/),h,1.5,189297,DB00030,Insulin Regular
,15893294,IC(50),"Compound 1, an isoleucine pyrazolidide with a phenyl urea group, inhibited rat plasma DPP-IV, porcine kidney DPP-IV, as well as human Caco-2 DPP-IV with IC(50) values of 1.70, 2.26, and 2.02 microM, respectively.",Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15893294/),μM,1.70,189469,DB00030,Insulin Regular
,15893294,IC(50),"Compound 1, an isoleucine pyrazolidide with a phenyl urea group, inhibited rat plasma DPP-IV, porcine kidney DPP-IV, as well as human Caco-2 DPP-IV with IC(50) values of 1.70, 2.26, and 2.02 microM, respectively.",Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15893294/),μM,2.26,189470,DB00030,Insulin Regular
,15893294,IC(50),"Compound 1, an isoleucine pyrazolidide with a phenyl urea group, inhibited rat plasma DPP-IV, porcine kidney DPP-IV, as well as human Caco-2 DPP-IV with IC(50) values of 1.70, 2.26, and 2.02 microM, respectively.",Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15893294/),μM,2.02,189471,DB00030,Insulin Regular
,15893294,ED(50),"Oral administration of Compound 2 resulted in potent and rapid inhibition of circulating DPP-IV in C57BL/6J mice, with ED(50) values of 26mg/kg (s.c.) and 42mg/kg (p.o.).",Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15893294/),[mg] / [kg],26,189472,DB00030,Insulin Regular
,15893294,ED(50),"Oral administration of Compound 2 resulted in potent and rapid inhibition of circulating DPP-IV in C57BL/6J mice, with ED(50) values of 26mg/kg (s.c.) and 42mg/kg (p.o.).",Inhibition of dipeptidyl peptidase IV by novel inhibitors with pyrazolidine scaffold. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15893294/),[mg] / [kg],42,189473,DB00030,Insulin Regular
,21937665,S(0.5),"Incubated in vitro with recombinant human glucokinase, 1 μM MK-0941 lowered the S(0.5) of this enzyme for glucose from 6.9 to 1.4 mM and increased the maximum velocity of glucose phosphorylation by 1.5-fold.",Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937665/),mM,6.9,189600,DB00030,Insulin Regular
,21937665,S(0.5),"Incubated in vitro with recombinant human glucokinase, 1 μM MK-0941 lowered the S(0.5) of this enzyme for glucose from 6.9 to 1.4 mM and increased the maximum velocity of glucose phosphorylation by 1.5-fold.",Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937665/),mM,1.4,189601,DB00030,Insulin Regular
,21937665,EC(50),"In 2.5 and 10 mM glucose, the EC(50) values for activation of GK by MK-0941 were 0.240 and 0.065 μM, respectively.",Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937665/),μM,0.240,189602,DB00030,Insulin Regular
,21937665,EC(50),"In 2.5 and 10 mM glucose, the EC(50) values for activation of GK by MK-0941 were 0.240 and 0.065 μM, respectively.",Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937665/),μM,0.065,189603,DB00030,Insulin Regular
,21937665,half-life,"In both mice and dogs, oral doses of MK-0941 were rapidly absorbed and rapidly cleared from the blood; plasma levels reached maximum within 1 h and fell thereafter with a half-life of ~2 h.",Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937665/),h,2,189604,DB00030,Insulin Regular
,29271699,CL,"Establishing a threshold value for mAb CL in human of 0.32 mL/hr/kg enabled refinement of thresholds for each in vitro assay parameter, and using a combinatorial triage approach enabled the successful differentiation of mAbs at high risk for rapid CL (unfavorable PK) from those with low risk (favorable PK), which allowed mAbs requiring further characterization to be identified.",Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29271699/),[ml] / [h·kg],0.32,191072,DB00030,Insulin Regular
,27870826,Duration of therapy,Duration of therapy in treated infants ranged 1-34.5 d.,Development and verification of a pharmacokinetic model to optimize physiologic replacement of rhIGF-1/rhIGFBP-3 in preterm infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27870826/),d,1-34.5,192860,DB00030,Insulin Regular
,27870826,IGF-1,"At baseline (before infusion and <24 h from birth), mean (SD) IGF-1 was 19.2 (8.0) μg/l (treated) and 15.4 (4.7) μg/l (controls).",Development and verification of a pharmacokinetic model to optimize physiologic replacement of rhIGF-1/rhIGFBP-3 in preterm infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27870826/),[μg] / [l],19.2,192861,DB00030,Insulin Regular
,27870826,IGF-1,"At baseline (before infusion and <24 h from birth), mean (SD) IGF-1 was 19.2 (8.0) μg/l (treated) and 15.4 (4.7) μg/l (controls).",Development and verification of a pharmacokinetic model to optimize physiologic replacement of rhIGF-1/rhIGFBP-3 in preterm infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27870826/),[μg] / [l],15.4,192862,DB00030,Insulin Regular
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,391,193001,DB00030,Insulin Regular
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,17,193002,DB00030,Insulin Regular
,19027057,bioavailability,"Prototype III exhibited the best physical characteristics and in vivo performance, with bioavailability of 45% relative to subcutaneous administration.","Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19027057/),%,45,193031,DB00030,Insulin Regular
,16338283,apparent terminal half-life,Sitagliptin was well absorbed (approximately 80% excreted unchanged in the urine) with an apparent terminal half-life ranging from 8 to 14 hours.,"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338283/),h,8 to 14,193415,DB00030,Insulin Regular
,16338283,Renal clearance,Renal clearance of sitagliptin averaged 388 mL/min and was largely uninfluenced by the dose administered.,"Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16338283/),[ml] / [min],388,193416,DB00030,Insulin Regular
,16289574,pharmacological availability,The pharmacological availability was 5.5% and significantly different from the reference formulation.,Effects of absorption promoters on insulin absorption through colon-targeted delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289574/),%,5.5,193496,DB00030,Insulin Regular
,16289574,absolute bioavailability,"The absolute bioavailability for CDS was 0.25%, and for CDSP it was 0.42%.",Effects of absorption promoters on insulin absorption through colon-targeted delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289574/),%,0.25,193497,DB00030,Insulin Regular
,16289574,absolute bioavailability,"The absolute bioavailability for CDS was 0.25%, and for CDSP it was 0.42%.",Effects of absorption promoters on insulin absorption through colon-targeted delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16289574/),%,0.42,193498,DB00030,Insulin Regular
,25854859,tmax,"Following a single oral dosing, pradigastat was absorbed slowly, with a median tmax of ∼10 hours and eliminated slowly with a long half-life.","Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854859/),h,∼10,194249,DB00030,Insulin Regular
,12616669,tmax,"Plasma nateglinide concentrations increased rapidly in patients undergoing dialysis and matched healthy subjects (tmax = 0.95 vs. 0.78 h, respectively) and was comparable with patients with IRF and matched healthy subjects (tmax = 0.80 vs. 0.65 h, respectively).",Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,0.95,194693,DB00030,Insulin Regular
,12616669,tmax,"Plasma nateglinide concentrations increased rapidly in patients undergoing dialysis and matched healthy subjects (tmax = 0.95 vs. 0.78 h, respectively) and was comparable with patients with IRF and matched healthy subjects (tmax = 0.80 vs. 0.65 h, respectively).",Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,0.78,194694,DB00030,Insulin Regular
,12616669,tmax,"Plasma nateglinide concentrations increased rapidly in patients undergoing dialysis and matched healthy subjects (tmax = 0.95 vs. 0.78 h, respectively) and was comparable with patients with IRF and matched healthy subjects (tmax = 0.80 vs. 0.65 h, respectively).",Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,0.80,194695,DB00030,Insulin Regular
,12616669,tmax,"Plasma nateglinide concentrations increased rapidly in patients undergoing dialysis and matched healthy subjects (tmax = 0.95 vs. 0.78 h, respectively) and was comparable with patients with IRF and matched healthy subjects (tmax = 0.80 vs. 0.65 h, respectively).",Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,0.65,194696,DB00030,Insulin Regular
,12616669,t1/2,Nateglinide was eliminated rapidly in all groups (t1/2 = 1.9-2.8 h).,Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),h,1.9-2.8,194697,DB00030,Insulin Regular
,12616669,renal excretion,There was a low extent of renal excretion of nateglinide in healthy subjects (11%) and diabetic patients with IRF (3%).,Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),%,11,194698,DB00030,Insulin Regular
,12616669,renal excretion,There was a low extent of renal excretion of nateglinide in healthy subjects (11%) and diabetic patients with IRF (3%).,Pharmacokinetics of nateglinide in renally impaired diabetic patients. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12616669/),%,3,194699,DB00030,Insulin Regular
,10841002,time,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,3.2,194793,DB00030,Insulin Regular
,10841002,time,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,8.8,194794,DB00030,Insulin Regular
,10841002,time,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,11.0,194795,DB00030,Insulin Regular
,10841002,absorption rate,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,3.2,194796,DB00030,Insulin Regular
,10841002,absorption rate,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,8.8,194797,DB00030,Insulin Regular
,10841002,absorption rate,"In study 1, the time in hours for 25% of the administered radioactivity to disappear after bolus subcutaneous injection (T75%) for NPH insulin indicated a significantly faster absorption rate compared with the 2 insulin glargine formulations (3.2 vs. 8.8 and 11.0 h, respectively P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,11.0,194798,DB00030,Insulin Regular
,10841002,residual radioactivity,"Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),%,21.9,194799,DB00030,Insulin Regular
,10841002,residual radioactivity,"Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),%,43.8,194800,DB00030,Insulin Regular
,10841002,residual radioactivity,"Mean residual radioactivity with NPH insulin was also significantly lower at 24 h (21.9 vs. 43.8 and 52.2%, P < 0.0001).",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),%,52.2,194801,DB00030,Insulin Regular
,10841002,T75%,"In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h.",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,11.9,194802,DB00030,Insulin Regular
,10841002,T75%,"In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h.",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,15.3,194803,DB00030,Insulin Regular
,10841002,T75%,"In study 2, there were no significant differences in the absorption characteristics of insulin glargine between the 3 injection sites (T75% = 11.9, 15.3, and 13.2 h for arm, leg, and abdomen, respectively) or in residual radioactivity at 24 h.",Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10841002/),h,13.2,194804,DB00030,Insulin Regular
,16490580,AUC accumulation ratio,"In the groups receiving sitagliptin QD doses, accumulation of sitagliptin was modest (AUC accumulation ratio [day 10/day 1] range, 1.05-1.29), and the apparent terminal elimination t((1/2)) was 11.8 to 14.4 hours.","Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490580/),,1.05-1.29,195225,DB00030,Insulin Regular
,16490580,apparent terminal elimination t((1/2)),"In the groups receiving sitagliptin QD doses, accumulation of sitagliptin was modest (AUC accumulation ratio [day 10/day 1] range, 1.05-1.29), and the apparent terminal elimination t((1/2)) was 11.8 to 14.4 hours.","Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490580/),h,11.8 to 14.4,195226,DB00030,Insulin Regular
<,29188801,bioavailability,"The pharmacokinetic studies in rats showed that intragastric administration of OCT had extremely low bioavailability (<0.5%), but it could specifically distribute to the gastric mucosa due to the high expression of somatostatin receptor 2 (SSTR2) in the rat stomach.",Pharmacokinetic and pharmacodynamic evidence for developing an oral formulation of octreotide against gastric mucosal injury. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29188801/),%,0.5,196253,DB00030,Insulin Regular
,31584244,peak serum concentration,The peak serum concentration of RHI was 517 ± 109 pmol/L in the ODP and 342 ± 50 pmol/L in the subcutaneous group (ns).,Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine-A pharmacokinetic and pharmacodynamic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31584244/),[pM] / [l],517,196305,DB00030,Insulin Regular
,31584244,peak serum concentration,The peak serum concentration of RHI was 517 ± 109 pmol/L in the ODP and 342 ± 50 pmol/L in the subcutaneous group (ns).,Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine-A pharmacokinetic and pharmacodynamic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31584244/),[pM] / [l],342,196306,DB00030,Insulin Regular
,31584244,areas under the insulin concentration curves,The areas under the insulin concentration curves (83 ± 18 and 81 ± 10 nmol/L·min) were also similar in both groups.,Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine-A pharmacokinetic and pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31584244/),[nM] / [l·min],83,196307,DB00030,Insulin Regular
,31584244,areas under the insulin concentration curves,The areas under the insulin concentration curves (83 ± 18 and 81 ± 10 nmol/L·min) were also similar in both groups.,Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine-A pharmacokinetic and pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31584244/),[nM] / [l·min],81,196308,DB00030,Insulin Regular
,31584244,time to peak serum concentration,The mean time to peak serum concentration of insulin was 139 ± 42 minutes in the ODP and 227 ± 24 minutes in the subcutaneous group (ns).,Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine-A pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31584244/),min,139,196309,DB00030,Insulin Regular
,31584244,time to peak serum concentration,The mean time to peak serum concentration of insulin was 139 ± 42 minutes in the ODP and 227 ± 24 minutes in the subcutaneous group (ns).,Jejunal wall delivery of insulin via an ingestible capsule in anesthetized swine-A pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31584244/),min,227,196310,DB00030,Insulin Regular
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,42,196903,DB00030,Insulin Regular
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,80,196904,DB00030,Insulin Regular
,19567522,bioavailability,"We report a 14.5-year-old boy with CAH who had reduced bioavailability [42% (normal 80% orally and 100% by im route)] and increased clearance [half-life 50 min (normal range, 70-100 min)] of oral doses of hydrocortisone leading to ambient serum 17-hydroxyprogesterone concentrations of 400 nmol/liter (14.5 ng/ml) and androstenedione concentrations of 24.9 nmol/liter (7.1 ng/ml).",Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567522/),%,100,196905,DB00030,Insulin Regular
,20807152,clearance,"Mean clearance of inulin and iohexol for the reference method was 2.72 and 2.48 mL/min/kg, respectively.",Glomerular filtration rate in dogs as estimated via plasma clearance of inulin and iohexol and use of limited-sample methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807152/),[ml] / [kg·min],2.72,197284,DB00030,Insulin Regular
,20807152,clearance,"Mean clearance of inulin and iohexol for the reference method was 2.72 and 2.48 mL/min/kg, respectively.",Glomerular filtration rate in dogs as estimated via plasma clearance of inulin and iohexol and use of limited-sample methods. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20807152/),[ml] / [kg·min],2.48,197285,DB00030,Insulin Regular
,12412826,maximum,The maximum hGH serum concentration of around 20 ng/ml was observed 3.5 to 4 hours after drug administration.,"Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412826/),[ng] / [ml],20,197367,DB00030,Insulin Regular
,12412826,terminal half-life,The terminal half-life was found to be around 2.5 hours.,"Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12412826/),h,2.5,197368,DB00030,Insulin Regular
,26819665,EC50,"The 2-thio-imidazole derivative 6g was identified as a novel, potent, and selective TGR5 agonist (hTGR5 EC50 = 57 pM, mTGR5 = 62 pM) with a favorable pharmacokinetic profile.",Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26819665/),pM,57,199390,DB00030,Insulin Regular
,26819665,EC50,"The 2-thio-imidazole derivative 6g was identified as a novel, potent, and selective TGR5 agonist (hTGR5 EC50 = 57 pM, mTGR5 = 62 pM) with a favorable pharmacokinetic profile.",Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26819665/),pM,62,199391,DB00030,Insulin Regular
,26819665,ED50,The compound 6g was found to have potent glucose lowering effects in vivo during an oral glucose tolerance test in DIO C57 mice with ED50 of 7.9 mg/kg and ED90 of 29.2 mg/kg.,Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26819665/),[mg] / [kg],7.9,199392,DB00030,Insulin Regular
,26819665,ED90,The compound 6g was found to have potent glucose lowering effects in vivo during an oral glucose tolerance test in DIO C57 mice with ED50 of 7.9 mg/kg and ED90 of 29.2 mg/kg.,Discovery of a Potent and Orally Efficacious TGR5 Receptor Agonist. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26819665/),[mg] / [kg],29.2,199393,DB00030,Insulin Regular
,27063928,terminal half-life (t1/2 ),The mean terminal half-life (t1/2 ) was 2-3 h.,"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27063928/),h,2-3,199850,DB00030,Insulin Regular
,11835120,time to peak action,"The time to peak action was significantly shorter with both i.v. injection and inhalation, as compared to s.c. (14 +/- 6 min and 39 +/- 36 min vs. 163 +/- 25 min; p < 0.0002 and p < 0.007 (mean +/- SD)).",Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835120/),min,14,200214,DB00030,Insulin Regular
,11835120,time to peak action,"The time to peak action was significantly shorter with both i.v. injection and inhalation, as compared to s.c. (14 +/- 6 min and 39 +/- 36 min vs. 163 +/- 25 min; p < 0.0002 and p < 0.007 (mean +/- SD)).",Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835120/),min,39,200215,DB00030,Insulin Regular
,11835120,time to peak action,"The time to peak action was significantly shorter with both i.v. injection and inhalation, as compared to s.c. (14 +/- 6 min and 39 +/- 36 min vs. 163 +/- 25 min; p < 0.0002 and p < 0.007 (mean +/- SD)).",Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835120/),min,163,200216,DB00030,Insulin Regular
,11835120,AUC0-180,The metabolic effect during the first 3 h after insulin administration was higher with inhaled TI than with HI s.c. (AUC0-180 for glucose infusion rate: 1.94 +/- 0.77 mg/kg * min vs. 1.15 +/- 0.50 mg/kg * min; p < 0.04).,Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835120/),[mg] / [kg·min],1.94,200217,DB00030,Insulin Regular
,11835120,AUC0-180,The metabolic effect during the first 3 h after insulin administration was higher with inhaled TI than with HI s.c. (AUC0-180 for glucose infusion rate: 1.94 +/- 0.77 mg/kg * min vs. 1.15 +/- 0.50 mg/kg * min; p < 0.04).,Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835120/),[mg] / [kg·min],1.15,200218,DB00030,Insulin Regular
,11835120,Relative,Relative and absolute bioavailability for the first 3 h were 26 +/- 12% and 15 +/- 5% respectively (6 h: 16 +/- 8 and 16 +/- 6%).,Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835120/),%,26,200219,DB00030,Insulin Regular
,11835120,absolute bioavailability,Relative and absolute bioavailability for the first 3 h were 26 +/- 12% and 15 +/- 5% respectively (6 h: 16 +/- 8 and 16 +/- 6%).,Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835120/),%,15,200220,DB00030,Insulin Regular
,11835120,absolute bioavailability,Relative and absolute bioavailability for the first 3 h were 26 +/- 12% and 15 +/- 5% respectively (6 h: 16 +/- 8 and 16 +/- 6%).,Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835120/),%,16,200221,DB00030,Insulin Regular
,11835120,absolute bioavailability,Relative and absolute bioavailability for the first 3 h were 26 +/- 12% and 15 +/- 5% respectively (6 h: 16 +/- 8 and 16 +/- 6%).,Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11835120/),%,16,200222,DB00030,Insulin Regular
,32537846,extraction recovery,"Further, the extraction recovery from the plasma was 41.8%-49.2% for liraglutide and 56.5%-69.7% for insulin degludec.",Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography-tandem mass spectrometry method and its application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32537846/),%,41.,200357,DB00030,Insulin Regular
,32537846,extraction recovery,"Further, the extraction recovery from the plasma was 41.8%-49.2% for liraglutide and 56.5%-69.7% for insulin degludec.",Simultaneous quantitative determination of liraglutide and insulin degludec in rat plasma by liquid chromatography-tandem mass spectrometry method and its application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32537846/),%,56.5,200358,DB00030,Insulin Regular
,29582248,maximum plasma concentration (Cmax),"On Day 7, the mean maximum plasma concentration (Cmax) was 812 ng/mL in the 50-mg group and 1310 ng/mL in the 100-mg group.","Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582248/),[ng] / [ml],812,200584,DB00030,Insulin Regular
,29582248,maximum plasma concentration (Cmax),"On Day 7, the mean maximum plasma concentration (Cmax) was 812 ng/mL in the 50-mg group and 1310 ng/mL in the 100-mg group.","Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582248/),[ng] / [ml],1310,200585,DB00030,Insulin Regular
,29582248,area under the plasma concentration-time curve during dosing interval (AUCtau),"The mean area under the plasma concentration-time curve during dosing interval (AUCtau) was 7910 and 13,200 ng·h/mL in the two treatment groups, respectively.","Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582248/),[h·ng] / [ml],7910,200586,DB00030,Insulin Regular
,29582248,area under the plasma concentration-time curve during dosing interval (AUCtau),"The mean area under the plasma concentration-time curve during dosing interval (AUCtau) was 7910 and 13,200 ng·h/mL in the two treatment groups, respectively.","Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582248/),[h·ng] / [ml],"13,200",200587,DB00030,Insulin Regular
,29582248,observed accumulation ratio,The observed accumulation ratio was 1.25 in the 50-mg group and 1.32 in the 100-mg group.,"Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582248/),,1.25,200588,DB00030,Insulin Regular
,29582248,observed accumulation ratio,The observed accumulation ratio was 1.25 in the 50-mg group and 1.32 in the 100-mg group.,"Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29582248/),,1.32,200589,DB00030,Insulin Regular
,16186270,late t(50%),"HIIP demonstrated a similar rapid onset but an extended time exposure and a prolonged duration of effect (late t(50%) 412 vs. 236 min, P < 0.001) compared with SC lispro.",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,412,200856,DB00030,Insulin Regular
,16186270,late t(50%),"HIIP demonstrated a similar rapid onset but an extended time exposure and a prolonged duration of effect (late t(50%) 412 vs. 236 min, P < 0.001) compared with SC lispro.",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,236,200857,DB00030,Insulin Regular
,16186270,insulin (t(max)),"The median insulin (t(max)) was not different between HIIP and SC lispro (45 min for both), although the median time of return to baseline for PK was apparently longer for HIIP compared with SC lispro (480 vs. 360 min).",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,45,200858,DB00030,Insulin Regular
,16186270,time of return to baseline,"The median insulin (t(max)) was not different between HIIP and SC lispro (45 min for both), although the median time of return to baseline for PK was apparently longer for HIIP compared with SC lispro (480 vs. 360 min).",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,480,200859,DB00030,Insulin Regular
,16186270,time of return to baseline,"The median insulin (t(max)) was not different between HIIP and SC lispro (45 min for both), although the median time of return to baseline for PK was apparently longer for HIIP compared with SC lispro (480 vs. 360 min).",Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),min,360,200860,DB00030,Insulin Regular
,16186270,Relative bioavailability,Relative bioavailability and relative biopotency of HIIP were consistent across doses (8 and 9%).,Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),%,8,200861,DB00030,Insulin Regular
,16186270,Relative bioavailability,Relative bioavailability and relative biopotency of HIIP were consistent across doses (8 and 9%).,Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),%,9,200862,DB00030,Insulin Regular
,16186270,relative biopotency,Relative bioavailability and relative biopotency of HIIP were consistent across doses (8 and 9%).,Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16186270/),%,9,200863,DB00030,Insulin Regular
,32325175,tmax,Insulin from Ins_SD was promptly absorbed (tmax 15 min and Cmaxx4.9 ± 1.5 mU/ml).,Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325175/),min,15,201054,DB00030,Insulin Regular
,32325175,Cmaxx,Insulin from Ins_SD was promptly absorbed (tmax 15 min and Cmaxx4.9 ± 1.5 mU/ml).,Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325175/),[mu] / [ml],4.9,201055,DB00030,Insulin Regular
,32325175,tmax,Afrezza had a slower absorption (tmax 30 min and Cmax of 1.8 ± 0.37 mU/ml).,Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325175/),min,30,201056,DB00030,Insulin Regular
,32325175,Cmax,Afrezza had a slower absorption (tmax 30 min and Cmax of 1.8 ± 0.37 mU/ml).,Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32325175/),[mu] / [ml],1.8,201057,DB00030,Insulin Regular
,12610021,area under the exogenous serum insulin curve from 0 to 6 h,The amount of insulin absorbed during the first 6 h after dosing (area under the exogenous serum insulin curve from 0 to 6 h [AUC((0-6 h))]) was significantly greater in smokers (63.2 vs.,The impact of smoking on inhaled insulin. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610021/),,63.2,201178,DB00030,Insulin Regular
,12610021,maximal serum concentration of insulin [C(max)],"40.0 mU l(-1) x h(-1), P = 0.0017); peak concentration was both higher and earlier in the smokers (maximal serum concentration of insulin [C(max)] 42.0 vs.",The impact of smoking on inhaled insulin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610021/),,42.0,201179,DB00030,Insulin Regular
,12610021,time to maximal serum concentration of insulin [t(max)],"13.9 mU/l, P < 0.0001; time to maximal serum concentration of insulin [t(max)] 31.5 vs. 53.9 min, P = 0.0003).",The impact of smoking on inhaled insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610021/),min,31.5,201180,DB00030,Insulin Regular
,12610021,time to maximal serum concentration of insulin [t(max)],"13.9 mU/l, P < 0.0001; time to maximal serum concentration of insulin [t(max)] 31.5 vs. 53.9 min, P = 0.0003).",The impact of smoking on inhaled insulin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12610021/),min,53.9,201181,DB00030,Insulin Regular
≤,23910664,T(max),"In both doses, dapagliflozin was rapidly absorbed (T(max), ≤1.5 h), accumulation (defined as the geometric mean ratio of AUC(τ) at day 10 to AUC(τ) at day 1) after multiple dosing was minimal (<1.13 fold), and elimination half-life was 10 to 12 h.","Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23910664/),h,1.5,201477,DB00030,Insulin Regular
,23910664,elimination half-life,"In both doses, dapagliflozin was rapidly absorbed (T(max), ≤1.5 h), accumulation (defined as the geometric mean ratio of AUC(τ) at day 10 to AUC(τ) at day 1) after multiple dosing was minimal (<1.13 fold), and elimination half-life was 10 to 12 h.","Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23910664/),h,10 to 12,201478,DB00030,Insulin Regular
≤,23910664,Tmax,D3OG showed a slightly longer median Tmax (≤2 h) but a similar plasma concentration-time profile and half-life compared with dapagliflozin.,"Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23910664/),h,2,201479,DB00030,Insulin Regular
,23910664,urinary glucose excretion,"Over a 24-hour period and at steady state (day 10), urinary glucose excretion values were 28.1 and 41.1 g with dapagliflozin 5 and 10 mg, respectively.","Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23910664/),g,28.1,201480,DB00030,Insulin Regular
,23910664,urinary glucose excretion,"Over a 24-hour period and at steady state (day 10), urinary glucose excretion values were 28.1 and 41.1 g with dapagliflozin 5 and 10 mg, respectively.","Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23910664/),g,41.1,201481,DB00030,Insulin Regular
,19405907,distribution half-life,Mean +/- SD distribution half-life of metformin following IV administration was 24.9 +/- 0.4 minutes with a volume of distribution of 0.3 +/- 0.1 L/kg.,Pharmacokinetics and bioavailability of metformin in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),min,24.9,201538,DB00030,Insulin Regular
,19405907,volume of distribution,Mean +/- SD distribution half-life of metformin following IV administration was 24.9 +/- 0.4 minutes with a volume of distribution of 0.3 +/- 0.1 L/kg.,Pharmacokinetics and bioavailability of metformin in horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[l] / [kg],0.3,201539,DB00030,Insulin Regular
,19405907,area under the curve,Mean area under the curve was 20.9 +/- 2.0 h.microg/mL for IV administration; PO administration resulted in area under the curves of 1.6 +/- 0.4 h.microg/mL in unfed horses and 0.8 +/- 0.2 h.microg/mL in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[h·μg] / [ml],20.9,201540,DB00030,Insulin Regular
,19405907,area under the curves,Mean area under the curve was 20.9 +/- 2.0 h.microg/mL for IV administration; PO administration resulted in area under the curves of 1.6 +/- 0.4 h.microg/mL in unfed horses and 0.8 +/- 0.2 h.microg/mL in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[h·μg] / [ml],1.6,201541,DB00030,Insulin Regular
,19405907,area under the curves,Mean area under the curve was 20.9 +/- 2.0 h.microg/mL for IV administration; PO administration resulted in area under the curves of 1.6 +/- 0.4 h.microg/mL in unfed horses and 0.8 +/- 0.2 h.microg/mL in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[h·μg] / [ml],0.8,201542,DB00030,Insulin Regular
,19405907,Bioavailability,Bioavailability was determined to be approximately 7.1 +/- 1.5% in unfed horses and 3.9 +/- 1.0% in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),%,7.1,201543,DB00030,Insulin Regular
,19405907,Bioavailability,Bioavailability was determined to be approximately 7.1 +/- 1.5% in unfed horses and 3.9 +/- 1.0% in fed horses.,Pharmacokinetics and bioavailability of metformin in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),%,3.9,201544,DB00030,Insulin Regular
,19405907,maximal concentration,The maximal concentration following PO administration in unfed horses was 0.4 +/- 0.1 microg/mL with a time at maximal concentration of 0.9 +/- 0.1 hours.,Pharmacokinetics and bioavailability of metformin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[μg] / [ml],0.4,201545,DB00030,Insulin Regular
,19405907,time at maximal concentration,The maximal concentration following PO administration in unfed horses was 0.4 +/- 0.1 microg/mL with a time at maximal concentration of 0.9 +/- 0.1 hours.,Pharmacokinetics and bioavailability of metformin in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),h,0.9,201546,DB00030,Insulin Regular
,19405907,maximal concentration,"In fed horses, maximal concentration was reduced to 0.3 +/- 0.04 microg/mL with a time at maximal concentration at 1.3 +/- 0.3 hours.",Pharmacokinetics and bioavailability of metformin in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),[μg] / [ml],0.3,201547,DB00030,Insulin Regular
,19405907,time at maximal concentration,"In fed horses, maximal concentration was reduced to 0.3 +/- 0.04 microg/mL with a time at maximal concentration at 1.3 +/- 0.3 hours.",Pharmacokinetics and bioavailability of metformin in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19405907/),h,1.3,201548,DB00030,Insulin Regular
,23107353,time to reach maximum insulin action (T(GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,35,202151,DB00030,Insulin Regular
,23107353,time to reach maximum insulin action (T(GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,18,202152,DB00030,Insulin Regular
,23107353,time to reach maximum insulin action (T(GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,125,202153,DB00030,Insulin Regular
,23107353,time to reach maximum insulin action (T(GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,90,202154,DB00030,Insulin Regular
,23107353,to reach 50% maximum action (T(50%GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,125,202155,DB00030,Insulin Regular
,23107353,to reach 50% maximum action (T(50%GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,90,202156,DB00030,Insulin Regular
,23107353,to reach 50% maximum action (T(50%GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,58,202157,DB00030,Insulin Regular
,23107353,to reach 50% maximum action (T(50%GIRmax)),"When the insulin bolus was given with IP activation as compared to without IP activation, time to reach maximum insulin action (T(GIRmax)) and to reach 50% maximum action (T(50%GIRmax)) were 35 and 18 min earlier (125 ± 8 min vs. 90 ± 6 min, p = 0.002 and 58 ± 5 min. vs. 40 ± 3 min, p = 0.01, respectively), and the area under curve, AUC(GIR 0-90 min), reflecting early glucodynamic action, was significantly greater (p = 0.001).",Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23107353/),min,40,202158,DB00030,Insulin Regular
,12060061,trough FSI,"Notably, the trough FSI at the end of the sampling periods was almost identical (day 1, 79 +/- 56 pmol/l, day 4, 77 +/- 56 pmol/l, day 11, 86 +/- 60 pmol/l).",No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060061/),[pM] / [l],79,202365,DB00030,Insulin Regular
,12060061,trough FSI,"Notably, the trough FSI at the end of the sampling periods was almost identical (day 1, 79 +/- 56 pmol/l, day 4, 77 +/- 56 pmol/l, day 11, 86 +/- 60 pmol/l).",No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060061/),[pM] / [l],77,202366,DB00030,Insulin Regular
,12060061,trough FSI,"Notably, the trough FSI at the end of the sampling periods was almost identical (day 1, 79 +/- 56 pmol/l, day 4, 77 +/- 56 pmol/l, day 11, 86 +/- 60 pmol/l).",No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12060061/),[pM] / [l],86,202367,DB00030,Insulin Regular
,27059951,half-life,PF-06291874 exposure was approximately dose-proportional with a half-life of ∼19.7-22.7 h.,Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27059951/),h,∼19.7-22.7,202516,DB00030,Insulin Regular
,19745765,area under the curve,"Patients received paclitaxel 200 mg/m2, carboplatin (area under the curve of 6), and F (0.05-20 mg/kg) q3 weeks for up to six cycles.","Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19745765/),,6,202814,DB00030,Insulin Regular
,30095210,tmax,Enteric delivery of tregopil brought about rapid absorption with tmax = 20 minutes in most cases.,Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30095210/),min,20,203334,DB00030,Insulin Regular
,30095210,tmax,Median tmax was 20 minutes for oral tregopil and inhaled insulin and 88 minutes for subcutaneous human insulin.,Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30095210/),min,20,203335,DB00030,Insulin Regular
,30095210,tmax,Median tmax was 20 minutes for oral tregopil and inhaled insulin and 88 minutes for subcutaneous human insulin.,Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30095210/),min,88,203336,DB00030,Insulin Regular
,30095210,time required,"The time required for arterial plasma insulin levels to return to baseline was approximately 90, 210 and 360 minutes for oral tregopil, inhaled insulin and subcutaneous insulin, respectively.",Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30095210/),min,90,203337,DB00030,Insulin Regular
,30095210,time required,"The time required for arterial plasma insulin levels to return to baseline was approximately 90, 210 and 360 minutes for oral tregopil, inhaled insulin and subcutaneous insulin, respectively.",Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30095210/),min,210,203338,DB00030,Insulin Regular
,30095210,time required,"The time required for arterial plasma insulin levels to return to baseline was approximately 90, 210 and 360 minutes for oral tregopil, inhaled insulin and subcutaneous insulin, respectively.",Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30095210/),min,360,203339,DB00030,Insulin Regular
,22226086,elimination half-life,"Canagliflozin pharmacokinetics were dose-dependent, and the elimination half-life ranged from 12 to 15 h.",Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22226086/),h,12 to 15,204020,DB00030,Insulin Regular
,30075208,p,"The insulin glulisine NPs exhibited an average size of 109 ± 9 nm, low polydispersity index (0.272) negative zeta potential (-25 ± 3 mV), high association efficiency (71.4 ± 3.37%) and an insulin loading of 10.2%.","Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30075208/),,0,204196,DB00030,Insulin Regular
,30075208,relative bioavailability,The relative bioavailability of the instilled insulin (50 IU/kg) from the NP was 5.5% compared to subcutaneous administration of insulin solution (1 IU/kg).,"Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30075208/),%,5.5,204197,DB00030,Insulin Regular
,19056578,peak concentrations,"Circulating GLP-1 concentrations increased in all study groups after glutamine ingestion, with peak concentrations at 30 min of 22.5 +/- 3.4, 17.9 +/- 1.1, and 17.3 +/- 3.4 pmol/L in LEAN, OB-CON, and OB-DIAB subjects, respectively.","Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19056578/),[pM] / [l],22.5,204701,DB00030,Insulin Regular
,19056578,peak concentrations,"Circulating GLP-1 concentrations increased in all study groups after glutamine ingestion, with peak concentrations at 30 min of 22.5 +/- 3.4, 17.9 +/- 1.1, and 17.3 +/- 3.4 pmol/L in LEAN, OB-CON, and OB-DIAB subjects, respectively.","Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19056578/),[pM] / [l],17.9,204702,DB00030,Insulin Regular
,19056578,peak concentrations,"Circulating GLP-1 concentrations increased in all study groups after glutamine ingestion, with peak concentrations at 30 min of 22.5 +/- 3.4, 17.9 +/- 1.1, and 17.3 +/- 3.4 pmol/L in LEAN, OB-CON, and OB-DIAB subjects, respectively.","Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19056578/),[pM] / [l],17.3,204703,DB00030,Insulin Regular
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,60,205664,DB00030,Insulin Regular
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,111,205665,DB00030,Insulin Regular
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,169,205666,DB00030,Insulin Regular
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,34,205667,DB00030,Insulin Regular
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,87,205668,DB00030,Insulin Regular
,18675854,T(50),"Exenatide slowed GE of both solid and liquid meal components [solid (T(50)(90% confidence interval [CI]); placebo, 60(50-70) min; 5 microg exenatide, 111(94-132) min; 10 microg exenatide, 169(143-201) min; both P<0.01); liquid (T(50)(90% CI), placebo, 34(25-46) min; 5 microg exenatide, 87(65-117) min; 10 microg exenatide, 114(85-154) min; both P<0.01)].",Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18675854/),min,114,205669,DB00030,Insulin Regular
,28201598,height velocity,"Annualized mean height velocity for the three TransCon GH doses ranged from 11.9 cm to 13.9 cm, which was not statistically different from 11.6 cm for Genotropin.",A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28201598/),cm,11.9,205767,DB00030,Insulin Regular
,28201598,height velocity,"Annualized mean height velocity for the three TransCon GH doses ranged from 11.9 cm to 13.9 cm, which was not statistically different from 11.6 cm for Genotropin.",A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28201598/),cm,13.9,205768,DB00030,Insulin Regular
,28201598,height velocity,"Annualized mean height velocity for the three TransCon GH doses ranged from 11.9 cm to 13.9 cm, which was not statistically different from 11.6 cm for Genotropin.",A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency. ,Vmax velocity-Q2,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28201598/),cm,11.6,205769,DB00030,Insulin Regular
≤,25313322,EC50s,"Thus, compound 3 is the first potent GPR39 agonist (EC50s ≤ 1 nM for human and rat receptor) that is orally bioavailable in mice and robustly induced acute GLP-1 levels.",Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25313322/),nM,1,205947,DB00030,Insulin Regular
,19047364,t(max),Exenatide was well absorbed with a median t(max) of 1.5 hours and mean t((1/2)) of 1.6 hours; exposure increased with dose.,"Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19047364/),h,1.5,205985,DB00030,Insulin Regular
,19047364,t((1/2)),Exenatide was well absorbed with a median t(max) of 1.5 hours and mean t((1/2)) of 1.6 hours; exposure increased with dose.,"Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19047364/),h,1.6,205986,DB00030,Insulin Regular
,31999478,Tmax,"Results: Tmax was 68.7 ± 21.6 min for faster aspart and 89.7 ± 31.8 min for aspart (mean paired difference faster aspart minus aspart -15.5 min, 95% CI [-31.6 to 0.6 min], P = 0.06).",Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31999478/),min,68.7,205987,DB00030,Insulin Regular
,31999478,Tmax,"Results: Tmax was 68.7 ± 21.6 min for faster aspart and 89.7 ± 31.8 min for aspart (mean paired difference faster aspart minus aspart -15.5 min, 95% CI [-31.6 to 0.6 min], P = 0.06).",Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31999478/),min,89.7,205988,DB00030,Insulin Regular
,24283460,relative bioavailability,In vivo pharmacodynamic and pharmacokinetic studies further revealed almost double hypoglycemia and approximately 20% relative bioavailability in comparison with subcutaneously administered standard insulin solution.,Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24283460/),%,20,206747,DB00030,Insulin Regular
,22639111,CL/F,"The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6).",Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22639111/),[l] / [h],19.0,207138,DB00030,Insulin Regular
,22639111,Vc/F,"The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6).",Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22639111/),l,"1,130",207139,DB00030,Insulin Regular
,22639111,Vp/F,"The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6).",Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22639111/),l,"4,020",207140,DB00030,Insulin Regular
,22639111,Q/F,"The typical population parameters were CL/F (19.0 L/h), Vc/F (1,130 L), Vp/F (4,020 L), and Q/F (38.6).",Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22639111/),,38.6,207141,DB00030,Insulin Regular
,11678967,area under the curve values: AUC,"As expected there was a significant decrease in postprandial glycaemia after glibenclamide administration compared to placebo (mean area under the curve values: AUC = 53.3 +/- 18.2 and 69.1 +/- 21.6 mm/h, P = 0.00009).",Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678967/),[mm] / [h],53.3,207393,DB00030,Insulin Regular
,11678967,area under the curve values: AUC,"As expected there was a significant decrease in postprandial glycaemia after glibenclamide administration compared to placebo (mean area under the curve values: AUC = 53.3 +/- 18.2 and 69.1 +/- 21.6 mm/h, P = 0.00009).",Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11678967/),[mm] / [h],69.1,207394,DB00030,Insulin Regular
,12230479,C peak,"Peak plasma concentrations (median C peak = 2.23 g/L) were observed at the end of the dwell (median Tmax = 12.7 h) and were significantly correlated with patients' body weight (R2 = 0.805, P < 0.001).",Pharmacokinetics of icodextrin in peritoneal dialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12230479/),[g] / [l],2.23,208161,DB00030,Insulin Regular
,12230479,Tmax,"Peak plasma concentrations (median C peak = 2.23 g/L) were observed at the end of the dwell (median Tmax = 12.7 h) and were significantly correlated with patients' body weight (R2 = 0.805, P < 0.001).",Pharmacokinetics of icodextrin in peritoneal dialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12230479/),h,12.7,208162,DB00030,Insulin Regular
,12230479,plasma half-life,Icodextrin had a plasma half-life of 14.73 hours and a median clearance of 1.09 L/h.,Pharmacokinetics of icodextrin in peritoneal dialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12230479/),h,14.73,208163,DB00030,Insulin Regular
,12230479,clearance,Icodextrin had a plasma half-life of 14.73 hours and a median clearance of 1.09 L/h.,Pharmacokinetics of icodextrin in peritoneal dialysis patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12230479/),[l] / [h],1.09,208164,DB00030,Insulin Regular
,12230479,daily,"In the nine patients with residual renal function, the average daily urinary excretion of icodextrin was 473 +/- 77 mg per mL of endogenous renal creatinine clearance.",Pharmacokinetics of icodextrin in peritoneal dialysis patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12230479/),[mg] / [ml],473,208165,DB00030,Insulin Regular
,12230479,urinary excretion,"In the nine patients with residual renal function, the average daily urinary excretion of icodextrin was 473 +/- 77 mg per mL of endogenous renal creatinine clearance.",Pharmacokinetics of icodextrin in peritoneal dialysis patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12230479/),[mg] / [ml],473,208166,DB00030,Insulin Regular
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,4.18,208555,DB00030,Insulin Regular
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,3.96,208556,DB00030,Insulin Regular
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,3.83,208557,DB00030,Insulin Regular
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,4.70,208558,DB00030,Insulin Regular
,18261363,terminal half-life,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),h,4.37,208559,DB00030,Insulin Regular
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],384.1,208560,DB00030,Insulin Regular
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],260.2,208561,DB00030,Insulin Regular
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],401.9,208562,DB00030,Insulin Regular
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],345.3,208563,DB00030,Insulin Regular
,18261363,Cmax,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[ng] / [ml],406.2,208564,DB00030,Insulin Regular
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],2078,208565,DB00030,Insulin Regular
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],1249,208566,DB00030,Insulin Regular
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],1901,208567,DB00030,Insulin Regular
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],1938,208568,DB00030,Insulin Regular
,18261363,AUC0-inf,"The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498.","Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18261363/),[h·ng] / [ml],2158,208569,DB00030,Insulin Regular
,14551179,tmax,"Ragaglitazar was rapidly absorbed (tmax: 1.5-1.7 h), with mean AUC0-24 h and Cmax proportional to dose after single and multiple dosing; t1/2 was 80 hours following a single dose and 104 hours in healthy subjects and 122 hours in patients after multiple dosing.","Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551179/),h,1.5-1.7,209379,DB00030,Insulin Regular
,14551179,t1/2,"Ragaglitazar was rapidly absorbed (tmax: 1.5-1.7 h), with mean AUC0-24 h and Cmax proportional to dose after single and multiple dosing; t1/2 was 80 hours following a single dose and 104 hours in healthy subjects and 122 hours in patients after multiple dosing.","Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551179/),h,80,209380,DB00030,Insulin Regular
,14551179,t1/2,"Ragaglitazar was rapidly absorbed (tmax: 1.5-1.7 h), with mean AUC0-24 h and Cmax proportional to dose after single and multiple dosing; t1/2 was 80 hours following a single dose and 104 hours in healthy subjects and 122 hours in patients after multiple dosing.","Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551179/),h,104,209381,DB00030,Insulin Regular
,14551179,t1/2,"Ragaglitazar was rapidly absorbed (tmax: 1.5-1.7 h), with mean AUC0-24 h and Cmax proportional to dose after single and multiple dosing; t1/2 was 80 hours following a single dose and 104 hours in healthy subjects and 122 hours in patients after multiple dosing.","Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14551179/),h,122,209382,DB00030,Insulin Regular
,32514704,relative oral bioavailability,"In serum, nanoparticles provided a maximum of insulin 4-h post-administration, and its relative oral bioavailability was 5.2% (compared with a sc formulation of insulin).",Zein-based nanoparticles for the oral delivery of insulin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32514704/),%,5.2,210534,DB00030,Insulin Regular
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,1.3,210928,DB00030,Insulin Regular
,12687332,half-life (t(1/2)),Gemfibrozil raised the area under the plasma concentration-time curve (AUC) of repaglinide 8.1-fold (range 5.5- to 15.0-fold; p<0.001) and prolonged its half-life (t(1/2)) from 1.3 to 3.7 h (p<0.001).,"Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,3.7,210929,DB00030,Insulin Regular
,12687332,t(1/2),"Although itraconazole alone raised repaglinide AUC only 1.4-fold (1.1- to 1.9-fold; p<0.001), the gemfibrozil-itraconazole combination raised it 19.4-fold (12.9- to 24.7-fold) and prolonged the t(1/2) of repaglinide to 6.1 h (p<0.001).","Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687332/),h,6.1,210930,DB00030,Insulin Regular
,28741871,half-life,RG7697 concentrations peaked at 2 to 4 hours post-dose with a half-life of 19 to 25 hours.,"Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741871/),h,19 to 25,210946,DB00030,Insulin Regular
,28741871,IC50,"Pharmacodynamic variables were well correlated to RG7697 average plasma concentration during MTT, with IC50 (average concentration required for 50% reduction) values of 49 and 24.5 ng/mL for glucose and insulin, respectively.","Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741871/),[ng] / [ml],49,210947,DB00030,Insulin Regular
,28741871,IC50,"Pharmacodynamic variables were well correlated to RG7697 average plasma concentration during MTT, with IC50 (average concentration required for 50% reduction) values of 49 and 24.5 ng/mL for glucose and insulin, respectively.","Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28741871/),[ng] / [ml],24.5,210948,DB00030,Insulin Regular
,22726241,terminal half-life,The terminal half-life of IDeg was approximately 25 h at steady state.,Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22726241/),h,25,211290,DB00030,Insulin Regular
,25359200,IC50,"In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 μM, respectively.",Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359200/),μM,7.28,211429,DB00030,Insulin Regular
,25359200,IC50,"In HEK293 cells, berberine inhibited OCT1- and OCT2-mediated metformin uptake in a concentration dependent manner and IC50 values for OCT1 and OCT2 were 7.28 and 11.3 μM, respectively.",Organic cation transporter-mediated drug-drug interaction potential between berberine and metformin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359200/),μM,11.3,211430,DB00030,Insulin Regular
,31826394,Zeta potential,"Zeta potential and polydispersity index, ranged from 22.1 to 31.2 mV and 0.155-0.185, respectively.",Insulin-loaded mucoadhesive nanoparticles based on mucin-chitosan complexes for oral delivery and diabetes treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31826394/),mv,22.1 to 31.2,211895,DB00030,Insulin Regular
,31826394,polydispersity index,"Zeta potential and polydispersity index, ranged from 22.1 to 31.2 mV and 0.155-0.185, respectively.",Insulin-loaded mucoadhesive nanoparticles based on mucin-chitosan complexes for oral delivery and diabetes treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31826394/),,0.155-0.185,211896,DB00030,Insulin Regular
,31826394,encapsulating efficiency,"The encapsulating efficiency for the systems A1 and A2 were 88.6 and 92.5, respectively, and a self-sustained release of encapsulated insulin was observed for over a period of 8 h.",Insulin-loaded mucoadhesive nanoparticles based on mucin-chitosan complexes for oral delivery and diabetes treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31826394/),,88.6,211897,DB00030,Insulin Regular
,31826394,encapsulating efficiency,"The encapsulating efficiency for the systems A1 and A2 were 88.6 and 92.5, respectively, and a self-sustained release of encapsulated insulin was observed for over a period of 8 h.",Insulin-loaded mucoadhesive nanoparticles based on mucin-chitosan complexes for oral delivery and diabetes treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31826394/),,92.5,211898,DB00030,Insulin Regular
,29453671,AUC0-24 h,The geometric LSM AUC0-24 h value for Glaritus® (1.09 h nmol/L) was comparable to Lantus (1.05 h nmol/L).,"Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453671/),[h·nM] / [l],1.09,212363,DB00030,Insulin Regular
,29453671,AUC0-24 h,The geometric LSM AUC0-24 h value for Glaritus® (1.09 h nmol/L) was comparable to Lantus (1.05 h nmol/L).,"Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453671/),[h·nM] / [l],1.05,212364,DB00030,Insulin Regular
,29453671,Tmax,"Median Tmax values were also identical (12 h for both), and median t1/2 values were also equal (18 h for both).","Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453671/),h,12,212365,DB00030,Insulin Regular
,29453671,t1/2,"Median Tmax values were also identical (12 h for both), and median t1/2 values were also equal (18 h for both).","Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29453671/),h,18,212366,DB00030,Insulin Regular
<,27528391,bioavailability,"In LDC sheep, bioavailability decreased to <2%; most of the dose was absorbed via the lymphatic system, with 88% ± 19% of the dose collected in the lymph after SC administration.",Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27528391/),%,2,212516,DB00030,Insulin Regular
,27528391,bioavailability,"In LDC sheep, bioavailability decreased to <2%; most of the dose was absorbed via the lymphatic system, with 88% ± 19% of the dose collected in the lymph after SC administration.",Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27528391/),%,88,212517,DB00030,Insulin Regular
,18199894,clearance,"Pharmacokinetic analysis revealed less than dose-proportional behavior of drug with low clearance (approximately 7 mL/h/kg), small volume of distribution (approximately 114 mL/kg), and half-life values of approximately 13 hours, which were independent of dose.","Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18199894/),[ml] / [h·kg],7,213405,DB00030,Insulin Regular
,18199894,volume of distribution,"Pharmacokinetic analysis revealed less than dose-proportional behavior of drug with low clearance (approximately 7 mL/h/kg), small volume of distribution (approximately 114 mL/kg), and half-life values of approximately 13 hours, which were independent of dose.","Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18199894/),[ml] / [kg],114,213406,DB00030,Insulin Regular
,18199894,half-life,"Pharmacokinetic analysis revealed less than dose-proportional behavior of drug with low clearance (approximately 7 mL/h/kg), small volume of distribution (approximately 114 mL/kg), and half-life values of approximately 13 hours, which were independent of dose.","Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18199894/),h,13,213407,DB00030,Insulin Regular
,19848574,AUC(120-360),"In the second part of the clamp procedure, plasma insulin levels (area under the curve versus time [AUC]) and the GIR was significantly higher after HIEX compared with IAFP (insulin AUC(120-360), 66,232 +/- 4,521 vs. 48,852 +/- 2,999 pmol/L, P < 0.05; GIR AUC(120-360), 8,928 +/- 1,334 vs. 6,805 +/- 1,655 mg/kg/min).",Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19848574/),[pM] / [l],"66,232",213887,DB00030,Insulin Regular
,19848574,AUC(120-360),"In the second part of the clamp procedure, plasma insulin levels (area under the curve versus time [AUC]) and the GIR was significantly higher after HIEX compared with IAFP (insulin AUC(120-360), 66,232 +/- 4,521 vs. 48,852 +/- 2,999 pmol/L, P < 0.05; GIR AUC(120-360), 8,928 +/- 1,334 vs. 6,805 +/- 1,655 mg/kg/min).",Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19848574/),[pM] / [l],"48,852",213888,DB00030,Insulin Regular
,19848574,AUC(120-360),"In the second part of the clamp procedure, plasma insulin levels (area under the curve versus time [AUC]) and the GIR was significantly higher after HIEX compared with IAFP (insulin AUC(120-360), 66,232 +/- 4,521 vs. 48,852 +/- 2,999 pmol/L, P < 0.05; GIR AUC(120-360), 8,928 +/- 1,334 vs. 6,805 +/- 1,655 mg/kg/min).",Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19848574/),[mg] / [kg·min],"8,928",213889,DB00030,Insulin Regular
,19848574,AUC(120-360),"In the second part of the clamp procedure, plasma insulin levels (area under the curve versus time [AUC]) and the GIR was significantly higher after HIEX compared with IAFP (insulin AUC(120-360), 66,232 +/- 4,521 vs. 48,852 +/- 2,999 pmol/L, P < 0.05; GIR AUC(120-360), 8,928 +/- 1,334 vs. 6,805 +/- 1,655 mg/kg/min).",Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19848574/),[mg] / [kg·min],"6,805",213890,DB00030,Insulin Regular
,10895899,Terminal phase half-life,Terminal phase half-life was 1.1 +/- 0.1 hours.,Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10895899/),h,1.1,214386,DB00030,Insulin Regular
,10895899,Steady-state volume of distribution,Steady-state volume of distribution was 0.23 +/- 0.15 L/kg.,Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10895899/),[l] / [kg],0.23,214387,DB00030,Insulin Regular
,10895899,clearance,"After i.v. administration, clearance was 0.33 +/- 0.04 L/h/kg.",Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10895899/),[l] / [h·kg],0.33,214388,DB00030,Insulin Regular
,10895899,bioavailability,Mean bioavailability of orally administered troglitazone was 6.9%.,Pharmacokinetics of the insulin-sensitizing agent troglitazone in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10895899/),%,6.9,214389,DB00030,Insulin Regular
>,19761358,duration of insulin action (tR(last)),The duration of insulin action (tR(last)) for ILPS at 0.8 U/kg was >23 hours and was similar to G (p = 0.114) and D (p = 0.570).,Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19761358/),h,23,214521,DB00030,Insulin Regular
,19236443,flow rate,Subjects were trained to inhale RHIIP with a flow rate of 90 +/- 30 l/min prior to dosing.,PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),[l] / [min],90,214607,DB00030,Insulin Regular
,19236443,time to reach 10% of,"RHIIP showed a faster onset of action than SCIns [time to reach 10% of total area under the glucose infusion rate (GIR) curves 73 +/- 2 vs. 95 +/- 3 min, time to maximal metabolic effect (T(max)GIR) 173 +/- 13 vs. 218 +/- 9 min, both p < 0.0001].",PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),min,73,214608,DB00030,Insulin Regular
,19236443,time to reach 10% of,"RHIIP showed a faster onset of action than SCIns [time to reach 10% of total area under the glucose infusion rate (GIR) curves 73 +/- 2 vs. 95 +/- 3 min, time to maximal metabolic effect (T(max)GIR) 173 +/- 13 vs. 218 +/- 9 min, both p < 0.0001].",PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),min,95,214609,DB00030,Insulin Regular
,19236443,time to maximal metabolic effect (T(max)GIR),"RHIIP showed a faster onset of action than SCIns [time to reach 10% of total area under the glucose infusion rate (GIR) curves 73 +/- 2 vs. 95 +/- 3 min, time to maximal metabolic effect (T(max)GIR) 173 +/- 13 vs. 218 +/- 9 min, both p < 0.0001].",PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),min,173,214610,DB00030,Insulin Regular
,19236443,time to maximal metabolic effect (T(max)GIR),"RHIIP showed a faster onset of action than SCIns [time to reach 10% of total area under the glucose infusion rate (GIR) curves 73 +/- 2 vs. 95 +/- 3 min, time to maximal metabolic effect (T(max)GIR) 173 +/- 13 vs. 218 +/- 9 min, both p < 0.0001].",PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),min,218,214611,DB00030,Insulin Regular
,19236443,Duration of action,Duration of action (371 +/- 11 vs. 366 +/- 7 min) and total metabolic effect (AUCGIR0-10 h 2734 +/- 274 vs. 2482 +/- 155 mg/kg) were comparable.,PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),min,371,214612,DB00030,Insulin Regular
,19236443,Duration of action,Duration of action (371 +/- 11 vs. 366 +/- 7 min) and total metabolic effect (AUCGIR0-10 h 2734 +/- 274 vs. 2482 +/- 155 mg/kg) were comparable.,PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),min,366,214613,DB00030,Insulin Regular
,19236443,total metabolic effect (AUCGIR0-10 h,Duration of action (371 +/- 11 vs. 366 +/- 7 min) and total metabolic effect (AUCGIR0-10 h 2734 +/- 274 vs. 2482 +/- 155 mg/kg) were comparable.,PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),[mg] / [kg],2734,214614,DB00030,Insulin Regular
,19236443,total metabolic effect (AUCGIR0-10 h,Duration of action (371 +/- 11 vs. 366 +/- 7 min) and total metabolic effect (AUCGIR0-10 h 2734 +/- 274 vs. 2482 +/- 155 mg/kg) were comparable.,PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),[mg] / [kg],2482,214615,DB00030,Insulin Regular
,19236443,Relative bioavailability (BA),"Relative bioavailability (BA) of RHIIP was 12 +/- 2%, and relative biopotency (BP) was 6 +/- 1%.",PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),%,12,214616,DB00030,Insulin Regular
,19236443,relative biopotency,"Relative bioavailability (BA) of RHIIP was 12 +/- 2%, and relative biopotency (BP) was 6 +/- 1%.",PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236443/),%,6,214617,DB00030,Insulin Regular
,24694337,plasma clearance,"Estradiol treatment, in contrast, reduced VLDL-TG concentration by approximately 30% due to accelerated VLDL-TG plasma clearance (25.1 ± 2.5 vs. 17.4 ± 2.7 mL/min; P < .01).","Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694337/),[ml] / [min],25.1,214776,DB00030,Insulin Regular
,24694337,plasma clearance,"Estradiol treatment, in contrast, reduced VLDL-TG concentration by approximately 30% due to accelerated VLDL-TG plasma clearance (25.1 ± 2.5 vs. 17.4 ± 2.7 mL/min; P < .01).","Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24694337/),[ml] / [min],17.4,214777,DB00030,Insulin Regular
,18471141,time to first nadir glucose,Mean time to first nadir glucose was longer for glargine (14 h) relative to PZI (4 h) and lente (5 h).,Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471141/),h,14,215799,DB00030,Insulin Regular
,18471141,time to first nadir glucose,Mean time to first nadir glucose was longer for glargine (14 h) relative to PZI (4 h) and lente (5 h).,Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471141/),h,4,215800,DB00030,Insulin Regular
,18471141,time to first nadir glucose,Mean time to first nadir glucose was longer for glargine (14 h) relative to PZI (4 h) and lente (5 h).,Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471141/),h,5,215801,DB00030,Insulin Regular
,15181040,t(1/2),"The mean t(1/2), CL, and volume of distribution at steady state of r-metHuLeptin are 3.4 +/- 1.5 h, 79 +/- 16 ml/kg.h, and 150 +/- 39 ml/kg, respectively.","Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15181040/),h,3.4,216322,DB00030,Insulin Regular
,15181040,CL,"The mean t(1/2), CL, and volume of distribution at steady state of r-metHuLeptin are 3.4 +/- 1.5 h, 79 +/- 16 ml/kg.h, and 150 +/- 39 ml/kg, respectively.","Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15181040/),[ml] / [h·kg],79,216323,DB00030,Insulin Regular
,15181040,volume of distribution at steady state,"The mean t(1/2), CL, and volume of distribution at steady state of r-metHuLeptin are 3.4 +/- 1.5 h, 79 +/- 16 ml/kg.h, and 150 +/- 39 ml/kg, respectively.","Leptin hormonal kinetics in the fed state: effects of adiposity, age, and gender on endogenous leptin production and clearance rates. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15181040/),[ml] / [kg],150,216324,DB00030,Insulin Regular
,18182992,peak increase,"The peak increase of GH, a biological marker of ghrelin action, was 25 ng ml(-1) with lower-dose and 42 ng ml(-1) with upper-dose ghrelin.","Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18182992/),[ng] / [ml],25,216350,DB00030,Insulin Regular
,18182992,peak increase,"The peak increase of GH, a biological marker of ghrelin action, was 25 ng ml(-1) with lower-dose and 42 ng ml(-1) with upper-dose ghrelin.","Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18182992/),[ng] / [ml],42,216351,DB00030,Insulin Regular
,22338110,clearance from the central compartment (CL(c)),"The clearance from the central compartment (CL(c)) (rats, 3.62 ml/min; monkeys, 2.39 ml · min(-1) · kg(-1); humans, 1.48 ml · min(-1) · kg(-1)) was similar to reported renal clearances.","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),[ml] / [min],3.62,216826,DB00030,Insulin Regular
,22338110,clearance from the central compartment (CL(c)),"The clearance from the central compartment (CL(c)) (rats, 3.62 ml/min; monkeys, 2.39 ml · min(-1) · kg(-1); humans, 1.48 ml · min(-1) · kg(-1)) was similar to reported renal clearances.","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),[ml] / [kg·min],2.39,216827,DB00030,Insulin Regular
,22338110,clearance from the central compartment (CL(c)),"The clearance from the central compartment (CL(c)) (rats, 3.62 ml/min; monkeys, 2.39 ml · min(-1) · kg(-1); humans, 1.48 ml · min(-1) · kg(-1)) was similar to reported renal clearances.","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),[ml] / [kg·min],1.48,216828,DB00030,Insulin Regular
,22338110,equilibrium dissociation constant (K(D)),"The equilibrium dissociation constant (K(D)) was within the reported range in rats (0.74 nM), whereas the value in monkeys (0.12 pM) was much lower than that in humans (1.38 nM).","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),nM,0.74,216829,DB00030,Insulin Regular
,22338110,equilibrium dissociation constant (K(D)),"The equilibrium dissociation constant (K(D)) was within the reported range in rats (0.74 nM), whereas the value in monkeys (0.12 pM) was much lower than that in humans (1.38 nM).","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),pM,0.12,216830,DB00030,Insulin Regular
,22338110,equilibrium dissociation constant (K(D)),"The equilibrium dissociation constant (K(D)) was within the reported range in rats (0.74 nM), whereas the value in monkeys (0.12 pM) was much lower than that in humans (1.38 nM).","Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys, and humans. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22338110/),nM,1.38,216831,DB00030,Insulin Regular
,25795488,relative bioavailability,"The relative bioavailability of total flavonols (sum of quercetin and its metabolites isorhamnetin, tamarixetin, and kaempferol) from RU was 72.5% on d 2 and 49.6% on d 29 when compared with QA (100%).",Bioavailability of the flavonol quercetin in neonatal calves after oral administration of quercetin aglycone or rutin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795488/),%,72.5,216887,DB00030,Insulin Regular
,25795488,relative bioavailability,"The relative bioavailability of total flavonols (sum of quercetin and its metabolites isorhamnetin, tamarixetin, and kaempferol) from RU was 72.5% on d 2 and 49.6% on d 29 when compared with QA (100%).",Bioavailability of the flavonol quercetin in neonatal calves after oral administration of quercetin aglycone or rutin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795488/),%,49.6,216888,DB00030,Insulin Regular
,25795488,relative bioavailability,"The relative bioavailability of total flavonols (sum of quercetin and its metabolites isorhamnetin, tamarixetin, and kaempferol) from RU was 72.5% on d 2 and 49.6% on d 29 when compared with QA (100%).",Bioavailability of the flavonol quercetin in neonatal calves after oral administration of quercetin aglycone or rutin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25795488/),%,100,216889,DB00030,Insulin Regular
,25299682,bioavailability,"Furthermore, the hydrochloride of 11c (11c·HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c·HCl at 50 mg/kg dose was better than that of Metformin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level.","Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25299682/),%,58.94,217569,DB00030,Insulin Regular
,25299682,bioavailability,"Furthermore, the hydrochloride of 11c (11c·HCl) showed excellent bioavailability, 58.94%, over 2 folds than that (28.03%) of 11c, and the anti-obesity effect of 11c·HCl at 50 mg/kg dose was better than that of Metformin at 150 mg/kg dose in DIO mice, almost reversed HFD to a normal level.","Synthesis and lipid-lowering evaluation of 3-methyl-1H-purine-2,6-dione derivatives as potent and orally available anti-obesity agents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25299682/),%,28.03,217570,DB00030,Insulin Regular
,17877397,Pharmacological availability,"Pharmacological availability was 5.6 and 3.4% for the 50 and 100 IU/kg doses, respectively, a significant increase over 1.6%, determined for oral insulin alone in solution.",Oral bioavailability of insulin contained in polysaccharide nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17877397/),%,5.6,217806,DB00030,Insulin Regular
,17877397,Pharmacological availability,"Pharmacological availability was 5.6 and 3.4% for the 50 and 100 IU/kg doses, respectively, a significant increase over 1.6%, determined for oral insulin alone in solution.",Oral bioavailability of insulin contained in polysaccharide nanoparticles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17877397/),%,3.4,217807,DB00030,Insulin Regular
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],7.9,217944,DB00030,Insulin Regular
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],8.4,217945,DB00030,Insulin Regular
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],6.5,217946,DB00030,Insulin Regular
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],6.9,217947,DB00030,Insulin Regular
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],5.8,217948,DB00030,Insulin Regular
,15005635,total clearances,"Median total clearances were 7.9, 8.4, 6.5, 6.9, 5.8 and 4.1 L/h in carriers of the CYP2C9 genotypes *1/*1, *1/*2, *2/*2, *1/*3, *2/*3 and *3/*3.",Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],4.1,217949,DB00030,Insulin Regular
,15005635,clearance,Median clearance in three carriers of two deficient CYP2D6 alleles was 9.4 L/h.,Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15005635/),[l] / [h],9.4,217950,DB00030,Insulin Regular
,12189780,flow rate,"A mobile phase consisting of phosphate buffer, acetonitrile and methanol was used at a flow rate of 1.0 ml/min on a C18 column.",HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189780/),[ml] / [min],1.0,218516,DB00030,Insulin Regular
>,12189780,absolute recovery,The absolute recovery was > 90% and the lower limit of quantitation was 5 ng/ml.,HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12189780/),%,90,218517,DB00030,Insulin Regular
,10885469,half-life (t(1/2)),"The clearance of vanadyl species from the blood in terms of half-life (t(1/2)) was determined as 15 min in VO(OPT)-treated rats, while t(1/2) of VOSO4-treated rats was 5 min, indicating the long-term acting character of VO(OPT).","An orally active antidiabetic vanadyl complex, bis(1-oxy-2-pyridinethiolato)oxovanadium(IV), with VO(S2O2) coordination mode; in vitro and in vivo evaluations in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885469/),min,15,218568,DB00030,Insulin Regular
,10885469,t(1/2),"The clearance of vanadyl species from the blood in terms of half-life (t(1/2)) was determined as 15 min in VO(OPT)-treated rats, while t(1/2) of VOSO4-treated rats was 5 min, indicating the long-term acting character of VO(OPT).","An orally active antidiabetic vanadyl complex, bis(1-oxy-2-pyridinethiolato)oxovanadium(IV), with VO(S2O2) coordination mode; in vitro and in vivo evaluations in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10885469/),min,5,218569,DB00030,Insulin Regular
,30300750,a,We have synthesized Lisofylline-Linoleic acid (LSF-LA) conjugate which self-assembled into micelles (156.9 nm; PDI 0.187; CMC 1 μg/mL; aggregation number 54) without any surfactant and showed enhanced cellular uptake.,Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30300750/),,54,219575,DB00030,Insulin Regular
,17202597,maximum concentrations,"However, steviol glucuronide (SV glu) was found in maximum concentrations of 33 micro g/ml (21.3 micro g steviol equivalents/ml).",Metabolism of stevioside by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202597/),[μg] / [ml],33,219657,DB00030,Insulin Regular
,17202597,maximum concentrations,"However, steviol glucuronide (SV glu) was found in maximum concentrations of 33 micro g/ml (21.3 micro g steviol equivalents/ml).",Metabolism of stevioside by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17202597/),μg,21.3,219658,DB00030,Insulin Regular
>,28987595,half-life,Fatty acid modification extended the half-life of native apelin-13 to >24 h in vitro.,"Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28987595/),h,24,220632,DB00030,Insulin Regular
,11719730,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.1 to 2.3 hours (P <.05) by gemfibrozil.,Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719730/),h,2.1,220867,DB00030,Insulin Regular
,11719730,elimination half-life,The mean elimination half-life of glimepiride was prolonged from 2.1 to 2.3 hours (P <.05) by gemfibrozil.,Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11719730/),h,2.3,220868,DB00030,Insulin Regular
less,29501738,bioavailability,"However, this system presents a bioavailability of less than 20% for insulin encapsulation.","Oral insulin delivery, the challenge to increase insulin bioavailability: Influence of surface charge in nanoparticle system. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29501738/),%,20,221356,DB00030,Insulin Regular
,15853836,C(max),"PK analysis showed a smaller early serum hGH peak followed by a broad sustained second peak of hGH (C(max) 1.20 microg/l at 7.2 days), and hGH levels were maintained above baseline for at least 14 days.","A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853836/),[μg] / [l],1.20,221389,DB00030,Insulin Regular
,15853836,C(max),"Resultant IGF-I concentrations were characterized by sustained elevation at a level near C(max) of 103 microg/l (at t(max) of 9.7 days), equal to an SD score of +0.8.","A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853836/),[μg] / [l],103,221390,DB00030,Insulin Regular
,15853836,t(max),"Resultant IGF-I concentrations were characterized by sustained elevation at a level near C(max) of 103 microg/l (at t(max) of 9.7 days), equal to an SD score of +0.8.","A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15853836/),d,9.7,221391,DB00030,Insulin Regular
,17368006,clearance half-life,"The conventional nasal spray deposited in the posterior nasal cavity in only one instance, with a rapid clearance half-life of 9.2 min.","Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17368006/),min,9.2,222323,DB00030,Insulin Regular
,17368006,nasal residence time,"The nasal insert formulations did not enhance nasal absorption of insulin, however an extended nasal residence time of 4-5 h was observed for the 2% HPMC formulation.","Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17368006/),h,4-5,222324,DB00030,Insulin Regular
,12365198,systemic clearance,The systemic clearance and volume of distribution of PAT-5A in rats were 83.1 mL/h and 177.1 mL respectively after i.v. administration.,"Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365198/),[ml] / [h],83.1,224053,DB00030,Insulin Regular
,12365198,volume of distribution,The systemic clearance and volume of distribution of PAT-5A in rats were 83.1 mL/h and 177.1 mL respectively after i.v. administration.,"Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365198/),ml,177.1,224054,DB00030,Insulin Regular
,12365198,terminal half-life,Plasma concentrations declined monoexponentially following oral as well as intravenous administration and terminal half-life was about 1.4 h.,"Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365198/),h,1.4,224055,DB00030,Insulin Regular
,12365198,Absolute oral bioavailability,Absolute oral bioavailability of PAT-5A across the doses tested was in the range of 73-100% and this indicates that PAT-5A is neither a candidate for pre-systemic metabolism nor prone to absorption-related issues.,"Oral bioavailability and pharmacokinetics of PAT-5A, a new insulin sensitizer in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12365198/),%,73-100,224056,DB00030,Insulin Regular
,16330292,Ins-T(max),"Ins-T(max) was shorter for 5, 10, and 20 puffs of oral insulin spray than for SC insulin (26.7 [13.7], 29.2 [7.4], 23.3 [5.2], and 142.5 [73.2] min, respectively; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,26.7,224131,DB00030,Insulin Regular
,16330292,Ins-T(max),"Ins-T(max) was shorter for 5, 10, and 20 puffs of oral insulin spray than for SC insulin (26.7 [13.7], 29.2 [7.4], 23.3 [5.2], and 142.5 [73.2] min, respectively; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,29.2,224132,DB00030,Insulin Regular
,16330292,Ins-T(max),"Ins-T(max) was shorter for 5, 10, and 20 puffs of oral insulin spray than for SC insulin (26.7 [13.7], 29.2 [7.4], 23.3 [5.2], and 142.5 [73.2] min, respectively; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,23.3,224133,DB00030,Insulin Regular
,16330292,Ins-T(max),"Ins-T(max) was shorter for 5, 10, and 20 puffs of oral insulin spray than for SC insulin (26.7 [13.7], 29.2 [7.4], 23.3 [5.2], and 142.5 [73.2] min, respectively; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,142.5,224134,DB00030,Insulin Regular
,16330292,Ca(max),"The Ins-AUC(0-120) for 5, 10, and 20 puffs of oral insulin spray (304.8 [277.9], 689.2 [353.0], and 1808.8 [1252.6] microU/mL per min, respectively; P < 0.05) and the corresponding Ins-Ca(max) (12.9 [8.7], 26.7 [14.5], and 47.6 [40.1] microU/mL; P < 0.05) suggested a dose-response relationship.","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),[μu] / [ml],12.9,224135,DB00030,Insulin Regular
,16330292,Ca(max),"The Ins-AUC(0-120) for 5, 10, and 20 puffs of oral insulin spray (304.8 [277.9], 689.2 [353.0], and 1808.8 [1252.6] microU/mL per min, respectively; P < 0.05) and the corresponding Ins-Ca(max) (12.9 [8.7], 26.7 [14.5], and 47.6 [40.1] microU/mL; P < 0.05) suggested a dose-response relationship.","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),[μu] / [ml],26.7,224136,DB00030,Insulin Regular
,16330292,Ca(max),"The Ins-AUC(0-120) for 5, 10, and 20 puffs of oral insulin spray (304.8 [277.9], 689.2 [353.0], and 1808.8 [1252.6] microU/mL per min, respectively; P < 0.05) and the corresponding Ins-Ca(max) (12.9 [8.7], 26.7 [14.5], and 47.6 [40.1] microU/mL; P < 0.05) suggested a dose-response relationship.","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),[μu] / [ml],47.6,224137,DB00030,Insulin Regular
,16330292,early T50%,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,23.3,224138,DB00030,Insulin Regular
,16330292,early T50%,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,28.3,224139,DB00030,Insulin Regular
,16330292,early T50%,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,31.2,224140,DB00030,Insulin Regular
,16330292,early T50%,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,87.0,224141,DB00030,Insulin Regular
,16330292,maximal effect,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,40.0,224142,DB00030,Insulin Regular
,16330292,maximal effect,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,45.8,224143,DB00030,Insulin Regular
,16330292,maximal effect,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,44.2,224144,DB00030,Insulin Regular
,16330292,maximal effect,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,145.0,224145,DB00030,Insulin Regular
,16330292,late T50%,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,56.5,224146,DB00030,Insulin Regular
,16330292,late T50%,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,70.2,224147,DB00030,Insulin Regular
,16330292,late T50%,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,75.5,224148,DB00030,Insulin Regular
,16330292,late T50%,"Five, 10, and 20 puffs of oral insulin spray had an earlier onset of action than SC insulin (early T50%: 23.3 [15.1], 28.3 [12.3], 31.2 [111.8], and 87.0 [39.6] min, respectively; P < 0.05), an earlier maximal effect (GIR-T(max): 40.0 [23.7], 45.8 [22.7], 44.2 [5.8], and 145.0 [43.7] min; P < 0.05), and a shorter duration of action (late T50%: 56.5 [31.0], 70.2 [12.9], 75.5 [6.0], and 290.8 [84.0] min; P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),min,290.8,224149,DB00030,Insulin Regular
,16330292,AUC(0-120),"Dose-dependent increases in maximal metabolic effect were observed with 5, 10, and 20 puffs: the GIR(max) was 0.9 (0.5), 2.0 (1.3), and 3.9 (2.5) mg/kg per minute, respectively (P < 0.05), and the GIR-AUC(0-120) was 39.6 (34.9), 76.8 (67.4), and 189.1 (163.0) mg/kg per minute (P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),[mg] / [kg·min],39.6,224150,DB00030,Insulin Regular
,16330292,AUC(0-120),"Dose-dependent increases in maximal metabolic effect were observed with 5, 10, and 20 puffs: the GIR(max) was 0.9 (0.5), 2.0 (1.3), and 3.9 (2.5) mg/kg per minute, respectively (P < 0.05), and the GIR-AUC(0-120) was 39.6 (34.9), 76.8 (67.4), and 189.1 (163.0) mg/kg per minute (P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),[mg] / [kg·min],76.8,224151,DB00030,Insulin Regular
,16330292,AUC(0-120),"Dose-dependent increases in maximal metabolic effect were observed with 5, 10, and 20 puffs: the GIR(max) was 0.9 (0.5), 2.0 (1.3), and 3.9 (2.5) mg/kg per minute, respectively (P < 0.05), and the GIR-AUC(0-120) was 39.6 (34.9), 76.8 (67.4), and 189.1 (163.0) mg/kg per minute (P < 0.05).","Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16330292/),[mg] / [kg·min],189.1,224152,DB00030,Insulin Regular
,12182252,absolute bioavailability,The absolute bioavailability of rosiglitazone was 99%.,The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182252/),%,99,224207,DB00030,Insulin Regular
,12182252,absolute bioavailability,"In this study of 12 healthy adult male volunteers, the absolute bioavailability of rosiglitazone was 99%, and the oral and IV single-dose pharmacokinetics of rosiglitazone were unaltered by concurrent treatment with ranitidine.",The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12182252/),%,99,224208,DB00030,Insulin Regular
,11007061,absolute bioavailability,"When insulin solutions in the absence of beta-CyDs were injected into the dorsal subcutaneous tissues of rats, the absolute bioavailability of insulin calculated from plasma immunoreactive insulin (IRI) levels was approximately 50%.",Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether beta-cyclodextrin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007061/),%,50,224626,DB00030,Insulin Regular
,11007061,bioavailability,The bioavailability of the insulin/SBE4-beta-CyD system was about twice that of insulin alone and approached 96%.,Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether beta-cyclodextrin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11007061/),%,96,224627,DB00030,Insulin Regular
,27552669,elimination half-lives,Exposure increased in a dose-dependent manner with peak concentrations at approximately 24h post-dosing and elimination half-lives in the range of 12 to 24h.,"Safety and PK/PD correlation of TV-1106, a recombinant fused human albumin-growth hormone, following repeat dose administration to monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27552669/),h,12 to 24,225226,DB00030,Insulin Regular
,11951812,Tmax (time to maximal plasma concentration),"The Tmax (time to maximal plasma concentration) of LA administered as CRLA was 1.25 hours and was approximately 2.5-fold longer in comparison with the Tmax for QRLA (Tn,5X = 0.5 hour; P<0.02).","Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11951812/),h,1.25,226840,DB00030,Insulin Regular
,11951812,Tn,"The Tmax (time to maximal plasma concentration) of LA administered as CRLA was 1.25 hours and was approximately 2.5-fold longer in comparison with the Tmax for QRLA (Tn,5X = 0.5 hour; P<0.02).","Pharmacokinetics, tolerability, and fructosamine-lowering effect of a novel, controlled-release formulation of alpha-lipoic acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11951812/),h,0.5,226841,DB00030,Insulin Regular
,32719315,Elimination plasma half-life,"Elimination plasma half-life of ~20 h in dogs and ~70 h in man is achieved by a strong albumin binding, and by lowering the insulin receptor affinity 500-fold to slow down receptor mediated clearance.",Molecular engineering of safe and efficacious oral basal insulin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32719315/),h,20,227214,DB00030,Insulin Regular
,32719315,Elimination plasma half-life,"Elimination plasma half-life of ~20 h in dogs and ~70 h in man is achieved by a strong albumin binding, and by lowering the insulin receptor affinity 500-fold to slow down receptor mediated clearance.",Molecular engineering of safe and efficacious oral basal insulin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32719315/),h,70,227215,DB00030,Insulin Regular
,11134132,area under the curve (AUC),"The area under the curve (AUC) of the GH response after GHRP-2 alone was 4.8 times higher compared with GHRH alone (1834 +/- 255 vs. 382 +/- 78 microg/L.60 min, P: < 0.001).",Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11134132/),[μg] / [60·l·min],1834,227362,DB00030,Insulin Regular
,11134132,area under the curve (AUC),"The area under the curve (AUC) of the GH response after GHRP-2 alone was 4.8 times higher compared with GHRH alone (1834 +/- 255 vs. 382 +/- 78 microg/L.60 min, P: < 0.001).",Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11134132/),[μg] / [60·l·min],382,227363,DB00030,Insulin Regular
,11134132,AUC,"Acipimox, which reduced FFAs from 607 micromol/L to 180 micromol/L, increased the GH AUC to 1087 after GHRH and to 2956 microg/L.60 min after GHRP-2 (P: < 0.01).",Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11134132/),[μg] / [l],1087,227364,DB00030,Insulin Regular
,11134132,AUC,"Acipimox, which reduced FFAs from 607 micromol/L to 180 micromol/L, increased the GH AUC to 1087 after GHRH and to 2956 microg/L.60 min after GHRP-2 (P: < 0.01).",Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11134132/),[μg] / [l],2956,227365,DB00030,Insulin Regular
,29273578,half-life,"Dasiglucagon demonstrated a dose-dependent and rapid increase in plasma concentrations, reaching a maximum at ∼35 min with a half-life of ∼0.5 h.","Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29273578/),h,∼0.5,227416,DB00030,Insulin Regular
,12459900,t(1/2)alpha,"Half-lives of fast phase uptake and slow phase disappearance for (14)C and V were calculated from a two-compartment model for whole blood, plasma, liver, kidney, bone, small intestine, and lung, ranging from 17 min ( t(1/2)alpha for (14)C, liver) to 30 days ( t(1/2)beta for V, bone).",Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459900/),min,17,227587,DB00030,Insulin Regular
,12459900,t(1/2)beta,"Half-lives of fast phase uptake and slow phase disappearance for (14)C and V were calculated from a two-compartment model for whole blood, plasma, liver, kidney, bone, small intestine, and lung, ranging from 17 min ( t(1/2)alpha for (14)C, liver) to 30 days ( t(1/2)beta for V, bone).",Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459900/),d,30,227588,DB00030,Insulin Regular
,12940610,AUC(0-6),"Mean pharmacokinetic parameters (AUC(0-6) 10.45 mg/l/h; t(1/2) 1.89 h, Cl/F 10.19 l/h) were comparable with those reported in healthy subjects.",Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12940610/),[mg] / [h·l],10.45,228071,DB00030,Insulin Regular
,12940610,t(1/2),"Mean pharmacokinetic parameters (AUC(0-6) 10.45 mg/l/h; t(1/2) 1.89 h, Cl/F 10.19 l/h) were comparable with those reported in healthy subjects.",Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12940610/),h,1.89,228072,DB00030,Insulin Regular
,12940610,Cl/F,"Mean pharmacokinetic parameters (AUC(0-6) 10.45 mg/l/h; t(1/2) 1.89 h, Cl/F 10.19 l/h) were comparable with those reported in healthy subjects.",Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12940610/),[l] / [h],10.19,228073,DB00030,Insulin Regular
,24488322,OS,"Estimated 6-month survival was 49.4 % (95 % CI 38.8-60.0) in Cohort A and 44.1 % (95 % CI 33.4-54.9) in Cohort B. Median OS was 5.8 and 5.6 months, respectively; median PFS was 1.4 months in both cohorts.","Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24488322/),month,5.8,228832,DB00030,Insulin Regular
,24488322,OS,"Estimated 6-month survival was 49.4 % (95 % CI 38.8-60.0) in Cohort A and 44.1 % (95 % CI 33.4-54.9) in Cohort B. Median OS was 5.8 and 5.6 months, respectively; median PFS was 1.4 months in both cohorts.","Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24488322/),month,5.6,228833,DB00030,Insulin Regular
,24488322,PFS,"Estimated 6-month survival was 49.4 % (95 % CI 38.8-60.0) in Cohort A and 44.1 % (95 % CI 33.4-54.9) in Cohort B. Median OS was 5.8 and 5.6 months, respectively; median PFS was 1.4 months in both cohorts.","Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24488322/),month,1.4,228834,DB00030,Insulin Regular
,28820081,available energy,"The available energy of 1,5-AG, which is absorbed readily from the small intestine and excreted quickly into the urine, is 0 kJ/g (0 kcal/g).","Effects of 1,5-anhydroglucitol on postprandial blood glucose and insulin levels and hydrogen excretion in rats and healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820081/),[kj] / [g],0,229212,DB00030,Insulin Regular
,28820081,available energy,"The available energy of 1,5-AG, which is absorbed readily from the small intestine and excreted quickly into the urine, is 0 kJ/g (0 kcal/g).","Effects of 1,5-anhydroglucitol on postprandial blood glucose and insulin levels and hydrogen excretion in rats and healthy humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28820081/),[kcal] / [g],0,229213,DB00030,Insulin Regular
,12663568,NGT-to-IGT ratio,"In the biphasic group, the NGT-to-IGT ratio was slightly higher (173/20 vs. 209/40, P = 0.08) and the male-to-female ratio was lower (60/133 vs. 120/129, P = 0.0003).",Assessing the shape of the glucose curve during an oral glucose tolerance test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663568/),,173/20,230434,DB00030,Insulin Regular
,12663568,NGT-to-IGT ratio,"In the biphasic group, the NGT-to-IGT ratio was slightly higher (173/20 vs. 209/40, P = 0.08) and the male-to-female ratio was lower (60/133 vs. 120/129, P = 0.0003).",Assessing the shape of the glucose curve during an oral glucose tolerance test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12663568/),,209/40,230435,DB00030,Insulin Regular
,25417447,terminal half-life,"The terminal half-life of IDeg is about 25 hours, which reflects a mean prolongation by factor 2 compared to Insulin glargin (lGlar).",[Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25417447/),h,25,231286,DB00030,Insulin Regular
,31137123,Maximum insulin concentration,"Result: Maximum insulin concentration [(667±141) pmol/L vs (267±68) pmol/L, P<0.01] and area under curve (AUC) of insulin concentration [(152±32) nmol·L(-1)·min vs (57±7) nmol·L(-1)·min, P<0.01] in A group were higher while maximum glucose infusion rate (GIR) [(3.70±0.70) mg·kg(-1)·min(-1) vs (7.66±2.11) mg·kg(-1)·min(-1), P<0.01] and AUC of GIR [(931±272) mg/kg vs (1 920±452) mg/kg, P<0.01] were lower compared to B group.",[Effect of peripheral hyperinsulinemia on assessment of pharmacokinetics and pharmacodynamics of insulin preparations in euglycemic clamp]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31137123/),[pM] / [l],667,231586,DB00030,Insulin Regular
,31137123,Maximum insulin concentration,"Result: Maximum insulin concentration [(667±141) pmol/L vs (267±68) pmol/L, P<0.01] and area under curve (AUC) of insulin concentration [(152±32) nmol·L(-1)·min vs (57±7) nmol·L(-1)·min, P<0.01] in A group were higher while maximum glucose infusion rate (GIR) [(3.70±0.70) mg·kg(-1)·min(-1) vs (7.66±2.11) mg·kg(-1)·min(-1), P<0.01] and AUC of GIR [(931±272) mg/kg vs (1 920±452) mg/kg, P<0.01] were lower compared to B group.",[Effect of peripheral hyperinsulinemia on assessment of pharmacokinetics and pharmacodynamics of insulin preparations in euglycemic clamp]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31137123/),[pM] / [l],267,231587,DB00030,Insulin Regular
,31137123,area under curve (AUC) of insulin concentration,"Result: Maximum insulin concentration [(667±141) pmol/L vs (267±68) pmol/L, P<0.01] and area under curve (AUC) of insulin concentration [(152±32) nmol·L(-1)·min vs (57±7) nmol·L(-1)·min, P<0.01] in A group were higher while maximum glucose infusion rate (GIR) [(3.70±0.70) mg·kg(-1)·min(-1) vs (7.66±2.11) mg·kg(-1)·min(-1), P<0.01] and AUC of GIR [(931±272) mg/kg vs (1 920±452) mg/kg, P<0.01] were lower compared to B group.",[Effect of peripheral hyperinsulinemia on assessment of pharmacokinetics and pharmacodynamics of insulin preparations in euglycemic clamp]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31137123/),[min·nM] / [l],152,231588,DB00030,Insulin Regular
,31137123,area under curve (AUC) of insulin concentration,"Result: Maximum insulin concentration [(667±141) pmol/L vs (267±68) pmol/L, P<0.01] and area under curve (AUC) of insulin concentration [(152±32) nmol·L(-1)·min vs (57±7) nmol·L(-1)·min, P<0.01] in A group were higher while maximum glucose infusion rate (GIR) [(3.70±0.70) mg·kg(-1)·min(-1) vs (7.66±2.11) mg·kg(-1)·min(-1), P<0.01] and AUC of GIR [(931±272) mg/kg vs (1 920±452) mg/kg, P<0.01] were lower compared to B group.",[Effect of peripheral hyperinsulinemia on assessment of pharmacokinetics and pharmacodynamics of insulin preparations in euglycemic clamp]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31137123/),[min·nM] / [l],57,231589,DB00030,Insulin Regular
,31137123,maximum glucose infusion rate,"Result: Maximum insulin concentration [(667±141) pmol/L vs (267±68) pmol/L, P<0.01] and area under curve (AUC) of insulin concentration [(152±32) nmol·L(-1)·min vs (57±7) nmol·L(-1)·min, P<0.01] in A group were higher while maximum glucose infusion rate (GIR) [(3.70±0.70) mg·kg(-1)·min(-1) vs (7.66±2.11) mg·kg(-1)·min(-1), P<0.01] and AUC of GIR [(931±272) mg/kg vs (1 920±452) mg/kg, P<0.01] were lower compared to B group.",[Effect of peripheral hyperinsulinemia on assessment of pharmacokinetics and pharmacodynamics of insulin preparations in euglycemic clamp]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31137123/),[mg] / [kg·min],3.70,231590,DB00030,Insulin Regular
,31137123,maximum glucose infusion rate,"Result: Maximum insulin concentration [(667±141) pmol/L vs (267±68) pmol/L, P<0.01] and area under curve (AUC) of insulin concentration [(152±32) nmol·L(-1)·min vs (57±7) nmol·L(-1)·min, P<0.01] in A group were higher while maximum glucose infusion rate (GIR) [(3.70±0.70) mg·kg(-1)·min(-1) vs (7.66±2.11) mg·kg(-1)·min(-1), P<0.01] and AUC of GIR [(931±272) mg/kg vs (1 920±452) mg/kg, P<0.01] were lower compared to B group.",[Effect of peripheral hyperinsulinemia on assessment of pharmacokinetics and pharmacodynamics of insulin preparations in euglycemic clamp]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31137123/),[mg] / [kg·min],7.66,231591,DB00030,Insulin Regular
,31137123,AUC,"Result: Maximum insulin concentration [(667±141) pmol/L vs (267±68) pmol/L, P<0.01] and area under curve (AUC) of insulin concentration [(152±32) nmol·L(-1)·min vs (57±7) nmol·L(-1)·min, P<0.01] in A group were higher while maximum glucose infusion rate (GIR) [(3.70±0.70) mg·kg(-1)·min(-1) vs (7.66±2.11) mg·kg(-1)·min(-1), P<0.01] and AUC of GIR [(931±272) mg/kg vs (1 920±452) mg/kg, P<0.01] were lower compared to B group.",[Effect of peripheral hyperinsulinemia on assessment of pharmacokinetics and pharmacodynamics of insulin preparations in euglycemic clamp]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31137123/),[mg] / [kg],931,231592,DB00030,Insulin Regular
,31137123,AUC,"Result: Maximum insulin concentration [(667±141) pmol/L vs (267±68) pmol/L, P<0.01] and area under curve (AUC) of insulin concentration [(152±32) nmol·L(-1)·min vs (57±7) nmol·L(-1)·min, P<0.01] in A group were higher while maximum glucose infusion rate (GIR) [(3.70±0.70) mg·kg(-1)·min(-1) vs (7.66±2.11) mg·kg(-1)·min(-1), P<0.01] and AUC of GIR [(931±272) mg/kg vs (1 920±452) mg/kg, P<0.01] were lower compared to B group.",[Effect of peripheral hyperinsulinemia on assessment of pharmacokinetics and pharmacodynamics of insulin preparations in euglycemic clamp]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31137123/),[mg] / [kg],1 920,231593,DB00030,Insulin Regular
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],149.6,231737,DB00030,Insulin Regular
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],103.3,231738,DB00030,Insulin Regular
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],31.4,231739,DB00030,Insulin Regular
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],20.2,231740,DB00030,Insulin Regular
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],41.9,231741,DB00030,Insulin Regular
,14522601,AUCs,"The AUCs of pioglitazone (149.6+/-22.6 vs. 103.3+/-14.0 microg.h/ml; P<0.01), M-III (31.4+/-8.1 vs. 20.2+/-4.7 microg.h/ml; P<0.05) and M-IV (41.9+/-15.5 vs. 14.1+/-1.6 microg.h/ml; P<0.01) were larger in female rats than in male rats, but the levels of M-II were similar.",Sex differences in the pharmacokinetics of pioglitazone in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522601/),[h·μg] / [ml],14.1,231742,DB00030,Insulin Regular
,16698134,elimination half-life,"During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05).","The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698134/),,0.117,232860,DB00030,Insulin Regular
,16698134,elimination half-life,"During the EGb 761 cycles, only the elimination half-life in the T2DM subjects was significantly increased (0.117+/-0.085 to 0.141+/-0.100, P<0.05).","The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16698134/),,0.141,232861,DB00030,Insulin Regular
,16418696,concentrations,"Mean (range) metformin concentrations in cord plasma and in maternal plasma were 0.81 (range, 0.1-2.6) mg/L and 1.2 (range, 0.1-2.9) mg/L, respectively.",Population pharmacokinetics of metformin in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),,0.81,234004,DB00030,Insulin Regular
,16418696,concentrations,"Mean (range) metformin concentrations in cord plasma and in maternal plasma were 0.81 (range, 0.1-2.6) mg/L and 1.2 (range, 0.1-2.9) mg/L, respectively.",Population pharmacokinetics of metformin in late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),,1.2,234005,DB00030,Insulin Regular
,16418696,clearance,"Typical population values (interindividual variability, CV%) for allometrically scaled maternal clearance and volume of distribution were 28 L/h/70 kg (17.1%) and 190 L/70 kg (46.3%), giving a derived population-wide half-life of 5.1 hours.",Population pharmacokinetics of metformin in late pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),[l] / [70·h·kg],28,234006,DB00030,Insulin Regular
,16418696,volume of distribution,"Typical population values (interindividual variability, CV%) for allometrically scaled maternal clearance and volume of distribution were 28 L/h/70 kg (17.1%) and 190 L/70 kg (46.3%), giving a derived population-wide half-life of 5.1 hours.",Population pharmacokinetics of metformin in late pregnancy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),[l] / [70·kg],190,234007,DB00030,Insulin Regular
,16418696,half-life,"Typical population values (interindividual variability, CV%) for allometrically scaled maternal clearance and volume of distribution were 28 L/h/70 kg (17.1%) and 190 L/70 kg (46.3%), giving a derived population-wide half-life of 5.1 hours.",Population pharmacokinetics of metformin in late pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),h,5.1,234008,DB00030,Insulin Regular
,16418696,placental partition coefficient,The placental partition coefficient for metformin was 1.07 (36.3%).,Population pharmacokinetics of metformin in late pregnancy. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418696/),,1.07,234009,DB00030,Insulin Regular
,24089542,time until peak plasma insulin level,Insulin administration by jet injection resulted in shorter time until peak plasma insulin level (51.3 ± 6.4 vs. 91.9 ± 10.2 min; P = 0.003) and reduced hyperglycemic burden during the first hour (154.3 ± 20.8 vs.,Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24089542/),min,51.3,234222,DB00030,Insulin Regular
,24089542,time until peak plasma insulin level,Insulin administration by jet injection resulted in shorter time until peak plasma insulin level (51.3 ± 6.4 vs. 91.9 ± 10.2 min; P = 0.003) and reduced hyperglycemic burden during the first hour (154.3 ± 20.8 vs.,Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24089542/),min,91.9,234223,DB00030,Insulin Regular
,16284921,Maximum relative bioavailability,Maximum relative bioavailability (relative to s.c - 0.26 U/kg) of spray-instilled insulin was 46%.,Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284921/),%,46,234244,DB00030,Insulin Regular
,16284921,"basal zero order production rate of glucose (k(G, prod))","The basal zero order production rate of glucose (k(G, prod)) was estimated as 0.98 mg/dl/min.",Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284921/),[mg] / [dl·min],0.98,234245,DB00030,Insulin Regular
,16284921,SC50,The SC50 was fixed at 80 mu U/ml based on literature reports and the S(max) was estimated to be 6.,Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284921/),[mu·u] / [ml],80,234246,DB00030,Insulin Regular
,16284921,S(max),The SC50 was fixed at 80 mu U/ml based on literature reports and the S(max) was estimated to be 6.,Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16284921/),,6,234247,DB00030,Insulin Regular
,11757582,half-life,"IGF-I concentrations increased only transiently because of the short half-life (1.3-3 h, compared to a normal range of 17-22 h).",Decreased half-life of insulin-like growth factor I in Rabson-Mendenhall syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11757582/),h,1.3-3,234284,DB00030,Insulin Regular
,11757582,half-life,"IGF-I concentrations increased only transiently because of the short half-life (1.3-3 h, compared to a normal range of 17-22 h).",Decreased half-life of insulin-like growth factor I in Rabson-Mendenhall syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11757582/),h,17-22,234285,DB00030,Insulin Regular
,18082254,bioavailability,The corresponding bioavailability of insulin was 5.11% compared with 0.87% for the control group (p=0.007).,The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082254/),%,5.11,234957,DB00030,Insulin Regular
,18082254,bioavailability,The corresponding bioavailability of insulin was 5.11% compared with 0.87% for the control group (p=0.007).,The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082254/),%,0.87,234958,DB00030,Insulin Regular
,25767259,AUC0-10,"Postmeal dosing had little impact, yet premeal dosing delayed and reduced 3-OMG absorption, with an AUC0-10 of 231±31 vs.",Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767259/),,231,235444,DB00030,Insulin Regular
,25767259,Recovery of tracer in urine,Recovery of tracer in urine was 1.2±0.7 g for premeal dosing and 2.2±0.1 g for placebo.,Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767259/),g,1.2,235445,DB00030,Insulin Regular
,25767259,Recovery of tracer in urine,Recovery of tracer in urine was 1.2±0.7 g for premeal dosing and 2.2±0.1 g for placebo.,Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25767259/),g,2.2,235446,DB00030,Insulin Regular
,17623819,area under the curve [AUC](0-end of GIR)),"Estimated total insulin activity (GIR area under the curve [AUC](0-end of GIR)) was 1,412 +/- 662 and 915 +/- 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),[mg] / [kg],"1,412",236079,DB00030,Insulin Regular
,17623819,area under the curve [AUC](0-end of GIR)),"Estimated total insulin activity (GIR area under the curve [AUC](0-end of GIR)) was 1,412 +/- 662 and 915 +/- 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),[mg] / [kg],915,236080,DB00030,Insulin Regular
,17623819,time of end of action,"Estimated total insulin activity (GIR area under the curve [AUC](0-end of GIR)) was 1,412 +/- 662 and 915 +/- 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),h,24,236081,DB00030,Insulin Regular
,17623819,time of end of action,"Estimated total insulin activity (GIR area under the curve [AUC](0-end of GIR)) was 1,412 +/- 662 and 915 +/- 225 mg/kg (glargine vs. detemir, P < 0.05), with median time of end of action at 24 and 17.5 h (glargine vs. detemir, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),h,17.5,236082,DB00030,Insulin Regular
,17623819,AUC free fatty acids(0-24 h),"The antilipolytic action of detemir was lower than that of glargine (AUC free fatty acids(0-24 h) 11 +/- 1.7 vs. 8 +/- 2.8 mmol/l, respectively, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),[mM] / [l],11,236083,DB00030,Insulin Regular
,17623819,AUC free fatty acids(0-24 h),"The antilipolytic action of detemir was lower than that of glargine (AUC free fatty acids(0-24 h) 11 +/- 1.7 vs. 8 +/- 2.8 mmol/l, respectively, P < 0.001).","Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17623819/),[mM] / [l],8,236084,DB00030,Insulin Regular
,21219436,absolute bioavailability,"Thus, absolute bioavailability was near 100% for both subcutaneous bolus insulin injection and continuous subcutaneous insulin infusion.","Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21219436/),%,100,236598,DB00030,Insulin Regular
,23400740,disposition half-life,"Median disposition half-life was 21.1 and 27.8 days at 10 and 20 mg/kg, respectively.","Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400740/),d,21.1,236855,DB00030,Insulin Regular
,23400740,disposition half-life,"Median disposition half-life was 21.1 and 27.8 days at 10 and 20 mg/kg, respectively.","Pharmacokinetics and pharmacodynamics of figitumumab, a monoclonal antibody targeting the insulin-like growth factor 1 receptor, in healthy participants. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23400740/),d,27.8,236856,DB00030,Insulin Regular
,14748619,bioavailability,"The pharmacokinetics of nateglinide are characterised by rapid absorption and elimination, with good (73%) bioavailability.","Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748619/),%,73,236941,DB00030,Insulin Regular
,24395457,MTD,The MTD of PF-04691502 was 8 mg orally once daily.,"Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24395457/),mg,8,237114,DB00030,Insulin Regular
,19885293,absorption,The comparative absorption of IN insulin relative to SC insulin was 12.0% (dominant nostril) or 15.4% (nondominant nostril) over 2 h.,Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin) administered to healthy male volunteers: infuence of the nasal cycle. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19885293/),%,12.0,237150,DB00030,Insulin Regular
,19885293,absorption,The comparative absorption of IN insulin relative to SC insulin was 12.0% (dominant nostril) or 15.4% (nondominant nostril) over 2 h.,Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin) administered to healthy male volunteers: infuence of the nasal cycle. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19885293/),%,15.4,237151,DB00030,Insulin Regular
,19300394,intestinal permeability coefficients,Optimized intestinal permeability coefficients (x10(-4)) of insulin best test and reference formulations were 0.084 and 0.179 cm/sec respectively.,Enhancement of oral bioavailability of insulin in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300394/),[cm] / [s],0.084,237530,DB00030,Insulin Regular
,19300394,intestinal permeability coefficients,Optimized intestinal permeability coefficients (x10(-4)) of insulin best test and reference formulations were 0.084 and 0.179 cm/sec respectively.,Enhancement of oral bioavailability of insulin in humans. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300394/),[cm] / [s],0.179,237531,DB00030,Insulin Regular
,19300394,Total fraction of insulin dose absorbed (Fa),Total fraction of insulin dose absorbed (Fa) for the test and reference products were 3.0% and 19% respectively.,Enhancement of oral bioavailability of insulin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300394/),%,3.0,237532,DB00030,Insulin Regular
,19300394,Total fraction of insulin dose absorbed (Fa),Total fraction of insulin dose absorbed (Fa) for the test and reference products were 3.0% and 19% respectively.,Enhancement of oral bioavailability of insulin in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19300394/),%,19,237533,DB00030,Insulin Regular
,19433973,first-order elimination half-life,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),h,11.3,239277,DB00030,Insulin Regular
,19433973,clearance,"Metformin concentrations decreased to 97 microg/mL 28 hours after the ingestion on CVVH, with a first-order elimination half-life of 11.3 hours (r(2) = 0.99) and a clearance of 56.2 mL/min.",The MALAdy of metformin poisoning: Is CVVH the cure? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19433973/),[ml] / [min],56.2,239278,DB00030,Insulin Regular
,32219329,AUC,"Within our study, mean (standard deviation) change from baseline to week 52 in MMTT-stimulated 2-h plasma C-peptide AUC was -0.16 nmol/L (0.366) with placebo and -0.13 nmol/L (0.244) with albiglutide.",Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32219329/),[nM] / [l],0.16,239928,DB00030,Insulin Regular
,23921573,C max,"The co-administration of MK-0646 with cetuximab and irinotecan did not affect the PK of cetuximab and irinotecan, but reduced the C max (from 16.8 to 13.0 ng/mL) and the AUC0-24h (by 13 %) of SN-38, the active metabolite of irinotecan.","Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23921573/),[ng] / [ml],16.8,240172,DB00030,Insulin Regular
,23921573,C max,"The co-administration of MK-0646 with cetuximab and irinotecan did not affect the PK of cetuximab and irinotecan, but reduced the C max (from 16.8 to 13.0 ng/mL) and the AUC0-24h (by 13 %) of SN-38, the active metabolite of irinotecan.","Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23921573/),[ng] / [ml],13.0,240173,DB00030,Insulin Regular
,29171848,half-life,Incremental doses of (+)-Epi increase the half-life of blood metabolites from 1.2-4.9 h.,A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29171848/),h,1.2-4.9,241379,DB00030,Insulin Regular
,26224751,en,"This was attributed to a more rapid release of dietary protein-derived AAs into the circulation, as evidenced by a higher peak plasma l-[1-(13)C]phenylalanine enrichment concentration (2.9 ± 0.2 vs. 2.2 ± 0.2 mole percent excess; P < 0.05).",Jejunal Casein Feeding Is Followed by More Rapid Protein Digestion and Amino Acid Absorption When Compared with Gastric Feeding in Healthy Young Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26224751/),%·mole,2.9,241549,DB00030,Insulin Regular
,26224751,en,"This was attributed to a more rapid release of dietary protein-derived AAs into the circulation, as evidenced by a higher peak plasma l-[1-(13)C]phenylalanine enrichment concentration (2.9 ± 0.2 vs. 2.2 ± 0.2 mole percent excess; P < 0.05).",Jejunal Casein Feeding Is Followed by More Rapid Protein Digestion and Amino Acid Absorption When Compared with Gastric Feeding in Healthy Young Men. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26224751/),%·mole,2.2,241550,DB00030,Insulin Regular
<,20856794,half-life (t1/2,"However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2<2 min).",Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856794/),min,2,242247,DB00030,Insulin Regular
,20856794,Kd,ELISA-based receptor binding assay demonstrated that GLP-1/hIgG2 had high binding affinity to the GLP-1R in INS-1 cells (Kd = 13.90±1.52 nM).,Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20856794/),nM,13.90,242248,DB00030,Insulin Regular
,23747732,C(max),"From the pharmacokinetic study after oral administration of the conjugate, a C(max) value of 344 pg/mL and a T(max) of 6 h were observed, and the bioavailability, relative to the subcutaneous counterpart, was found to be 6.4%.",Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23747732/),[pg] / [ml],344,242257,DB00030,Insulin Regular
,23747732,T(max),"From the pharmacokinetic study after oral administration of the conjugate, a C(max) value of 344 pg/mL and a T(max) of 6 h were observed, and the bioavailability, relative to the subcutaneous counterpart, was found to be 6.4%.",Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23747732/),h,6,242258,DB00030,Insulin Regular
,23747732,bioavailability,"From the pharmacokinetic study after oral administration of the conjugate, a C(max) value of 344 pg/mL and a T(max) of 6 h were observed, and the bioavailability, relative to the subcutaneous counterpart, was found to be 6.4%.",Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23747732/),%,6.4,242259,DB00030,Insulin Regular
,15846462,bioavailability,"Creation of MCs in the outer layers of the skin enabled efficient delivery of hGH, with a bioavailability of 75% (rats) or 33% (GPs) relative to subcutaneous (s.c.) injection with plasma profiles resembling that of s.c. injection.",Transdermal delivery of human growth hormone through RF-microchannels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846462/),%,75,242492,DB00030,Insulin Regular
,15846462,bioavailability,"Creation of MCs in the outer layers of the skin enabled efficient delivery of hGH, with a bioavailability of 75% (rats) or 33% (GPs) relative to subcutaneous (s.c.) injection with plasma profiles resembling that of s.c. injection.",Transdermal delivery of human growth hormone through RF-microchannels. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15846462/),%,33,242493,DB00030,Insulin Regular
,26839476,peak of glucose,"Compared to CC, DC intake exhibited a lower post-breakfast 2-hours glucose level (198.5±12.8 vs. 245.9±15.2 mg/dL, P<0.05) and a lower incremental peak of glucose from baseline (101.8±9.1 vs. 140.3±14.3 mg/dL, P<0.001).",Improving Effect of the Acute Administration of Dietary Fiber-Enriched Cereals on Blood Glucose Levels and Gut Hormone Secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839476/),[mg] / [dl],101.8,242727,DB00030,Insulin Regular
,26839476,peak of glucose,"Compared to CC, DC intake exhibited a lower post-breakfast 2-hours glucose level (198.5±12.8 vs. 245.9±15.2 mg/dL, P<0.05) and a lower incremental peak of glucose from baseline (101.8±9.1 vs. 140.3±14.3 mg/dL, P<0.001).",Improving Effect of the Acute Administration of Dietary Fiber-Enriched Cereals on Blood Glucose Levels and Gut Hormone Secretion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26839476/),[mg] / [dl],140.3,242728,DB00030,Insulin Regular
,31407113,absolute bioavailability,Approximately 6% absolute bioavailability in the bloodstream was estimated for the same formulation through in vivo pharmacokinetic studies in rats.,Lipid nanoparticles as vehicles for oral delivery of insulin and insulin analogs: preliminary ex vivo and in vivo studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31407113/),%,6,242840,DB00030,Insulin Regular
,14534520,elimination half-life,Rifampin decreased the mean area under the plasma concentration-time curve for gliclazide by 70% (P <.001) and the mean elimination half-life from 9.5 to 3.3 hours (P <.05).,Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534520/),h,9.5,243244,DB00030,Insulin Regular
,14534520,elimination half-life,Rifampin decreased the mean area under the plasma concentration-time curve for gliclazide by 70% (P <.001) and the mean elimination half-life from 9.5 to 3.3 hours (P <.05).,Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14534520/),h,3.3,243245,DB00030,Insulin Regular
,22378938,k(pl),Animal handling and placebo treatment affected glucose turnover with k(pl) = 0.388 kg/mg/day.,Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22378938/),[kg] / [d·mg],0.388,243579,DB00030,Insulin Regular
,22378938,I(max),The effect of rosiglitazone was described as inhibition of k(inG) with I(max) = 0.296 and IC(50) = 1.97 μg/ml.,Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22378938/),,0.296,243580,DB00030,Insulin Regular
,22378938,IC(50),The effect of rosiglitazone was described as inhibition of k(inG) with I(max) = 0.296 and IC(50) = 1.97 μg/ml.,Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22378938/),[μg] / [ml],1.97,243581,DB00030,Insulin Regular
,22378938,ID(50),"Weight gain was characterized with body weight input (k(s)(w)) and output (k(d)(w)), and rosiglitazone inhibited k(d)(w) with ID(50) = 96.8 mg/kg.",Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22378938/),mg,96,243582,DB00030,Insulin Regular
,11452245,elimination half-life,The mean elimination half-life of repaglinide was prolonged from 1.4 to 1.7 hours (P <.05) by clarithromycin.,The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452245/),h,1.4,244247,DB00030,Insulin Regular
,11452245,elimination half-life,The mean elimination half-life of repaglinide was prolonged from 1.4 to 1.7 hours (P <.05) by clarithromycin.,The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11452245/),h,1.7,244248,DB00030,Insulin Regular
>,31280022,duration of action,"The duration of action of IDeg in people is > 42 h, allowing flexibility in daily administration.",Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31280022/),h,42,244397,DB00030,Insulin Regular
,31280022,time to peak action (TPEAK),"On average, time to peak action (TPEAK) of IGla-U300 was 145 ± 114 min (95% confidence interval [CI] = 25-264) longer than TPEAK of IDeg (P = 0.03) and duration of action (TDUR) of IGla-U300 was 250 ± 173 min (95% CI = 68-432) longer than TDUR of IDeg (P = 0.02).",Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31280022/),min,145,244398,DB00030,Insulin Regular
,31280022,duration of action (TDUR),"On average, time to peak action (TPEAK) of IGla-U300 was 145 ± 114 min (95% confidence interval [CI] = 25-264) longer than TPEAK of IDeg (P = 0.03) and duration of action (TDUR) of IGla-U300 was 250 ± 173 min (95% CI = 68-432) longer than TDUR of IDeg (P = 0.02).",Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31280022/),min,250,244399,DB00030,Insulin Regular
,16797489,EC50,KR-62980 acted as a selective PPARgamma agonist in transactivation assay with an EC50 of 15 nM.,KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16797489/),nM,15,245232,DB00030,Insulin Regular
,16797489,oral bioavailability,In vivo pharmacokinetic profile of KR-62980 revealed that the compound exhibited good oral bioavailability of 65% with a terminal elimination half-life of 2.5 h in the rat.,KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16797489/),%,65,245233,DB00030,Insulin Regular
,16797489,terminal elimination half-life,In vivo pharmacokinetic profile of KR-62980 revealed that the compound exhibited good oral bioavailability of 65% with a terminal elimination half-life of 2.5 h in the rat.,KR-62980: a novel peroxisome proliferator-activated receptor gamma agonist with weak adipogenic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16797489/),h,2.5,245234,DB00030,Insulin Regular
,26510924,half-maximum effective concentration [EC50 ],"Unadjusted results showed that with regard to UGE response, dapagliflozin was more potent in patients with T1DM {mean half-maximum effective concentration [EC50 ] = 2.72 ng/ml [95% confidence interval (CI) 1.14, 5.08]} than in patients with T2DM [EC50 = 12.2 ng/ml (95% CI 4.91, 21.1)].",Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26510924/),[ng] / [ml],2.72,245292,DB00030,Insulin Regular
,26510924,EC50,"Unadjusted results showed that with regard to UGE response, dapagliflozin was more potent in patients with T1DM {mean half-maximum effective concentration [EC50 ] = 2.72 ng/ml [95% confidence interval (CI) 1.14, 5.08]} than in patients with T2DM [EC50 = 12.2 ng/ml (95% CI 4.91, 21.1)].",Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26510924/),[ng] / [ml],12.2,245293,DB00030,Insulin Regular
,26510924,EC50,"After normalization for baseline fasting plasma glucose, estimated glomerular filtration rate and UGE, however, the UGE potency of dapagliflozin was similar between the two populations [T1DM: mean EC50 , 8.12 ng/ml (95% CI 2.95, 14.6); T2DM: mean EC50 , 7.75 ng/ml (95% CI 1.35, 18.1)].",Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26510924/),[ng] / [ml],8.12,245294,DB00030,Insulin Regular
,26510924,EC50,"After normalization for baseline fasting plasma glucose, estimated glomerular filtration rate and UGE, however, the UGE potency of dapagliflozin was similar between the two populations [T1DM: mean EC50 , 8.12 ng/ml (95% CI 2.95, 14.6); T2DM: mean EC50 , 7.75 ng/ml (95% CI 1.35, 18.1)].",Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26510924/),[ng] / [ml],7.75,245295,DB00030,Insulin Regular
up to,16859800,drug,The drug entrapment efficiency was up to 90%.,"Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859800/),%,90,245823,DB00030,Insulin Regular
up to,16859800,entrapment efficiency,The drug entrapment efficiency was up to 90%.,"Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859800/),%,90,245824,DB00030,Insulin Regular
,16859800,oral bioavailability,PK/PD analysis indicated that 7.7% of oral bioavailability relative to subcutaneous injection was obtained.,"Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16859800/),%,7.7,245825,DB00030,Insulin Regular
,21156817,T(max),"After intravenous doses, exendin-4 rapidly disappeared from the circulation, whereas it exhibited rapid absorption (T(max) = 15-20 min) and incomplete bioavailability (F = 0.51) after the subcutaneous dose.",Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21156817/),min,15-20,246594,DB00030,Insulin Regular
,21156817,bioavailability (F,"After intravenous doses, exendin-4 rapidly disappeared from the circulation, whereas it exhibited rapid absorption (T(max) = 15-20 min) and incomplete bioavailability (F = 0.51) after the subcutaneous dose.",Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21156817/),,0.51,246595,DB00030,Insulin Regular
,21156817,capacity S(max),"Exendin-4 increased insulin release at 2 to 5 min with capacity S(max) = 6.91 and sensitivity SC₅₀ = 1.29 nM, followed by a rebound at 10 to 15 min and a slow return to the baseline.",Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21156817/),,6.91,246596,DB00030,Insulin Regular
,21156817,sensitivity SC₅₀,"Exendin-4 increased insulin release at 2 to 5 min with capacity S(max) = 6.91 and sensitivity SC₅₀ = 1.29 nM, followed by a rebound at 10 to 15 min and a slow return to the baseline.",Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21156817/),nM,1.29,246597,DB00030,Insulin Regular
,20498254,half-life,"GLP-1-Tf activated the GLP-1 receptor, was resistant to inactivation by peptidases, and had a half-life of approximately 2 days, compared with 1 to 2 min for native GLP-1.",Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498254/),d,2,246730,DB00030,Insulin Regular
,20498254,half-life,"GLP-1-Tf activated the GLP-1 receptor, was resistant to inactivation by peptidases, and had a half-life of approximately 2 days, compared with 1 to 2 min for native GLP-1.",Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498254/),min,1 to 2,246731,DB00030,Insulin Regular
,17065354,half-life,"The half-life of plasma glucosamine after oral dosing was approximately 150 min, with no significant changes in steady-state glucosamine levels detectable after 6 weeks of therapy.",Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17065354/),min,150,249096,DB00030,Insulin Regular
,28721067,MTD,MTD was defined at 120 mg for pasireotide LAR in patients with advanced NETs.,Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28721067/),mg,120,250857,DB00030,Insulin Regular
,24351176,time-to-peak plasma concentrations [t(max),"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),min,51,250895,DB00030,Insulin Regular
,24351176,t(max),"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),min,19,250896,DB00030,Insulin Regular
,24351176,metabolic clearance rate,"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),[l] / [kg·min],0.019,250897,DB00030,Insulin Regular
,24351176,metabolic clearance rate,"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),[l] / [kg·min],0.012,250898,DB00030,Insulin Regular
,24351176,I(b),"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),[mu] / [l],10.2,250899,DB00030,Insulin Regular
,24351176,I(b),"A pharmacokinetic model estimated time-to-peak plasma concentrations [t(max) insulin 51 (19) min, t(max) glucagon 19 (4) min, mean (standard deviation)], metabolic clearance rate [MCR insulin 0.019 (0.015-0.026) liter/kg/min, MCR glucagon 0.012 (0.010-0.014) liter/kg/min, median (interquartile range)], and the background plasma concentrations [I(b) insulin 10.2 (6.3-15.2) mU/liter, I(b) glucagon 50 (45-56) pg/ml, median (interquartile range)].",Pharmacokinetics of insulin aspart and glucagon in type 1 diabetes during closed-loop operation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24351176/),[pg] / [ml],50,250900,DB00030,Insulin Regular
,21715522,time to maximal GIR,"The time to maximal GIR was significantly shorter when insulin was injected with the jet injector compared with conventional pen administration (51 ± 3 vs. 105 ± 11 min, P < 0.0001).",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),min,51,250971,DB00030,Insulin Regular
,21715522,time to maximal GIR,"The time to maximal GIR was significantly shorter when insulin was injected with the jet injector compared with conventional pen administration (51 ± 3 vs. 105 ± 11 min, P < 0.0001).",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),min,105,250972,DB00030,Insulin Regular
,21715522,time to peak insulin concentration,"The time to peak insulin concentration was similarly reduced (31 ± 3 vs. 64 ± 6 min, P < 0.0001) and peak insulin concentrations were increased (108 ± 13 vs. 79 ± 7 mU/L, P = 0.01) when insulin was injected by jet injection compared with conventional pen injection.",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),min,31,250973,DB00030,Insulin Regular
,21715522,time to peak insulin concentration,"The time to peak insulin concentration was similarly reduced (31 ± 3 vs. 64 ± 6 min, P < 0.0001) and peak insulin concentrations were increased (108 ± 13 vs. 79 ± 7 mU/L, P = 0.01) when insulin was injected by jet injection compared with conventional pen injection.",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),min,64,250974,DB00030,Insulin Regular
,21715522,peak insulin concentrations,"The time to peak insulin concentration was similarly reduced (31 ± 3 vs. 64 ± 6 min, P < 0.0001) and peak insulin concentrations were increased (108 ± 13 vs. 79 ± 7 mU/L, P = 0.01) when insulin was injected by jet injection compared with conventional pen injection.",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),[mu] / [l],108,250975,DB00030,Insulin Regular
,21715522,peak insulin concentrations,"The time to peak insulin concentration was similarly reduced (31 ± 3 vs. 64 ± 6 min, P < 0.0001) and peak insulin concentrations were increased (108 ± 13 vs. 79 ± 7 mU/L, P = 0.01) when insulin was injected by jet injection compared with conventional pen injection.",Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21715522/),[mu] / [l],79,250976,DB00030,Insulin Regular
,25846340,onset of appearance,"Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing.",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,4.9,251051,DB00030,Insulin Regular
,25846340,onset of appearance,"Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing.",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,11.2,251052,DB00030,Insulin Regular
,25846340,time to reach 50% maximum concentration,"Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing.",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,20.7,251053,DB00030,Insulin Regular
,25846340,time to reach 50% maximum concentration,"Faster-acting insulin aspart had a faster onset of exposure compared with insulin aspart, shown by a 57% earlier onset of appearance [4.9 vs 11.2 min; ratio 0.43, 95% confidence interval (CI) 0.36; 0.51], a 35% earlier time to reach 50% maximum concentration (20.7 vs 31.6 min; ratio 0.65, 95% CI 0.59; 0.72) and a greater early exposure within 90 min after dosing.",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,31.6,251054,DB00030,Insulin Regular
,25846340,time to reach 50% maximum glucose infusion rate,"Faster-acting insulin aspart had a significantly greater glucose-lowering effect within 90 min after dosing [largest difference: area under the curve for the glucose infusion rate (AUC(GIR), 0-30 min) ratio 1.48, 95% CI 1.13; 2.02] and 17% earlier time to reach 50% maximum glucose infusion rate (38.3 vs 46.1 min; ratio 0.83, 95% CI 0.73; 0.94).",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,38.3,251055,DB00030,Insulin Regular
,25846340,time to reach 50% maximum glucose infusion rate,"Faster-acting insulin aspart had a significantly greater glucose-lowering effect within 90 min after dosing [largest difference: area under the curve for the glucose infusion rate (AUC(GIR), 0-30 min) ratio 1.48, 95% CI 1.13; 2.02] and 17% earlier time to reach 50% maximum glucose infusion rate (38.3 vs 46.1 min; ratio 0.83, 95% CI 0.73; 0.94).",Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25846340/),min,46.1,251056,DB00030,Insulin Regular
,33892274,maximum T/N ratio,"The maximum T/N ratio of probe 5d was 4.9, which was about 3 times that of indocyanine green (ICG).",An innovative fluorescent probe targeting IGF1R for breast cancer diagnosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33892274/),,4.9,251341,DB00030,Insulin Regular
,16174724,area under the curve,"Female participants across the range of BMI had significantly higher PYY area under the curve (17,464 +/- 1,240 vs. 14,120 +/- 806 pmol/liter x min, female vs. male; P < 0.05) compared with male participants.",Peptide YY is secreted after oral glucose administration in a gender-specific manner. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16174724/),[pM] / [l·min],"17,464",251933,DB00030,Insulin Regular
,16174724,area under the curve,"Female participants across the range of BMI had significantly higher PYY area under the curve (17,464 +/- 1,240 vs. 14,120 +/- 806 pmol/liter x min, female vs. male; P < 0.05) compared with male participants.",Peptide YY is secreted after oral glucose administration in a gender-specific manner. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16174724/),[pM] / [l·min],"14,120",251934,DB00030,Insulin Regular
,20841613,time to lispro plasma peak (T(max)),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,48.3,252607,DB00030,Insulin Regular
,20841613,time to lispro plasma peak (T(max)),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,55.7,252608,DB00030,Insulin Regular
,20841613,maximal glucose infusion rate (,"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),[mg] / [kg·min],9.0,252609,DB00030,Insulin Regular
,20841613,maximal glucose infusion rate (,"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),[mg] / [kg·min],0.6,252610,DB00030,Insulin Regular
,20841613,maximal glucose infusion rate (,"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,69,252611,DB00030,Insulin Regular
,20841613,maximal glucose infusion rate (,"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,130,252612,DB00030,Insulin Regular
,20841613,GIR(max),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),[mg] / [kg·min],9.0,252613,DB00030,Insulin Regular
,20841613,GIR(max),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),[mg] / [kg·min],0.6,252614,DB00030,Insulin Regular
,20841613,GIR(max),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,69,252615,DB00030,Insulin Regular
,20841613,GIR(max),"After 10 units injection, time to lispro plasma peak (T(max)) was similar (48.3 vs. 55.7 min; control subjects versus type 2 diabetic subjects), although maximal concentration (C(max))/dose was 41% lower in subjects with type 2 diabetes, with lower and delayed maximal glucose infusion rate (GIR(max): 9.0 vs. 0.6 mg/kg/min, P < 0.0001, 69 vs. 130 min, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,130,252616,DB00030,Insulin Regular
,20841613,T(max),"After 30- and 50-unit injections, T(max) (88.6 and 130.0 min, respectively) and time to GIR(max) (175 and 245 min) were further delayed and dose related (r(2) = 0.51, P = 0.0004 and r(2) = 0.76, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,88.6,252617,DB00030,Insulin Regular
,20841613,T(max),"After 30- and 50-unit injections, T(max) (88.6 and 130.0 min, respectively) and time to GIR(max) (175 and 245 min) were further delayed and dose related (r(2) = 0.51, P = 0.0004 and r(2) = 0.76, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,130.0,252618,DB00030,Insulin Regular
,20841613,time to GIR(max),"After 30- and 50-unit injections, T(max) (88.6 and 130.0 min, respectively) and time to GIR(max) (175 and 245 min) were further delayed and dose related (r(2) = 0.51, P = 0.0004 and r(2) = 0.76, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,175,252619,DB00030,Insulin Regular
,20841613,time to GIR(max),"After 30- and 50-unit injections, T(max) (88.6 and 130.0 min, respectively) and time to GIR(max) (175 and 245 min) were further delayed and dose related (r(2) = 0.51, P = 0.0004 and r(2) = 0.76, P < 0.0001, respectively).",Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20841613/),min,245,252620,DB00030,Insulin Regular
,12364460,metabolic clearance rate,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),[ml] / [(meter)^2·min],57.2,253291,DB00030,Insulin Regular
,12364460,metabolic clearance rate,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),[ml] / [(meter)^2·min],45.2,253292,DB00030,Insulin Regular
,12364460,metabolic clearance rate,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),[ml] / [(meter)^2·min],39.2,253293,DB00030,Insulin Regular
,12364460,half-time,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),min,14.2,253294,DB00030,Insulin Regular
,12364460,half-time,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),min,16.2,253295,DB00030,Insulin Regular
,12364460,half-time,"The metabolic clearance rate was dose dependently reduced with increasing GH doses (57.2 +/- 5.1, 45.2 +/- 3.8, and 39.2 +/- 2.4 ml/min(-1) per meter(-2) following injection of 1, 3, and 6 micro g/kg(-1) GH, respectively, P < 0.001), and half-time was increased (14.2 +/- 0.6, 16.2 +/- 0.4, and 18.0 +/- 0.5 min, respectively, P < 0.0001).",Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12364460/),min,18.0,253296,DB00030,Insulin Regular
,21975348,terminal elimination half-life,The terminal elimination half-life was ~13 h when administered as an oral suspension formulation.,"Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21975348/),h,13,254723,DB00030,Insulin Regular
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],2.3,255437,DB00030,Insulin Regular
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],1.3,255438,DB00030,Insulin Regular
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],1.15,255439,DB00030,Insulin Regular
,11194245,rates of insulin rise,"Nateglinide induced insulin secretion more rapidly than 2 and 0.5 mg repaglinide and placebo (10 min preprandial), with mean rates of insulin rise of 2.3, 1.3, 1.15, and 0.8 microU x ml(-1) x min(-1), respectively, over the 0- to 30-min postmeal interval.",Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11194245/),[μu] / [min·ml],0.8,255440,DB00030,Insulin Regular
,14681716,Plasma osmolality,"Plasma osmolality increased from 285+/-1 to 296+/-1 mosm/kg (P<0.001 during hyperosmolality, and decreased from 286+/-1 to 265+/-1 mosm/kg during hypo-osmolality (P<0.001).","Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681716/),[mosm] / [kg],285,255761,DB00030,Insulin Regular
,14681716,Plasma osmolality,"Plasma osmolality increased from 285+/-1 to 296+/-1 mosm/kg (P<0.001 during hyperosmolality, and decreased from 286+/-1 to 265+/-1 mosm/kg during hypo-osmolality (P<0.001).","Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681716/),[mosm] / [kg],296,255762,DB00030,Insulin Regular
,14681716,Plasma osmolality,"Plasma osmolality increased from 285+/-1 to 296+/-1 mosm/kg (P<0.001 during hyperosmolality, and decreased from 286+/-1 to 265+/-1 mosm/kg during hypo-osmolality (P<0.001).","Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681716/),[mosm] / [kg],286,255763,DB00030,Insulin Regular
,14681716,Plasma osmolality,"Plasma osmolality increased from 285+/-1 to 296+/-1 mosm/kg (P<0.001 during hyperosmolality, and decreased from 286+/-1 to 265+/-1 mosm/kg during hypo-osmolality (P<0.001).","Effects of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681716/),[mosm] / [kg],265,255764,DB00030,Insulin Regular
,33242998,AUC0-tlast,"The ratio of geometric least squares AUC0-tlast means SC:CSII (90% CI) is 0.857 (0.729, 1.01) with correction (mean AUC0-tlast: 5230 pmol*L/h [SC injection] and 6070 pmol*L/h [CSII, with correction]) and 0.424 (0.361, 0.499) without correction (mean AUC0-tlast: 12300 pmol*L/h [CSII, without correction]).",Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33242998/),[l·pM] / [h],5230,257569,DB00030,Insulin Regular
,33242998,AUC0-tlast,"The ratio of geometric least squares AUC0-tlast means SC:CSII (90% CI) is 0.857 (0.729, 1.01) with correction (mean AUC0-tlast: 5230 pmol*L/h [SC injection] and 6070 pmol*L/h [CSII, with correction]) and 0.424 (0.361, 0.499) without correction (mean AUC0-tlast: 12300 pmol*L/h [CSII, without correction]).",Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33242998/),[l·pM] / [h],6070,257570,DB00030,Insulin Regular
,33242998,AUC0-tlast,"The ratio of geometric least squares AUC0-tlast means SC:CSII (90% CI) is 0.857 (0.729, 1.01) with correction (mean AUC0-tlast: 5230 pmol*L/h [SC injection] and 6070 pmol*L/h [CSII, with correction]) and 0.424 (0.361, 0.499) without correction (mean AUC0-tlast: 12300 pmol*L/h [CSII, without correction]).",Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33242998/),[l·pM] / [h],12300,257571,DB00030,Insulin Regular
,33242998,time-to-peak insulin concentration,Median time-to-peak insulin concentration was six hours (range 0.5-8 hours) via SC injection and five hours (0.5-12 hours) via CSII.,Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33242998/),h,six,257572,DB00030,Insulin Regular
,33242998,time-to-peak insulin concentration,Median time-to-peak insulin concentration was six hours (range 0.5-8 hours) via SC injection and five hours (0.5-12 hours) via CSII.,Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33242998/),h,five,257573,DB00030,Insulin Regular
,26831715,MTDs,"MTDs for linsitinib/erlotinib were 450/150 mg (S1), 400/100 mg (S2).",Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26831715/),mg,450,257700,DB00030,Insulin Regular
,26831715,MTDs,"MTDs for linsitinib/erlotinib were 450/150 mg (S1), 400/100 mg (S2).",Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26831715/),,400,257701,DB00030,Insulin Regular
,19783444,EC(50),"Among the new compounds, (S)-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,3-triazol-2-yl-propionic acid (17j), was identified as a potent human PPARalpha/gamma dual agonist (EC(50)=0.013 and 0.061 microM, respectively) with demonstrated oral bioavailability in rat and dog.",Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19783444/),μM,0.013,257895,DB00030,Insulin Regular
,19783444,EC(50),"Among the new compounds, (S)-3-{4-[3-(5-methyl-2-phenyl-oxazol-4-yl)-propyl]-phenyl}-2-1,2,3-triazol-2-yl-propionic acid (17j), was identified as a potent human PPARalpha/gamma dual agonist (EC(50)=0.013 and 0.061 microM, respectively) with demonstrated oral bioavailability in rat and dog.",Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19783444/),μM,0.061,257896,DB00030,Insulin Regular
,15979534,k(a),Insulin absorption occurred largely by passive diffusion with values for k(a) = 0.39-0.50 h(-1).,The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979534/),1/[h],0.39-0.50,257946,DB00030,Insulin Regular
,15979534,bioavailabilities,"With DF = 0.91 following 0.1 ml doses, 11.9 +/- 3.4% of bioavailabilities were observed in 1h.",The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979534/),%,11.9,257947,DB00030,Insulin Regular
,15979534,k(nal),"In contrast, derived values for k(nal) = 2.34-3.45 h(-1) were significantly larger than the rate constant for mucociliary clearance determined previously in this IPRL (0.96-1.74 h(-1)) due to lung metabolism.",The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979534/),1/[h],2.34-3.45,257948,DB00030,Insulin Regular
,15979534,rate,"In contrast, derived values for k(nal) = 2.34-3.45 h(-1) were significantly larger than the rate constant for mucociliary clearance determined previously in this IPRL (0.96-1.74 h(-1)) due to lung metabolism.",The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979534/),1/[h],0.96-1.74,257949,DB00030,Insulin Regular
,15979534,k(a),"Shallower lung distribution with DF = 0.73 following 0.02 ml doses resulted in reduced values for k(a) = 0.27 h(-1) and k(nal) = 2.79 h(-1), indicating that these kinetic processes may be lung-region dependent, even within this model and emphasizing the likely importance of reliable lung deposition in vivo.",The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979534/),1/[h],0.27,257950,DB00030,Insulin Regular
,15979534,k(nal),"Shallower lung distribution with DF = 0.73 following 0.02 ml doses resulted in reduced values for k(a) = 0.27 h(-1) and k(nal) = 2.79 h(-1), indicating that these kinetic processes may be lung-region dependent, even within this model and emphasizing the likely importance of reliable lung deposition in vivo.",The pharmacokinetics of pulmonary insulin in the in vitro isolated perfused rat lung: implications of metabolism and regional deposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15979534/),1/[h],2.79,257951,DB00030,Insulin Regular
,11107002,half-life of the rapid,The half-life of the rapid elimination phase was 83.5 min and of the slower phase was 12 h.,Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107002/),min,83.5,257972,DB00030,Insulin Regular
,11107002,half-life of the rapid,The half-life of the rapid elimination phase was 83.5 min and of the slower phase was 12 h.,Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107002/),h,12,257973,DB00030,Insulin Regular
,11107002,(,The term (Vss/Vc)-1was 12.3 indicating extensive distribution into the tissues.,Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107002/),,12.3,257974,DB00030,Insulin Regular
,11107002,Vss/Vc),The term (Vss/Vc)-1was 12.3 indicating extensive distribution into the tissues.,Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107002/),,12.3,257975,DB00030,Insulin Regular
,21810918,terminal half-life,"At dose levels or more than 5 mg/kg, dalotuzumab mean terminal half-life was 95 hours or more, mean C(min) was more than 25 μg/mL, clearance was constant, and serum exposures were approximately dose proportional.","A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21810918/),h·more·or,95,258391,DB00030,Insulin Regular
more,21810918,C(min),"At dose levels or more than 5 mg/kg, dalotuzumab mean terminal half-life was 95 hours or more, mean C(min) was more than 25 μg/mL, clearance was constant, and serum exposures were approximately dose proportional.","A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21810918/),[μg] / [ml],25,258392,DB00030,Insulin Regular
,30371791,maximum dosage,The maximum dosage of BIM23B065 administered in this study was 1.5 mg.,A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30371791/),mg,1,258706,DB00030,Insulin Regular
,22799036,polydispersity index,"The mean diameter of INS-NP was (179.0 +/- 5.2) nm and the polydispersity index was 0.152 +/- 0.042, while the entrapment efficiency was (29.10 +/- 2.59) %.",[Poly(arginine)8 enhanced intestinal absorption of insulin-loaded nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22799036/),,0.152,258889,DB00030,Insulin Regular
,22799036,entrapment efficiency,"The mean diameter of INS-NP was (179.0 +/- 5.2) nm and the polydispersity index was 0.152 +/- 0.042, while the entrapment efficiency was (29.10 +/- 2.59) %.",[Poly(arginine)8 enhanced intestinal absorption of insulin-loaded nanoparticles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22799036/),%,29.10,258890,DB00030,Insulin Regular
,22799036,relative bioavailabilities,"Compared to subcutaneous injection, the relative bioavailabilities of insulin were 0.52%, 4.78%, 8.39%, and the pharmacological bioavailabilities were 2.07%, 3.90%, 8.24%, separately.",[Poly(arginine)8 enhanced intestinal absorption of insulin-loaded nanoparticles]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22799036/),%,0.52,258891,DB00030,Insulin Regular
,22799036,relative bioavailabilities,"Compared to subcutaneous injection, the relative bioavailabilities of insulin were 0.52%, 4.78%, 8.39%, and the pharmacological bioavailabilities were 2.07%, 3.90%, 8.24%, separately.",[Poly(arginine)8 enhanced intestinal absorption of insulin-loaded nanoparticles]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22799036/),%,4.78,258892,DB00030,Insulin Regular
,22799036,relative bioavailabilities,"Compared to subcutaneous injection, the relative bioavailabilities of insulin were 0.52%, 4.78%, 8.39%, and the pharmacological bioavailabilities were 2.07%, 3.90%, 8.24%, separately.",[Poly(arginine)8 enhanced intestinal absorption of insulin-loaded nanoparticles]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22799036/),%,8.39,258893,DB00030,Insulin Regular
,22799036,bioavailabilities,"Compared to subcutaneous injection, the relative bioavailabilities of insulin were 0.52%, 4.78%, 8.39%, and the pharmacological bioavailabilities were 2.07%, 3.90%, 8.24%, separately.",[Poly(arginine)8 enhanced intestinal absorption of insulin-loaded nanoparticles]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22799036/),%,2.07,258894,DB00030,Insulin Regular
,22799036,bioavailabilities,"Compared to subcutaneous injection, the relative bioavailabilities of insulin were 0.52%, 4.78%, 8.39%, and the pharmacological bioavailabilities were 2.07%, 3.90%, 8.24%, separately.",[Poly(arginine)8 enhanced intestinal absorption of insulin-loaded nanoparticles]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22799036/),%,3.90,258895,DB00030,Insulin Regular
,22799036,bioavailabilities,"Compared to subcutaneous injection, the relative bioavailabilities of insulin were 0.52%, 4.78%, 8.39%, and the pharmacological bioavailabilities were 2.07%, 3.90%, 8.24%, separately.",[Poly(arginine)8 enhanced intestinal absorption of insulin-loaded nanoparticles]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22799036/),%,8.24,258896,DB00030,Insulin Regular
,19966898,entrapment,"Poly(ethyl 2-cyanoacrylate) nanoparticles were produced with a uniform particle size of 200-300 nm, and the mean entrapment of insulin was 78%.",Polymeric nanoparticles as an oral delivery system for biocontrol agents for the brushtail possum (Trichosurus vulpecula). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19966898/),%,78,258943,DB00030,Insulin Regular
<,19966898,bioavailability,"The bioavailability of insulin when administered in a PECA nanoparticulate formulation injected directly into the caecum was <1%, and was not increased by addition of the permeation enhancer.",Polymeric nanoparticles as an oral delivery system for biocontrol agents for the brushtail possum (Trichosurus vulpecula). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19966898/),%,1,258944,DB00030,Insulin Regular
,14973299,constant rate,"Following drug administration, subjects received intravenous glucose in 0.5-mg/kg/min increments every 30 minutes, followed by a constant rate of 2.0 mg/kg/min for up to 12 hours.","Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese american subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14973299/),[mg] / [kg·min],2.0,259535,DB00030,Insulin Regular
,15738710,maximum measured insulin concentration,"For the 25 IU dose (a single 90-microL spray), the maximum measured insulin concentration was 19.52 +/- 9.28 mIU/L, and the area under the concentration-time curve from 0 to 4 h was 19.06 +/- 5.56 mIU/L/h.",Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15738710/),[miu] / [l],19.52,259887,DB00030,Insulin Regular
,15738710,area under the concentration-time curve from 0 to 4 h,"For the 25 IU dose (a single 90-microL spray), the maximum measured insulin concentration was 19.52 +/- 9.28 mIU/L, and the area under the concentration-time curve from 0 to 4 h was 19.06 +/- 5.56 mIU/L/h.",Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15738710/),[miu] / [h·l],19.06,259888,DB00030,Insulin Regular
,10900252,bioavailability,"In rat, bioavailability was high (92%), whereas it was lower in dog (approximately 65%).",Pharmacokinetics of sodium tungstate in rat and dog: a population approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10900252/),%,92,259951,DB00030,Insulin Regular
,10900252,bioavailability,"In rat, bioavailability was high (92%), whereas it was lower in dog (approximately 65%).",Pharmacokinetics of sodium tungstate in rat and dog: a population approach. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10900252/),%,65,259952,DB00030,Insulin Regular
,10900252,total volume of distribution,The total volume of distribution expressed by unit of body weight was much higher when the animal was smaller (0.46 l/kg in rat versus 0.23 l/kg in dog).,Pharmacokinetics of sodium tungstate in rat and dog: a population approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10900252/),[l] / [kg],0.46,259953,DB00030,Insulin Regular
,10900252,total volume of distribution,The total volume of distribution expressed by unit of body weight was much higher when the animal was smaller (0.46 l/kg in rat versus 0.23 l/kg in dog).,Pharmacokinetics of sodium tungstate in rat and dog: a population approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10900252/),[l] / [kg],0.23,259954,DB00030,Insulin Regular
,10900252,total body clearance,"The total body clearance normalized by weight, 0.19 l/h/kg in rat versus 0.043 l/h/kg in dog, changed as for the volume of distribution.",Pharmacokinetics of sodium tungstate in rat and dog: a population approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10900252/),[l] / [h·kg],0.19,259955,DB00030,Insulin Regular
,10900252,total body clearance,"The total body clearance normalized by weight, 0.19 l/h/kg in rat versus 0.043 l/h/kg in dog, changed as for the volume of distribution.",Pharmacokinetics of sodium tungstate in rat and dog: a population approach. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10900252/),[l] / [h·kg],0.043,259956,DB00030,Insulin Regular
,10900252,elimination half-life,The elimination half-life was two times higher in dog (approximately 4 h) than in rat (approximately 1.7 h).,Pharmacokinetics of sodium tungstate in rat and dog: a population approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10900252/),h,4,259957,DB00030,Insulin Regular
,10900252,elimination half-life,The elimination half-life was two times higher in dog (approximately 4 h) than in rat (approximately 1.7 h).,Pharmacokinetics of sodium tungstate in rat and dog: a population approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10900252/),h,1.7,259958,DB00030,Insulin Regular
,32543150,relative biological effectiveness,The relative biological effectiveness (reflecting gloucose-lowing effect) and bioavailability on behalf of plasma-drug concentration were 98.3±18.8% and 97.3%±8.3% respectively.,"[The Pharmacokinetics, Pharmacodynamics and Bioequivalence of Insulin Aspart Produced by the United Laboratories Evaluated by Euglycemic Clamp Study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32543150/),%,98.3,261131,DB00030,Insulin Regular
,32543150,bioavailability,The relative biological effectiveness (reflecting gloucose-lowing effect) and bioavailability on behalf of plasma-drug concentration were 98.3±18.8% and 97.3%±8.3% respectively.,"[The Pharmacokinetics, Pharmacodynamics and Bioequivalence of Insulin Aspart Produced by the United Laboratories Evaluated by Euglycemic Clamp Study]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32543150/),%,97.3,261132,DB00030,Insulin Regular
,31647676,polydispersity index,"In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF-linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF-LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and Nagg: 14.82 at 10 cmc] of methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) (mPEG-b-P(CB-co-LA)) block copolymer.",Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),,0.209,261675,DB00030,Insulin Regular
,31647676,critical micelle concentration (cmc),"In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF-linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF-LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and Nagg: 14.82 at 10 cmc] of methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) (mPEG-b-P(CB-co-LA)) block copolymer.",Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),[μg] / [ml],5.95,261676,DB00030,Insulin Regular
,31647676,Nagg,"In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug [LSF-linoleic acid (LA) prodrug] into biodegradable self-assembling polymeric micelles [LSF-LA PLM, size: 149.3 nm; polydispersity index: 0.209; critical micelle concentration (cmc); 5.95 μg/mL and Nagg: 14.82 at 10 cmc] of methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) (mPEG-b-P(CB-co-LA)) block copolymer.",Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),,14.82,261677,DB00030,Insulin Regular
,31647676,oral bioavailability,PK of LSF-LA PLM (10 mg/kg dose) revealed a significant improvement in oral bioavailability of LSF (74.86%; 3.3-fold increase in comparison to free LSF) and drastic reduction in the drug metabolism.,Scalable Self-Assembling Micellar System for Enhanced Oral Bioavailability and Efficacy of Lisofylline for Treatment of Type-I Diabetes. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31647676/),%,74.86,261678,DB00030,Insulin Regular
,25208878,terminal half-life,"The pharmacokinetics of OSI-906 was dose linear, and the terminal half-life ranged between 2 and 6 hours.",Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25208878/),h,2 and 6,262928,DB00030,Insulin Regular
,28457895,Kd,"A phage display screen of a library of aptides, yielded an HSA-specific aptide (APTHSA) that bound HSA with a Kd of 188nM.",An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28457895/),nM,188,262938,DB00030,Insulin Regular
,28457895,plasma half-life,A pharmacokinetic analysis of exenatide-APTHSA after subcutaneous administration revealed a 4-fold longer plasma half-life (1.3 vs. 0.35h) compared with exenatide.,An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28457895/),h,1.3,262939,DB00030,Insulin Regular
,28457895,plasma half-life,A pharmacokinetic analysis of exenatide-APTHSA after subcutaneous administration revealed a 4-fold longer plasma half-life (1.3 vs. 0.35h) compared with exenatide.,An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28457895/),h,0.35,262940,DB00030,Insulin Regular
,25073106,m/z,The monitored transitions were set at m/z 1563.4→1563.4 for HS061 by pseudo-MRM and m/z 1184.7→454.5 for IS by MRM.,"Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25073106/),,1563.4,263686,DB00030,Insulin Regular
,25073106,m/z,The monitored transitions were set at m/z 1563.4→1563.4 for HS061 by pseudo-MRM and m/z 1184.7→454.5 for IS by MRM.,"Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25073106/),,1184.7,263687,DB00030,Insulin Regular
,25073106,m/z,The monitored transitions were set at m/z 1563.4→1563.4 for HS061 by pseudo-MRM and m/z 1184.7→454.5 for IS by MRM.,"Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25073106/),,454.5,263688,DB00030,Insulin Regular
greater,25073106,extraction recoveries,"The mean extraction recoveries of HS061 at three concentrations of 20, 100, 800 ng/mL were greater than 95.17%.","Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25073106/),%,95.17,263689,DB00030,Insulin Regular
,25073106,absolute bioavailability,The absolute bioavailability of HS061 after subcutaneous administration at 1.0 U/kg was estimated to be 70.40%.,"Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography-tandem mass spectrometry. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25073106/),%,70.40,263690,DB00030,Insulin Regular
,33125674,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) of globalagliatin increased from 7.76 to 138.13 ng/mL (stage I), and 29.36 to 471.50 ng/mL (stage II), which occurred at 3-5 h post-dose.","Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125674/),[ng] / [ml],7.76 to 138.13,264560,DB00030,Insulin Regular
,33125674,maximum plasma concentration (Cmax),"The mean maximum plasma concentration (Cmax) of globalagliatin increased from 7.76 to 138.13 ng/mL (stage I), and 29.36 to 471.50 ng/mL (stage II), which occurred at 3-5 h post-dose.","Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125674/),[ng] / [ml],29.36 to 471.50,264561,DB00030,Insulin Regular
,33125674,area under the plasma-concentration curve for steady-state 24-h interval (AUC0-24),Mean area under the plasma-concentration curve for steady-state 24-h interval (AUC0-24) increased from 106.13 to 2461.95 ng·h/mL (stage I) and 369.71 to 9218.38 ng·h/mL (stage II).,"Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125674/),[h·ng] / [ml],106.13 to 2461.95,264562,DB00030,Insulin Regular
,33125674,area under the plasma-concentration curve for steady-state 24-h interval (AUC0-24),Mean area under the plasma-concentration curve for steady-state 24-h interval (AUC0-24) increased from 106.13 to 2461.95 ng·h/mL (stage I) and 369.71 to 9218.38 ng·h/mL (stage II).,"Safety, Pharmacokinetics, and Pharmacodynamics of Globalagliatin, a Glucokinase Activator, in Chinese Patients with Type 2 Diabetes Mellitus: A Randomized, Phase Ib, 28-day Ascending Dose Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125674/),[h·ng] / [ml],369.71 to 9218.38,264563,DB00030,Insulin Regular
,27513815,plasma bioavailability,The HIRMAb is readily absorbed into the systemic circulation following SQ injection with a 42% plasma bioavailability.,Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513815/),%,42,264967,DB00030,Insulin Regular
,27513815,rate of plasma clearance,"The rate of plasma clearance of the antibody, 0.04-0.06 mL/min/kg, is the same following either IV or SQ administration.",Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27513815/),[ml] / [kg·min],0.04-0.06,264968,DB00030,Insulin Regular
,24139704,peak,"Following injection of insulin detemir, GIR increased, reaching a mean peak of 2.29 mg/kg/min (95% CI 1.64, 2.94) at 11.6h (range 8.9 to 14.3) compared to 1.71 mg/kg/min (95% CI 1.4, 2.0) at 10.2 h (8.1 to 12.3) for insulin glargine (P=0.025 for GIR(max)).",A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24139704/),[mg] / [kg·min],2.29,265150,DB00030,Insulin Regular
,24139704,peak,"Following injection of insulin detemir, GIR increased, reaching a mean peak of 2.29 mg/kg/min (95% CI 1.64, 2.94) at 11.6h (range 8.9 to 14.3) compared to 1.71 mg/kg/min (95% CI 1.4, 2.0) at 10.2 h (8.1 to 12.3) for insulin glargine (P=0.025 for GIR(max)).",A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24139704/),[mg] / [kg·min],1.71,265151,DB00030,Insulin Regular
,26086190,half-life,"At SS, the half-life was 25.4 (IDeg) versus 12.1 h (IGlar).",Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26086190/),h,25.4,265556,DB00030,Insulin Regular
,26086190,half-life,"At SS, the half-life was 25.4 (IDeg) versus 12.1 h (IGlar).",Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26086190/),h,12.1,265557,DB00030,Insulin Regular
>,26086190,half-life,IDeg has a longer half-life (> 25 h) than IGlar.,Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26086190/),h,25,265558,DB00030,Insulin Regular
,23195963,times for maximal metabolic effects,"The mean times for maximal metabolic effects for 50, 100, and 200 U of oral enteric insulin were 250 (118), 170 (58), and 236 (132) minutes, respectively, compared with 243 (79) minutes for NPH insulin.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,250,265811,DB00030,Insulin Regular
,23195963,times for maximal metabolic effects,"The mean times for maximal metabolic effects for 50, 100, and 200 U of oral enteric insulin were 250 (118), 170 (58), and 236 (132) minutes, respectively, compared with 243 (79) minutes for NPH insulin.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,170,265812,DB00030,Insulin Regular
,23195963,times for maximal metabolic effects,"The mean times for maximal metabolic effects for 50, 100, and 200 U of oral enteric insulin were 250 (118), 170 (58), and 236 (132) minutes, respectively, compared with 243 (79) minutes for NPH insulin.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,236,265813,DB00030,Insulin Regular
,23195963,times for maximal metabolic effects,"The mean times for maximal metabolic effects for 50, 100, and 200 U of oral enteric insulin were 250 (118), 170 (58), and 236 (132) minutes, respectively, compared with 243 (79) minutes for NPH insulin.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,243,265814,DB00030,Insulin Regular
,23195963,onset of action,"The onset of action was slower for oral enteric insulin at 50 U (38 [10] minutes), 100 U (41 [18] minutes), and 200 U (65 [58] minutes) compared with NPH insulin (35 [8] minutes).",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,38,265815,DB00030,Insulin Regular
,23195963,onset of action,"The onset of action was slower for oral enteric insulin at 50 U (38 [10] minutes), 100 U (41 [18] minutes), and 200 U (65 [58] minutes) compared with NPH insulin (35 [8] minutes).",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,41,265816,DB00030,Insulin Regular
,23195963,onset of action,"The onset of action was slower for oral enteric insulin at 50 U (38 [10] minutes), 100 U (41 [18] minutes), and 200 U (65 [58] minutes) compared with NPH insulin (35 [8] minutes).",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,65,265817,DB00030,Insulin Regular
,23195963,onset of action,"The onset of action was slower for oral enteric insulin at 50 U (38 [10] minutes), 100 U (41 [18] minutes), and 200 U (65 [58] minutes) compared with NPH insulin (35 [8] minutes).",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),min,35,265818,DB00030,Insulin Regular
,23195963,maximum glucose infusion rates,"The maximum glucose infusion rates for oral enteric insulin treatment (1.66 [0.50], 1.61 [1.00], and 1.80 [0.60] mg/kg/min for 50, 100, and 200 U, respectively) were lower compared with NPH insulin (2.06 [0.82] mg/kg/min), although these differences were not statistically significant.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),[mg] / [kg·min],1.66,265819,DB00030,Insulin Regular
,23195963,maximum glucose infusion rates,"The maximum glucose infusion rates for oral enteric insulin treatment (1.66 [0.50], 1.61 [1.00], and 1.80 [0.60] mg/kg/min for 50, 100, and 200 U, respectively) were lower compared with NPH insulin (2.06 [0.82] mg/kg/min), although these differences were not statistically significant.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),[mg] / [kg·min],1.61,265820,DB00030,Insulin Regular
,23195963,maximum glucose infusion rates,"The maximum glucose infusion rates for oral enteric insulin treatment (1.66 [0.50], 1.61 [1.00], and 1.80 [0.60] mg/kg/min for 50, 100, and 200 U, respectively) were lower compared with NPH insulin (2.06 [0.82] mg/kg/min), although these differences were not statistically significant.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),[mg] / [kg·min],1.80,265821,DB00030,Insulin Regular
,23195963,maximum glucose infusion rates,"The maximum glucose infusion rates for oral enteric insulin treatment (1.66 [0.50], 1.61 [1.00], and 1.80 [0.60] mg/kg/min for 50, 100, and 200 U, respectively) were lower compared with NPH insulin (2.06 [0.82] mg/kg/min), although these differences were not statistically significant.",Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23195963/),[mg] / [kg·min],2.06,265822,DB00030,Insulin Regular
,24430725,terminal half-life,"The mean terminal half-life ranged from 5.6 to 13.1 h in single rising-dose studies, and from 10.3 to 18.8 h in multiple-dose studies.","Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24430725/),h,5.6 to 13.1,265997,DB00030,Insulin Regular
,24430725,terminal half-life,"The mean terminal half-life ranged from 5.6 to 13.1 h in single rising-dose studies, and from 10.3 to 18.8 h in multiple-dose studies.","Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24430725/),h,10.3 to 18.8,265998,DB00030,Insulin Regular
,31633515,half-lives,"IGF-MTX concentrations declined rapidly, with half-lives of 5.2 to 14 minutes for the initial distribution phase and 6.5 to 7.5 hours for the terminal elimination phase.",Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633515/),min,5.2 to 14,266048,DB00030,Insulin Regular
,31633515,half-lives,"IGF-MTX concentrations declined rapidly, with half-lives of 5.2 to 14 minutes for the initial distribution phase and 6.5 to 7.5 hours for the terminal elimination phase.",Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633515/),h,6.5 to 7.5,266049,DB00030,Insulin Regular
,12860494,half-life,"Mean nateglinide half-life was similar for all 5 treatments (range, 81.3-94.6 minutes).",The effect of nateglinide taken with food on gastric emptying rates in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12860494/),min,81.3-94.6,266093,DB00030,Insulin Regular
,27672108,MTD,The MTD was 0.8 mg/kg copanlisib.,"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27672108/),[mg] / [kg],0.8,266345,DB00030,Insulin Regular
,27672108,MTD,"Copanlisib, dosed intermittently on days 1, 8, and 15 of a 28-day cycle, was well tolerated and the MTD was determined to be 0.8 mg/kg.","First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27672108/),[mg] / [kg],0.8,266346,DB00030,Insulin Regular
,29540491,net hepatic glucose uptake,"In P2, both treatments induced net hepatic glucose uptake (HGU) (HI mean ± SEM 2.1 ± 0.5 vs. 3.3 ± 0.4 GRI mg/kg/min).",Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29540491/),[mg] / [kg·min],2.1,266466,DB00030,Insulin Regular
,29540491,net hepatic glucose uptake,"In P2, both treatments induced net hepatic glucose uptake (HGU) (HI mean ± SEM 2.1 ± 0.5 vs. 3.3 ± 0.4 GRI mg/kg/min).",Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29540491/),[mg] / [kg·min],3.3,266467,DB00030,Insulin Regular
,29540491,Nonhepatic glucose uptake,"Nonhepatic glucose uptake in P1 and P2, respectively, differed between treatments (2.6 ± 0.3 and 7.4 ± 0.6 mg/kg/min with HI vs. 2.0 ± 0.2 and 8.1 ± 0.8 mg/kg/min with GRI).",Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29540491/),[mg] / [kg·min],2.6,266468,DB00030,Insulin Regular
,29540491,Nonhepatic glucose uptake,"Nonhepatic glucose uptake in P1 and P2, respectively, differed between treatments (2.6 ± 0.3 and 7.4 ± 0.6 mg/kg/min with HI vs. 2.0 ± 0.2 and 8.1 ± 0.8 mg/kg/min with GRI).",Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29540491/),[mg] / [kg·min],7.4,266469,DB00030,Insulin Regular
,29540491,Nonhepatic glucose uptake,"Nonhepatic glucose uptake in P1 and P2, respectively, differed between treatments (2.6 ± 0.3 and 7.4 ± 0.6 mg/kg/min with HI vs. 2.0 ± 0.2 and 8.1 ± 0.8 mg/kg/min with GRI).",Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29540491/),[mg] / [kg·min],2.0,266470,DB00030,Insulin Regular
,29540491,Nonhepatic glucose uptake,"Nonhepatic glucose uptake in P1 and P2, respectively, differed between treatments (2.6 ± 0.3 and 7.4 ± 0.6 mg/kg/min with HI vs. 2.0 ± 0.2 and 8.1 ± 0.8 mg/kg/min with GRI).",Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29540491/),[mg] / [kg·min],8.1,266471,DB00030,Insulin Regular
,30711829,IC50,"The most potent compound 22 (LXQ46) inhibited PTP1B with an IC50 value of 0.190 μM, and showed remarkable selectivity over other protein tyrosine phosphatases (PTPs, 20-200 folds).",Toward a treatment of diabesity: In vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30711829/),μM,0.190,267066,DB00030,Insulin Regular
,18353483,volume aerodynamic diameter,"They had a median volume diameter and median volume aerodynamic diameter of about 6-10 microm and 4 microm, respectively.",Efficacy of pulmonary insulin delivery in diabetic rats: use of a model-based approach in the evaluation of insulin powder formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353483/),μm,4,267289,DB00030,Insulin Regular
,18353483,bioavailability,"The bioavailability of the pulmonarily administered dextran-, TMC20- and TMC60-insulin microparticles relative to subcutaneously (SC) administered insulin, was 0.48, 0.59 and 0.95, respectively.",Efficacy of pulmonary insulin delivery in diabetic rats: use of a model-based approach in the evaluation of insulin powder formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353483/),,0.48,267290,DB00030,Insulin Regular
,18353483,bioavailability,"The bioavailability of the pulmonarily administered dextran-, TMC20- and TMC60-insulin microparticles relative to subcutaneously (SC) administered insulin, was 0.48, 0.59 and 0.95, respectively.",Efficacy of pulmonary insulin delivery in diabetic rats: use of a model-based approach in the evaluation of insulin powder formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353483/),,0.59,267291,DB00030,Insulin Regular
,18353483,bioavailability,"The bioavailability of the pulmonarily administered dextran-, TMC20- and TMC60-insulin microparticles relative to subcutaneously (SC) administered insulin, was 0.48, 0.59 and 0.95, respectively.",Efficacy of pulmonary insulin delivery in diabetic rats: use of a model-based approach in the evaluation of insulin powder formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18353483/),,0.95,267292,DB00030,Insulin Regular
,16013082,formation rate constant,The estimated proinsulin formation rate constant was significantly higher in the obese group compared with the lean group (1.60 +/- 43.1 vs 0.378 +/- 40.9 min(-1)).,Pharmacokinetic/pharmacodynamic differentiation of pancreatic responsiveness in obese and lean children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013082/),1/[min],1.60,267407,DB00030,Insulin Regular
,16013082,formation rate constant,The estimated proinsulin formation rate constant was significantly higher in the obese group compared with the lean group (1.60 +/- 43.1 vs 0.378 +/- 40.9 min(-1)).,Pharmacokinetic/pharmacodynamic differentiation of pancreatic responsiveness in obese and lean children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013082/),1/[min],0.378,267408,DB00030,Insulin Regular
,16013082,half-life,The half-life of insulin in plasma was calculated to be 6.36 +/- 39.9 min for the obese group and 6.84 +/- 30.1 min for the lean group.,Pharmacokinetic/pharmacodynamic differentiation of pancreatic responsiveness in obese and lean children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013082/),min,6.36,267409,DB00030,Insulin Regular
,16013082,half-life,The half-life of insulin in plasma was calculated to be 6.36 +/- 39.9 min for the obese group and 6.84 +/- 30.1 min for the lean group.,Pharmacokinetic/pharmacodynamic differentiation of pancreatic responsiveness in obese and lean children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013082/),min,6.84,267410,DB00030,Insulin Regular
,12006143,bioavailability,"The bioavailability of inhaled insulin (1.5 U) with 0.25% DOSS was estimated to be 16% in comparison with 7% for intratracheally (0.15 mL), 1% intranasally, and 0.8% sublingually administered insulin (1.5 U with 0.25% DOSS), respectively.",Enhanced insulin absorption in the rabbit airways and lung by sodium dioctyl sulfosuccinate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006143/),%,16,267425,DB00030,Insulin Regular
,12006143,bioavailability,"The bioavailability of inhaled insulin (1.5 U) with 0.25% DOSS was estimated to be 16% in comparison with 7% for intratracheally (0.15 mL), 1% intranasally, and 0.8% sublingually administered insulin (1.5 U with 0.25% DOSS), respectively.",Enhanced insulin absorption in the rabbit airways and lung by sodium dioctyl sulfosuccinate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006143/),%,7,267426,DB00030,Insulin Regular
,12006143,bioavailability,"The bioavailability of inhaled insulin (1.5 U) with 0.25% DOSS was estimated to be 16% in comparison with 7% for intratracheally (0.15 mL), 1% intranasally, and 0.8% sublingually administered insulin (1.5 U with 0.25% DOSS), respectively.",Enhanced insulin absorption in the rabbit airways and lung by sodium dioctyl sulfosuccinate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006143/),%,1,267427,DB00030,Insulin Regular
,12006143,bioavailability,"The bioavailability of inhaled insulin (1.5 U) with 0.25% DOSS was estimated to be 16% in comparison with 7% for intratracheally (0.15 mL), 1% intranasally, and 0.8% sublingually administered insulin (1.5 U with 0.25% DOSS), respectively.",Enhanced insulin absorption in the rabbit airways and lung by sodium dioctyl sulfosuccinate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12006143/),%,0.8,267428,DB00030,Insulin Regular
,27042281,AUCID,"At steady state, total glucose-lowering effect (area under the glucose infusion rate [GIR] curve during one dosing interval [τ, 0-24 h] at steady state [AUCGIR ,τ, SS]) was 1,446 mg/kg and total exposure (geometric mean) of IDeg (AUCID eg,τ, SS) was 81,270 pmol h/L.",Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27042281/),[h·pM] / [l],"81,270",268430,DB00030,Insulin Regular
,33336850,∆AUC,"Compared with Lispro, ADO09 reduced postprandial blood glucose (ppBG) excursions by more than 95% in the first hour postmeal (mean ± SD ∆AUC BG 0-1 h: 1.4 ± 9.9 mg*h/dL vs. 43.5 ± 15.3 mg*h/dL; p < .0001).","ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[h·mg] / [dl],1.4,268693,DB00030,Insulin Regular
,33336850,Maximum ppBG,Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).,"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[mg] / [dl],87.0,268694,DB00030,Insulin Regular
,33336850,Maximum ppBG,Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).,"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[mg] / [dl],109.2,268695,DB00030,Insulin Regular
,33336850,Maximum ppBG,Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357).,"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33336850/),[mg] / [dl],109.4,268696,DB00030,Insulin Regular
,12075827,availability,"The pharmacological availability of insulin from Labrasol solution was found to be 3.9, 8.9 and 9.1% following jejunal, ileal and colonic administrations, respectively, by comparing the serum glucose level vs. time profiles obtained after intestinal and i.v. administrations.",Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12075827/),%,3.9,268858,DB00030,Insulin Regular
,12075827,availability,"The pharmacological availability of insulin from Labrasol solution was found to be 3.9, 8.9 and 9.1% following jejunal, ileal and colonic administrations, respectively, by comparing the serum glucose level vs. time profiles obtained after intestinal and i.v. administrations.",Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12075827/),%,8.9,268859,DB00030,Insulin Regular
,12075827,availability,"The pharmacological availability of insulin from Labrasol solution was found to be 3.9, 8.9 and 9.1% following jejunal, ileal and colonic administrations, respectively, by comparing the serum glucose level vs. time profiles obtained after intestinal and i.v. administrations.",Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12075827/),%,9.1,268860,DB00030,Insulin Regular
,12075827,bioavailability,"By comparing the serum insulin levels vs. time profiles, the bioavailability of insulin was found to be 0.25 and 0.20% for intra-ileum and colonic administrations, respectively.",Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12075827/),%,0.25,268861,DB00030,Insulin Regular
,12075827,bioavailability,"By comparing the serum insulin levels vs. time profiles, the bioavailability of insulin was found to be 0.25 and 0.20% for intra-ileum and colonic administrations, respectively.",Absorption enhancing effect of labrasol on the intestinal absorption of insulin in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12075827/),%,0.20,268862,DB00030,Insulin Regular
,23412078,UGE0-6h,"Compared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC0-2h] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE0-6h, 18.2 ± 5.6 vs. <0.2 g; P < 0.001), and delayed RaO.","Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23412078/),g,18.2,269383,DB00030,Insulin Regular
,23412078,total AUC Ra,"Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003).","Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23412078/),[mg] / [kg],960,269384,DB00030,Insulin Regular
,23412078,total AUC Ra,"Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003).","Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23412078/),[mg] / [kg],"1,018",269385,DB00030,Insulin Regular
,26017100,relative bioavailability,"A significant enhancement of relative bioavailability of insulin was observed, i.e. approximately five times of pure insulin solution when loaded in SLN (8.26% versus 1.7% only).",Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26017100/),%,8.26,269422,DB00030,Insulin Regular
,26017100,relative bioavailability,"A significant enhancement of relative bioavailability of insulin was observed, i.e. approximately five times of pure insulin solution when loaded in SLN (8.26% versus 1.7% only).",Enhanced oral bioavailability of insulin-loaded solid lipid nanoparticles: pharmacokinetic bioavailability of insulin-loaded solid lipid nanoparticles in diabetic rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26017100/),%,1.7,269423,DB00030,Insulin Regular
,24504686,Time-to-maximum plasma concentration,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,18.0 to 42.0,271201,DB00030,Insulin Regular
,24504686,Time-to-maximum plasma concentration,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,10.0-12.0,271202,DB00030,Insulin Regular
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,18.0 to 42.0,271203,DB00030,Insulin Regular
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,24.4-45.5,271204,DB00030,Insulin Regular
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,10.0-12.0,271205,DB00030,Insulin Regular
,24504686,half-life (t½ ),"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,12.2-14.9,271206,DB00030,Insulin Regular
,24504686,apparent clearance,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,24.4-45.5,271207,DB00030,Insulin Regular
,24504686,apparent clearance,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),[l] / [h],1.8-2.8,271208,DB00030,Insulin Regular
,24504686,apparent clearance,"Time-to-maximum plasma concentration (medians) and geometric means for half-life (t½ ) and apparent clearance, respectively, ranged from 18.0 to 42.0 hours, 24.4-45.5 hours, and 1.8-2.8 L/h for SC LY2605541, versus 10.0-12.0 hours, 12.2-14.9 hours, and 51.4-65.2 L/h for SC insulin glargine.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,10.0-12.0,271209,DB00030,Insulin Regular
,24504686,t½,"After IV administration, LY2605541's geometric mean t½ was 2.3 hours.","Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504686/),h,2.3,271210,DB00030,Insulin Regular
,25669174,maximum concentration (Cmax ),"The maximum concentration (Cmax ) and area under the concentration-time curve (AUC0-last ) of morphine glucuronide in serum were increased in NASH patients (343 vs. 225 nM and 58.8 vs. 37.2 µM*min, respectively; P ≤ 0.005); morphine pharmacokinetics did not differ between groups.",Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669174/),nM,343,271914,DB00030,Insulin Regular
,25669174,maximum concentration (Cmax ),"The maximum concentration (Cmax ) and area under the concentration-time curve (AUC0-last ) of morphine glucuronide in serum were increased in NASH patients (343 vs. 225 nM and 58.8 vs. 37.2 µM*min, respectively; P ≤ 0.005); morphine pharmacokinetics did not differ between groups.",Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669174/),nM,225,271915,DB00030,Insulin Regular
,25669174,area under the concentration-time curve (AUC0-last ),"The maximum concentration (Cmax ) and area under the concentration-time curve (AUC0-last ) of morphine glucuronide in serum were increased in NASH patients (343 vs. 225 nM and 58.8 vs. 37.2 µM*min, respectively; P ≤ 0.005); morphine pharmacokinetics did not differ between groups.",Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669174/),min·μM,58.8,271916,DB00030,Insulin Regular
,25669174,area under the concentration-time curve (AUC0-last ),"The maximum concentration (Cmax ) and area under the concentration-time curve (AUC0-last ) of morphine glucuronide in serum were increased in NASH patients (343 vs. 225 nM and 58.8 vs. 37.2 µM*min, respectively; P ≤ 0.005); morphine pharmacokinetics did not differ between groups.",Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25669174/),min·μM,37.2,271917,DB00030,Insulin Regular
,29291938,EC50,"Further structure-based design and chiral resolution provided the most potent compound 11 (EC50 = 7.9 nM), which exhibited improved lipophilicity (LogD7.4: 1.93), ligand efficiency (LE = 0.32) and ligand lipophilicity efficiency (LLE = 6.2).",Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29291938/),nM,7.9,272294,DB00030,Insulin Regular
,15756033,K(d),"By use of XenoMouse technology, we generated CP-751,871, a fully human IgG2 antibody with high affinity (K(d) = 1.5 nmol/L) for human IGF-1R and evaluated its biological, pharmacologic, and antitumor properties.","Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15756033/),[nM] / [l],1.5,272311,DB00030,Insulin Regular
,15756033,IC(50),"This antibody blocks binding of IGF-1 to its receptor (IC(50) 1.8 nmol/L), IGF-1-induced receptor autophosphorylation (IC(50) 0.42 nmol/L) and induced the down-regulation of IGF-1R in vitro and in tumor xenografts.","Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15756033/),[nM] / [l],1.8,272312,DB00030,Insulin Regular
,15756033,IC(50),"This antibody blocks binding of IGF-1 to its receptor (IC(50) 1.8 nmol/L), IGF-1-induced receptor autophosphorylation (IC(50) 0.42 nmol/L) and induced the down-regulation of IGF-1R in vitro and in tumor xenografts.","Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15756033/),[nM] / [l],0.42,272313,DB00030,Insulin Regular
,11994362,MCRs,"During primed constant infusions of GH at rates of 1.5 and 3.0 microg/kg x h, the corresponding MCRs of GH were 148.8 +/- 5.4 and 89.8 +/- 2.4 ml/min x m(-2), respectively, and the MCRs were inversely related to the achieved steady state GH levels (P < 0.0001).","Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994362/),[min·ml] / [(m)^2],148.8,272323,DB00030,Insulin Regular
,11994362,MCRs,"During primed constant infusions of GH at rates of 1.5 and 3.0 microg/kg x h, the corresponding MCRs of GH were 148.8 +/- 5.4 and 89.8 +/- 2.4 ml/min x m(-2), respectively, and the MCRs were inversely related to the achieved steady state GH levels (P < 0.0001).","Body composition and circulating levels of insulin, insulin-like growth factor-binding protein-1 and growth hormone (GH)-binding protein affect the pharmacokinetics of GH in adults independently of age. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11994362/),[min·ml] / [(m)^2],89.8,272324,DB00030,Insulin Regular
,15833329,T(max),The VAC could be rapidly absorbed and T(max) values ranged from 0.9 +/- 0.3 h for s.c. injection to 3.0 +/- 0.9 h for i.g. administration.,Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15833329/),h,0.9,272354,DB00030,Insulin Regular
,15833329,T(max),The VAC could be rapidly absorbed and T(max) values ranged from 0.9 +/- 0.3 h for s.c. injection to 3.0 +/- 0.9 h for i.g. administration.,Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15833329/),h,3.0,272355,DB00030,Insulin Regular
,15833329,absolute bioavailabilities,"The average absolute bioavailabilities for i.g. administrations at a single dose of 3, 6, and 10 mg V/kg were 34.7%, 28.1%, and 22.8%, respectively.",Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15833329/),%,34.7,272356,DB00030,Insulin Regular
,15833329,absolute bioavailabilities,"The average absolute bioavailabilities for i.g. administrations at a single dose of 3, 6, and 10 mg V/kg were 34.7%, 28.1%, and 22.8%, respectively.",Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15833329/),%,28.1,272357,DB00030,Insulin Regular
,15833329,absolute bioavailabilities,"The average absolute bioavailabilities for i.g. administrations at a single dose of 3, 6, and 10 mg V/kg were 34.7%, 28.1%, and 22.8%, respectively.",Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15833329/),%,22.8,272358,DB00030,Insulin Regular
,15833329,elimination half-lives,"After i.g. administration at a single dose of 10 mg V/kg, the average elimination half-lives obtained from non-diabetic rats were very long ranging from 144.7 +/- 8.7 h in plasma to 657.3 +/- 34.8 h in femur tissue.",Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15833329/),h,144.7,272359,DB00030,Insulin Regular
,15833329,elimination half-lives,"After i.g. administration at a single dose of 10 mg V/kg, the average elimination half-lives obtained from non-diabetic rats were very long ranging from 144.7 +/- 8.7 h in plasma to 657.3 +/- 34.8 h in femur tissue.",Pharmacodynamics and pharmacokinetics of the insulin-mimetic agent vanadyl acetylacetonate in non-diabetic and diabetic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15833329/),h,657.3,272360,DB00030,Insulin Regular
,11785686,elimination half-life,"The PK of insulin administered either by SI to the lungs or SC injection were absorption rate dependent, resulting in post-peak half-lives 10 to 25-fold greater than the reported intravenous elimination half-life (3 min).",Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11785686/),min,3,272464,DB00030,Insulin Regular
,11785686,relative bioavailability (F'),"The relative bioavailability (F') of insulin administered alone by SI varied from 23.8 to 80% for the lowest and highest insulin dose, respectively.",Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11785686/),%,23.8,272465,DB00030,Insulin Regular
,11785686,relative bioavailability (F'),"The relative bioavailability (F') of insulin administered alone by SI varied from 23.8 to 80% for the lowest and highest insulin dose, respectively.",Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11785686/),%,80,272466,DB00030,Insulin Regular
,16817815,peak insulin,Insulin responses were higher in patients (peak insulin 96.33 +/- 9.71 mU/l) in relation to values found in controls (58.11 +/- 9.03 mU/l; P < 0.01).,Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[mu] / [l],96.33,272890,DB00030,Insulin Regular
,16817815,peak insulin,Insulin responses were higher in patients (peak insulin 96.33 +/- 9.71 mU/l) in relation to values found in controls (58.11 +/- 9.03 mU/l; P < 0.01).,Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[mu] / [l],58.11,272891,DB00030,Insulin Regular
,16817815,minimum concentration,"The minimum concentration of IGFBP-1 and the area under the curve (AUC) of IGFBP-1 after OGTT were higher after parathyroidectomy (3.34 +/- 0.69 microg/l and 8.94 +/- 1.72 microg x h/l, respectively) than at diagnosis (2.19 +/- 0.42 microg/l and 6.74 +/- 1.28 microg x h/l, respectively; P < 0.05).",Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[μg] / [l],3.34,272892,DB00030,Insulin Regular
,16817815,minimum concentration,"The minimum concentration of IGFBP-1 and the area under the curve (AUC) of IGFBP-1 after OGTT were higher after parathyroidectomy (3.34 +/- 0.69 microg/l and 8.94 +/- 1.72 microg x h/l, respectively) than at diagnosis (2.19 +/- 0.42 microg/l and 6.74 +/- 1.28 microg x h/l, respectively; P < 0.05).",Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[μg] / [l],2.19,272893,DB00030,Insulin Regular
,16817815,area under the curve (AUC),"The minimum concentration of IGFBP-1 and the area under the curve (AUC) of IGFBP-1 after OGTT were higher after parathyroidectomy (3.34 +/- 0.69 microg/l and 8.94 +/- 1.72 microg x h/l, respectively) than at diagnosis (2.19 +/- 0.42 microg/l and 6.74 +/- 1.28 microg x h/l, respectively; P < 0.05).",Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[h·μg] / [l],8.94,272894,DB00030,Insulin Regular
,16817815,area under the curve (AUC),"The minimum concentration of IGFBP-1 and the area under the curve (AUC) of IGFBP-1 after OGTT were higher after parathyroidectomy (3.34 +/- 0.69 microg/l and 8.94 +/- 1.72 microg x h/l, respectively) than at diagnosis (2.19 +/- 0.42 microg/l and 6.74 +/- 1.28 microg x h/l, respectively; P < 0.05).",Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16817815/),[h·μg] / [l],6.74,272895,DB00030,Insulin Regular
